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CHAPTER 1: INTRODUCTION 
 
1.1 Introduction 
Recent figures suggest that, in England, more than 250,000 people are diagnosed 
with cancer each year (Office for National Statistics, 2010). There are over 200 
different types of cancer which together are a significant cause of death in this 
country. Although the incidence of cancer is increasing, promisingly over the last ten 
years mortality rates have fallen by around ten percent (Office for National 
Statistics, 2009). There are several reasons for this, such as implementation of 
national screening programmes and improved diagnostic techniques, as well as the 
advancement of cancer research resulting in better treatment options (Cancer 
Research UK, 2009). As people are living longer with cancer, it is inevitable that the 
numbers experiencing associated nutritional problems and a deterioration in 
nutritional status will increase. More specifically, the high incidence of the multi-
dimensional metabolic syndrome of cachexia, alongside malnutrition, can lead to an 
increase in morbidity and mortality within this population (Lainscak et al., 2007). 
Over recent years, despite an apparent increase in research investigating weight 
loss and cachexia, advances in the field have been limited, and there remains no 
agreed treatment pathway (Braiteh et al., 2009; National Institutes of Health, 2010). 
One thing is clear, for any treatment to be effective, early identification of those at 
risk and timely intervention are paramount. Numerous screening instruments have 
been developed to identify malnutrition and a small number have been validated in 
people with cancer (Ottery, 1994; Thoresen et al., 2002; Isenring et al., 2006). 
However, no one tool encompasses all elements of the cachexia syndrome or is 
able to predict those people with cancer who will develop cachexia or lose weight.  
 
The purpose of the research presented here was to develop a greater 
understanding of the complex processes that influence, and can predict, weight loss 
in people with cancer. The intention was that an increase in knowledge will enhance 
the nutritional management strategies in clinical practice. 
 
This introductory chapter has three main aims. Firstly, it puts the importance of early 
identification of those people with cancer who are at risk of weight loss into context. 
Secondly, it provides information on the research conducted leading up to the 
Predicting Weight Loss Study which makes up the majority of the thesis. Finally, 
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structured around the seven chapters, an overview of the content of the thesis is 
given.  
 
1.2 Background to the Predicting Weight Loss in People with Cancer study 
In 2005, researchers in Nottingham began to investigate the potential use and ability 
of, the Council on Nutrition Appetite Questionnaire (CNAQ) (Appendix 1) to predict 
weight loss within the cancer population. The CNAQ was developed in the United 
States of America (USA) from the 29-item Appetite, Hunger and Sensory Perception 
Questionnaire (AHSP) (Wilson et al., 2005). The AHSP had previously been 
validated as an instrument to evaluate appetite in the healthy older population in 
The Netherlands. Testing had demonstrated good correlation with an alternative 
screening instrument, the Mini Nutritional Assessment, and with body weight 
(Mathey, 2001). Using the Delphi technique (Crisp et al., 1997) to obtain consensus 
opinion, content validity work by a group of experts from the Council for Nutritional 
Strategies in Long Term Care group developed, from the AHSP, an eight-item 
instrument which they called the CNAQ. The eight items of the CNAQ relate 
specifically to appetite and symptoms. Each item is equally scored, one to five, and 
a final CNAQ score is obtained by summing the eight scores.  Reliability testing 
suggested that, when tested in the USA in a group of community dwellers and a 
group of residents in long term care,  the CNAQ had good, and reasonable, internal 
consistHQF\ &URQEDFK¶V DOSKD     DQG  UHVSHFWLYHO\ &ULWHULRQ YDOLGLW\
testing within the same two groups implied that, using a cut point of less than or 
equal to 28, within this population, the CNAQ scores had predictive validity in terms 
of five percent weight loss over six months. As the aim of the study was to validate a 
simple screening instrument, factor analysis was subsequently used to see if a 
shorter version of the CNAQ would also have predictive capabilities. Predictive 
validity testing showed this to be the case and four of the eight questions were put 
together to form the Simplified Nutritional Appetite Questionnaire (SNAQ) (Appendix 
2).  
 
1.2.1 Development of the Cancer Appetite and Symptom Questionnaire  
As a screening instrument is only reliable and valid within the population that it was 
tested, further research would need to be undertaken for the CNAQ to be used to 
predict weight loss in people with cancer. Content validity testing was conducted in 
2005 by members of the palliative care research team at Nottingham University 
Hospitals NHS Trust.  
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1.2.2 Content validation  
The content validity of the CNAQ was established using the judgement 
quantification process as described by Lynn (1986). An expert panel comprised of 
20 cancer service users, one caregiver and 21 oncology health care professionals 
was asked to rate the relevance and the succinctness of the eight items on the 
CNAQ. Using the scale 1 = not relevant, 2 = unable to assess without item revision, 
3 = relevant but needs minor alteration and 4 = very relevant and succinct, a content 
validity index (CVI) was calculated as the proportion of panel members who gave a 
score of 3 or 4. The required minimum level of agreement was set at a CVI of 
greater than 0.70. Panel members were also asked to comment on the clarity of the 
wording and note any appetite and symptom issues that they did not feel were 
covered in the questionnaire. The resulting CVIs are shown in Table 1.1. All but 
one, item five, met the set level of agreement. In response to the comments from 
the expert panel, the wording of items two, four, five and six was amended. In 
particular, comments were made on item four which assessed taste. These related 
to the loss or alteration in taste experienced by patients with cancer, together with 
the degree to which food is enjoyed, rather than just how good or bad food tastes 
over all. To accommodate these comments, two new items were created to replace 
WKHRULJLQDOLWHPIRXUµ,HQMR\WKHIRRG,GRHDW- most of the time, often, sometimes, 
UDUHO\ RU QHYHU¶ DQG µ$W SUHVHQW , KDYH - no changes in taste, mild, moderate or 
VHYHUHFKDQJHVLQWDVWHRUQRWDVWHDWDOO¶$QDGGLWLRQDOLWHPZDVDOVRLQWURGXFHGWR
cover the frequency of snacking. As the majority of the 23 overall comments related 
to a lack of inclusion of other symptoms considered likely to impact on appetite, 
most frequently pain and energy (fatigue), two new items were added to include 
these. Thus, the process resulted in the 8-item CNAQ being modified to a 12-item 
instrument, which was named the Cancer Appetite and Symptom Questionnaire 
(CASQ) (Appendix 3). The need for further reliability and validity testing of this 
instrument led to the research that was conducted for this doctoral degree. 
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Table 1.1: Content validity index (CVI) for the individual items and overall 
CNAQ  
 
Item Item theme Frequency of 
comments 
CVI Changes 
made 
1 Appetite 10 0.95 No 
2 Satiety 10 0.84 Yes 
3 Hunger 7 0.98 No 
4 Food taste 18 0.84 Yes 
5 Change in taste 19 0.57 Yes 
6 Number of meals 10 0.93 Yes 
7 Nausea 6 0.95 No 
8 Mood 8 0.96 No 
Instrument Overall comments 23 0.88 Yes 
Derived from an expert panel with 42 members, the frequency of comments and content 
validity index for each of the eight CNAQ items, along with the complete instrument is 
shown. In addition to the theme of the question, the table also indicates where changes to 
the wording were made.  
 
 
1.3 Content of the thesis 
This thesis is comprised of three studies, each contributing to the aim of predicting 
weight loss and understanding the experience of weight loss in people with lung and 
upper gastrointestinal (upper GI) cancer. Chapter 1 has introduced the thesis and 
provided the background research which led to the development of the three 
studies. 
 
Chapter 2 reports an overview and critical appraisal of the literature within the field 
of malnutrition, cancer cachexia and nutritional screening.  In particular, it will focus 
on the nutritional aspects of the condition and treatment. Current nutritional 
screening tools will be identified and appraised.  
 
Chapter 3 outlines the theory underpinning the methodological approaches taken in 
this mixed methods, three phase study. The principles of psychometric testing of 
health measurement scales, specifically reliability and predictive validity testing, are 
discussed alongside the methods used for the Phase I and Phase II quantitative 
studies. The qualitative research tradition of grounded theory is presented and 
discussed in relation to the methods that were followed for the Phase III qualitative 
study. The ethical considerations of the research are also addressed in this chapter.  
 
Chapter 4 presents the first of two quantitative phases of the study. Phase I tested 
the reliability of the Cancer Appetite and Symptom Questionnaire (CASQ). In this 
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chapter the results of such testing are described and statistically analysed. Findings 
are then discussed in the context of the existing literature and conclusions as to the 
reliability of the CASQ are drawn. 
 
Chapter 5 describes the second quantitative study, Phase II. To determine the 
predictive validity of the CASQ, as a screening instrument for weight change in 
people with cancer, results from this longitudinal, observational study were 
statistically analysed. Specifically, Receiver Operating Characteristic (ROC) curves 
were used to determine the optimal cut points, sensitivity and specificity of the 
CASQ. In addition, the performance of the CASQ at predicting weight loss was 
compared with existing screening instruments. This chapter also contains results 
from exploratory modelling, using multiple linear regression techniques, to 
determine the optimum set of variables that could be included in a screening 
LQVWUXPHQW WR SUHGLFW ZHLJKW ORVV 7KH WHVWLQJ FRQFOXGHV ZLWK D &R[¶V UHJUHVVLRQ
survival analysis to determine the ability of the CASQ, and other measured 
variables, at predicting survival. This chapter ends with a discussion of the results, 
focusing on the use of the CASQ as a predictor of weight loss in the cancer 
population. 
 
Chapter 6 reports the qualitative study which explored and analysed the 
experiences of people with cancer and their carers. This qualitative, Phase III study 
followed the principles of grounded theory and used semi-structured interviews as a 
data collection method. Key categories are discussed along with a substantive 
theory of the influences on weight change in people with cancer.  
 
Chapter 7 brings together the discussion from all three phases of the study. Final 
conclusions are drawn in terms of the conceptual framework and optimum 
screening instrument that can be used in clinical practice to predict weight loss in 
people with cancer. Consideration is given to the limitations of this study as well as 
the implications for practice and recommendations for future research. 
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CHAPTER 2: LITERATURE REVIEW 
 
Over recent years there has been a significant increase in research investigating 
weight loss and the cachexia syndrome in people with cancer. In addition, 
development of screening instruments to identify people at risk of malnutrition has 
been widespread. The aim of this chapter of the thesis is to provide an overview and 
critical appraisal of the literature within the field of malnutrition and cancer cachexia, 
as well as identifying and discussing the strengths and weaknesses of existing 
screening instruments.  
 
2.1 Introduction 
It is estimated that worldwide approximately 11 million people are diagnosed with 
cancer each year, with a suggested prevalence of 24.6 million (Parkin et al., 2005). 
Across the globe, incidence rates of specific cancers vary, with environmental, 
genetic and lifestyle factors contributing to the risk of developing the condition. In 
the U.K. the four most commonly diagnosed cancers, which contribute to just over 
half of all new diagnoses, are breast (16%), lung (13%), colorectal (13%) and 
prostate (12%) (Cancer Research U.K., 2009). The prognosis for patients 
diagnosed with these types of cancers is improving (Office for National Statistics, 
2009). However, five year survival for those with lung, oesophageal and pancreatic 
cancer remains at less than 10% (Office for National Statistics, 2009).  
 
Irrespective of the type of cancer, the impact on the person physically and 
psychologically is significant, with the range of symptoms experienced being 
associated with the site and stage of the disease (Reeve et al., 2009). In addition, 
the treatments provided to cure or palliate the disease frequently add to the 
symptom burden, increasing the risk of malnutrition and impacting considerably on 
quality of life (Ozturk et al., 2009; Saffiedine et al., 2009).  
 
2.2 Incidence of malnutrition  
Malnutrition has been defined as a deficiency [or excess] of macronutrients and/or 
PLFURQXWULHQWVZKLFKKDVDQDGYHUVHHIIHFWRQ WKHERG\¶VSK\VLRORJLFDOPHWDEROLF
and functional capacity (NICE, 2006). There is no consensus to the specific 
elements, and the levels of deficiency or loss which define malnutrition (Meijers et 
al., 2009). Thus, in this thesis, the term malnutrition will be used when referring to a 
deficiency of nutrients, resulting in a loss of body mass.  
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Recent figures suggest that globally, the number of people suffering from 
malnutrition is estimated to be in excess of 1.02 billion (Food and Agriculture 
Organisation of the United Nations (FAO), 2010). By far the majority (>90%) of 
these people live in Africa or Asia where economic, environmental and political 
factors contribute to this devastating condition. People in developing countries 
frequently suffer from a combination of protein energy malnutrition and micronutrient 
deficiencies, for example, iron, vitamin A and zinc. In the more developed countries 
of the world, the incidence of malnutrition in the general population is lower, with the 
condition being more frequently associated with the presence of clinical conditions 
such as cancer. Within the U.K. protein energy malnutrition appears to be most 
predominant with specific micronutrient deficiencies being less commonly reported. 
 
Over recent years there has been an increase in the level of research conducted to 
identify the incidence of malnutrition, particularly in populations that are most at risk, 
such as those with chronic diseases. However, due to its complexity, there is no 
single test to diagnose malnutrition and this has made determining its prevalence a 
challenge. It also means that comparison of incidence rates and trends need to be 
interpreted with caution. More recently the following criteria have been suggested to 
identify people who are at risk of the condition (NICE, 2006):   
 Body mass index (BMI) less than 18.5kg/m2. 
 Percentage weight loss of greater than 10% over the previous 3 to 6 months. 
 BMI less than 20kg/m2 and percentage weight loss between 5 and 10% over 
previous 3 to 6 months. 
 
To determine the extent of the problem within the U.K., for the last three years, the 
British Association for Parenteral and Enteral Nutrition (BAPEN) has coordinated 
the collection of data to establish the incidence of malnutrition in hospitals, care 
homes and mental health units. The most recent figures, from the screening of 
5,888 people, suggest that one in three people admitted to hospital or a care home, 
and one in five admitted to a mental health unit, are affected by the condition 
(BAPEN, 2009). Research in the 1990s concluded that 40% of adults admitted into 
hospital were malnourished (McWhirter and Pennington, 1994). This data suggests 
that there has been little change in the prevalence of malnutrition over the last two 
decades. Acute illness is unlikely to explain this incidence alone and so it is 
probable that within the U.K. community, malnutrition is widespread. Analysis of the 
data collected by BAPEN also suggests that in addition to older age influencing 
nutritional status, certain clinical diagnoses are associated with a higher incidence. 
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For example, of those with cancer, 40% admitted to hospital and 55% admitted into 
care homes were malnourished (BAPEN, 2009). These figures imply that this 
particular disease leads to an increased risk of malnutrition, with previous studies 
suggesting that people with cancers of the upper GI tract are at higher risk from the 
condition (Segura et al. 2005; Read et al., 2006; Bozzetti, 2009). Local research in 
Nottingham, using the National Institute for Health and Clinical Excellence (NICE) 
(2006) criteria for malnutrition, also supports these findings, concluding that 58% of 
people, within four months of diagnosis with upper GI cancer, are malnourished 
(Halliday et al., 2009). In addition, a high prevalence of malnutrition has also been 
found in people with lung cancer (Kisner, 1982; Bozzetti, 2009). Locally, using the 
NICE criteria, 36% of people at the time of diagnosis with lung cancer have been 
shown to be malnourished (Chauhan et al., 2007). 
 
2.3 The cancer cachexia syndrome and malnutrition 
The cachexia syndrome is important in the aetiology of malnutrition in people with 
cancer (Tisdale, 2002). It is also experienced by those with other conditions such as 
AIDS, chronic obstructive pulmonary disease and end-stage cardiac and renal 
failure (Von Haehling et al., 2009; Marks, 2009). Cachexia is a complex, multi-
factorial syndrome, often defined in terms of loss of body weight. To date there is no 
agreed definition of the condition. Recently, in an attempt to overcome this issue, a 
group of experts proposed the following clinical definition of cachexia (Evans et al., 
2008):  
 
³&DFKH[LD LV D FRPSOH[ PHWDEROLF V\QGURPH DVVRFLDWHG ZLWK XQGHUO\LQJ
illness and characterized by loss of muscle with or without loss of fat mass. 
The prominent clinical feature of cachexia is weight loss in adults (corrected 
for fluid retention) or growth failure in children (excluding endocrine 
disorders). Anorexia, inflammation, insulin resistance and increased muscle 
protein breakdown are frequently associated with cachexia. Cachexia is 
distinct from starvation, age-related loss of muscle mass, primary 
depression, malabsorption and hyperthyroidism and is associated with 
LQFUHDVHGPRUELGLW\´ 
 
In conjunction with this definition, the following diagnostic criteria have been 
proposed (Evans et al., 2008): 
Weight loss of at least 5% body weight in the previous 12 months, or a BMI of less 
than 20kg/m2, plus three of the following:  
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 decreased muscle strength 
 fatigue 
 anorexia 
 low fat-free mass index  
 abnormal biochemistry (increased inflammatory markers: C-Reactive Protein 
or interlekin-6, anaemia: haemoglobin less than 12g/dL, or a low albumin of 
less than 3.2g/dL)  
These criteria for diagnosis are more comprehensive than those previously used. 
For example, involuntary weight loss of greater than 5% in the preceding six 
months, with no other clinical cause, has been suggested by some clinicians (Inui, 
2002), while others also require the presence of anorexia (Strasser and Bruera, 
2002).  
 
The significance of identifying patients who are in a pre-cachectic state has recently 
been discussed in the literature (Muscaritoli et al., 2009). Identification of patients at 
this stage may mean that interventions can be initiated earlier, helping to prevent or 
slow the progression of some of the devastating consequences of the cachexia 
syndrome. The proposed criteria for diagnosing pre-cachexia are the presence of a 
chronic disease accompanied by (Muscaritoli et al., 2009):  
 weight loss of 5% or less in the previous six months 
 a recurrent or chronic inflammatory state 
 anorexia or anorexia related symptoms  
Within the research and medical community, a consensus definition with clinically 
workable diagnosis criteria for pre-cachexia and cachexia, will strengthen research 
efforts and improve the care of patients. 
 
Variability in the diagnosis of cachexia has impacted on prevalence studies and the 
capacity to establish the incidence of cachexia in the cancer population. Allowing for 
the absence of an agreed definition, research suggests that those people with 
gastrointestinal, head and neck or lung cancer are at most risk from the condition, 
this being due to the high prevalence of weight loss in these patient groups (Laviano 
et al., 2005). Recent work by Fox and colleagues (2009), following retrospective 
case note comparison using four definitions of cachexia, found that 23% of patients 
experienced the syndrome at some point during their cancer journey (Fox et al., 
2009). In this particular study there was a high proportion of patients with breast, 
colorectal and prostate cancer included in the sample. This could therefore be an 
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underestimation of the cachexia incidence, particularly in the lung and upper GI 
cancer groups. 
  
2.3.1 Metabolic mechanisms of cachexia 
Primary cachexia is the term given to the metabolic changes that occur within the 
body in response to a tumour (Strasser and Bruera, 2002). The result is systemic 
inflammation and weight loss ensues, even in those people whose food intake 
remains normal (Tisdale, 2009). During uncomplicated starvation, after an initial 
SHULRG RI DGDSWDWLRQ WKH ERG\¶V UHVSRQVH LV D SUHVHUYDWLRQ RI OHDQ ERG\ PDVV
utilisation of lipid as an energy source and an overall decrease in resting energy 
expenditure (REE). In cachexia the response is very different as there is a 
prolonged increase in skeletal muscle protein catabolism and an overall decrease in 
protein synthesis. This is accompanied by insulin resistance and an increase in 
lipolysis resulting in reduced adipose stores (Tisdale, 2009). This cascade of 
PHWDEROLF FKDQJH LV VLPLODU WR WKH ERG\¶V UHVSRQVH WR WUDXPD LQMXU\ RU VHSVLV
(Desborough, 2000). In people with cachexia REE has also been seen to be 
affected. Dependent on the site of the tumour, REE may be increased, decreased or 
remain unchanged (Tisdale, 1997). When REE is increased, whether there is an 
overall increase in total energy expenditure remains an area for debate. It is likely 
that in people, particularly with advanced disease, physical activity levels will be 
lower and potentially, due to a reduced food intake, energy required for diet induced 
thermogenesis will be less. Few research studies have been conducted to confirm 
this belief. Those that have use small sample sizes, no doubt in part due to the 
challenges involved in measuring energy expenditure in this vulnerable population. 
In patients with pancreatic and lung cancer, research suggests that, despite an 
increase in REE, total energy expenditure is not altered (Gibney et al., 1997; Moses 
et al., 2004). At a molecular level it has also been postulated that in patients with 
cancer, a shift from aerobic to less nutrient efficient anaerobic energy production in 
K\SR[LFWLVVXHUHVXOWVLQZDVWDJHRIµIXHO¶DQGHQVXLQJZHLJKWORVV7LVGDOH 
 
There are several known mechanisms by which these metabolic changes of 
cachexia occur (Figure 2.1) (Tisdale, 2009). Pro-inflammatory cytokines, including 
tumour necrosis factor-alpha (TNF-Į LQWHUOHXNLQ-1 (IL-1), interleukin-6 (IL-6) and 
interferon gamma are released by the host cells in response to the tumour (Argilés 
et al., 2003). These humoral factors act as mediators of inflammation, one of their 
roles being to initiate the release of positive acute phase proteins from the liver such 
as C-Reactive Protein. Circulating levels of albumin, a negative acute phase protein, 
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are decreased. Additionally, cytokines, specifically IL-1 and TNF-Į KDYH EHHQ
shown to induce cancer related anorexia (Argilés et al., 2006). It has also been 
demonstrated that some play a role in protein degradation in skeletal muscle 
through an increase in expression of the ubiquitin-proteasome proteolytic pathway 
(Tisdale, 2009). Furthermore, lipid metabolism is said to be influenced by the 
presence of IL-6 and TNF-Į0DQ]DWRDQG5RPDQDWR,QDGGLtion to humoral 
factors, it is also probable that mediators released by the tumour play a role in the 
observed metabolic changes. Research has shown that proteolysis-inducing factor 
(PIF) enhances the catabolism of skeletal muscle into constituent amino acids 
(Tisdale, 2009). Lipid-mobilising factor (LMF), which is also released by tumours, 
leads to the lipolysis of adipose tissue into free fatty acids and glycerol (Laviano et 
al., 2006). Research is ongoing to determine additional actions of humoral and 
tumoral mediators.  It is important to consider the complexity of this area of science, 
the majority of our understanding is derived from in vitro studies and animal models. 
Whether this translates directly to humans needs further investigation. 
 
 
 
 
Figure 2.1: Metabolic mechanisms of cachexia contributing to weight loss (Adapted 
from Argilés et al., 2005). A solid line demonstrates where evidence exists to 
support the mechanism, a dotted line where the evidence is inconclusive. 
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2.3.2 Symptoms associated with the cachexia syndrome 
Patients who have cancer experience numerous symptoms. A systematic review by 
Teunissen and colleagues (2007) found that in patients with incurable cancer, 37 
different symptoms were described in the literature. The five most commonly 
reported, experienced by half of all patients, were fatigue, pain, lack of energy, 
weakness and anorexia. These symptoms, with the exception of pain, are 
commonly reported as part of the cachexia syndrome (Inui, 2002). In addition, 
psychological disturbances have also been associated with the syndrome. Overall, 
the occurrence of symptoms may be attributable to the physical presence of the 
tumour, including the metabolic mechanisms of cachexia, or as a side effect of 
surgery, chemotherapy, radiotherapy and other pharmacological management 
strategies. It is also clear that symptom burden, defined as the patient-reported 
experience of symptoms and their impact on activities of daily living and quality of 
life, may vary between individuals and at different stages of the disease trajectory 
(Davis and Kirkova, 2008).  
 
Many studies have investigated the prevalence of single and multiple symptoms in 
cancer (Cooley, 2000; Teunissen et al., 2007; Bovio et al., 2009). In addition, 
research has demonstrated how symptoms may predict factors such as physical 
function and clinical outcomes (Dodd et al., 2001; Walsh et al., 2002). More recently 
the focus has turned to the existence of symptom clusters. Fan and colleagues 
(2007) defined a symptom cluster as two or more concurrently occurring related 
symptoms, with or without a common cause. Findings from their review of the 
literature showed that several studies had been conducted which investigated the 
symptom clusters seen within specific cancer types as well as the collective 
disease. Although there were some similarities between the types of clusters seen, 
particularly ones associated with gastrointestinal symptoms, mood and pain, it was 
clear that methodological difference regarding the tools used for assessment and 
statistical analysis meant that findings needed to be interpreted with caution. 
Furthermore, there is discrepancy within the literature as to the number of 
symptoms comprising a cluster. It is likely that further research in this area will lead 
to an improved understanding of symptom clusters, which in turn may help to guide 
treatment within clinical practice. 
 
2.3.2.1 Anorexia  
Anorexia, which can be defined as a pathologically persistent loss of the desire to 
eat, is intertwined with the cachexia syndrome (Wilcock, 2006). Research suggests 
13 
 
that the number of people with cancer experiencing anorexia is high, with more than 
50% of patients with incurable disease reporting the symptom (Teunissen et al., 
2007). The pathophysiology of anorexia is complex and not fully understood. Food 
intake is controlled primarily by the hypothalamus, specifically the arcuate nucleus 
(Figure 2.2) (Laviano et al., 2003). Peripheral signals regarding food intake, energy 
balance and adiposity status are received by the brain via the circulatory system. 
Within the hypothalamus these signals are transformed into neuronal responses. 
The metabolic and behavioural responses are then triggered through second order 
neuronal pathways (Laviano et al., 2003). Some signals such as insulin and ghrelin 
stimulate energy intake. Other signals such as peptide YY, leptin and 
cholecystokinin (CCK) inhibit energy intake. Under normal circumstances, when 
there is a negative energy balance, orexigenic (pro-phagic) neurones within the 
hypothalamus are stimulated and anorexigenic (anorexia inducing) neurones are 
inhibited leading to an increase in the desire to eat (Wilcock, 2006). It appears that 
in cachexia, cytokines directly, and indirectly via serotonin, play a role in the 
deregulation of the hypothalamic response, inhibiting the orexigenic neuropeptides 
and stimulating the anorexigenic neuropeptides (Laviano et al., 2003).  This leads to 
an increase in anorexic signalling, resulting in a reduced food intake, which 
contributes to the decrease in body weight. Overall, research suggests that anorexia 
in people with cancer is associated with reduced survival (Heismayr et al., 2009). 
 
Figure 2.2: Hypothalamic regulation of appetite in cachexia (Adapted from Inui, 
2002 and Laviano et al., 20 05). Pathways involved in the regulation of appetite in 
the arcuate nucleus of the hypothalamus in cachexia are shown. POMC, pro-
opiomelanocortin; NPY, neuropeptide Y. 
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2.3.3 Psychosocial factors associated with the cachexia syndrome 
In addition to the impact of the metabolic changes and symptom burden on patients 
with cachexia, the psychosocial aspects of the condition should not be forgotten. 
Indeed, more than 50% of people with advanced cancer express concern over 
weight loss, anorexia and eating (Hopkinson et al., 2006). For many people eating is 
a pleasurable experience and a social occasion. Research suggests that a loss of 
desire to eat results in meal times and eating becoming a chore (Hopkinson and 
Corner, 2006). In addition, embarrassment may result from uncontrolled symptoms 
or an inability to eat an adult portion. Studies have also shown the impact of 
anorexia on those caring for people with cancer (McClement et al., 2004). Poole 
and Froggatt (2002) describe the conflict between patients and family members. 
Keen to give advice and encouragement, carers often feel guilty at not being able to 
help or get frustrated with an inability to imSURYH WKH SHUVRQ¶V IRRG LQWDNH DQG
nutritional status. Patients also express guilt at not being able to eat the food that 
has been prepared for them, or at being unable to help themselves to feel stronger 
and get better. A change in, or a loss of identity, can also be difficult for both patient 
and carer to adjust to. For example, a wife who has always carried out the domestic 
duties within the home, once diagnosed with cancer, if experiencing a loss of 
function and independence, may no longer be able to fulfil this role (Locher et al., 
2009). Furthermore, in some cases concern may be related to body image. To both 
the patient and the family or carers, weight loss can be a constant reminder of the 
illness and when excessive, it is often associated with disease progression and 
proximity to death (Hopkinson, 2006).  
 
2.4 Consequences of the cachexia syndrome and malnutrition 
The physical effects of the cachexia syndrome manifest as malnutrition, alongside 
which, is a change in body composition (Fouladiun et al., 2005). When cachexia is 
present, the changes in body composition appear different to those experienced by 
people exposed to simple starvation, or the condition of age-related muscle wasting 
termed sarcopenia (Sergi et al., 2006). In simple starvation, lean body mass is 
preserved and adipose stores are used as an energy source. Put simplistically, 
when energy requirements exceed energy intake, weight loss ensues. This state 
however, can be reversed when energy intake is restored (Sergi et al., 2006).  Age-
related sarcopenia occurs in the older population and is a consequence of complex 
interactions of internal and external factors. An altered anabolic hormone profile, 
increase in oxidative stress, alongside reduced mobility and oral intake, go some 
way to explaining the pathophysiology (Muscaritoli et al., 2009). In addition, pro-
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inflammatory cytokines, often associated with co-morbidities, are also likely to play a 
role. The resulting effect is a loss of lean body mass and associated reduction in 
physical function. In people with cachexia, body weight reduction occurs as a result 
of the metabolic factors and symptoms previously discussed. Importantly, the 
observed loss of lean body mass and fat mass, may be resistant to treatment (Sergi 
et al., 2006). Noteworthy at this point, is the incidence of sarcopenic obesity in the 
cancer population. Defined as obesity alongside depleted lean body mass, Prado 
and colleagues (2008) have demonstrated the increased risks for this group of 
people in terms of loss of function and mortality. The added threat within this 
population is that the signs and symptoms of the cachexia syndrome and 
malnutrition may be masked by obesity and, as a consequence of late detection, 
treatment interventions could be delayed.  
 
Loss of lean body mass and malnutrition, whether due to the cachexia syndrome, 
starvation or age-related sarcopenia, have significant systemic consequences. Due 
to ethical issues, research into the effects of malnutrition in humans is limited, and is 
mainly reliant on studies carried out on conscientious objectors, individual case 
studies and those, often political prisoners, who choose voluntary total fasting (Altun 
et al., 2004; Kalm and Semba, 2005; Sidiropoulos, 2007). In addition, 
epidemiological work has added to our understanding of the macronutrient and 
micronutrient deficiencies seen in developing countries (Muller and Krawinkel, 
2005). Specifically, in people who are malnourished, respiratory muscle weakness 
can result in breathlessness and difficulty expectorating. This can lead to an 
increased risk, or exacerbation, of a chest infection (Rochester and Esau, 1984). 
Compromised cardiovascular function, resulting from myocardial atrophy, can cause 
a reduced cardiac output, poor tissue perfusion and hypotension (Webb et al. 1986). 
Following less than a week of fasting, mucosal cell atrophy within the 
gastrointestinal tract can be seen (Hernandez et al., 1999). This can theoretically 
lead to an increased risk of bacterial translocation from the gastrointestinal tract, 
infection and sepsis. Reduced gastric and pancreatic exocrine function can also 
impair digestion. Furthermore, in patients with cardiac cachexia it has been 
suggested that impaired gastrointestinal function, due to oedema and poor 
perfusion, can result in fat and protein malabsorption (Celik et al., 2009). 
Malnutrition is quite clearly associated with immunodeficiency, with an increased 
risk of infection (Macallan, 2009) and delayed wound healing (Stechmiller, 2010). 
Thermoregulation is also affected by low body weight leading to an increased risk of 
hypothermia (Mansell et al., 1990). Psychologically the malnourished patient can 
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experience an array of symptoms including fatigue and exhaustion, deterioration in 
intellectual function, apathy, changes in behaviour and personality, low mood or 
depression (Kalm and Samba, 2005). All of these factors lead to an increase risk in 
terms of morbidity and mortality (Norman et al., 2008). More specifically, in people 
with cancer, conclusive evidence exists to demonstrate that those who lose weight 
have poorer treatment outcomes, extended hospital stays, reduced quality of life 
and an adverse prognosis (DeWys et al., 1980; Shaw-Stiffel et al., 1993; Andreyev 
et al., 1998; Capuano et al., 2008; Nourissat et al., 2008; Swinton et al., 2008). 
Although no conclusive data is available to determine the mechanisms by which 
cachexia causes death, it is likely that cardiovascular insufficiency plays a key role 
(Lainscak, 2009).  
 
2.5 Management of the cachexia syndrome and malnutrition 
There is no agreed management strategy for the treatment of cachexia. It is evident 
that to successfully treat the condition all elements; metabolic, symptomatic and 
psychosocial issues, will need to be addressed. Research is ongoing as to which 
management strategy; pharmacological, nutritional, exercise, or combination, will be 
most effective in alleviating the symptoms. 
 
2.5.1 Pharmacological management 
As the cachexia syndrome is multi-factorial it is unlikely that one drug will be able to 
combat the condition. Indeed, research into the pharmacological management 
focuses on the different aspects of the syndrome, resulting in four broad 
approaches to treatment; drugs used for the control of exacerbating symptoms, 
appetite stimulants, inflammatory and metabolic modulators aimed at addressing 
the observed metabolic changes and anabolic agents (Argilés et al., 2010).  
 
To improve nutritional status, the first step should be to address and treat any 
V\PSWRPVZKLFKPD\EHLPSDFWLQJRQWKHSDWLHQW¶VDELOLW\WRWDNHRUDOQXWULWLRQDQG
fluids. Treatment of symptoms such as pain, constipation, nausea and vomiting are 
well understood and in general appropriately addressed. However, other common 
symptoms in people with cancer, such as early satiety, impaired taste or a sore 
mouth can be missed. Prokinetics, primarily metoclopramide, promote gastric 
emptying and, in addition to treating nausea and vomiting, can improve appetite and 
food intake (Von Roenn, 2002). Taste may be impaired due to the tumour, anti-
cancer treatments or simply poor mouth care. Good oral hygiene is essential to 
prevent infections such as oral candidiasis, mouth ulcers, mucositis and a dry 
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mouth, all of which are common in this patient group (Brown et al., 2009). If present, 
these symptoms should be treated with a systemic antifungal such as fluconazole, 
topical corticosteroids, benzydamine mouthwashes and, for a dry mouth, pilocarpine 
and artificial saliva (Andrews et al. 2007). Also, there is some, albeit limited 
evidence to suggest that zinc deficiency may cause altered taste, and in some 
patients zinc supplementation may be indicated (Andrews et al., 2007). 
 
Several drugs have been investigated as appetite stimulants to treat anorexia. The 
most frequently studied are the corticosteroids (methylprednisolone, prednisolone, 
and dexamethasone) and progestogens (megestrol acetate and 
medroxyprogesterone acetate). Although not fully understood, it is likely that the 
mechanisms by which corticosteroids and progestogens influence appetite is similar 
(Mantovani, 2006). Corticosteroids act by inhibiting prostaglandin and cytokine 
expression. In addition they have an anti-emetic and analgesic effect. Progestogens 
influence the production of pro-inflammatory cytokines and are also thought to 
stimulate appetite by the neuropeptide Y pathway. Although there remains no 
consensus as to the optimum dose or treatment duration for corticosteroids and 
progestogens, a systematic review of the literature concludes that they are the only 
drugs which have the evidence base to support their efficacy in the treatment of 
anorexia (Yavuzsen et al., 2005). Other drugs which have been investigated as 
appetite stimulants include the cannabinoids, in particular oral dronabinol. Research 
suggests that this group of drugs may have some effect on appetite, although when 
compared with megestrol acetate, efficacy was lower (Jatoi et al., 2002). Finally, 
studies into the effect of cyproheptadine, an antihistamine and antiserotonergic, 
have given conflicting results (Yavuzsen et al., 2005).    
 
To manage the metabolic consequences of the cachexia syndrome, the action of 
several drugs has been investigated. Results between studies have been variable. 
As non-steroidal anti-inflammatory drugs decrease the production of prostaglandins 
and suppress cytokine production, theory suggests that they may have an effect on 
the systemic inflammatory response in the cachexia syndrome. Indeed one study 
has shown that ibuprofen, in combination with megestrol acetate, significantly 
increases weight, appetite and quality of life in people with gastric cancer (McMillan 
et al., 1999). However, the adverse gastrointestinal side effects of these drugs 
should be not forgotten and may even aggravate symptoms of anorexia. 
Thalidomide also impacts on the inflammatory response, acting to down-regulate 
the production of the cytokine TNF-Į'HVSLWHSRVLWLYHUHVXOts in people with AIDS, 
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prospective randomised controlled trials in cancer are limited. A small study by 
Gordon and colleagues (2005) suggests that thalidomide may help to stabilise 
weight in patients with advanced pancreatic cancer. Another drug of interest which 
suppresses circulating TNF-Į OHYHOV LVPHODWRQLQ$VWXG\E\/LVVRQL et al. (1996) 
showed that oral melatonin reduces weight loss, however, appetite and nutritional 
intake do not improve. Studies investigating the use of hydrazine sulphate, which 
inhibits hepatic gluconeogenesis and pentoxifylline, an anti-inflammatory drug, have 
failed to show any benefit in patients with cachexia (Loprinzi et al., 1994a; Loprinzi 
et al., 1994b; Goldberg et al., 1995). More recently, the action of insulin sensitisers 
(glitazones) has attracted interest. Insulin resistance is a characteristic of the 
cachexia syndrome and as such means that energy metabolism requires an 
increase in fatty acid utilisation. This in turn is less energy efficient. An incidental 
finding from the PROactive trial studying the use of glitazones in people with type II 
diabetes was a mean weight gain of 3.8kg (Dormandy et al, 2009). Improving insulin 
sensitivity in patients with cachexia may influence the anabolic effects of insulin, in 
addition to optimising peripheral glucose uptake and utilisation (Dohner, 2006). 
The potential for anabolic agents to be used to treat anorexia and cachexia has not 
yet been determined as few studies have been conducted within the cancer 
population. Agents such as growth hormone and testosterone may maintain or 
improve lean body mass in people with cachexia (Mantovani, 2006). In particular, 
oxandrolone, a synthetic anabolic steroid, is currently being studied. Previous 
results from trials of the drug with patients with AIDS related cachexia were 
promising, showing a significant increase in weight, appetite, physical activity and 
strength (Berger, 1996). More recently, when used in combination with megestrol 
acetate, the drug has been shown to preserve lean body mass in patients receiving 
chemotherapy (Lesser et al., 2008). 
 
The overall efficacy and safety of any pharmacological therapy needs to be 
determined. For drugs used to treat anorexia and cachexia, challenges in study 
design mean that it is often difficult to determine whether nutritional status and 
physical function has actually improved. More specifically, if participants are gaining 
lean body mass, fat mass or fluid (Von Roenn, 2006). Psychologically, patients and 
their carers may benefit from any type of weight gain. However, it is an increase in 
lean body mass, and an improved macronutrient and micronutrient intake, that is 
likely to improve physiological and functional capacity. Potential side-effects of the 
drugs must also be considered and in some cases may increase the symptom 
burden to an unacceptable level. It is evident that further prospective randomised 
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controlled trials are needed in all these areas in order to determine an optimal 
pharmacological strategy for the treatment of the cachexia syndrome. 
 
2.5.2 Nutritional Support   
As previously discussed, in people with cancer, there are numerous factors which 
contribute to a sub-optimal nutritional intake. A combination of anorexia along with 
systemic metabolic changes, symptom burden, anti-cancer therapies and the 
psychosocial aspects of the disease put patients at high risk of malnutrition. In an 
attempt to address the consequential increase in morbidity and mortality, U.K. 
national guidelines produced by NICE suggest that nutritional support should be 
considered in all malnourished patients (NICE, 2006). Indeed, within the cancer 
population it is likely that the majority of people at some stage of their illness would 
benefit from nutritional advice. The nature and level of the support will be dependent 
on many factors such as diagnosis, prognosis, function of the gastrointestinal tract, 
tolerance and individual wishes. Interventions should be tailored to the individual 
and may range from advice on food fortification, texture modification, eating patterns 
and oral nutritional supplements to the prescription of artificial enteral or parenteral 
nutrition. Remarkably, the evidence base around nutrition support and cancer 
cachexia is limited with no clear conclusion as to the benefits of providing nutritional 
interventions in this patient group. Furthermore, it has been suggested by some that 
WKHSURYLVLRQRIDUWLILFLDOQXWULWLRQVXSSRUWPD\µIHHG¶WKHWXPRXU$UHFHQWUHYLHZRI
the literature concludes that there is no reliable evidence upon which to base this 
theory (Arends et al., 2006). The following section will discuss how oral and artificial 
nutrition support can be used to treat malnutrition. 
 
2.5.2.1 Oral nutritional support 
The provision of normal food and fluids, with the required practical assistance to 
enable feeding, should be the first stage of providing oral nutritional support (NICE, 
2006). Where nutritional requirements fail to be met, the next step should be food 
fortification using energy and protein dense foods and the provision of nutritious 
fluids (Thomas and Bishop, 2007). As the portion size eaten is likely to diminish in 
anorexic patients, it is also important that the frequency of eating episodes should 
increase. Despite its widespread application, this area of practice lacks a firm 
evidence base. A study by Barton and colleagues (2000) suggests that, within the 
hospital setting, fortification of the diet with energy, and provision of snacks, can 
improve overall energy intake in older patients. Conversely, with a group of 
malnourished nursing home residents, the same type of intervention showed an 
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improvement in protein, but no change to energy intake (Smoliner et al., 2008). 
Overall, in this study, functional status, as measured by physical functioning 
questionnaires, deteriorated. For the free living community population and those 
with cancer it is not clear whether fortification of the diet does improve energy, 
protein and micronutrient ingestion, or if it provides benefit, particularly in terms of 
physical function and quality of life.  
 
Within the U.K., dietitians possess the necessary skills to provide individualised 
dietary counselling to people regarding food fortification. Recent studies in patients 
with cancer investigating the efficacy of dietary counselling are limited, and confined 
to those patients undergoing radiotherapy treatment. In patients with colorectal 
cancer receiving radiotherapy, research suggests that this type of counselling can 
improve energy and protein intake (Ravasco et al., 2005). In this study, quality of 
life, when measured using the European Organisation for Research and Treatment 
of Cancer Quality of Life Questionnaire version 3.0 (EORTC QLQ-C30) (Appendix 
4) , also improved. Furthermore, three months after completion of the radiotherapy 
the benefits remained. The findings from a recent study by Weekes and colleagues 
(2009), in a patient population with chronic obstructive pulmonary disease, concur. 
The results suggest that dietary counselling and food fortification lead to an 
increased energy and protein intake when compared with simple provision of a 
dietary information leaflet. This improvement in intake corresponded to an increased 
weight and improved quality of life score. There was however, no observed increase 
in objective functional measures such as muscle strength and respiratory function. 
In contrast, in a study of patients receiving chemotherapy for lung, breast or ovarian 
cancer, only a non significant increase in weight was detected in the group receiving 
dietary counselling (Ovesen et al., 1993). Although in the same group there was a 
statistically significant increase in triceps skinfold thickness, the conclusion of the 
authors was that there was no clinical benefit of providing dietary counselling in this 
patient group. 
 
For some people, regardless of being counselled on ways to maximise their 
macronutrient and micronutrient intake, the desired increase in food ingestion is not 
achievable. At this point the provision of prescribed propriety oral nutritional 
supplements should be considered (NICE, 2006). An extensive range of nutritionally 
complete oral sip feeds exist. The majority are milk-based sweet drinks although 
juice-style and soups are also available. In addition, powder carbohydrate, fat and 
protein modulars, which can be added into foods and fluids, can be prescribed. 
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Previous evidence suggests that in a malnourished population, when compared with 
routine clinical care, oral nutritional supplement drinks can reduce complications 
and mortality rates (Stratton, 2000). More recently, in adults with illness-related 
malnutrition, a review of the literature investigating the benefit of oral nutritional 
supplements compared with the use of dietary advice showed that nutritional 
interventions can improve anthropometric measures (Baldwin and Weekes, 2008). 
However, findings from the review did not allow for a conclusion to be made in 
terms of which intervention was most effective. Two other systematic reviews which 
investigated the use of nutritional supplements have recently been conducted. Milne 
and colleagues (2009) conclude that in older people who are at risk of malnutrition 
the use of nutritional supplements can lead to a small but consistent increase in 
weight. In contrast, in patients with stable COPD, a review of 14 studies suggests 
that there was no significant effect of nutrition supplementation in terms of improved 
anthropometrics, physical or lung function (Ferreira et al., 2005). Overall, none of 
the reviews found a significant decrease in mortality in those taking nutritional 
supplements. Despite these inconclusive findings, and the small number of studies 
specifically investigating the cancer population, recent guidelines produced by the 
European Society for Parenteral and Enteral Nutrition (ESPEN) propose that in 
patients with cancer receiving radiotherapy, or radio-chemotherapy, there is 
sufficient evidence to support the use of oral nutritional supplements (Arends et al., 
2006). For those patients receiving radiotherapy, this conclusion is based on the 
findings from four small studies, all but one being conducted pre 2000, with a 
combined sample of predominantly patients with head and neck cancer, and from a 
recent meta-analysis (Thiel et al., 1988; Arnold et al., 1989; Nayel et al., 1992; 
Isenring et al., 2004; Elia et al., 2006). More specifically, the meta-analysis 
established that the use of oral nutritional supplements can significantly increase 
energy intake by 381kcal/day (95%CI 193 to 569) (Elia et al., 2006). However, this 
finding should be interpreted with caution as it was calculated using the results of 
only three studies, all conducted in the 1980s, and one of which used elemental 
supplements as treatment. For patients undergoing chemotherapy it is apparent that 
the ESPEN recommendations for the use of oral nutritional support are based on 
expert opinion, rather than on randomised controlled trials. As the reviewed studies 
involved mainly patients with head and neck cancer receiving radiotherapy, it is not 
appropriate for inferences to be made about a population of patients receiving 
chemotherapy, particularly when that treatment is likely to have a palliative intent. 
The main reason for this is the differences between the  patient groups. For those 
22 
 
who have incurable cancer, outcomes will differ as a consequence of disease and 
symptom progression, thus masking the true effects of the trialled intervention.  
 
It is likely that dietary counselling and oral nutritional supplements can be beneficial 
to malnourished patients with cancer. Larger randomised controlled trials are 
needed to determine their efficacy and long term benefits. In addition, studies need 
to focus on the inclusion of patients with a range of cancer diagnoses, stages of 
disease and treatment plans. The use of modular products as well as the sip feeds 
which have traditionally been included in research should also be investigated. 
Furthermore, patient compliance with prescribed supplements has been identified 
as an issue and must be addressed if the benefits are to be optimised (Bruce et al., 
2003). Overall, careful consideration needs to be given to the outcome measures 
chosen to determine the efficacy of the nutritional intervention, and these may differ 
dependent on the population being studied and the stage of their disease. 
 
2.5.2.2 Nutraceuticals 
In addition to food fortification advice, and the use of nutritionally complete 
supplement drinks, the potential benefit of other nutrients has been investigated. 
7KHWHUPµQXWUDFHXWLFDOV¶DULVHVIURPQXWULHQWVEHLQJXVHGDVSKDUPDFHXWLFDODJHQWV
in an attempt to influence the metabolic pathways of the cachexia syndrome 
(Dahele, 2006). Eicosapentaenoic acid (EPA) is a n-3 fatty acid. Research suggests 
that EPA impairs the action of proteolytic inducing factor (PIF) and also down-
regulates the cytokine induced systemic inflammatory response (Barber et al., 
2005). In people with pancreatic cancer, at a dose of 6g a day, EPA capsules have 
been shown to stabilise weight (Barber et al., 2001). In contrast to these results, 
when used in a population of patients with advanced cancer, EPA had no significant 
effect on any of the measured parameters (Bruera et al., 2003). Despite the 
uncertainty within the evidence base, oral nutritional supplement drinks containing 
EPA, for example, Prosure (Abbott Nutrition), are available and can be prescribed 
for people with cancer. To date, published data on their efficacy is confined to those 
with pancreatic cancer. In a randomised control trial conducted by Fearon and 
colleagues (2003), despite poor compliance, there was a significant increase in 
energy intake in those receiving EPA compared with those having a standard 
supplement. Further research is required to establish their usefulness within other 
cancer groups. 
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Synthesis of muscle protein is reliant on an optimal supply of amino acids. In people 
with cachexia circulating serum levels of amino acids, including branch chain amino 
DFLGV%&$$¶VKDYHEHHQVKRZQWREHUHGXFHG1RUWRQet al7KH%&$$¶V
particularly leucine, and to a lesser extent isoleucine and valine, are not only 
important for protein synthesis, they are also a key component in the signalling 
pathways which initiate muscle protein synthesis (Nakashima et al., 2005). Recent 
research using cachectic-tumour induced mice as a model has shown that leucine 
and valine increase protein synthesis and decrease protein catabolism resulting in 
significant suppression of weight loss (Eley et al., 2007).   
 
Increased serotonergic activity in the brain results in a decrease in the desire to eat 
(Davis et al., 2004). Tryptophan, a BCAA, is a precursor to serotonin and therefore 
has a role to play in the pathogenesis of anorexia. Research suggests that in 
response to a tumour, circulating concentrations of tryptophan are increased. This 
results in tryptophan competing with other B&$$¶VWRFURVVWKHEORRGEUDLQEDUULHU
higher levels of serotonin in the brain and ultimately an increase in anorexia 
(Cangiano et al  2UDO VXSSOHPHQWDWLRQ RI FRPSHWLQJ %&$$¶V OHXFLQH
isoleucine and valine) in a small group of people with cancer has been shown to 
significantly reduce anorexia and increase food intake (Cangiano et al., 1996).  
 
The effect of other amino acids on the cachexia syndrome has also been 
investigated. Glutamine, arginine and hydroxy-beta-methylbutyrate (HMB) which is 
a precursor of leucine, have been shown to positively influence protein turnover. In 
a study by May and colleagues (2002) patients with advanced cancer given a 
supplement of glutamine, arginine and HMB showed an increase in fat free mass. 
The exact mechanism for this is not yet understood and further research is required. 
In addition, both glutamine and arginine have been shown to influence the immune 
system, and supplementation of arginine to improve wound healing (Lind, 2004; 
Medina, 2001).   
 
2.5.2.3 Artificial nutritional support 
When macronutrient and micronutrient requirements are unable to be met orally, 
consideration needs to be given to the use of artificial nutrition support (NICE, 
2006). There are two types of artificial nutrition support; enteral and parenteral. 
Enteral nutrition involves the placement of a feeding tube into the stomach or small 
bowel, usually via the nasal cavity or directly through a stoma. A nutritionally 
complete liquid feed is then delivered into the gastrointestinal tract. Parenteral 
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nutrition is the provision of nutrients intravenously via a central or peripherally 
inserted catheter. When the gastrointestinal tract is functioning, enteral feeding is 
regarded as the route of choice (NICE, 2006). However, both forms of nutrition 
support carry some element of risk, such as the possibility of infection or metabolic 
disturbances (Cataldi-Belcher et al., 1983; Gomez et al., 2008). Some authors 
argue that the increased risks associated with parenteral nutrition may have been 
exaggerated with a previous review of the literature suggesting that it is as effective 
and as safe as the enteral route (Jeejeebhoy, 2001). In addition, others have found 
parenteral nutrition to be better tolerated by patients (Bozzetti et al., 2001). 
However, a more recent meta-analysis concluded that in patients with cancer 
having surgery, post-operative enteral tube feeding resulted in a shorter hospital 
stay (1.7 days 95%CI 0.9 to 2.5) and fewer complications (OR 0.62 95%CI 0.50 to 
0.77) compared with parenteral nutrition (Elia et al., 2006).  
 
In people with cancer, based on a review of the literature, the recommendation is 
that enteral nutrition should be commenced when food intake is, or is likely to be, 
less than 60% of requirements for more than 10 days (Arends et al., 2006). The 
same guidelines also state that for patients receiving palliative care, providing they 
are not in the terminal phase of the disease trajectory and that they are in 
agreement, enteral nutrition should be provided to minimise weight loss. There is 
some evidence to suggest that the use of enteral nutrition in patients with head and 
neck or gastrointestinal cancer can stabilise weight (Raykher et al., 2008; Sironi et 
al., 2008). However, there is little evidence to show that body composition or 
functional status is improved. 
 
Recently, guidelines regarding the use of parenteral nutrition in people with cancer, 
based on a review of the literature, have been published. In patients with cancer 
who have a prognosis of more than two to three months, and whose gastrointestinal 
tract is not accessible or is not functioning, parenteral nutrition should be considered 
(NICE, 2006; Bozzetti et al., 2009). It appears that there is evidence to support the 
use of this type of intervention in patients who are unable to be fed enterally. 
However, conclusions on the clinical benefits should be made tentatively. A very 
small study (n=3) of patients with gastric disease showed that compared with before 
parenteral nutrition was initiated, intravenous feeding resulted in a statistically 
significant increase in protein synthesis, although protein turnover remained 
constant (Bozzetti et al., 2000). Another study suggests that in patients receiving 
supportive palliative care, weight and quality of life indices remained stable until 
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death (Bozzetti et al., 2002). It is not clear if the observed weight gain in this study 
was due to an increase in body water, fat or lean mass. In addition, there are still 
questions as to whether this type of therapy results in an improvement in functional 
status. However, in a population where deterioration in nutritional status is almost 
inevitable, maintenance of nutritional and quality of life parameters are likely to be 
appropriate outcomes. 
 
Across Europe there appears to be a vast difference in the provision of parenteral 
nutrition in the cancer population. In 1997 ESPEN conducted a survey investigating 
the number of people from seven E.U. countries who were on home parenteral 
nutrition (Van Gossum et al., 1999). At this time it was clear that the picture in the 
U.K. was very different to that seen in other countries. Only five percent of patients 
in the U.K on home parenteral nutrition had a primary diagnosis of cancer. This was 
much less than in other countries such as The Netherlands where the numbers of 
patients receiving this type of nutrition therapy who had cancer was 60%. The 
survey also suggested that in Germany and Sweden the prevalence was likely to be 
even higher, at 70% and 80% respectively, although overall reporting in these 
countries was said to be below the optimum (Van Gossum et al., 1999). Ten years 
later, the picture does not appear to have changed. Data from 2008 suggests that 
the point prevalence of people receiving home parenteral nutrition in the U.K. was 
6.7/106 (British Artificial Nutrition Survey, 2009). Only six percent of these patients 
had a diagnosis of cancer. Results from a recent study in Italy showed that point 
prevalence of home parenteral nutrition was 31.7/106, with 61% having cancer 
(Pironi et al., 2007). Furthermore, in contrast to the U.K., there appears to be a 
significant number of patients in Italy receiving both parenteral and enteral nutrition 
simultaneously. This is a practice reflected in other countries where patients are 
receiving home parenteral nutrition alongside oral diet and nutritional supplements 
(Orrevall et al., 2009). The reasons behind this disparity in practice are not fully 
understood, although they are likely to be related to differences in culture and 
attitudes of healthcare staff, as well as the economic pressures around funding of 
this intervention (Orrevall et al., 2009). 
 
2.5.3 Exercise 
Skeletal muscle atrophy in patients with cancer may occur as a consequence of the 
cachexia syndrome. The likely cause is a combination of metabolic processes, 
exacerbated by inactivity, resulting in reduced protein synthesis and increased 
protein degradation (Tisdale, 2009). Contractile activity may help in part to attenuate 
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muscle loss by suppressing the local inflammatory response and enhancing insulin 
sensitivity (Ardies, 2002). Exercise has been shown to have a protective effect 
against the loss of muscle fibre by inhibiting the pathways used to cause muscle 
atrophy (Sandri et al., 2006). Research suggests that a therapeutic exercise 
programme can help to promote physical, as well as psychological well being in 
people with cancer (Oldervoll et al., 2004; Oldervoll et al., 2006; Velthuis et al., 
2010). Within the literature the majority of studies, using both home-based and 
aerobic exercise programmes, appear to have been done with patients who have 
non metastatic breast or prostate cancer (Velthuis et al., 2010). There remains a 
lack of research looking at therapeutic exercise in people with incurable lung, upper 
GI, and advanced cancer, particularly, those with a poorer performance status. This 
may, in part, be due to the symptom burden experienced by this group, and difficulty 
in adherence to activity programmes.  
 
An alternative to physical activity programmes in people with cancer is 
neuromuscular electrical stimulation (NMES). In people with chronic obstructive 
pulmonary disease NMES has shown positive results in improving muscle strength, 
endurance and quality of life (Neder et al., 2002). Research is ongoing into the 
effect of NMES in people with lung cancer (Maddocks et al., 2006). 
 
2.5.4 Supportive care 
As discussed earlier, the psychosocial aspects of malnutrition and cachexia are 
important to consider. Supportive care, in this instance, is the term used to help 
people with cancer, their families and caregivers cope with the symptoms of the 
cachexia syndrome. Hopkinson (2007) suggests how supportive care should be 
managed, highlighting the need for assessment of the situation, acknowledgement 
and normalisation of the problem, provision of information and ongoing support in 
managing conflict and change or loss of identity. Rosenbaum and colleagues (2004) 
share this view and report how a cancer supportive care programme improved the 
satisfaction and quality of life of patients in their locality. In particular, participants 
reported an improved sense of wellbeing, increase in energy and feelings of 
empowerment. Noteworthy is the sometimes controversial use of complementary 
and alternative medicine in cancer care. There is evidence to suggest that for some 
people, use of this type of therapy may improve physical and psychological 
symptom burden, (Jacobsen et al., 2000) with reflexology and aromatherapy being 
some of the most commonly used treatments (Gage et al., 2009). However, a 
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review by the NICE suggests that overall, conventional evidence to their benefit is 
lacking (NICE, 2004). 
 2.6 Screening for malnutrition and cachexia 
Whatever the management strategy of choice for malnutrition and cachexia, early 
identification of people at risk and timely intervention is vital. Although there are 
screening tools that individually screen for malnutrition, adverse symptoms and 
systemic inflammation, to date there is no one simple and practical tool that 
encompasses all aspects of the cachexia syndrome. The subsequent sections will 
focus on the screening instruments which are most frequently discussed in the 
literature, in relation to the cancer population. 
 
2.6.1 Screening for malnutrition 
Within the literature there appears to be some confusion as to the definition of 
nutritional screening and nutritional assessment. To clarify, screening and 
assessment as defined by the British Dietetic Association (1999) are as follows: 
³1XWULWLRQDO VFUHHQLQJ LV D simple and rapid process of identifying clinical 
characteristics known to be associated with malnutrition. The screening 
process is intended to identify individuals who are at risk of becoming 
malnourished and who require referral to a state registered dietitian for a 
FRPSUHKHQVLYHQXWULWLRQDODVVHVVPHQW´ 
 
³1XWULWLRQDl assessment is a comprehensive process of identifying and 
evaluating the nutritional status of an individual using appropriate, 
measurable methods. It consists of gathering data using four main 
techniques: history taking, nutritional anthropometry, physical examination 
and biochemical tests. Nutritional assessment is able to quantify impairment 
RIQXWULWLRQDOVWDWXV´ 
 
Within the U.K, in an attempt to combat the absence of awareness of malnutrition in 
both the hospital and community settings, recommendations on screening practices 
were made by The National Institute for Health and Clinical Excellence. The 
guidelines state that all patients admitted to hospital should be screened for risk of 
malnutrition, at admission and weekly thereafter (NICE, 2006). In addition, out-
patients should be screened at their first appointment, as should new registrants at 
G.P. practices. Finally, all people entering a care home should be screened on 
admission and, as in all other settings, when there is clinical concern. The 
guidelines suggest that the screening process should involve measurement of body 
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mass index and percentage unintentional weight loss over time, plus whether there 
has been, or is likely to be, a reduced food intake. The Malnutrition Universal 
Screening Tool (MUST) (Appendix 5) is given as an example of an instrument that 
could be used. 
 
As will be discussed in Chapter 3, development of any screening instrument is a 
complex and lengthy process. The ultimate aim of a tool is for it to be successfully 
implemented into clinical practice. For this to happen, it should be quick and easy to 
use, and have proven reliability and validity. Over the last two decades numerous 
screening instruments have been developed to identify people at risk of malnutrition. 
A review of the literature by Green and Watson (2005) found published information 
on 71 different screening/assessment instruments for malnutrition. Most of the 35 
reviewed instruments incorporated anthropometric measurements such as weight 
change. In view of the difficulties involved in weighing some patients, other 
instruments used a subjective assessment of body weight or mid upper-arm 
anthropometry as an indicator of muscle mass. Factors associated with nutritional 
intake and nutritional requirements, such as presence of disease or symptoms were 
also included in other tools. Most instruments used a scoring system to identify 
those at risk of malnutrition although some relied on a subjective assessment of 
risk. Since an agreed definition and gold-standard test for malnutrition do not exist, 
consensus on the most appropriate instrument, and if it is indeed identifying those at 
risk of malnutrition, is limited (Green and Watson, 2005; Meijers et a., 2009). The 
ambiguity around the condition also makes it difficult to compare the outcomes from 
previous research studies where definitions may differ. Furthermore, the use of 
diverse methodologies and limited statistical analysis included in some papers 
hinder the process further (Green and Watson, 2005).  
 
To date, only a handful of tools have been validated for use specifically with people 
who have cancer. As studies are limited, and due to the heterogeneity of the cancer 
diagnosis, these instruments should be viewed and used with caution until more 
thorough testing within a range of tumour types is conducted. A universal 
consensus definition amongst experts as to what constitutes malnutrition will benefit 
this area of research. 
 
2.6.1.1 Subjective Global Assessment 
Subjective global assessment (SGA) (Appendix 6) was first validated as a screening 
tool to detect malnutrition in 1987, with the original study investigating its use in 
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patients undergoing gastrointestinal surgery (Detsky et al. 1987). The SGA is 
designed to be completed by the health care professional. Five questions relating to 
change in weight, change in food intake, gastrointestinal symptoms, functional 
capacity and disease-related metabolic stress are followed by a physical 
examination to determine muscle and adipose status and fluid balance. Patients are 
subjectively categorised as well nourished, moderately malnourished or severely 
malnourished. More recently the SGA has undergone validity testing in an in-patient 
palliative care setting (Thoresen et al., 2002). Comparing the results of the SGA to 
objective anthropometric and serum protein measurements to identify malnutrition, 
the sensitivity and specificity of the SGA was 96% and 83% respectively. However, 
consideration must be given to the small sample size (n=46), the high incidence rate 
of malnutrition (61%) and the fact that only one observer was used. The predictive 
validity of the SGA has also been investigated in people with advanced colorectal 
and ovarian cancer (Gupta et al., 2004; Gupta et al., 2008).  In both groups there 
was a significantly shorter prognosis for patients who were identified as being 
severely malnourished by SGA compared with those classified as well nourished.  
 
2.6.1.2 Patient Generated Subjective Global Assessment 
In order to improve the sensitivity of the SGA, particularly in measuring changes in 
nutritional status over short periods of time, the tool was adapted to form the patient 
generated subjective global assessment (PG-SGA) (Appendix 7) (Ottery, 1994).   
This modification was made, in part, to improve the use of the tool within the 
oncology setting. The content of the PG-SGA is similar to the SGA, including 
questions about recent weight change, food intake, symptoms, activity and function 
which are self-completed by the patient. The physical assessment, subjective 
classification of the degree of risk and scoring are then completed by a health care 
professional. The PG-SGA has been shown to have demonstrated validity and inter-
rater reproducibility when used with in-patients with cancer, oncology patients 
receiving radiotherapy and medical oncology patients attending a day unit (Bauer et 
al., 2002; Isenring et al., 2003; Read et al., 2005). The need to perform a physical 
examination  in order to complete both the SGA and the PG-SGA can be time 
consuming, and this, coupled with the need to be trained in its use, has meant that 
implementation of either tool within clinical settings in the U.K. has been limited.  
 
A recent study by Stoyanoff and colleagues (2009) tested an abridged version of the 
PG-SGA (ab-PG-SGA) (Appendix 8). The results suggest that this shorter, less 
complex screening instrument, when tested in an oncology out-patient setting with 
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patients undergoing chemotherapy, has a comparable sensitivity and specificity to 
the PG-SGA. Although further testing in other cancer groups is necessary, these 
findings may influence use of the ab-PG-SGA within U.K. oncology out-patient 
clinics. 
 
2.6.1.3 Malnutrition Screening Tool 
The malnutrition screening tool (MST) (Appendix 9) was developed in Australia and 
has been validated against the SGA in patients with cancer receiving radiotherapy 
and against the PG-SGA in people being treated with chemotherapy (Ferguson et 
al., 1999; Isenring et al., 2006). Unlike the SGA and PG-SGA the MST is simple and 
quick to complete, although it provides little information in terms of food intake, 
symptoms and function. The MST takes a three step scored approach. Patients are 
asked if they have recently unintentionally lost weight, if so, how much and if they 
have a reduced food intake due to a decrease in appetite. A score of two or more, 
derived from a weight loss of greater than six kilograms, or less than five kilograms 
with a decreased appetite, classifies the patient at risk of malnutrition. Although the 
sample size across the two completed studies was relatively small (n=156), the 
MST was shown to have good inter-rater reliability, 100% sensitivity and a 
specificity of 81% and 92% respectively (Ferguson et al., 1999; Isenring et al., 
2006). More recently, lower levels of sensitivity (81%) and specificity (72%) were 
found by Stoyanoff and colleagues (2009) when they compared the use of the MST 
to the ab-PG-SGA in a group of oncology patients who were receiving 
chemotherapy. The authors concluded that the ab-PG-SGA should be the 
instrument of choice in the oncology out-patient setting. 
 
2.6.1.4 Malnutrition Universal Screening Tool 
The Malnutrition Universal Screening Tool (MUST) (Appendix 5) was developed in 
2003 by the Malnutrition Advisory Group, a standing committee of BAPEN (Elia, 
2003). Although not specifically tested in the cancer population, the MUST was 
validated against various other screening tools such as the SGA, Mini Nutritional 
Assessment (MNA) and MST (Stratton et al., 2004). It is validated for use in both 
acute and community settings and has proven reliability, face validity, content and 
concurrent validity (Elia, 2003). In the acute hospital setting, research suggests that 
in the elderly population, MUST also has predictive validity for length of stay, 
discharge destination and mortality (Stratton et al., 2006). Calculation of the MUST 
score is relatively simple and quick, with research suggesting that it takes between 
three and five minutes to complete (Stratton et al., 2004). Identification of patients at 
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risk of malnutrition using the MUST involves five steps. The first step is the 
calculation of body mass index (BMI). A BMI below 18.5kg/m2 results in a score of 
two being awarded, between 18.5 kg/m2 and 20 kg/m2 a score of one and above 20 
kg/m2 a score of zero. The second step is the calculation of percentage 
unintentional weight loss over the previous three to six months. Greater than 10% 
weight loss scores two, between 5% and 10% scores one and where weight loss is 
less than 5% a score of zero is awarded. Determination of whether disease state 
has resulted in, or is likely to result in, no nutritional intake for more than five days is 
the third step, and where this is likely, a score of two is given. The fourth step 
involves adding up the scores. A score of two or more indicates that the patient is at 
high risk of malnutrition, a score of one, medium risk and zero, low risk. The final 
step is the action which is taken as a result of the screening process. This is 
dependent on the severity of the risk and local policy but may, for example, include 
a referral to the dietetic service for those deemed at high risk.  
 
Although good to excellent agreement was found between the MUST and SGA (k = 
0.78), and the MUST and MST (k = 0.71) in groups of medical in-patients, when 
tested with in-patients at an oncology hospital, the sensitivity and specificity of the 
MUST was found to be low. This led to the conclusion that it should not be used in 
hospitalised people with cancer (Bauer and Capra, 2003). The findings from 
research by Roulston and McDermott (2008) appear to concur with this conclusion. 
However, this study was conducted retrospectively using the case notes of 52 
patients accessing an oncology service. As only an abstract has been published, no 
information is available regarding the diagnoses of patients or what constituted the 
dietetic objective assessment. Further research investigating the use of the MUST is 
needed to clarify whether indeed the instrument is reliable and valid within the 
cancer population. 
 
2.6.1.5 The Mini Nutritional Assessment 
The Mini Nutritional Assessment (MNA) (Appendix 10) was initially developed and 
validated to screen for malnutrition in the older population. It consists of six scored 
questions relating to weight loss, BMI, acute physical and mental disease state and 
mobility. Validity testing demonstrated that the tool had a high sensitivity and 
specificity of 96% and 98% respectively when tested in an older age group (Vellas 
et al., 1999). More recently, use of the tool has been investigated in people with 
cancer (Slaviero et al., 2003; Read et al., 2005; Gioulbasanis et al., 2008; Roulston 
and McDermott, 2008). In a group of patients with advanced cancer receiving 
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chemotherapy Slaviero and colleagues (2003) demonstrated that the MNA was 
correlated with C-Reactive Protein serum concentration and baseline weight loss. It 
has also been claimed that the MNA can be used to identify early cachexia in 
patients with lung cancer (Gioulbasanis et al., 2008). In this study, those identified 
as malnourished or at risk by the MNA were shown to have reduced mortality. The 
authors also demonstrated a relationship between results of the MNA and 
biochemical markers of cachexia such as C-Reactive Protein, albumin, interleukin-6 
and interleukin-8. Results of a small study suggest that the MNA is comparable to 
the MST at identifying patients at risk of malnutrition in the oncology setting 
(Roulston and McDermott, 2008). However, in a group of newly diagnosed patients 
with cancer, when compared with the PG-SGA, the MNA has been shown to lack 
specificity (Read et al., 2005). 
 
2.6.1.6 The Nutrition Risk Screening 2002 
A final screening instrument which is noteworthy is the Nutrition Risk Screening 
2002 (NRS 2002) (Appendix 11). This two step screening approach has been 
endorsed by ESPEN for use in the hospital setting (Kondrup et al., 2003a). Similar 
in content to the MUST, the NRS 2002 uses a two stage approach to identify 
patients as no, low, medium or high risk of malnutrition. The second stage requires 
a percentage quantification of food intake compared with normal requirements as 
well as considering the impact of disease on requirements. The methodology used 
to validate this instrument involved the application of the screening instrument to 
retrospective analysis of randomised controlled trials which had been conducted to 
investigate the benefits of nutrition support on outcome (Kondrup et al., 2003b). 
Details regarding prospective psychometric testing were not found in the literature. 
As it is likely that this instrument would be completed predominantly by nursing staff, 
the need to determine what percentage of nutritional requirements are being met by 
current food intake may prove difficult in routine clinical practice. However, that 
along with the potential impact of disease status on nutritional requirements, are 
important factors to consider when determining risk from malnutrition.  
 
2.6.2 Screening for the metabolic changes of cachexia 
As with malnutrition, there is no agreed gold standard test to screen or diagnose a 
person with cachexia. Research has been conducted to investigate the use of 
biochemical markers as screening or assessment parameters to identify patients at 
risk from the condition, with the focus predominantly on the use of serum proteins 
such as albumin, or the inflammatory marker, C-Reactive Protein. Serum 
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concentrations of albumin decrease during times of metabolic stress, infection and 
inflammation. Albumin is also affected by hydration status and has a long half-life 
making its use as an indicator of nutritional status questionable (Chojnowska, 1996). 
Pre-albumin may be of greater use as it has a much shorter turnover time and has 
been shown to have prognostic capabilities when measured in a group of patients 
with cancer receiving parenteral nutrition (Bourry et al., 1982). Overall, there 
appears to be a lack of research into the use of pre-albumin as a marker of 
nutritional status, particularly in people with cancer.  
 
During times of metabolic stress, inflammation and infection the release of C-
Reactive Protein from the liver is mediated by cytokine activity, in particular 
interleukin-6 (Heinrich et al., 1990). C-Reactive Protein serum concentrations 
appear elevated in people with cancer and, in addition, have been shown to be a 
prognostic indicator of survival in people with advanced disease (Nelson and Walsh, 
2002; Walsh et al., 2003). Raised interleukin-6 levels have also been associated 
with increased weight loss in people with lung, pancreatic and advanced cancer 
(Falconer, 1994; Scott, 1996; Walsh et al., 2003). Two prognostic scoring systems 
have been developed and validated in people with cancer. The simplest is the 
Glasgow Prognostic Score (GPS) (Appendix 12) which involves the measurement of 
serum albumin and C-Reactive Protein levels. Serum albumin concentrations less 
than 35g/l and C-Reactive Protein levels greater than 10mg/l score one point. An 
overall score of one or two is classed as abnormal, and in people with lung and 
upper GI cancer, this has been correlated with a reduced performance status and 
survival (Brown et al., 2006). However, the study also showed that raised levels of 
C-Reactive Protein alone showed similar correlations, questioning the need to 
measure albumin and calculate the GPS.  
 
The other scoring system is the Prognostic Inflammatory and Nutritional Index 
(PINI) (Appendix 13) which was originally developed and validated as a predictor of 
morbidity and mortality in patients with burns (Kudlackova et al., 1990). The PINI 
measures serum levels of C-Reactive Protein, alpha-1-acid glycoprotein which is 
another positive acute phase protein against albumin and pre-albumin. In 50 in-
patients, at a palliative care unit, the PINI scores were significantly higher in those 
with advanced cancer, anorexia and weight loss (Nelson and Walsh, 2002). 
However, the authors of this study also suggested that C-Reactive Protein alone is 
a useful predictive nutritional indicator.  
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2.6.3 Screening for symptoms of cachexia 
Of the nutritional screening tools previously discussed, there is no consistent 
approach to determining what symptoms may be impacting on the nutritional status 
of the patient. A recent systematic review of the literature found 21 cancer symptom 
assessment instruments which the authors judged appropriate for use within the 
clinical setting, the majority of which had been developed to assess the physical and 
psychological symptoms of a general cancer population (Kirkova et al., 2006). The 
methodological quality of the studies varied, as did the estimated reliability and 
validity of the instruments and, in the opinion of the authors, none met all the criteria 
for an ideal assessment tool. Furthermore, there was often no attempt to assess 
symptom severity and level of distress which are important factors when 
determining overall burden. Finally, all instruments appeared to have been designed 
for assessment of symptoms rather than for screening purposes per se.  
 
Several instruments have been developed to measure overall quality of life. For 
example, the EORTC QLQ-C30 (Appendix 4) which involves patients rating their 
symptom severity on a four point scale (Aaronson et al., 1993). Another, the 
Functional Assessment of Anorexia/Cachexia Therapy (FAACT) (Appendix 14) 
appetite scale was designed to measure the impact of appetite and the cachexia 
syndrome on quality of life (Chang et al. 2005). Both of these instruments have 
some proven predictive ability in terms of survival (Chang et al., 2005; Grande et al., 
2009). However, neither were designed for the purpose of screening. Their main 
use being as a research instrument or, for example, as a tool to monitor changes in 
self-reported quality of life following the instigation of a new therapy.  
 
One appetite and symptom screening instrument that has been validated for use 
within the general population in the United States of America is the Council of 
Nutrition Appetite Questionnaire (CNAQ) (Appendix 1) (Wilson et al., 2005). The 
eight-item CNAQ was developed from a longer, previously validated, tool using the 
Delphi technique (Crisp, 1997; Mathey, 2001). The aim of the research study was to 
develop a short and practical instrument that was able to identify adults in long-term 
care and in the community who were at risk of weight loss and malnutrition. Each 
item of the questionnaire, which is self-completed by the patient, includes five 
possible responses. Each response grades the severity of the symptom and scores 
between one and five, where lower scores indicate increased risk. Results from the 
study demonstrated that the CNAQ, and a four item shorter version termed the 
Simplified Nutritional Appetite Questionnaire (SNAQ) (Appendix 2), were both able 
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to predict weight loss in adults living in long term care and the community. Statistical 
analysis using Receiver Operating Characteristic curves suggested an optimum cut 
off point of 28 or less being predictive of at least 5% weight loss over six months for 
the CNAQ and 14 or less for the SNAQ.  The sensitivity and specificity of the CNAQ 
at predicting 5% weight loss were both 80% and at predicting 10% weight loss, 
82%. The four-item SNAQ wielded similar results; 81% sensitivity and 76% 
specificity for prediction of 5% weight loss and 88% sensitivity and 84% specificity 
for 10% weight loss. Further research is required to establish if the CNAQ could be 
used within the cancer population. 
 
2.7 Summary 
As discussed, malnutrition and the cachexia syndrome have many adverse physical 
and psychological consequences resulting in an increase in morbidity, treatment 
complications and overall mortality. Financially, within the health care system, this 
equates to higher treatment costs of complications, increased staffing levels and 
longer hospital stays. It is clear that the successful management of malnutrition and 
cachexia needs timely intervention and therefore early recognition of the problem. 
However, no agreed international definition of malnutrition or cachexia exists, 
meaning that progress in this important area of research is sluggish. Also, as a 
result, there is no consensus as to the most appropriate screening instrument to use 
to identify patients at risk of malnutrition and little work has been done thus far to 
develop a screening instrument for cachexia. A simple and practical screening 
instrument, validated within the cancer population and encompassing all elements 
of cachexia syndrome will help to move this work forward. Coupled with a multi-
professional approach, this should help to improve treatment outcomes, functional 
capacity and quality of life for people with cancer. 
 
2.8 Study aim, hypothesis and key objectives  
2.8.1 Aim 
The overall aim of this study was to develop a greater understanding of the complex 
factors that have an effect on, and can predict, weight loss in people with cancer, 
with the intention of influencing nutritional management strategies in clinical 
practice. 
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2.8.2 Hypothesis (Phases I and II) 
A simple and practical screening instrument, with demonstrated reliability and 
validity, can predict clinically significant weight loss in people with lung or upper 
gastrointestinal cancer. 
 
2.8.3 Key objectives 
The key objectives for this project were to: 
1. Obtain an estimate of the reliability of the CASQ. 
2. Determine the predictive validity of the CASQ 
3. Determine the optimal cut points and overall performance of the CASQ at 
predicting clinically significant weight loss over three months.  
4. Propose an optimum screening instrument to predict clinically significant 
weight loss over three months.  
5. Describe the experiences of people with lung or upper gastrointestinal 
cancer, and their carers, regarding the factors influencing weight change 
6. Explore the causes and influencing factors of weight change in people with 
lung or upper GI cancer.  
7. Propose a conceptual model of influences on weight change in people with 
cancer. 
8. Identify areas for improvement regarding the nutritional management of 
people with cancer. 
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CHAPTER 3: RESEARCH METHODOLOGY 
 
3.1 Introduction 
The aim of chapter three is to outline the underlying theories of quantitative and 
qualitative research that were adopted for this project. In particular, the use of a 
mixed methods study design will be examined. Following on from this, the 
development and validation of health measurement scales, and the quantitative 
methods used within Phase I and II of the study are discussed. This chapter 
continues with an overview of the principles of qualitative research, in particular 
grounded theory, and the methods followed in the qualitative Phase III study. It 
concludes with a discussion of the ethical considerations of the study. 
 
3.2 Theory of research methodologies 
3.2.1 Research paradigms 
A paradigm can be defined as a theoretical or philosophical framework. Within 
health and social care research, several paradigms have developed over the years. 
Tashakkori and Teddlie (1998) named positivism, postpositivism, pragmatism and 
constructivism as four important paradigms to discuss. Figure 3.1 demonstrates 
how these four paradigms interplay within the research cycle. Purist researchers 
who take the approach of positivism believe that quantitative research studies, using 
deductive reasoning, can determine a single truth with a cause and effect 
UHODWLRQVKLS,QDGGLWLRQWKHUHLVDQXQGHUVWDQGLQJWKDWWKHUHVHDUFKHU¶VYDOXHVDQG
beliefs play no part in the process. During the mid 20th century, theorists began to 
question the assumptions of this paradigm, believing that understanding is 
FRQVWUXFWHG DQG WKDW WKH UHVHDUFKHU¶V YDOXHV DQG EHOLHIV PD\ LQIOXHQFH WKH
outcome (Schutz, 1967; Oakley, 1999). The postpositivist approach continues to 
utilise mainly quantitative methodologies and deductive reasoning. In addition, there 
is acknowledgement of how realism may influence the conclusions (Guba, 1990; 
Clark, 1998).  
 
At the opposite end of the spectrum from positivism is the constructivist paradigm, 
where qualitative research methods are used to induce reasoning. The 
constructivist approach directly opposes that of the positivist, and, to a great extent, 
the postpositivist position. Constructivists believe that there are numerous realities 
and that it is not possible to differentiate between cause and effect (Guba and 
Lincoln, 1994). During the 1980s, these contrasting standpoints led to what has 
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EHHQWHUPHG LQ WKH OLWHUDWXUHDV µSDUDGLJPZDUV¶1RQ-purist researchers however 
do believe that these paradigms can co-exist. From this concept of co-existence 
came a fourth paradigm, pragmatism (Howe, 1988; Datta, 1994). The pragmatic 
approach encompasses both quantitative and qualitative methodologies, focussing 
on the facilitation of human problem solving with an acceptance of reality (Carr, 
2009). In healthcare research, using this pragmatic mixed methods approach, can 
aid understanding of the multi-dimensional and multi-faceted issues which exist 
within this complex field (Mason, 2006).   
 
 
Figure 3.1: Research paradigms and their interplay with the research cycle 
(Adapted from Tashakkori and Teddlie, 1998). 
 
3.2.2 Mixed method research 
Mixed methods research can be defined as using quantitative and qualitative 
methods and data in a single study or series of studies, to investigate the same 
underlying concept (Leech and Onwuegbuzie, 2009). The advantages of such 
methodology are many. Jick (1979) discussed how a mixed method approach can 
allow for triangulation or cross-validation of results, providing a deeper, more holistic 
knowledge. Others debate whether cross-validation is truly possible in mixed 
method research, as such diverse paradigms cannot measure the same 
phenomenon (Sale et al., 2002). There is certainly agreement that methods can be 
combined for complementary purposes. Since its origin, the classification of mixed 
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method study design has become complex, with no agreed terminology. Despite 
this confusion, its use appears to be increasing in popularity, particularly within 
health and educational research. To help clarify the categories of research design, 
VHYHUDO DXWKRUV KDYH GHYHORSHG D µW\SRORJ\¶ 7DVKDNNRUL DQG 7HGGOLH 
Johnson and Onwuegbuzie, 2004; Leech and Onwuegbuzie, 2009). Johnson and 
Onwuegbuzie (2004) describe a continuum of research design from mono-methods 
(quantitative or qualitative), through partially mixed, to fully mixed methods. A fully 
mixed design incorporates both quantitative and qualitative methods and data within 
the same phase of the study. A partially mixed design conducts quantitative and 
qualitative phases in their entirety, mixing the data at the interpretation stage. This 
description, aside from whether the studies are performed concurrently or 
sequentially, forms the basis for most mixed method designs. Whether the 
quantitative and qualitative methods have equal or dominant status is also added to 
the typology described by other authors (Leech and Onwuegbuzie, 2009).  
 
3.2.3 Predicting weight loss in people with cancer: A mixed methods approach 
A mixed methods approach to research can provide a deeper insight and superior 
understanding of the concept of interest (Johnson and Onwuegbuzie, 2004). Using 
both quantitative and qualitative methods to investigate and explore the causes and 
influencing factors of weight change in people with cancer, in a mixed method 
exploratory research design, should allow the qualitative data to explain, and 
provide a greater understanding of, the findings from the quantitative data (Ivankova 
et al., 2006). In line with this approach, the predicting weight loss study described in 
this thesis included three phases. Phases I and II were conducted sequentially and 
used quantitative methodology, principally to determine the reliability and the validity 
of the Cancer Appetite and Symptom Questionnaire (CASQ). Phase III was 
conducted concurrently alongside Phase II using qualitative methodology. It was 
designed to explore the influences on weight change in people with cancer. The 
underlying philosophical framework that was supported for this study was 
pragmatism. This was not solely based on the appropriateness of conducting a 
mixed methods study to answer the research question. Throughout there was 
certainly an emphasis on the importance of the outcome and how it might work in 
clinical practice. Taking this non-purist or compatibilist approach also stemmed from 
the belief that both the positivist and constructivist paradigms have their strengths 
and weaknesses. Using the principles of grounded theory, (Strauss and Corbin, 
1994) the hope was that from the study would emerge a framework which can help 
us to understand the complex social processes which surround the issue of weight 
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loss in people with cancer. Integration of this with the results from the quantitative 
work had the potential to result in more rigorous conclusions and practical 
outcomes. 
 
3.3 Quantitative research methods 
Phase I and Phase II of the predicting weight loss study involved the psychometric 
testing of a health measurement scale, namely the Cancer Appetite and Symptom 
Questionnaire. To meet the key objectives listed below, the approach taken was 
quantitative in nature. 
Key objectives for Phase I and Phase II were to:  
1. Obtain an estimate of the reliability of the CASQ (Phase I). 
2. Determine the predictive validity of the CASQ (Phase II). 
3. Determine the optimal cut points and overall performance of the CASQ at 
predicting clinically significant weight loss over three months (Phase II). 
4. Propose an optimum screening instrument to predict clinically significant 
weight loss over three months (Phase II).  
 
Before describing the methodology that was followed for this part of the study, it is 
important to consider some of the theory behind the development and psychometric 
testing of health measurement scales. 
 
3.3.1 Theory of health measurement scale development  
A multitude of instruments have been developed to measure various subjective 
elements of health and disease. Several of these instruments, such as the McGill 
Pain Index are self-report measurement scales consisting of a series of items which 
collectively measure the same concept (Melzack, 1975). Others, particularly those 
aimed at measuring a multi-faceted phenomenon such as quality of life, for example 
the EORTC QLQ-C30, are multi-dimensional in that they measure a number of 
FRQFHSWVZKLFKFRQWULEXWHWRDSHUVRQ¶VTXDOLW\RI OLIH$DURQVRQet al., 1995). The 
subjectivity of the conditions that such instruments are attempting to measure, 
results in a complex development and validation process. In view of this, the first 
course of action for the researcher should be a review and evaluation of all existing 
instruments which have been designed to measure the same concept. Only when 
the possibility of using an existing reliable and valid tool has been excluded should a 
new one be developed. When developing a new instrument, the purpose for which it 
will be used is paramount and should help determine the characteristics of scale.   
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3.3.1.1 Developmental approach 
6WUHLQHU DQG 1RUPDQ  GHVFULEH WKH µWUDGLWLRQV RI DVVHVVPHQW¶ ZKLFK KDYH
resulted in two measurement scale models; the categorical and the dimensional 
model. These models have emerged from the different approaches taken by 
medical, psychology and educational researchers.  An example of an instrument 
developed using the categorical model is for the purpose of diagnosing a condition 
such as iron deficiency anaemia in order to then provide treatment. Responses to 
items on this type of instrument are likely to be dichotomous, yes or no, with 
resulting nominal (categorical) data. There are clear limitations to a model that 
categorises people as having the condition or not. Under these circumstances 
qualitative and quantitative information on the extent of such symptoms or attitudes 
is not obtained making evaluation of the condition, or comparison of severity, not 
possible. 
 
The dimensional model theory is based on the work of Stevens (1946) and has 
traditionally been used in the psychology and educational disciplines. Stevens 
proposed that levels, defined as nominal, ordinal, interval and ratio, should exist 
within measurement scales. The reasoning for this is that the complexity of 
symptoms, attitudes, thoughts and feelings means that there is usually a scale to 
WKHLUPDJQLWXGH)RUH[DPSOHDQVZHUVWRDTXHVWLRQVXFKDV³GR\RXIHHOQDXVHRXV
EHIRUH HDWLQJ´ FRXOG HOLFLW VHYHUDO UHVSRQVHV IURP ³QHYHU´ ³UDUHO\´ ³VRPHWLPHV´
³RIWHQ´DQG³PRVW WLPHV´7RDQVZHUVXFKDTXHVWLRQZLWK³\HV´RU ³QR´ZRXOGEH
GLIILFXOW IRU PRVW DV WKH UHVSRQGHQW¶V VWDWH ZLOO OLNHO\ IDOO DORQJ D FRQWLQXXP $V
described by Streiner and Norman (2008), a greater number of response categories 
for each item may also result in an instrument with better precision as respondent 
error is likely to be lower. This is because, for example, if there are only three 
response categories there will be greater extremes between possible answers. 
Respondents may not be able to give the response that most closely matches their 
condition, consequently, the instrument will not be able to detect small changes in 
states. Unlike categorical models, instruments designed using the dimensional 
model do not classify people into, for example, cases or non-cases. In order to use 
this type of instrument diagnostically, consideration needs to be given to the 
optimum cut point (Altman and Bland, 1994). This would need to be determined 
based on research that tests the instrument. Nonetheless, the dimensional model 
does allow for comparison of severity of symptoms and conditions between subjects 
and for evaluation of change over time. 
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3.3.1.2 Characteristics of the Cancer Appetite and Symptom Questionnaire  
The CASQ is an instrument based on the dimensional model of measurement 
scales. It consists of 12 items and each item has five possible response categories 
scored zero to four, where lower scores indicate a higher appetite and symptom 
burden. It is not possible to know the true interval between responses given in 
questions such as those in the CASQ. For this reason the data collected cannot be 
classed as interval or ratio data. The responses given by patients will in effect elicit 
continuous, ordinal data which is ranked. Therefore, the relationship between each 
of the responses can be ascertained in terms of whether a response category is 
greater or less than another. Although instrument scales which provide interval or 
ratio data allow for the most comprehensive, parametric statistical analysis, the 
results of those that elicit ordinal data, are often analysed using the same 
techniques. Debate is ongoing as to whether this is appropriate. Streiner and 
Norman (2008) conclude that providing the data from rating scales is not skewed, it 
can be analysed as interval data, without the introduction of bias.  
 
As identified above, the CASQ has five response categories in each item. The ideal 
number of categories is an area which is often debated. Too many and the 
respondent could get confused, whilst too few may result in missing information, 
respondent measurement error and lack of precision (Streiner and Norman, 2008). 
A study by Hawthorne (2006) suggests that reducing the number of response 
categories from nine to five has no effect on the psychometric properties of an 
instrument designed to measure pain (Hawthorne, 2006).  Findings of another study 
have established that seven to 10 categories are optimal in terms of the reliability of 
an instrument (Preston and Coleman, 2000). Streiner and Norman (2008) conclude 
that the optimum number of categories within an item should be between five and 
seven. However, it is also worth considering the literacy levels of the intended 
respondents, as scales with fewer responses may lead to improved psychometric 
properties of an instrument when used in people with very low literacy 
(Chachamovich et al., 2009). It may be assumed, from the supporting literature that 
the number of categories in each item of the CASQ is appropriate. 
 
A further point to consider when aiming to reduce respondent error and improve 
response rates is the wording of questions and response categories. If an 
instrument is to be used with the general public, using plain English can improve 
understanding and completion of the instrument (Plain English Campaign, 2009). 
The wording of the CASQ was determined prior to this research study. It is therefore 
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not possible to know if this was an issue that was considered. When calculating the 
readability of the CASQ using the Flesch Reading Ease formula the resulting score 
was 79. This test rates the text on a 100-point scale with scores higher than 60 
being considered as acceptable for literate adults (Dollahite et al. 1996). Although 
the CASQ does not appear to contain jargon, and is written using simple words and 
short sentences, the use of adjectival scales which inFOXGHIRUH[DPSOH³RIWHQ´RU
³UDUHO\´ PXVW EH FRQVLGHUHG 7KHVH ZRUGV PD\ KDYH GLIIHUHQW FRQQRWDWLRQV WR
respondents depending on their point of reference. Including an actual frequency, 
such as less than once a day may have helped to overcome this issue. 
 
A final issue to discuss is the scoring of the instrument. All 12 items in the CASQ 
are scored in the same way, with equal weighting. Once completed by the 
respondent, the scores from each item are summed, giving a total score for the 
instrument. In this case possible scores ranged from zero to 48. This method is 
simple but consideration needs to be given to the fact that two individuals may, for 
example, have the same total score which has been derived from very different 
responses. An alternative is to weight the items dependent on their importance in 
measuring the concept. Importance may be judged by the investigator or expert, or 
ascertained using multiple regression techniques (Streiner and Norman, 2008). An 
alternative method is to ask respondents to self-weight items within the instrument 
dependent on how they perceive for example, the severity of their symptoms. There 
appears to be no clear answer as to whether weighting can improve the 
psychometric properties of an instrument (Locker et al., 2007; Streiner and Norman, 
2008).  
 
3.3.2 Psychometric testing of health measurement scales 
Psychometric theory is likely to have originated in the late 19th Century when 
researchers such as Francis Galton developed mathematical techniques to 
measure intelligence (Galton, 1879). In recent times it has been used to measure a 
number of unobservable and subjective phenomena, for instance, attitudes, beliefs 
and personality. Within the healthcare setting, this has been extended to the 
development of scales to measure things such as quality of life, symptoms and 
experiences. For example, the EORTC QLQ-30 and the Functional Assessment of 
Cancer questionnaire are frequently used instruments developed to measure the 
quality of life and function in people with cancer (Aaronson et al., 1993; Cella et al., 
1993). Two main theories exist with regard to testing of measurement scales; item 
response theory (IRT) and classical test theory (CTT). Both models are based on 
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mathematical techniques (Wilson et al., 2006). One key difference is that the 
information obtained through applying CTT relates to the instrument as a whole, 
whereas using the IRT model will elicit information at an item level.  
 
Item response theory is a framework based on mathematical modelling which has 
developed over recent years (Harvey, 1999). Simplistically, IRT utilises a model 
ZKLFK FDQ GHWHUPLQH WKH SUREDELOLW\ RU µDELOLW\ HVWLPDWH¶ RI HDFK LWHP UHVSRQVH
based on the latent trait, such as anxiety, and the item parameters. What appear to 
be complex theory and analysis techniques may be what is holding back many 
healthcare researchers from using IRT. However it is likely that over the coming 
years, as agreed standards for use and reporting of IRT develop, its application will 
begin to increase within this field of research (Hays and Lipscomb, 2007). 
 
Whereas IRT has only developed relatively recently, CTT has been the method of 
choice for many years (Jette, 1980; Cella et al., 1995). The foremost concepts of 
CTT are the reliability and validity testing of an instrument. The underlining principle 
is that the observed score obtained from an item in a measurement scale is equal to 
the true score plus measurement error. CTT assumes that for each item within the 
scale, the amount of measurement error is not associated with the true score, i.e. 
the difference in measurement error is the same irrespective of what the true score 
is and, the average measurement error for the instrument is zero (Streiner and 
Norman, 2008). Phase I and Phase II of the predicting weight loss study use the 
concepts of CTT to test the reliability and validity of the CASQ, as such the theory 
behind these concepts will be discussed in more detail in the following sections. In 
addition, some of the considerations which need to be given to the interpretation of 
information from CTT analysis will be discussed in subsequent chapters. 
 
3.3.3 Phase I study methodology 
Phase I of the predicting weight loss study was a short-term longitudinal study, with 
two test points one week apart. The objective of this part of the study was to 
HVWLPDWH WKH UHOLDELOLW\ RI WKH &$64 5HOLDELOLW\ LV D PHDVXUH RI DQ LQVWUXPHQW¶V
reproducibility. As such, for an instrument to be reliable it should have the ability to 
produce consistent results over two or more time points, with a group of subjects in 
whom there has been no evidence of change (Streiner and Norman, 2008). 
Reliability can be estimated in several ways, depending on the type of instrument 
being tested. For this study, a measure of the internal consistency reliability and 
test-retest reliability of the CASQ was made. Details of these measurement 
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techniques are discussed below. Following this, the details of the Phase I study 
sample, recruitment, data collection and analysis are given. 
 
3.3.3.1 Internal consistency reliability 
Internal consistency reliability is a measure of the degree to which all items within 
an instrument are measuring the same concept (Bland and Altman, 2002). It is 
based on the correlations between the scores derived from the individual items in 
the instrument i.e. item-item correlation, and between the item scores and the 
LQVWUXPHQW¶V WRWDO VFRUH LH LWHP-total correlation. In order to estimate the internal 
FRQVLVWHQF\RIDQLQVWUXPHQWWKH&URQEDFK¶VDOSKDFRHIILFLHQWLs often used. This is 
EHFDXVH &URQEDFK¶V DOSKD JLYHV DQ HVWLPDWH EDVHG RQ DOO SRVVLEOH FRUUHODWLRQV
between the items in a scale (Bland and Altman, 1997). Although there is no agreed 
acceptable standard, the closer the resulting value is to one, the higher the internal 
consistency. 
 
3.3.3.2 Test-retest reliability 
Many instruments used within the healthcare setting, including the CASQ, are self-
administered. In order to determine the stability of such an instrument over time, 
test-retest reliability is estimated (Bland and Altman, 2002). The procedure for this 
requires the administration of the instrument, to the same population, at two time 
points. The length of time between the time points is an area of debate and previous 
research has used anything from one hour to one year. It is thought that a retest 
interval of between two to 14 days is appropriate (Streiner and Norman, 2008). 
Once the scores from the items and instrument have been obtained, several 
statistical techniques can be employed to estimate the test-retest reliability of the 
instrument. Bowling (2002), suggests that for nominal data the kappa coefficient 
should be used, and for ordinal data, the weighted kappa coefficient. For interval 
GDWD 3HDUVRQ¶V FRUUHODWLRQV VKRXOG EH FDOFXODWHG $V ZLWK WKH &URQEDFK¶V DOSKD
coefficient, the closer the resulting value is to one, the higher the correlation and the 
better the reliability of the instrument. As will be discussed in Chapter Four, there 
are limitations to the interpretation of such correlations, with some researchers 
preferring to use the Bland-Altman type plot, defining the limits of agreement 
(Altman, 1991). A final, favoured measure of test-retest reliability is the intraclass 
correlation coefficient (ICC). Statistically, the ICC is a ratio of the variance between 
subjects to the total variability where the total variability is the sum of between 
VXEMHFWYDULDELOLW\DQGPHDVXUHPHQWHUURURUµZLWKLQVXEMHFW¶YDULDQFH.LUNZRRGDQG
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Sterne, 2003).  An ICC value equal to one suggests that there is no measurement 
error and therefore a perfect instrument.  
 
3.3.3.3 Phase I sample 
In the present study, the selected group members had a diagnosis of cancer and 
were likely to be clinically stable over the duration of one week, i.e. not at high risk 
of disease or treatment related appetite and weight loss. On a practical level, they 
were easy to access as they attended the hospital Monday to Friday for treatment. 
Table 3.1 shows the participant inclusion and exclusion criteria. Any patient 
receiving radiotherapy to the head, neck or upper gastrointestinal tract area and 
those with a condition impairing their ability to swallow were excluded as this could 
potentially have influenced their clinical condition and stability. 
 
Table 3.1: Phase I study participant inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
1. Adults, over 18 years of age 
 
1. Receiving radiotherapy to the head, 
neck or upper gastrointestinal tract 
area. 
 
2. Confirmed diagnosis of 
cancer 
 
2. Any condition impairing their ability to 
swallow. 
 
3. Receiving radiotherapy 3. Unable to provide written informed 
consent and therefore complete the 
questionnaire due to cognitive 
impairment.  
The inclusion and exclusion criteria for the participants of the Phase I study are 
shown. 
 
3.3.3.4 Phase I sample size 
A sample size of 35 at two time points would allow detection of a correlation 
coefficient of 0.7 with 95% confidence intervals that exclude a lower limit of 0.5. 
(Streiner and Norman, 2008). This is at an appropriate level to determine the 
reliability of the CASQ. 
 
3.3.3.5 Phase I participant recruitment 
During September and October 2007, the medical notes of all patients undergoing 
radiotherapy treatment at Nottingham City Hospital Campus of The University of 
Nottingham Hospitals NHS Trust were reviewed by the superintendant therapy 
radiographer. Those who met the study inclusion criteria were offered a participant 
information sheet (Appendix 15) by the radiotherapy department staff. The number 
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of patients who declined to take an information sheet was not recorded. Anecdotally 
it was noted that a small number of female patients, who were having curative 
radiotherapy treatment post surgery for breast cancer, were concerned at being 
offered an information sheet which was aimed at people with cancer. A minimum of 
24 hours later, potential participants were approached by the researcher, asked if 
they had any questions about the study and if they would like to take part. Written 
informed consent (Appendix 16) was obtained from those wishing to participate. 
Data was not collected regarding the number of patients  who declined to take part 
in the study, and their reasoning, at this point.  
 
3.3.3.6 Phase I data collection 
At time point one, participants were asked during their hospital visit to self-complete 
the CASQ. The instruction they received was to answer the 12 questions by ticking 
the box that most closely reflected their experience of appetite and symptoms at 
that present time. The completed questionnaires were put in an envelope by the 
patient and placed in a box in the radiotherapy department waiting room. At their 
visit one week later, time point two, participants were again asked to complete the 
CASQ, this time also noting if anything had affected their appetite and symptoms 
over the previous week. Demographic information including date of birth, gender, 
diagnosis and Eastern Cooperative Oncology Group (ECOG) performance status 
(Appendix 17) were documented by the researcher. 
 
3.3.3.7 Phase I data analysis 
The CASQ was completed in its entirety by all participants. For data analysis 
purposes, a score of zero to four was assigned to answers within each of the 12 
items on the CASQ. As items four, eight, eleven and twelve were worded in the 
opposite direction to the other questions the scores were re-coded accordingly. A 
score of four was given to the answer which represented no symptom or appetite 
problems. Hence, low scores represented more appetite and symptom problems. To 
estimate the reliability of the CASQ, the internal consistency reliability and the test-
UHWHVW UHOLDELOLW\ ZHUH GHWHUPLQHG &URQEDFK¶V DOSKD FR-efficient was used to 
examine the internal consistency reliability of the CASQ. Test-retest reliability was 
GHWHUPLQHGIURPDQXPEHURIHVWLPDWHV LQFOXGLQJ3HDUVRQ¶VFRUUHODWLRQVD%ODQd-
Altman plot and the intraclass correlation coefficient. All data was analysed using 
SPSS version 14.5 and STATA version 9. 
3.3.4 Phase II study methodology 
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The Phase II study involved a longitudinal observational study with two test points 
three months apart. It was conducted following the completion of the Phase I work. 
One of the key objectives of this part of the study was to establish the predictive 
validity of the CASQ in terms of weight loss. Validity per se can be defined as the 
extent to which an instrument measures what it is supposed to measure. 
Statistically, it is the degree of confidence that can be placed on the inferences that 
arise from the test scores (Streiner and Norman, 2008). There are a number of 
techniques for determining the validity of a measurement scale such as construct, 
convergent, discriminant and criterion validity (Bowling, 2002). Predictive validity is 
a form of criterion validation and for this reason an explanation of criterion validity 
has been given below.  When developing the CASQ, as described in Chapter One, 
the content validity of the instrument was also determined. Therefore, the principles 
of content validity have also been discussed here. This section concludes with 
details of the Phase II study sample, recruitment, data collection and analysis. 
 
3.3.4.1 Content and face validity 
Face validity can be defined as how an instrument looks and whether it covers what 
we think it should. This is different to content validity which considers if all factors 
relevant to the subject being measured have been included (Bland and Altman, 
2002). To many researchers, the technique used to determine content and face 
validity is similar. Both involve an expert or group of experts giving their subjective 
judgement as to whether items within a scale are relevant, appropriate and clear. 
For this reason, some have questioned its use within psychometric testing 
(Fitzpatrick, 1983). Indeed, assessment of face validity rarely involves more than the 
process described above. In contrast, assessment of content validity appears to 
have more substance. Lynn (1986) describes how content validity can be 
determined using a two stage judgement quantification process. From this process 
the content validity index (CVI) is calculated as a proportion of expert panel 
members who rate the item as relevant. As this technique does not adjust for 
chance agreement, more recent work has been conducted defining how the kappa 
coefficient can be used to determine a more accurate item-level content validity 
index (Polit et al., 2007).  
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3.3.4.2 Criterion validation 
The technique for determining criterion validity is the comparison or correlation of 
WKHQHZPHDVXUHPHQWVFDOHZLWKDQH[LVWLQJDQGYDOLGDWHGµJROGVWDQGDUG¶PHDVXUH
(Bland and Altman, 2002). Concurrent and predictive validity are examples of 
criterion validity. 
 
Concurrent validity can be established by administering the new and established 
gold standard measurement scales to the same population at the same time or 
within a short time frame of each other (Streiner and Norman, 2008). A question that 
must be asked is, if there is already a gold standard measure, then why is another 
one needed? Possible answers to this question, and therefore reasons for 
developing a new test, may be that the existing test is expensive, time consuming or 
dangerous. For example, to diagnose colorectal cancer, the gold standard is 
colonoscopy. Results of a study comparing colonoscopy to a new, less invasive 
test, which involves swallowing and excreting a colon capsule endoscopy are 
promising (Schoofs et al., 2006). Concurrent validity can be determined by 
estimating the correlation between the results from the new and gold standard test 
(Kirkwood and Sterne, 2003). To analyse the results from the two tests, where 
outcomes are dichotomous, a simple four-fold cross-tabulation can be used. For 
FRQWLQXRXV GDWD WKH 3HDUVRQ¶V FRUUHODWLRQ FRHIILFLHQW FDQ DOVR EH FDOFXODWHG ,Q
addition, the sensitivity and specificity of the new test can be estimated. As defined 
by the gold standard test, if the new test has high sensitivity it will be able to detect 
accurately most or all of those subjects who are at risk, or diagnosed with the 
condition. In addition, if the new test has high specificity, it will correctly identify 
those who are not at risk, or free from the condition (Streiner and Norman, 2008). 
 
When testing the predictive validity of a new measurement scale, the criterion which 
it has been developed to predict, will not be evident until some time in the future, 
when it will be determined by the gold standard test (Streiner and Norman, 2008).  
One reason for developing a new instrument with predictive validity is that in some 
circumstances it may be advantageous to intervene in a proactive rather that 
reactive way. With established tests, the outcome may not be evident until it is too 
late to do anything about it. This is often the case with weight loss in people with 
cancer. Being able to predict those patients who are going to lose weight, with 
intervention, may prevent or reduce the problem from occurring. Predictive validity is 
expressed as a four-fold cross-WDEXODWLRQ RU 3HDUVRQ¶V FRUUHODWLRQ EHWZHHQ WKH
results from the new measurement scale and those obtained, in the future, by the 
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gold standard test (Streiner and Norman, 2008). An important consideration when 
conducting predictive validation studies is that practice is not changed due to the 
outcome from administering the new instrument. Should this occur, the correlations 
are likely to be lower due to having a reduced or truncated sample. As with 
concurrent validation, the sensitivity and specificity of the new instrument can also 
be determined.  
 
3.3.4.3 Phase II sample  
Patients with lung or upper GI cancer were chosen as they are known to have a 
high incidence of nutritional deficiencies (Stratton et al., 2003). Table 3.2 shows the 
participant inclusion and exclusion criteria. As the aim was to develop a screening 
instrument that would predict weight loss, those who were already malnourished, as 
indicated by a Malnutrition Universal Screening Tool (MUST) score of two or more, 
were excluded (Stratton et al., 2004). Any patient with oedema, or ascites was 
H[FOXGHGRQ WKHEDVLV WKDW LWZRXOGKDYHEHHQGLIILFXOW WRDVFHUWDLQ WKHLU WUXH µGU\¶
weight. Patients were not excluded on the basis of their treatment plan or stage of 
disease.  
 
Table 3.2: Phase II study participant inclusion and exclusion criteria 
 Inclusion criteria Exclusion criteria 
1. Adults, over 18 years of 
age 
1. Lost > 10% of their pre-illness 
stable body weight 
2. Confirmed diagnosis of 
primary lung or 
gastrointestinal cancer. 
2. Lost between 5 and 10% of their 
pre-illness stable body weight 
with a BMI < 20kg/m2 
 3. BMI < 18.5 kg/m2 
 4. Presence of oedema or ascites 
 5. Receiving enteral tube feeding 
or parenteral nutrition 
 6. Unable to provide written 
informed consent and therefore 
complete the questionnaire due 
to cognitive impairment 
 7. Not able to be weighed 
The inclusion and exclusion criteria for the participants of the Phase II study are 
shown. 
 
3.3.4.4 Phase II sample size 
When developing a screening instrument, a minimum of 10 participants is required 
for each item to be tested (Peduzzi et al., 1996). It was the intention to test 16 items 
in the screening tool; 12 items of the CASQ, C-Reactive Protein, plus baseline 
measurements for body mass index, percentage weight loss and the MUST score. 
51 
 
Thus, a sample of 160 was required. Within oncology and palliative care settings 
research suggests that a 15% attrition rate is typical (Addington-Hall, 2002). 
Allowing for this attrition rate a recruitment target of 185 participants was set. 
 
3.3.4.5 Phase II participant recruitment 
Participants were recruited from the oncology out-patient clinics at Nottingham City 
Hospital Campus between October 2007 and February 2009. Depending on the 
format and running of the clinic that they were attending, participants were recruited 
in one of two ways. As several clinics were running concurrently, and with only one 
researcher, it was not possible for all patients attending the clinics to be screened. 
Therefore patients were approached in an ad hoc manner, on the basis of 
practicality and convenience. For the majority of patients, on arrival at clinic, they 
were approached by the researcher and given a letter (Appendix 18) from their 
clinician informing them that they would be screened for risk of malnutrition using 
the MUST. The letter also indicated to them that if their weight was stable they 
would be asked if they were interested in taking part in the study. In most of the 
FOLQLFVWKHSDWLHQWV¶ZHLJKWDQGKHLJKWZHUHURXWLQHO\PHDVXUHGE\DPHPEHURIWKH
clinic staff. Where this was not the case the researcher ensured that this was done. 
At this point, with verbal agreement from the patient, the MUST score was 
calculated by the researcher, and those who met the inclusion criteria, were asked 
to read a participant information sheet (Appendix 19) whilst they waited to see their 
doctor. Usually following their consultation, for those wishing to take part, informed 
written consent (Appendix 20) was taken by the researcher and the CASQ 
administered immediately. 
 
The alternative method involved the patient, after their consultation, being informed 
by their doctor about the study and being asked if they were happy to speak to the 
researcher for more details. At this point their MUST score was calculated by the 
researcher and those who met the inclusion criteria, were asked to read the 
participant information sheet. Again, for those wishing to take part, informed consent 
was taken by the researcher and the CASQ administered. A minority of patients 
were unable to take part on the day due to time constraints, but were keen to 
participate. For this group an appointment was made by the researcher to see them 
at another time, usually within two to three days, when they were attending the 
hospital for chemotherapy. A log of patients who were approached, screened and 
recruited was maintained throughout the study to avoid re-approaching those who 
had already been seen. Those patients who were identified as being at risk of 
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malnutrition based upon the MUST score, i.e. a score of two or above, were 
highlighted to the clinician in clinic and a copy of the MUST documentation was put 
in their medical notes (Appendix 21). The clinicians were advised to follow their 
normal practice with regards to the nutritional management of the patient. All 
participants were offered a standard written advice leaflet about ways to improve 
their nutritional intake (Appendix 22).  
 
3.3.4.6 Phase II data collection 
Participants were asked to self-complete the CASQ. They were instructed to 
respond to the questions considering how they had felt over the last day or two. As 
many of the patients were having a blood sample taken on the recruitment day for 
chemotherapy bloods, C-Reactive Protein analysis was requested from the same 
sample. All other consented subjects were given a blood test form and invited to go 
to the clinic phlebotomist. If they were unable to wait they were asked to visit their 
GP clinic at their earliest convenience. All blood samples were analysed by the 
Nottingham University Hospitals NHS Trust pathology laboratory. 
 
Demographic information, diagnosis and stage of disease, treatment plan, 
performance status as well as weight, height, previous weight and MUST score 
ZHUHGRFXPHQWHGE\ WKHUHVHDUFKHU:LWKWKHSDUWLFLSDQWV¶SHUPLVVLRQWKHLU*3V
were informed of their involvement in the study (Appendix 23).Twelve weeks later, 
SOXV RU PLQXV RQH ZHHN SDUWLFLSDQWV¶ ZHLJKWV ZHUe measured and percentage 
weight change calculated. The majority of subjects were attending the hospital 
within this time frame and had their weight measured in clinic. As it was not 
practically possible to visit all of those who did not have a hospital appointment, 
approximately ten percent of patients were asked to self-report their weight based 
RQ PHDVXUHPHQWV WDNHQ IURP WKHLU RZQ RU *3 SUDFWLFH¶V ZHLJKLQJ VFDOHV
Participants that were unable to weigh themselves within the time frame were 
excluded from the data analysis. Previous research suggests that, when asked to 
self-report, men and women, particularly those who are overweight, are inclined to 
under-estimate their body weight (Spencer et al., 2002; Gorber et al., 2007). 
However, unlike in the present study, this work has focussed on an overweight 
population and does not take into account the use of weighing scales.  Although 
self-reporting of weight in the present study could have led to a degree of 
imprecision when obtaining the follow up weight, it was felt that the extent of this 
had been minimised. In addition, the data was primarily used to categorise patients 
into groups of percentage weight loss or BMI.  
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Further information, with regard to date of death for those study participants who 
had died, was collected using the hospital data base on the 25th of August 2009. 
 
Outcome measures 
The primary outcome measure was percentage weight loss over the three month 
study period. Additional key outcome measures taken at baseline were: 
1. Responses to the 12 items on the Cancer Appetite and Symptom Questionnaire 
2. C-Reactive Protein serum concentration.  
3. Malnutrition Universal Screening Tool Score. 
 
3.3.4.7 Phase II data analysis 
As in Phase I of the study, for data analysis purposes, a score of zero to four was 
assigned to answers within each of the 12 items on the CASQ. As items four, eight, 
eleven and twelve were worded in the opposite direction to the other questions the 
scores were re-coded accordingly. A score of four was given to the answer which 
represented no symptom or appetite problems. Hence, low scores represented 
greater impairment. To compare the significance of the responses to the CASQ 
IURP WKH WZR WXPRXU JURXSV WKH 0DQQ:KLWQH\ 8 WHVW ZDV XVHG 3HDUVRQ¶V DQG
6SHDUPDQ¶VFRUUHODWLRQV established the predictive validity of the individual items of 
the CASQ and the total score in terms of percentage weight change. The optimal 
cut point for the instrument, and the sensitivity and specificity of each cut point, were 
determined from Receiver Operating Characteristics (ROC) curve analysis. Positive 
and negative predictive values were also estimated at each cut-off. This analysis 
was conducted for both 5% and 10% weight loss. Reasoning for this was that 
although guidance from NICE (2006) suggest a weight loss of greater than 10% to 
be of clinical significance, others have associated a weight loss of greater than only 
5% as having adverse outcomes (Evans et al., 2008).The level of agreement of the 
CASQ results at predicting those people who were at risk of malnutrition was 
compared with results from the pre-existing validated screening instruments, the 
MUST, MST and from C-Reactive Protein. This was evaluated using cross-
tabulations and the proportion of agreement determined. ROC curve analysis was 
also used to establish how the CASQ performed when predicting 5% and 10% 
weight loss compared with the other screening instruments. 
 
Exploratory multiple linear regression analysis, using a backward variable selection 
process, was used to build a model of the optimal set of variables that could 
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comprise a screening instrument. Variables were retained where P < 0.10 for log-
likelihood ratio tests. Cox proportional hazard survival regression was used to 
determine if the CASQ had predictive validity in terms of length of survival post 
diagnosis. All data was analysed using SPSS version 16.0 and STATA version 9. 
 
3.4 Qualitative research methods 
Phase III of the predicting weight loss study was a qualitative exploratory study 
conducted following the principles of the Straussian approach to grounded theory 
(Strauss and Corbin, 1994). The key objectives were to: 
1. Describe the experiences of people with lung or upper gastrointestinal 
cancer, and their carers, regarding the factors influencing weight change. 
2. Explore the causes and influencing factors of weight change in people with 
lung or upper GI cancer.  
3. Propose a conceptual model of influences on weight change in people with 
cancer. 
4. Identify areas for improvement regarding the nutritional management of 
people with cancer. 
 
An understanding of the origin and theory of qualitative research is important for any 
researcher wanting to participate in this type of work. This section will discuss some 
of the philosophy of qualitative research and, in particular as they are followed in 
this study, the principles of grounded theory. The section will conclude with a 
description of the methods followed in Phase III of this study. 
 
3.4.1 Qualitative research traditions 
Pope and Mays (1995) describe the goal of qualitative reseDUFK DV ³WKH
development of concepts which help us to understand social phenomena in natural 
(rather than experimental) settings, giving due emphasis to the meanings, 
H[SHULHQFHV DQG YLHZV RI DOO SDUWLFLSDQWV´ 7R DFKLHYH WKLV JRDO WKHUH DUH VHYHUDO
methodological approaches, or traditions, which can be followed. All traditions share 
the same underlying characteristics of qualitative research. Included in this is that 
the researcher holds the belief of the existence of multiple realities and plays an 
active role in the study. Also, that they have a commitment to understanding each 
SDUWLFLSDQW¶VLQGLYLGXDOSHUVSHFWLYH7KHFKRVHQDSSURDFKPD\EHGHWHUPLQHGE\WKH
type of research question which is to be answered. Some of the traditions which can 
be considered include grounded theory, phenomenology and ethnography. The 
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principles of grounded theory were followed in the present study to describe and 
explore the influences on weight change in people with cancer, with the overall aim 
being to guide intervention to improve the patient experience. As will be discussed 
in the next section, this tradition allows for theory on social processes to be 
constructed rather than, for example, the phenomenological or ethnographical 
methods which, are purely descriptive in their interpretation of lived experience or 
culture (Speziale and Carpenter, 2003). 
 
3.4.2 Principles of grounded theory 
Grounded theory was discovered by social scientists Glaser and Strauss in the 
1960s (Glaser and Strauss, 1967). The underlying principle of grounded theory is 
that new theories are developed from a systematic inductive, constant comparative, 
analysis of the data. These theories can then be used not only to advance 
understanding within that specific field of study, but also to be able to predict and 
explain human behaviour. Grounded theory differs from the other traditions in 
several ways. Firstly, it aims to develop theories on social processes rather than 
specific phenomena. In particular, it looks at how individual complex interactions 
lead to diversity within social processes. Secondly, the analysis of data commences 
as soon as it has been collected and, as a consequence, the sampling of 
participants, as well as the research schedule, may be adapted throughout the 
course of the study to focus on more pertinent points. Grounded theory is widely 
used within health and educational research and has been reported as the 
qualitative methodological approach of choice (Miller and Fredericks, 1999).  
Despite this, it has attracted criticism from some. Thomas and James (2006) 
highlight the limitations of the approach. A key area of disapproval is the rigidity of 
the analysis process, resulting in the potential for theory to be invented rather than 
discovered. For the novice researcher, possibly drawn to using grounded theory 
because of its structured approach, an understanding of these limitations will help to 
improve the validity and reliability of the study. 
 
From the time when grounded theory was first described by Glaser and Strauss, 
some of the fundamental aspects of this method have diversified. In part this has 
been due to the founders developing differing views regarding the detail of this 
research approach. Heath and Cowley (2004) describe some of the main 
GLIIHUHQFHV EHWZHHQ WKH WZR UHVHDUFKHUV¶ ideas. In summary, it seems that these 
are mainly methodological, rather than ontological or epistemological, in nature. In 
other words, both accept that there are multiple variations of reality regarding social 
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processes and both believe that new knowledge can emerge from the generation of 
theory. It is the techniques that are employed for the purpose of data analysis which 
differ. 
 
3.4.2.1 Grounded theory data collection  
Data collection begins with the sampling of participants. Within qualitative research 
studies, purposeful and theoretical sampling are widely used techniques. Although 
in some of the literature the terms appear to be used inter-changeably, there are 
pronounced differences between the two (Coyne, 1997). One of the key principles 
of grounded theory is the employment of theoretical sampling (Glaser, 1978). Here 
the researcher collects, codes and analyses data from the start of the study. 
Emerging theories direct the sampling of future participants and, as such, sample 
size cannot be pre-determined. There is the acknowledgement that in the initial 
stages purposeful sampling will need to be used to enable data collection to 
commence. As such, these participants will be selected on the basis of, for 
example, their gender, age or lived experiences. Data collection continues until 
saturation is reached and no new codes are emerging from the data. 
 
Interviews, observations and focus groups are frequently used enquiry techniques 
within qualitative research, although the exact method may be determined by the 
research question and chosen tradition. Unlike observation, talking to people allows 
one to gain an insight in to their individual perspective, emotions and feelings. 
Patton (2002) describes three structures of interviews which can be employed to 
help elicit the required information. The standardised open-ended interview, or 
structured interview, is a set of pre-determined questions asked to all participants. 
This allows for little flexibility in terms of probing for further information but is useful 
if a consistent approach is required. The general interview guide, or semi-structured 
interview, consists of an outlined schedule of questions. With this, method 
deviations and further exploration of themes brought up by the interviewee can be 
explored. The third type is the informal conversational interview, or un-structured 
interview. Here there are no pre-determined set of questions and no specific 
agenda. Conversation flows in a natural manner. As with all methods of inquiry the 
quality of the data collected is somewhat dependent on the skills of the interviewer. 
There is direction within the literature in terms of the suggested ordering of 
questions and the communication skills which the researcher should aim to use 
(Whyte and Whyte, 1984; Patton, 2002).  
3.4.2.2 Grounded theory data analysis 
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As previously highlighted, grounded theory uses a constant comparative approach 
to data analysis. Initially, as described by Glaser and Strauss (1967), this was a two 
stage process. The generation of multiple codes from the data is followed by 
reduction and comparison of the data from which emerges a conceptual framework 
around the core themes. Through continued modification and interpretation this 
framework can develop from a model, which describes and explains basic social 
and psychological processes, to a theory (Speziale and Carpenter, 2003). One of 
the main differences with the Straussian model is that it takes a more systematic 
approach to analysis (Heath and Cowley 2004). An intermediate phase termed 
µD[LDOFRGLQJ¶LVDGGHGZKHUHWKHLQLWLDOFRGHVDUHWKHQUHGXFHGGRZQLQQXPEHUE\
categorising them into similar concepts. The appropriateness of this, in terms of the 
UHVHDUFKHUµFKRRVLQJ¶WKHNH\WKHPHVDWDQHDUOLHUVWDJHRIWKHDQDO\VLVKDVEHHQ
highlighted as a limitation (Heath and Cowley, 2004).  
 
3.4.2.3 Trustworthiness in qualitative research 
Discussion of validity or rigor of qualitative research is an ongoing debate (Creswell 
and Miller, 2000). To determine the trustworthiness of qualitative research, Lincoln 
and Guba (1985) describe four questions that should be asked. Firstly, what is the 
credibility, or the level of confidence that we can have that the study findings are 
LQGHHGWKHµWUXWK¶"6HFRQGO\GRWKHILQGLQJVKDYHWUDQVIHUDELOLW\LHZKDWLQferences 
beyond the study population can be made? Thirdly, do the findings have 
dependability, would they be the same if the study was to be repeated? Finally, to 
what extent may the findings have been influenced by the researcher? Systems that 
can be used to influence the trustworthiness are described in the literature (Patton, 
1999; Mays and Pope, 2000; Creswell and Miller, 2000). These include 
methodologically developing analysis techniques to test for alternative explanations, 
including the use of triangulation, as well as determination of the credibility of the 
researcher. As the researcher acts as the data collection tool, analysis of their role, 
termed researcher reflexivity, can identify their belief systems, assumptions and any 
areas of bias. Additional methods may also involve the participants reviewing the 
interpretation of findings to ensure that it truly reflects their perspective. 
 
 
3.4.3 Phase III study participants 
Potential interviewees were those patients with lung or upper GI cancer, and their 
partner or carer, who were attending the out-patient clinics at Nottingham City 
Hospital and who were recruited into Phase II of the study.  
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3.4.4 Phase III sampling, recruitment and consent 
From August 2008 to February 2009, following ethical approval of the Phase III 
study, participants recruited in to Phase II of the study were asked to indicate on the 
consent form if they agreed to being interviewed if selected. Following the principles 
of grounded theory, the aim was to use theoretical sampling techniques. As such, 
the final sample size could not be predicted. Initially, to allow data collection to 
commence, sampling was purposeful. Potential interviewees were chosen on the 
basis of their diagnosis and level of weight loss over the three month, Phase II, 
study period.  Potential participants were approached by the researcher in the 
oncology out-patient clinic, or by telephone following their consultation, and invited 
to take part in the interviews. Where a partner or main carer was identified by the 
patient, they too were asked if they were interested in participating. If they were in 
agreement, a volunteer information sheet (Appendix 24) was given or posted out to 
them. It was envisaged that including the partner or carer would add to the depth of 
information, particularly regarding indicators of weight loss, appetite and food 
preparation. Following initial analysis of the data, rather than only including those 
people who had lost more than five percent of their body weight during the study 
period, theoretical sampling led to the inclusion of patients who had not lost a 
significant amount of weight. It was thought that this would provide information on 
strategies used by participants to maintain weight. 
 
3.4.5 Phase III data collection 
Interviewees were asked to attend the hospital at a time convenient to themselves, 
or they were given the option to be visited at home by the researcher. Prior to the 
interview commencing, informed written consent was given by the interviewee 
(Appendix 20) and, where appropriate, their partner or carer (Appendix 25). The 
interview process was explained by the researcher with the understanding that if at 
any point they wanted to stop they were able. Interview length was not constrained 
and varied from 17 to 70 minutes. All followed the same semi-structured format 
(Appendix 26) and began by asking interviewees to describe how their diagnosis of 
cancer had been made and the treatment that they had received to date. This was 
to help establish a time line of their weight prior to diagnosis, to current day. 
Interviewees were then asked to recall their experiences or observations of weight 
change, particularly regarding any signs and factors that contributed to weight loss. 
Information about the amount, type and source of any dietary advice that they had 
received was also gathered as was their experiences of any influences on ability to 
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comply. To avoid leading the interview, open questions were used by the 
researcher. In addition, where appropriate, probing questions were asked to gain 
more depth to the information discussed. Subsequent to the preliminary analysis of 
the first two interviews, the schedule was amended. Interviewees were asked to 
describe the information they would give to someone in a similar position with 
regards to the initial signs of weight loss and/or how to minimise weight loss.  
 
At the end of the interview patient participants were asked to once again complete 
the CASQ. This was to help gauge any potential changes in appetite and symptom 
burden from when they first joined the study. 
 
Within 24 hours of each interview, field notes were documented by the researcher. 
These included any thoughts about how the interviewees had responded, emotions 
expressed and underlying instincts regarding the key points raised. 
 
All interviews were digitally recorded and then transcribed verbatim by an assistant. 
Following this, the researcher went through all recordings and transcripts to check 
for accuracy and amendments were made where necessary. To ensure anonymity, 
false names were assigned to participants as well as any other family members, 
friends or health care workers who had been named in the conversation. 
 
3.4.6 Phase III data analysis  
Data organisation and retrieval was managed using the qualitative software 
package NVivo 8. Using techniques described within the tradition of grounded 
theory, the data was analysed to highlight similarities or differences between each 
SDUWLFLSDQW¶VH[SHULHQFHZLWK UHJDUGV WRDSDUWLFXODU WRSLF ,QLWLDOO\ WUDQVFULSWVZHUH
read and re-read. Multiple codes were then generated from the transcript data until 
saturation was reached and no new codes were emerging, at this point data 
collection ceased. More specifically, this stage of the analysis involved exploring 
small sections, sentences and paragraphs, of each transcript to establish what was 
happening in the data. Axial coding followed where codes were reduced in number 
and categorised into similar concepts. Relationships between the categories and 
sub-categories were established and checked within, and across, each of the 
transcripts.  Finally, summarisation and interpretation of key categories led to the 
emergence of core categories. From this, a conceptual framework was proposed. 
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3.5 Ethics 
3.5.1 Ethical approval 
The protocol and supporting information (Appendix 27) for all three phases of the 
study were given ethical approval by the Local Research Ethics Committee 
(Appendix 28) and the Research and Development Department at The University of 
Nottingham Hospitals NHS Trust (Appendix 29). 7KH1+67UXVW¶V2QFRORJ\&OLQLFDO
Trials Strategy Group also approved the study. Phases II and III were adopted by 
the National Cancer Research Network and were included within their portfolio of 
studies. 
 
3.5.2 Ethical issues 
The study was conducted in line with the Good Clinical Practice (GCP) guidelines 
(International Conference on Harmonisation, 1996). All patients and, where 
appropriate, their carer, gave informed written consent to take part in the study. To 
ensure anonymity and confidentiality all information about participants was entered 
onto a database in an anonymised form. Access to the database was restricted to 
authorised personnel and password protected. All hard copies of forms and 
questionnaires were kept in the research office which was locked when not in use.  
 
The main ethical issue for the study was that during Phase II potential participants 
were not given 24 hours to decide if they wished to take part. Justification for not 
giving longer was that if patients were identified at clinic as being eligible to 
participate they would be given the information sheet to take home. Those that 
decided to take part would then be required to come back to the hospital in a few 
days time to be consented, complete the CASQ and have a blood test. This would 
be on average a 10 to 15 minute appointment, for which there would be travel cost 
implications as well as the potential to increase levels of inconvenience and stress 
for the patient. Ethical approval was obtained to give participants as long a time 
period that was practical within the clinic setting between receiving the information 
sheet and being asked to give consent. There were minimal risks to participants 
recruited to the study. However, it was acknowledged that this was a vulnerable 
group of people, many having recently been diagnosed with a terminal condition. 
Discussing their condition and symptoms for some may have been emotionally 
distressing. 
CHAPTER 4: PHASE I: RELIABILITY TESTING OF THE CANCER APPETITE AND 
SYMPTOM QUESTIONNAIRE 
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4.1 Introduction 
Reliability testing is a key step in the development and evaluation of any 
measurement scale (Bland and Altman, 2002). Estimating reliability will determine 
the amount of error which is intrinsic to a screening instrument. The outcome from 
such testing may establish if an instrument will give reproducible results when 
administered to a specific population. If the Cancer Appetite and Symptom 
Questionnaire (CASQ) is to be of value within the clinical setting, reliability is 
therefore an important factor to consider.  
 
Phase I of the predicting weight loss study was a short-term longitudinal study, with 
two test points one week apart. The study sample included clinically stable adults 
diagnosed with cancer. The key objective was an estimate of the reliability of the 
CASQ. For a self-reported instrument such as the CASQ, test-retest and internal 
consistency were estimated as appropriate measures of reliability. 
 
The results of the analysis of the Phase I study data is presented in the subsequent 
section of this chapter. What follows is a discussion of the results specifically related 
to the estimated reliability of the CASQ. 
 
4.2 Phase I results  
4.2.1 Demographics 
Fifty-one potential participants were approached, 38 consented to take part and all 
38 completed the study. Twenty were female (53%) and the mean (SD) age was 60 
(11.3) years. The most common diagnosis was breast cancer (50%), then prostate 
cancer (39%), bladder cancer (8%) and rectal cancer (3%). Thirty- seven 
participants had an Eastern Cooperative Oncology Group (ECOG) performance 
status of zero, and one a performance status of one. At time point two, four of the 
participants noted an event over the previous week that had affected their appetite 
and/or symptoms. In pursuit of a stable population on which to test the reliability of  
the CASQ, these four subjects were therefore excluded from the test-retest 
analysis. 
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4.2.2 Mean scores and differences 
For the remaining participants (n=34), the mean (SD) total CASQ scores were 34 
(4.7) and 33 (4.4) at time point one and two respectively. The range of scores was 
from 22 to 42 at time point one, and 24 to 40 at time point two. 
 
4.2.3 Internal consistency  
Internal consistency quantifies the extent to which all items in an instrument 
measure the same concept. In effect, this indicates if and how the items are 
correlated with each other. To determine the internal consistency between the 12 
LWHPVRIWKH&$64&URQEDFK¶VDOSKDZDVFDOFXODWHG7DEOH&URQEDFK¶VDOSKD
estimates reliability based on an average of all possible correlations between items. 
Although there is no agreed acceptable level, a value of 0.7 to 0.8 is deemed 
satisfactory by most researchers (Streiner and Norman, 2008). In addition to 
calculating the &URQEDFK¶V DOSKD FRHIILFLHQW IRU WKH  LWHP &$64 LW ZDV DOVR
calculated for each of the three domains, i.e. questions one to four relating to 
appetite, questions five and six about food intake and the remaining questions about 
symptoms. To determine if any of the CASQ items were reliability reducing, the 
&URQEDFK¶VDOSKDFRHIILFLHQWVIRUHDFKRIWKHUHPDLQLQJLWHP&$64PRGHOVZHUH
DOVR FDOFXODWHG 7DEOH  *HQHUDOO\ WKH &URQEDFK¶V DOSKD FRHIILFLHQWV DW HDFK
time point were similar. For all models, except the one containing only the food 
LQWDNHTXHVWLRQVWKH&URQEDFK¶VDOSKDFRHIILFLHQWVPHWWKHDFFHSWDEOHOHYHO 
 
&DOFXODWHGDWWLPHSRLQWRQHDQGWLPHSRLQWWZRWKH&URQEDFK¶VDOSKDFRHIILFLHQWIRU
the 12 item CASQ is shown, along with the calculated coefficient for each of the 
WKUHH GRPDLQV DSSHWLWH IRRG LQWDNH DQG V\PSWRPV 7KH &URQEDFK¶V DOSKD
coefficient for the 10 questions relating to appetite and symptoms is also shown.  
 
 
 
 
7DEOH&URQEDFK¶VDOSKDFRHIILFLHQWVIRUWKH&$64TXHVWLRQV 
 &URQEDFK¶VDOSKDFRHIILFLHQW 
CASQ questions Time point 1 Time point 2 
1 to 12 0.76 (95%CI 0.63 to 0.86) 0.74 (95% CI 0.60 to 0.85) 
1 to 4 Appetite 0.72 (95%CI 0.54 to 0.84) 0.82 (95% CI 0.70 to 0.90) 
5 to 6 Food intake -0.40 (95%CI -1.69 to 0.27) -0.18 (95%CI -1.26 to 0.39) 
7 to 12 Symptoms 0.65 (95%CI 0.45 to 0.80) 0.72 (95% CI 0.55 to 0.84) 
1 to 4 and 7 to 12 
Appetite & symptoms 
0.80 (95%CI 0.68 to 0.89) 0.78 (95% CI 0.65 to 0.87) 
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$V FDOFXODWHG DW WLPH SRLQW RQH DQG WLPH SRLQW WZR WKH &URQEDFK¶V DOSKD FRHIILFLHQW DQG
95% confidence intervals, for each of the 11 item CASQ models is shown. 
 
4.2.4 Test-retest reliability: Measurement of agreement 
4.2.4.1 Correlations 
A scatter plot was drawn to determine the correlation of the results given by each 
participant at time point one and time point two. Figure 4.1 shows the line of 
regularity with a high positive correlation between the results. Using PeDUVRQ¶V
correlation method, r = 0.80 (P<0.01). 
 
4.2.4.2 Bland-Altman plot 
To determine the extent of agreement between the total CASQ scores at the two 
time points, the results were plotted on a Bland-Altman plot (Figure 4.2). This type 
of plot allows a graphical representation of the between time point differences 
among the CASQ scores. On the Y axis, for each participant, the difference 
between their total CASQ scores at time point one and time point two is plotted, and 
on the X axis the mean of these two scores. The mean difference of the scores 
between the two time points was -0.20 (95% CI = -1.21 to 0.80), with a within 
subject standard deviation of the differences of 2.91. The upper limit of agreement 
was 5.62, and was estimated as plus 1.96 standard deviations from the mean. The 
lower limit of agreement, estimated as minus 1.96 standard deviations from the 
mean, was -5.90. No obvious relationship could be seen between the differences 
and the mean and there was a random scatter around zero. As 95% of the 
differences fell between the limits of agreement we can assume that the differences 
are normally distributed (Bland and Altman, 1986). 
 
7DEOH&URQEDFK¶VDOSKDFRHIILFLHQWVIRUWKHLWHP&$64PRGHOV 
 &URQEDFK¶VDOSKDFRHIILFLHQWRILWHPPRGHO 
CASQ question removed Time point 1 Time point 2 
1 (Appetite) 0.71 (95% CI 0.56 to 0.83) 0.71 (95% CI 0.55 to 0.83) 
2 (Satiety) 0.72 (95% CI 0.56 to 0.83) 0.71 (95% CI 0.55 to 0.83) 
3 (Hunger) 0.76 (95% CI 0.62 to 0.86) 0.74 (95% CI 0.59 to 0.85) 
4 (Enjoyment) 0.72 (95% CI 0.56 to 0.83) 0.70 (95% CI 0.54 to 0.83) 
5 (Meals) 0.75 (95% CI 0.62 to 0.86) 0.73 (95% CI 0.59 to 0.84) 
6 (Snacks) 0.80 (95% CI 0.69 to 0.88) 0.78 (95% CI 0.66 to 0.87) 
7 (Taste) 0.74 (95% CI 0.60 to 0.85) 0.72 (95% CI 0.57 to 0.84) 
8 (Taste change) 0.72 (95% CI 0.57 to 0.84) 0.69 (95% CI 0.52 to 0.82) 
9 (Nausea and vomiting) 0.73 (95% CI 0.59 to 0.84) 0.70 (95% CI 0.54 to 0.83) 
10 (Mood) 0.75 (95% CI 0.61 to 0.85) 0.70 (95% CI 0.54 to 0.83) 
11 (Energy) 0.72 (95% CI 0.57 to 0.84) 0.75 (95% CI 0.61 to 0.85) 
12 (Pain) 0.75 (95% CI 0.61 to 0.85) 0.76 (95% CI 0.62 to 0.86) 
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Figure 4.1: Agreement between total CASQ score completed at time point one and 
time point two, one week apart. For this positive correlation r = 0.80 (P < 0.01). The 
95% confidence intervals demonstrate that the majority of the scores fall within 
these parameters. 
-
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Figure 4.2: Bland-Altman plot to show the extent of the agreement between the total 
CASQ scores at time point one and time point two. The limits of agreement are 
included and demonstrate that 95% of the differences fall between these 
parameters. 
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4.2.4.3 Kappa coefficient 
In order to measure the level of agreement of the CASQ scores, for each of the12 
items in the instrument, between the two time points, the un-weighted and weighted 
&RKHQ¶V NDSSD FRHIILFLHQWV ZHUH FDOFXODWHG 7DEOH  5DWKHU WKDQ VLPSO\
calculating the percentage agreement between the two scores, the kappa coefficient 
takes into account the level of agreement that can occur by chance. A kappa value 
of one would indicate perfect agreement between the two scores, whereas a value 
of zero would indicate no agreement more than chance alone. A negative value 
would imply a level of agreement worse than chance. Table 4.4 shows the 
suggested levels of agreement attached to kappa by Landis and Koch (1977). 
 
Table 4.3: Weighted and un-weighted kappa scores for each of the 12 items of 
CASQ 
 
Question 
number 
Question theme Un-weighted 
kappa 
Weighted 
kappa 
5 Number of meals 1.00 1.00 
2 Satiety 0.75 0.82 
10 Mood 0.67 0.74 
7 Taste compared with pre-illness 0.64 0.74 
8 Taste changes 0.60 0.68 
6 Number of snacks 0.52 0.63 
11 Energy level 0.58 0.59 
12 Pain 0.56 0.54 
3 Hunger 0.46 0.54 
4 Enjoyment of food 0.42 0.53 
9 Nausea 0.41 0.53 
1 Appetite 0.37 0.51 
For each of the 12 items of the CASQ, the un-weighted and weighted kappa scores 
are shown. 
 
Table 4.4:Suggested levels of agreement for values of kappa 
  
Value of kappa Strength of agreement 
< 0.20 Poor 
0.21 ± 0.40 Fair 
0.41 ± 0.60 Moderate 
0.61 ± 0.80 Good 
0.80 -1.00 Very good 
The suggested levels of agreement for values of kappa, as suggested by Landis 
and Koch (1977) are shown. 
 
Taking these suggested values into consideration, all 12 items of the CASQ had 
weighted kappa values above 0.5. This implies that there was moderate to very 
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good agreement between the CASQ scores produced at the two time points. 
      
4.2.4.4 Intraclass correlation coefficient 
The intraclass correlation coefficient (ICC) is a ratio of the variance between 
subjects to the total variability, where total variability is the sum of between subject 
YDULDELOLW\DQGPHDVXUHPHQWHUURURUµZLWKLQVXEMHFW¶YDULDQFH$YDOXHRIRQHZRXOG
imply that there was no measurement HUURUD µSHUIHFW LQVWUXPHQW¶)RU WKH&$64
the ICC was calculated as 0.80 (95% CI = 0.68 to 0.92). 
 
4.3 Discussion 
4.3.1 Study design  
The key objective for Phase I of the study was to derive an estimate of the reliability 
of the CASQ. Indeed, reliability testing is an important step in the development of 
any new instrument which is to be used within the healthcare setting. Yet, reliability 
is not necessarily something that is easy to determine and the varied terminology 
within the literature often leads to confusion when interpreting reliability statistics.   
 
An area of much debate, when determining the test-retest reliability of an 
instrument, is how long the time interval should be between administrations of the 
instrument. If it is too long there is a risk that the characteristics of the sample may 
have changed. Too short an interval may result in a memory effect and subjects will 
remember their previous responses. A study by Marx et al. (2003), comparing test-
retest reliability (ICC and limits of agreement) of a health related quality of life 
instrument, at two days and two weeks, found no statistical differences over the two 
time intervals. This concurs with the suggestion from Streiner and Norman (2008) 
who suggest the retest interval should be between two and fourteen days.  In this 
study the time interval between participants completing the CASQ was one week. 
As there is no agreed retest period it can be assumed that this is appropriate. There 
is however the possibility that completing the questionnaire at time point one made 
the participants more aware of their appetite and symptoms. This could have 
influenced their subsequent responses and indeed the estimated reliability of the 
instrument.  
 
4.3.2 Study population 
It is intended that the CASQ will be used with people who have got cancer and it is 
within this population that the reliability study was conducted. The sample tested in 
this study included similar numbers of males and females. It was also diverse in 
67 
 
terms of age and diagnosis. This is important as if the population tested is vastly 
different to the one that the instrument is intended to be used with one could argue 
that the estimated reliability may not be valid (Streiner and Norman, 2008). When 
determining test-retest reliability of an instrument, not only is the time frame over 
which the test takes place important, so is the stability of the sample. Testing the 
instrument on a population which has a rapidly changing clinical status, for example 
patients having chemotherapy, could lead to a dramatic change in appetite and 
symptoms over the course of even a few days. As patients in this study were 
receiving adjuvant rather than palliative radiotherapy, and those receiving treatment 
to the head, neck or upper gastrointestinal tract area or with a condition impairing 
their ability to swallow were excluded, it can be argued that the sample was 
clinically stable. In addition, all participants had a good performance status (ECOG 
0/1) indicating that they were independent and overall able to perform all activities of 
daily living. What must be questioned is if the sample population is similar enough to 
the population where the CASQ will ultimately be used. From the results, there was 
certainly a difference in the variance of responses that the sample gave compared 
ZLWKZKDW\RXZRXOGH[SHFWWRVHHLQDµKHDOWK\SRSXODWLRQ¶7KLVFDQEHVHHQIURP
the large range (22 to 42) of total CASQ scores. This indicates that some subjects 
had an impaired appetite and presence of symptoms and is likely to be similar to the 
wider cancer population. However, it is possible that a sample taken from another 
group of patients, for example those undergoing chemotherapy or who have had 
recent surgery, would yield different results. In these groups CASQ scores may 
overall be lower and, if many of the patients were experiencing similar problems, the 
variance narrower. When developing a new instrument, practically it would be 
extremely time consuming to have to re-evaluate its reliability in a number of 
different patient groups. Plus, the clinical instability within such groups, between 
even the shortest time points, may lead to unreliable results. For these reasons 
testing the reliability of the CASQ in a wider and probably unstable cancer 
population would have been unsound, thus suggesting that the sample selection 
used in this study was likely to be the best possible. 
 
4.3.3 Internal consistency  
Based on the correlation between responses to items in the CASQ using the 
&URQEDFK¶V DOSKD FRHIILFLHQW WKH LQWHUQDO FRQVLVWHQF\ RI WKH LQVWUXPHQW ZDV
assessed (Cronbach, 1951). It is generally stated that the closer the resulting value 
is to one, the stronger the correlation and the higher the reliability. However, there is 
a lack of agreement in the literature as to what constitutes an acceptable level. 
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There is a body of evidence that suggests the acceptable value should be 
dependent on whether the instrument being tested is to be used as a research tool 
or in clinical practice (Bland and Altman, 1997; Charter, 2008). If the aim is the latter 
then the necessary level of acceptability is higher as it is more important to 
determine the population reliability. Others take the approach that the acceptable 
level is dependent also on the sample size (Ponterotto and Ruckdeschel, 2007). 
Streiner and Norman (2008) summarise that a value higher than 0.7 and lower than 
LVLGHDO$YHU\KLJK&URQEDFK¶VDOSKDYDOXHLHJUeater than 0.9, may simply be 
reflecting a large number of items being tested or suggesting that some of the items 
may be repetition of information and therefore unnecessary.  
 
When looking at the internal consistency of the CASQ over all 12 items, the results 
were similar at time point one (0.76) and time point two (0.74). This result can be 
interpreted as there being an acceptable average reliability between the 12 items of 
the CASQ, with approximately 70% of the measured variability being reliable and 
30% down to random error. As a research or clinical instrument, 0.7 has been 
proposed as the absolute minimum internal consistency reliability of test scores 
(Charter, 2008). This provides evidence to support the use of the CASQ in research 
or clinical practice. However, the 95% confidence intervals indicate that the true 
value could be as low as 0.6 or as high as 0.85 and this must be considered when 
interpreting the results.  
 
6LPLODU &URQEDFK¶V DOSKD YDOXHV ZHUH DFKLHYHG ZKHQ ORRNLQJ DW DSSHWLWH VSHFLILF
(0.72 at time point 1 and 0.82 at time point 2) and symptom specific (0.65 at time 
point 1 and 0.72 at time point 2) items. Other areas of the CASQ appeared to be 
less well correlated. Items five and six both focus on level of food intake; meals and 
snacks. Generally some level of agreement between responses to these items 
would be expected. However, at both time points these items were negatively 
correlated (-0.40 and ± 0.18 respectively). This negative value is possibly due to the 
ordering and response options available. Three meals a day is the standard meal 
pattern within the U.K. For items five and six to be correlated, subjects would also 
need to have three snacks a day. This may be unlikely in this particular population. 
Response options may also account for poor correlations between other questions. 
)RUH[DPSOHZKHQUHVSRQGLQJWRLWHPVHYHQVXEMHFWVZKRWKRXJKWIRRGWDVWHGµMXVW
DV JRRG¶ ZHUH OLNHO\ WR UHVSRQG WRTXHVWLRQ HLJKW ZLWK µQR FKDQJHV LQ WDVWH¶7KLV
would have resulted in a poor correlation between these items. Of course another 
UHDVRQ IRU ORZHU &URQEDFK¶V DOSKD YDOXHV DQG LQGHHG WKH QHJDWLYH YDOXH LV WKDW
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there are only two items being tested. The more items in a scale the less random 
error matters as it will cancel itself out, resulting LQDODUJHU&URQEDFK¶VDOSKDYDOXH
(Streiner and Norman, 2008). Interestingly, when each item was removed from the 
CASQ, one by one, the value never dropped below 0.7. This suggests that none of 
the individual items significantly reduced reliability. However, removing items five 
DQGVL[GLGLQFUHDVHWKH&URQEDFK¶VDOSKDYDOXHDWERWKWLPHSRLQWVDQG 
 
4.3.3.1 Unidimensionality 
:LWKLQWKHOLWHUDWXUHWKH&URQEDFK¶VDOSKDFRHIILFLHQWLVRIWHQTXRWHGDVDPHDVXUH
of unidimensionality, or the extent to which all items within an instrument are 
measuring the same concept or dimension. However, there is debate as to the 
DSSURSULDWHQHVVRIXVLQJ&URQEDFK¶VDOSKDDVDPHDVXUHRIXQLGLPHQVLRQDOLW\RIDQ
instrument as the coefficient accounts for only a low limit of variance attributable to 
common factors (Falissard, 1999; Sijtsma, 2009).  Despite its limitations, the use of 
&URQEDFK¶V DOSKD DV D PHDVXUH RI LQWHUQDO FRQVLVWHQF\ FRQWLQXHV WR EH
recommended by experts (Streiner and Norman, 2008). 
 
It is important to consider how important it is for the CASQ to have 
XQLGLPHQVLRQDOLW\7KHRYHUDOOSXUSRVHRIWKH&$64LVWRGHWHUPLQHDSHUVRQ¶VOHYHO
of nutritional risk so that nutritional treatment can be initiated, where necessary, in a 
timely manner. It is not the intention to compare one person to another or draw 
conclusions in terms of severity of appetite or symptoms experienced by an 
individual. Nutritional risk is not a homogenous entity. There are several dimensions 
WKDW FDQ FRQWULEXWH WRZDUGV D SHUVRQ¶V Qutritional risk. Indeed the CASQ 
incorporates three such dimensions; items relating to appetite, food intake and 
symptoms. In addition, one of the objectives of this study was to propose a multi-
dimensional screening instrument, encompassing all aspects of the cachexia 
syndrome, which will predict weight loss in people with cancer. Therefore, one must 
question the need for the CASQ, as a 12 item tool, to have proven 
unidimensionality. If in clinical practice the CASQ is only to be used as a screening 
instrument, why the individual is at nutritional risk is of low importance. Whether 
they have one severe symptom or several minor ones, or if indeed they are 
symptom free but have a poor appetite and intake due to other factors, they will be 
at nutritional risk and this is ultimately the issue which needs to be addressed.  
 
One way of determining if indeed the CASQ is composed of different dimensions 
would be to use factor analysis. However, it is possible that using this technique 
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would result in an instrument with reduced content validity and with key clinical 
questions made redundant. Instead, as suggested by Kessler and Mroczek (1995), 
multiple logistic regression was used in Phase II of the study to explore the optimum 
combination of items to include in the screening instrument. 
 
4.3.4 Test-retest reliability: Measurement of agreement  
Test-retest reliability is used to determine the consistency of a measure from one 
time point to another. In this study, it is the reproducibility of the CASQ scores 
between two time points one week apart, when administered to the same 
population, which was determined. To minimise contamination by external factors, 
the CASQ was administered within the same setting. To ensure a stable population, 
all subjects who documented an event during the previous week that had impacted 
on their appetite and/or symptoms, were excluded from this analysis. 
 
4.3.4.1 Correlations 
As can be seen from the scatter plot (Figure 4.1), there was a strong positive 
correlation between the total CASQ scores at the two time points, with minimal 
variation from the line of regularity. The Pearson correlation coefficient (r = 0.80, P< 
0.01) also supports this finding. However, the correlation coefficient is a measure of 
the relationship between two items, not the level of agreement and therefore must 
be interpreted with caution. In addition, when testing the significance of the result, 
the null hypothesis is that the CASQ scores at time point one and time point two are 
not linearly related. It would be surprising if at the repeat administration of the 
CASQ, in a stable population, the responses were not related to those given initially.  
 
4.3.4.2 Bland-Altman plot 
To demonstrate more clearly the size of the differences between the total CASQ 
scores at the two time points and the scatter around zero, the results were plotted 
on a Bland-Altman plot. The Bland-Altman Plot (Figure 4.2) shows several important 
and positive points when considering the reliability of the CASQ. Firstly, 95% of the 
measurements fell within the limits of agreement (-5.90 to 5.92) demonstrating a 
normal distribution of the data (Bland and Altman, 1986). If the CASQ was 
administered to a new individual on two occasions we would expect the difference in 
their scores to be less than 5 in either direction. Secondly there was a random 
scatter of measurements around the point of zero. This is a positive result as it 
demonstrates that the size of the difference is not related to where participants were 
ranked in terms of appetite and symptoms. Finally, as the confidence interval for the 
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mean difference included zero, this suggests that there is no evidence of bias, i.e. 
total CASQ scores do not have a tendency to drift up or down.  
 
4.3.4.3 Kappa coefficient 
Simply calculating the proportion of participants giving the same answer to each 
question on the CASQ at time point one and time point two, would not take into 
account how the results were influenced by chance. For this reason the kappa 
coefficient for each of the 12 items of the CASQ can be calculated. The kappa 
coefficient gives a chance-corrected agreement. However, when the un-weighted 
kappa coefficient is calculated, there is no consideration for the extent of 
disagreement and values are likely to be lower. For this reason, as the data is 
ordinal, calculating the weighted kappa coefficient is favoured (Cohen, 1968). In this 
case, to calculate weighted kappa, responses to the 12 items of the CASQ, as 
described by Altman (1991), were given linear weightings of 1.0, 0.75, 0.5, 0.25 and 
0 depending on their distance from the diagonal that indicates agreement. For the 
12 individual items, values for weighted kappa ranged from 0.51 to 1.0. Several 
authors have proposed cut-off values for interpreting the kappa value (Fleiss and 
Cohen, 1973; Landis and Koch 1977), suggesting that the values obtained in this 
study indicate moderate to very good agreement between the two time points. 
Streiner and Norman (2008) however suggest that any value less than 0.6 should 
be disregarded as having an unacceptably low level of agreement. This would mean 
that six items in the CASQ have a questionable level of reliability. One possible 
UHDVRQIRUWKHVHORZHUYDOXHVFRXOGEHGXHWRDUHDOYDULDWLRQLQVXEMHFW¶VDSSHWLWH
and symptoms over the course of the week. Questions which had strong agreement 
asked about, for example, the number of meals or snacks eaten or changes in taste. 
These are all likely to be more stable variables over the course of one week. 
 
4.3.4.4 Intraclass correlation coefficient 
An intraclass correlation coefficient of 0.80 (95%CI = 0.68 to 0.92) suggests that 
80% of the total variability is between subjects rather than within total CASQ scores 
at the two time points. This demonstrates good reliability of the CASQ as the 
measurement error, or difference between the CASQ scores at the two time points, 
is low. 
 
4.3.5 Reliability of other nutrition screening instruments 
Due to the way that reliability statistics are reported in the literature, comparison 
between screening instruments is not always possible. In addition, when there are 
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differences in the number of categories within items, and indeed the number of 
items in the instrument, comparisons need to be made with caution (Altman, 1991). 
Often, authors do not provide sufficient evidence to show how the reliability of their 
instrument has been determined, with many describing only the inter-rater reliability 
of the instrument (Detsky et al., 1987; Ferguson et al., 1999; Burden et al., 2001; 
Jones, 2002; Weekes et al., 2004). As the CASQ is self-reported, inter-rater 
reliability has not been established in this study and so cannot be compared. Few 
papers report the internal consistency or ICC of their instrument. The eight item 
Council on Nutrition Appetite Questionnaire (CNAQ), from which the CASQ was 
GHULYHGKDVDQHVWLPDWHG&URQEDFK¶VDOSKDYDOXHRILQDJURXSRI subjects in 
long-term care, and of 0.72 in community-dwellers (Wilson et al., 2005). The results 
from the CASQ analysis are similar in strength to those found by Wilson and 
colleagues (2005). However, the difference in the number of items in the two 
instruments should be considered. The ICC of the CNAQ was not reported so this 
cannot be compared. The Mini Nutritional Assessment (MNA) is an instrument that 
was developed to identify elderly patients who are malnourished (Vellas et al., 
1999). Reliability testing of the MNA suggests an ICC of 0.89 (confidence intervals 
QRWUHSRUWHGDQG&URQEDFK¶VDOSKDYDOXHRI%OHGDet al., 2002). These results 
are not too dissimilar to those estimated for the CASQ, suggesting that this level of 
reliability is acceptable when comparing it to other more established tools. 
 
4.4 Conclusion 
Reliability cannot be calculated. However, by using a combination of methods, 
giving consideration to the strengths and weakness of each, reliability can be 
estimated. In this study, two classes of reliability estimates have be used; internal 
consistency and test-retest reliability. The results suggest that within the test 
population, the CASQ scores had good test-retest reliability, and the 12 items show 
an acceptable degree of internal consistency. Phase II will determine the validity of 
the CASQ to predict weight loss in people with cancer. 
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CHAPTER 5: PHASE II: VALIDITY TESTING OF THE CANCER APPETITE AND 
SYMPTOM QUESIONNAIRE  
 
5.1 Introduction 
Many people experience a degree of weight loss prior to being diagnosed with 
cancer. Upon diagnosis some patients will present with the symptoms of the 
cachexia syndrome and malnutrition. Existing nutrition screening instruments, such 
as the Patient Generated Subjective Global Assessment (PG-SGA) and Malnutrition 
Screening Tool (MST), have been validated in people with cancer to identify those 
who are already exhibiting signs of malnutrition (Bauer et al., 2002; Isenring et al., 
2006). In addition, some instruments, for example the Malnutrition Universal 
Screening Tool (MUST), Mini Nutritional Assessment (MNA) and Nutritional Risk 
Screening 2002 (NRS-2002), when used in a hospital population, have proven 
predictive validity in terms of length of stay, clinical outcome and morbidity (Bauer et 
al., 2005; Kyle et al., 2006; Stratton et al., 2006). However, no tool, when tested with 
people who have cancer, appears to be predictive of weight loss. A screening 
instrument that can predict those people who are not already malnourished but who 
are likely to lose weight in the future may help to target nutritional advice and 
treatment in a proactive manner.  
The key objectives for Phase II of the study were to: 
9. Obtain an estimate of the reliability of the CASQ. 
10. Determine the predictive validity of the CASQ 
11. Determine the optimal cut points and overall performance of the CASQ at 
predicting clinically significant weight loss over three months.  
12. Propose an optimum screening instrument to predict clinically significant 
weight loss over three months.  
 
A longitudinal observational study with two test points, three months apart was used 
to meet these objectives. The study sample included patients with lung or upper GI 
cancer who were not at high risk of malnutrition. Self-completed CASQ scores, 
anthropometric data and serum concentrations of C-Reactive Protein (CRP) and 
albumin were collected and analysed. To estimate the predictive validity of the 
CASQ, correlations were calculated. Receiver Operating Characteristic (ROC) curve 
analysis was used to determine the optimal cut point, sensitivity and specificity of 
the instrument. To explore the optimum set of variables that could be included in a 
screening instrument to predict weight loss, multiple linear regression techniques 
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ZHUHXVHG)LQDOO\D&R[¶VUHJUHVVLRQVXUYLYDODQDO\VLVZDVSHUIRUPHGWRGHWHUPLQH
the ability of the CASQ, and other measured variables, to predict survival. The 
results of the analysis of the Phase II study data are presented in the subsequent 
section of this chapter. What follows is a discussion of the results, specifically 
focusing on the use of the CASQ as a predictor of weight loss in the cancer 
population. 
 
5.2 Results 
5.2.1 Phase II participant recruitment 
In all, 346 subjects diagnosed with lung or upper GI cancer were approached and 
asked if they agreed to be screened for risk of malnutrition using the MUST. As 
demonstrated by the flow chart (Figure 5.1), only a small number (nine) declined the 
initial screening process. Of the remaining 337, 70% (236) met the study inclusion 
criteria of having a MUST score of less than two. Of those screened, 22% had no 
further involvement in the study. Whereas 16 patients failed to meet the other 
inclusion criteria for the study, 35 declined to take part. Anecdotally, reasons most 
frequently given for not wanting to take part were the burden of having to read 
through the participant information sheet or, not having their spectacles available. 
6RPHUHSRUWHGKDYLQJ³WRRPXFKRQ´DWWKHPRPHQWOf the 16 that did not meet the 
inclusion criteria, one patient had ascites, one dementia and in two cases the 
primary cancer site had not been determined. The remaining 12 patients were 
excluded as the researcher deemed their inclusion inappropriate at that point in 
time. This was due to the patient being too unwell, receiving bad news or already 
currently participating in another research study. A total of 185 patients gave 
consent to take part. With a lower than expected attrition rate of 10%, this meant 
that 167 completed the three month study. 
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Population approached
n = 346
Screened using MUST
n = 337
Declined MUST screening
n = 9
Did not meet criteria 
Dh^dш ?
n = 101
Met criteria MUST < 2
n = 236
Not recruited
n = 51
Recruited
n = 185
Did not meet 
inclusion criteria
n = 16
Declined
n = 35
Completed study
n = 167
 
Figure 5.1: Flow chart of Phase II study population. The number of patients who 
were approached and asked to take part in the study, along with the number who 
were screened and finally recruited is shown. 
 
 
5.2.2 Baseline characteristics of Phase II study population 
The baseline characteristics of the 185 patients consented to take part can be seen 
in Table 5.1. Sixty-one percent of the study sample was male and the mean (SD) 
age was 66.7 (9.4) years. The majority (99.5%) of the population were white British. 
Ninety percent of the group had an ECOG performance status of zero or one. This 
suggests that the majority were independent and able to carry out all but the most 
strenuous activities of daily living. There was a reasonable split of participants 
between the two tumour groups, with 59% having a cancer of the upper 
gastrointestinal tract and 41% being diagnosed with lung cancer. The length of time 
since diagnosis ranged from less than one month to over five years (mean (SD) = 
7.9 (9.6) months). The majority of patients (68%) were undergoing chemotherapy at 
some stage during the study period. For most of the study population the intent of 
their treatment was palliative, thus indicating that 72% had incurable disease. 
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Baseline demographic, anthropometric and clinical details are shown. For the age and time 
since diagnosis, and the anthropometric measurements, the mean, standard deviation and 
range is given. Remaining results are shown as frequencies. The numbers of missing cases 
are also highlighted. 
Table 5.1: Baseline characteristics of Phase II study sample (n=185) 
 
   Missing (n) 
 Mean (SD) Range  
Age (years) 66.7 (9.4) 42.9 to 86.7 0 
Time since diagnosis (months) 7.9 (9.6) 0.2 to 63.3 0 
Weight (kg) 74.4 (14.3) 44.2 to 121.2 1 
Body Mass Index (kg/m2) 26.0 (4.0) 18.8 to 41.5 1 
% 3 to 6 months weight change -0.3 (5.6) -9.8 to 25.9 2 
    
 n (%)   
Sex   0 
  Male 113 (61.1)   
  Female 72 (38.9)   
    
Ethnicity   0 
  White British 184 (99.5)   
  Other 1 (0.5)   
    
Social circumstances   1 
  Lives with partner 142 (76.8)   
  Lives alone 34 (18.4)   
  Lives with son or daughter 6 (3.2)   
  Lives with other 2 (1.1)   
    
East Coast Oncology Group 
performance status 
  0 
  0-1 167 (90.1)   
   >1 18 (9.7)   
    
Tumour group   0 
  Upper gastrointestinal 109 (58.9)   
  Lung 76 (41.1)   
    
Primary tumour site    0 
  Pancreas 51 (27.6)   
  Gastro-oesophageal 43 (23.2)   
  Cholangiocarcinoma 12 (6.5)   
  Liver 3 (1.6)   
  Non small cell lung cancer  46 (24.9)   
  Small cell lung cancer  26 (14.1)   
  Mesothelioma 4 (2.2)   
    
Treatment intent   0 
  Curative 52 (28.1)   
  Palliative 
 
Treatment during study 
  Chemotherapy  
  Chemotherapy and surgery 
  Chemotherapy and radiotherapy 
  Radiotherapy 
  Supportive care  
133 (71.9) 
 
 
115 (62.2) 
3 (1.6) 
2 (1.1) 
7 (3.8) 
58 (31.4) 
  
 
0 
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5.2.3 Baseline nutritional screening 
As shown in Table 5.1, at baseline, the mean (SD) body weight and BMI of the 
study population was 74.4 (14.3) kg and 26 (4.0) kg/m2 respectively. Table 5.2 
shows additional baseline nutritional screening characteristics, including the 
categorisation according to BMI and percentage weight change of participants. Due 
to the exclusion criteria those with a MUST score greater than or equal to two, 
indicated by a  BMI less than 18kg/m2 or percentage weight change greater than ten 
percent, were excluded from taking part. The majority of participants (78%) had a 
MUST score of zero, with the remainder scoring one, indicating a moderate risk of 
malnutrition. Information collected also enabled the completion of an alternative 
screening instrument, the Malnutrition Screening Tool (MST) (Appendix 9). In 
contradiction to the MUST, a significant proportion of subjects were classified by the 
MST as being at high and medium risk of malnutrition, 28% and 21% respectively. 
Blood biochemistry monitoring showed that 53 participants had serum C-Reactive 
Protein concentrations greater than 10mg/L, which may be indicative of a systemic 
inflammatory response. One in five patients had an albumin level which was below 
the lower limit of normality. All participants were asked to provide a blood sample. 
As this frequently meant waiting for the clinic phlebotomist following their 
consultation with the doctor, compliance with this part of the study was poor. This 
resulted in the higher number of missing cases. 
 
5.2.4 Cancer Appetite and Symptom Questionnaire responses 
One hundred and eighty-one subjects completed the CASQ at baseline. Potential 
scores were zero to 48, with higher scores indicating fewer appetite and symptom 
problems. The mean score (SD) was 30 (6.5) and scores ranged from five to 45. 
The overall frequency of responses is shown in Table 5.3 and the percentage 
distribution in Figure 5.2. In total, 21% of respondents rated their appetite as poor or 
very poor. Most prominent symptoms potentially contributing towards a poor 
appetite included moderate or severe taste changes, and pain, reported by 33% and 
27% of subjects respectively. In addition, just less than half (42%) of people 
reported never feeling sick or nauseated before eating. The majority of participants 
ate three meals (57%) and one or two (69%) snacks a day. 
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Table 5.2: Baseline nutrition screening characteristics of Phase II study 
population (n=185) 
 
 Frequency (%) Missing (n) 
Body Mass Index (kg/m2)  1 
  <18.5 0 (0)  
  18.5 to 20 4 (2.2)  
  20 to 25 78 (42.4)  
  25 to 30 72 (39.1)  
  30 to 35 27 (14.7)  
  >35 3 (1.6)  
   
Weight change over previous 3 months (%)  2 
+>10 8 (4.4)  
  +5 to10 19 (10.4)  
  0 to +5 57 (31.1)  
  0 to -5 61 (33.3)  
  -5 to10 38 (20.8)  
  - >10 0 (0)  
   
   
Malnutrition Universal Screening Tool score  2 
  0 142 (77.6)  
  1 41 (22.4)  
   0 (0)  
   
Malnutrition Screening Tool score   
  0   94 (51.1) 1 
  1 38 (20.7)  
   52 (28.3)  
   
C-Reactive Protein (mg/L)  40 
  <5 72 (49.7)  
  5 to 10 20 (13.8)  
   53 (36.6)  
   
Albumin (g/L)  49 
  <30 29 (21.3)  
  30 to 50 107 (78.7)  
  >50 0 (0) 
 
 
Measured at baseline, the number of participants in each category of BMI, percentage 
weight change, MUST and MST scores are shown as frequencies. In addition, the C-
Reactive Protein and albumin results are included. The numbers of missing cases are also 
highlighted.
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The frequency of the responses given to the 12 items on the CASQ are shown. 
 
 
Table 5.3: CASQ responses of Phase II study population at baseline (n=181) 
 
 n (%)  n (%) 
40\DSSHWLWHLV«  4:KHQ,HDW,IHHOIXOO«  
Very poor 8 (4.3) Without having eaten anything 2 (1.1) 
Poor 31 (16.8) After eating only a few mouthfuls 16 (8.6) 
Average  49 (26.5) After eating about a third of a meal 19 (10.3) 
Good 58 (31.4) After eating over half of a meal 64 (34.6) 
Very good 39 (21.1) After eating a full meal 84 (45.4) 
    
Q3.Before eating I feel 
KXQJU\« 
 4,HQMR\WKHIRRG,HDW«  
Rarely 18 (9.7) Most times 115 (62.2) 
Occasionally 31 (16.8) Often 21 (11.4) 
Some of the time 71 (38.4) Sometimes 39 (21.1) 
Most of the time 54 (29.2) Rarely 7 (3.8) 
All of the time 11 (5.9) Never  3 (1.6) 
    
4$WSUHVHQW,HDW«  Q6. At present I eat (in addition to 
RULQVWHDGRIDPHDO« 
 
Less than one meal a day 3 (1.6) No snacks 37 (20.0) 
One meal a day 15 (8.1) One snack a day 67 (36.2) 
Two meals a day 50 (27.0) Two snacks a day 61 (33.0) 
Three meals a day 105 (56.8) Three snacks a day 16 (8.6) 
More than three meals a 
day 
11 (5.9) Four or more snacks a day 3 (1.6) 
    
Q7. Compared to before I 
ZDVLOOIRRGWDVWHV« 
 4$WSUHVHQW,KDYH«  
Much worse 15 (8.1) No changes in taste 76 (41.1) 
Worse 55 (29.7) Mild taste changes 43 (23.2) 
Just as good 100 (54.1) Moderate taste changes 48 (25.9) 
Better 9 (4.9) Severe taste changes 14 (7.5) 
Much better 6 (3.2) No taste at all 4 (2.2) 
    
Q.9 I feel sick or 
nauseated before I eat or 
ZKHQ,HDW« 
 Q10. Most of the time my mood 
LV« 
 
Most times 5 (2.7) Very sad 3 (1.6) 
Often 4 (2.2) Sad 7 (3.8) 
Sometimes 48 (25.9) Neither sad nor happy 84 (45.4) 
Rarely 50 (27.0) Happy 75 (40.5) 
Never  78 (42.2) Very happy 15 (8.1) 
    
Q11.Most of the time my 
HQHUJ\OHYHOLV« 
 40RVWRIWKHWLPHP\SDLQLV«  
Very high 2 (1.1) Very mild or no pain 108 (58.4) 
High 27 (14.6) Mild 26 (14.1) 
Moderate 91 (49.2) Moderate 41 (22.2) 
Low 53 (28.6) Severe 1 (0.5) 
Very low 12 (6.5) Very severe 9 (4.9) 
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Figure 5.2: Percentage frequency distribution of total CASQ scores given by the 181 
respondents. 
 
It is of interest to determine whether there was a difference in appetite and 
symptoms between participants with different tumour group diagnoses. Table 5.4 
provides the responses from the lung and upper GI cancer groups. The mean score 
(SD) for the respondents with upper GI cancer (n=106) was 30 (7.3) and the range 
five to 42. For those with lung cancer (n=75) the mean score (SD) was also 30 (6.3), 
range 16 to 45. There was no statistical difference between the two groups in terms 
of total CASQ score (P = 0.61). Twenty-three percent of those with upper GI cancer 
reported a poor or very poor appetite, compared with 18% of those from the lung 
cancer group (not significant). Generally, frequency of responses was similar across 
the two groups. Differences were not statistically significant at the 5% level. There 
was however a noticeable difference in reported energy levels between the two 
groups, with 42% of those with lung cancer responding to the low or very low 
category compared with 30% of subjects with upper GI cancer (P=0.07). 
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*Mann Whitney U test 
The frequency of the responses given to the 12 items on the CASQ, comparing those 
participants who had lung and upper GI cancer, are shown. The statistical significance of the 
differences between the results is demonstrated using the Mann Whitney U test
Table 5.4: CASQ responses for upper GI and lung cancer groups at baseline  
 
 Frequency (%)  Frequency (%) 
 Upper GI     Lung  Upper GI      Lung 
40\DSSHWLWHLV«   4:KHQ,HDW,IHHOIXOO«   
Very poor 7(6.4) 1(1.3) Without having eaten anything 0 (0) 2(2.6) 
Poor 18(16.5) 13(17.1) After eating only a few mouthfuls 14(12.8) 2(2.6) 
Average  27(24.8) 22(28.9) After eating about a third of a  
meal 
12(11.0) 7(9.2) 
Good 36(33.0) 22(28.9) After eating over half of a meal 37(33.9) 27(35.5) 
Very good 21(14.3) 18(23.7) After eating a full meal 46(42.2) 38(50.0) 
      
 P* = 0.51  P* = 0.15 
Q3.Before eating I feel 
hungry. 
  4,HQMR\WKHIRRG,HDW«   
Rarely 12(11.0) 6(7.9) Most times 68(62.4) 47(61.8) 
Occasionally 16(14.7) 15(19.7) Often 9(8.3) 12(15.8) 
Some of the time 43(39.4) 28(36.8) Sometimes 25(22.9) 14(18.4) 
Most of the time 33(30.3) 21(27.6) Rarely 5(4.6) 2(2.6) 
All of the time 5(4.6) 6(7.9) Never  2(1.8) 1(1.3) 
      
 P* = 0.87  P* = 0.74 
4$WSUHVHQW,HDW«   Q6. At present I eat (in addition 
WRRULQVWHDGRIPHDO« 
  
Less than one meal a day 2(1.9) 1(1.3) No snacks 19(17.6) 18(23.7) 
One meal a day 9(8.3) 6(7.9) One snack a day 43(39.8) 24(31.6) 
Two meals a day 25(23.1) 25(32.9) Two snacks a day 37(34.3) 24(31.6) 
Three meals a day 68(63.0) 37(48.7) Three snacks a day 8(7.4) 8(10.5) 
More than three meals a 
day 
4(3.7) 7(9.2) Four or more snacks a day 1(0.9) 2(2.6) 
      
 P* = 0.65  P* = 0.98 
Q7. Compared to before I 
ZDVLOOIRRGWDVWHV« 
  4$WSUHVHQW,KDYH«   
Much worse 12(11.0) 3(3.9) No changes in taste 46(42.2) 30(39.5) 
Worse 31(28.4) 24(31.6) Mild taste changes 26(23.9) 17(32.4) 
Just as good 60(55.0) 40(52.6) Moderate taste changes 29(26.6) 19(25.0) 
Better 3(2.8) 6(7.9) Severe taste changes 7(6.4) 7(9.2) 
Much better 3(2.8) 3(3.9) No taste at all 1(0.9) 3(3.9) 
      
 P* = 0.21  P* = 0.40 
Q.9 I feel sick or 
nauseated before I eat or 
ZKHQ,HDW« 
  Q10. Most of the time my  
PRRGLV« 
  
Most times 4(3.7) 1(1.3) Very sad 2(1.8) 1(1.3) 
Often 3(2.8) 1(1.3) Sad 5(4.6) 2(2.7) 
Sometimes 34(31.2) 14(18.4) Neither sad nor happy 47(43.1) 37(49.3) 
Rarely 24(22.0) 26(34.2) Happy 45(41.3) 30(40.0) 
Never  44(40.4) 34(44.7) Very happy 10(9.2) 5(6.7) 
      
 P* = 0.11  P* = 0.68 
Q11.Most of the time my 
energy level LV« 
  Q12. Most of the time my  
SDLQLV« 
  
Very high 2(1.8) 0(0) Very mild or no pain 58(53.2) 50(65.8) 
High 19(17.4) 8(10.5) Mild 20(18.3) 6(7.9) 
Moderate 55(50.5) 36(47.4) Moderate 24(22.0) 17(22.4) 
Low 25(22.9) 28(36.8) Severe 7(6.4) 3(3.9) 
Very low 8(7.3) 4(5.3) Very severe 0(0) 0(0) 
      
 P* = 0.07  P* = 0.20 
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5.2.5 Follow-up status and characteristics  
Three month follow-up data was obtained from 167 (90%) subjects (Table 5.5). Of 
those who did not complete the study, fourteen (8%) participants had died. It was 
not possible to collect body weight from four other people within the follow up 
period.   
 
Table 5.5: Characteristics of Phase II study population at three month follow-up 
(n=185) 
 
   Missing  
 Mean (SD) Range (n) 
Weight (kg) 73.2 (14.2) 42.2 to 116.0 18 
Body Mass Index (kg/m2) 25.6 (4.1) 18.8 to 40.8 18 
% weight change  over  3 month 
study * 
-1.4 (6.2) -25.8 to 13.6 18 
    
 n (%)   
Body Mass Index (kg/m2)   18 
  <18.5 0 (0)   
  18.5 to 20 11 (6.6)   
  20 to 25 76 (45.5)   
  25 to 30 54 (32.3)   
  30 to 35 24 (14.4)   
  >35 2 (1.2)   
    
% weight change over 3 month study   18 
  + >10 6 (3.6)   
  + 5 to 10 16 (9.6)   
  +0 to 5 53 (31.7)   
  - 0 to 5 54 (32.3)   
  -5 to 10 20 (12.0)   
  -> 10 18 (10.8)   
  -> 10 18 (10.8)   
*Negative values indicate weight loss, positive values indicated weight gain 
The mean, standard deviation and range for the anthropometric measurements that were 
recorded at the three month follow-up period are shown. The frequency of participants falling 
into BMI and percentage weight loss categories has also been presented. 
 
 
The mean (SD) body weight of those reassessed at follow up was 73.2 (14.2) kg. 
Figure 5.3 shows the mean body weight of participants at baseline and at three 
month follow-up. When tested using a paired sample T-Test, this analysis suggests 
that there was a small (1.2 kg), but statistically significant, change in mean body 
weight in the cohort overall (t = 2.91, P = 0.004). The mean (SD) percentage weight 
change over the three month period was -1% (6). Percentage weight change ranged 
from a weight loss of 26% to a weight gain of 14%. Fifty-five percent of participants 
lost some weight during the study period and for almost half of this group (23%), 
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that weight loss was clinically significant, i.e. greater than five percent. In addition, 
as seen in Figure 5.4, there was a shift in BMI categorisation compared with 
baseline with more people falling into the underweight and healthy weight class than 
the overweight and obese categories. Analysing the change in BMI between the two 
time points, using the paired sample T-Test, suggests that this shift was statistically 
significant (t = 3.07, P = 0.003). 
 
 
Figure 5.3: Mean weight of participants (with 95% confidence intervals) at baseline 
and three months. The mean difference from baseline to three months was -1.2kg 
where t = 2.91 (P = 0.004). 
 
 
Figure 5.4: Percentage frequency distribution of SDUWLFLSDQWV¶ BMI at baseline and 
three month follow-up. 
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5.2.6 Predictive validity of the Cancer Appetite and Symptom Questionnaire 
To determine the predictive validity of the CASQ, in terms of weight change at three 
PRQWKV WKH3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQWZDVGHWHUPLQHG)LJXUHVKRZVD
positive correlation between the two variables, CASQ score at baseline and 
percentage weight change at three months, where r = 0.32 (P<0.001). The graphical 
representation also demonstrates that there were fewer participants with a very low 
total CASQ score. 
 
 
Figure 5.5: Correlation between total CASQ score at baseline and percentage 
weight change at three months. For this correlation r = 0.32 and P < 0.001. Trend 
line and 95% confidence intervals are plotted for these data. 
 
To explore the association between total CASQ score and weight loss further, 
unadjusted linear regression was performed. This suggests that there was an 
estimated percentage weight gain of 0.3% (95%CI = 0.17 to 0.47) for every one unit 
increase in CASQ score (P<0.001). 
 
7KH6SHDUPDQ¶VFRHIILFLHQWZDVXVHGWRGHWHUPLQHWKHFRUUHODWLRQEHWZHHQWKH
individual items on the CASQ and weight change at three months (Table 5.6). All 
items were positively correlated with percentage weight change. That is to say, as 
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appetite and symptoms improved, percentage weight change was increased. For six 
of the items, items three, five, seven, eight, ten and eleven, the correlations were 
not statistically significant. Other items were shown to be more strongly correlated 
with percentage weight change. Values for items one, two, four, nine and twelve 
were statistically significant at the P=0.01 level and item six at the P=0.05 level. 
 
Table 5.6: Correlation between item CASQ score at baseline and 
percentage weight change at three months 
 
CASQ Item 6SHDUPDQUKRȡ P value Missing (n) 
2 (Satiety) 0.33 <0.001 18 
1 (Appetite) 0.30 <0.001 18 
4 (Enjoy food) 0.29 <0.001 18 
9 (Nausea) 0.25 <0.01 19 
12 (Pain) 0.24 <0.01 19 
6 (Snacks) 0.18 0.02 18 
10 (Mood) 0.13 0.11 19 
3 (Hunger) 0.12 0.14 18 
7 (Taste) 0.11 0.16 18 
8 (Taste change) 0.10 0.21 19 
5 (Meals) 0.01 0.26 19 
11 (Energy) 0.03 0.67 18 
For each of the 12 items in the CASQ, the score at baseline has been correlated with 
SHUFHQWDJHZHLJKWFKDQJHDWWKUHHPRQWKV7KH6SHDUPDQ¶VFRHIILFLHQWVDUHVKRZQDORQJ
with the P value and the number of missing cases. The items are ordered according to the 
strength of the correlation. 
 
5.2.7 Other predictors of weight loss 
Correlations were also used to determine the relationship between the additional 
measured variables and percentage weight change at three months (Table 5.7). 
The strongest correlation (r = -0.34, P < 0.001) was found with C-Reactive Protein 
and percentage weight loss (Figure 5.6). This indicates that as C-Reactive Protein 
concentrations rise, there is a tendency for percentage weight loss to increase. 
Interestingly, there was also a weak negative correlation between two previously 
validated nutrition screening instruments, the MUST and MST, and percentage 
weight change. Only the MST result was statistically significant. Baseline 
percentage weight change and percentage weight change at follow-up were also 
found to be positively correlated (r = 0.22, P < 0.01). 
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Table 5.7: Correlation between measured variables and percentage weight 
change at three months 
 
Variable Pearson coefficient (r) P value Missing (n) 
C-Reactive Protein -0.34 <0.001 53 
Baseline % weight change 0.22 <0.01 19 
Age -0.17 0.03 18 
Baseline BMI -0.09 0.23 19 
Albumin 0.01 0.92 62 
Variable 6SHDUPDQUKRȡ P value Missing (n) 
MST score -0.16 0.05 19 
MUST score -0.13 0.09 20 
Performance status -0.04 0.60 18 
7KH FRUUHODWLRQ FRHIILFLHQWV 3HDUVRQ¶V IRU SDUDPHWULF GDWD DQG 6SHDUPDQ¶V IRU QRQ
parametric data, show the association between the measured variables and weight change 
at three month follow-up. The corresponding P value is also included, along with the number 
of missing cases. 
 
 
    
Figure 5.6: Correlation between C-Reactive Protein concentration at baseline and 
percentage weight change at three months. For this correlation r = -0.34 and P < 
0.01. Trend line and 95% confidence intervals are plotted for these data. 
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To explore the association between C-Reactive Protein and weight loss further, 
unadjusted linear regression analysis was performed using dichotomous response 
YDULDEOHV RI    PJ/ DQG    !PJ/ 7DEOH  7KLV GHPonstrated that 
transition from a low C-5HDFWLYH3URWHLQJURXS&53PJ/WRDKLJK&-Reactive 
Protein group (CRP >10mg/L) was associated with an estimated average 
percentage weight loss of 3% (95%CI -5.33 to -1.06, P < 0.01). 
 
Table 5.8: Unadjusted linear regression analysis of C-Reactive Protein and 
percentage weight change 
 
Predictor variable Regression coefficient 
(B) 
S.E. 95% confidence 
intervals 
P 
value 
C-Reactive Protein -3.19 1.08 -5.33 to -1.06 <0.01 
The results from unadjusted linear regression of C-Reactive Protein and percentage weight 
change are shown. For this regression, the regression coefficient (B) = -3.19 (95%CI -5.33 
to -1.06, P <0.01). 
 
 
To examine the association between percentage weight change of greater than 5% 
or 10%, and the categorical variables of treatment intent, diagnosis or gender, the 
Chi squared test was used (Table 5.9). Strong evidence of an association between 
diagnosis and percentage weight change was found. Just over one third (37%) of 
those diagnosed with gastro-oesophageal cancer lost more than 5% of their body 
weight during the study period.  This was in comparison to 24% of those with 
pancreatic cancer. In addition, 12% and 16% of subjects with non small cell lung 
cancer (NSCLC) and small cell lung cancer (SCLC) respectively experienced 5% 
weight loss or more (P=0.06). There did not appear to be any relationship between 
treatment intent and percentage weight change and only a weak, non-significant 
association with gender and 10% weight loss (P = 0.15). 
 
Table 5.9: Association between percentage weight loss and treatment intent, 
diagnosis or gender 
 
 >5% weight loss >10% weight loss 
Variable Chi 2 P value Chi2 P value 
Diagnosis 12.1 0.06 13.5 0.04 
Gender 0.2 0.90 2.1 0.15 
Treatment intent 0.1 0.80 0.8 0.40 
Tested by the chi2 coefficient and the corresponding P value, the association between 
percentage weight loss at the 5% and 10% levels, and the categorical variables of diagnosis, 
gender and treatment intent is shown. 
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5.2.8 The Cancer Appetite and Symptom Questionnaire as a screening instrument 
for weight change.  
To determine the diagnostic performance of the CASQ as a screening instrument to 
predict weight change in people with cancer, Receiver Operating Characteristic 
(ROC) curve analysis was used (Altman and Bland, 1994). The analysis was 
performed at two levels to ascertain the performance of the CASQ at predicting 5% 
weight loss (Figure 5.7) and 10% weight loss (Figure 5.8). The ROC curve is 
determined by plotting the sensitivity against (1-specificity) for every possible cut 
point of the CASQ scores. Sensitivity is expressed as a proportion of the true 
positive rate. This is the percentage of patients who have greater than 5% weight 
loss and who have a positive test result, i.e. low CASQ score. Specificity is 
expressed as a proportion of the true negative rate. This is the percentage of 
patients who have not lost greater than 5% body weight and who have a negative 
test result, i.e. high CASQ score. A perfect instrument or test, with 100% sensitivity 
and 100% specificity would have an area under the ROC curve (C statistic) equal to 
one and the curve would pass through the left and top sides of the graph. In this 
study, the area under the curve represents the probability that a randomly chosen 
person who has lost 5 or 10% of their body weight during the study period will have 
a lower CASQ score than a randomly chosen person who has not lost 5 or 10% 
weight. 
 
5.2.8.1 Test for 5% weight loss 
The area under the ROC curve (C statistic) in Figure 5.7 was 0.64 (S.E. = 0.05, 
95% CI 0.54 to 0.75, P <0.01). This means that if two people were selected at 
random from our sample, one who had lost more than 5% body weight and one who 
had not, the probability of the one who had lost more than 5% body weight having a 
low CASQ score would be 64%. 
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Figure 5.7: ROC curve for CASQ scores as a test for 5% weight loss. The ROC 
curve shows the sensitivity and specificity corresponding to different choices of cut-
off points for CASQ scores as a test for 5% weight loss. Area under the curve = 
0.64 (95%CI 0.54 to 0.75, P <0.01). 
 
5.2.8.2 Determining the optimal cut point for the CASQ scores for predicting 5% 
weight loss 
The level of sensitivity and specificity corresponding to each of the different cut 
points for the CASQ scores for 5% weight loss is shown in Table 5.10. The optimal 
cut point can be determined by taking the maximum sum of sensitivity and 
specificity, where the specificity/sensitivity is nearest to one (Altman and Bland, 
1994). For predicting 5% weight loss this would mean the optimal cut point would be 
a CASQ score of 31 or less. To predict 5% weight loss, using a cut point of 31, the 
sensitivity of the CASQ was 65% and the specificity 62%. In addition, the positive 
predictive value (PPV), or proportion of patients with a positive test result, i.e. a low 
CASQ score, who were correctly identified as losing greater than 5% weight loss 
was 33%. The negative predictive value (NPV), or proportion of patients with a 
negative test result i.e. a high CASQ scores, who were correctly identified as not 
losing greater than 5% weight loss, was 86%.  
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Table 5.10: Sensitivity and specificity corresponding to different choices of cut-off 
points for CASQ score as a test for 5% weight loss  
 
Cut 
Point 
Sensitivity 
(%) 
Specificity 
(%) 
PPV(%) NPV(%) Specificity/Sensitivity 
20 8.1 96.1 37.5 78.2 11.9 
25 32.4 87.4 42.9 81.6 2.7 
30 54.1 66.9 32.3 83.3 1.2 
31 64.9 62.2 33.3 85.9 1.0 
32 67.6 55.1 30.5 85.4 0.8 
35 81.1 33.9 26.3 86.0 0.4 
40 94.6 3.9 22.3 31.4 0.04 
Calculated using ROC curve analysis for 5% weight loss, the sensitivity (Sn), specificity (Sp) 
and positive (PPV) and negative (NPV) predictive values are shown at seven cut-off points 
of total CASQ scores. The sensitivity divided by the specificity is also shown to demonstrate 
the optimal cut point which is where it is equal to one. 
 
5.2.8.3 Test for 10% weight loss 
For subjects with more than 10% weight loss the area under the ROC curve (C 
statistic) in Figure 5.8 was 0.75 (S.E. = 0.049, 95% CI 0.65 to 0.84, P = 0.001). As 
interpreted above, this means that if two people were selected at random from our 
sample, one who had lost more than 10% body weight and one who had not, the 
probability of the one who had lost more than 10% body weight having a low CASQ 
score would be 75%. 
 
Figure 5.8: ROC curve for CASQ scores as a test for 10% weight loss. The ROC 
curve shows the sensitivity and specificity corresponding to different choices of cut-
off points for CASQ scores as a test for 10% weight loss. Area under the curve = 
0.75 (95%CI 0.65 to 0.84, P = 0.001). 
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5.2.8.4 Determining the optimal cut point for the CASQ scores for predicting 10% 
weight loss 
The level of sensitivity and specificity corresponding to each of the different cut 
points for the CASQ scores for 10% weight loss is shown in Table 5.11. Using a cut 
point of 29 or less, to predict 10% weight loss, the sensitivity of the CASQ was 71% 
and the specificity 69%. The PPV and NPV were 21% and 95% respectively. 
 
Table 5.11: Sensitivity and specificity corresponding to different choices of cut-off 
points for CASQ score as a test for 10% weight loss  
 
Cut 
Point 
Sensitivity 
(%) 
Specificity 
(%) 
PPV(%) NPV(%) Specificity/Sensitivity 
20 11.8 95.5 25.0 90.4 8.2 
25 41.2 85.7 25.0 92.6 2.1 
28 47.1 74.1 17.4 92.4 1.6 
29 70.6 68.7 20.7 95.3 1.0 
30 70.6 66.0 19.4 95.1 0.9 
35 100 34.0 14.9 100 0.3 
40 100 4.8 10.8 100 0.1 
Calculated using ROC curve analysis for 10% weight loss, the sensitivity (Sn), specificity 
(Sp) and positive (PPV) and negative (NPV) predictive values are shown at seven cut-off 
points of total CASQ scores. The sensitivity divided by the specificity is also shown to 
demonstrate the optimal cut point which is nearest to one. 
 
5.2.9 Level of agreement between the CASQ and other screening instruments at 
identifying at risk patients 
To determine the level of agreement between the CASQ and other existing 
screening instruments at identifying at risk patients, results were cross-tabulated 
and the proportion of agreement calculated (Table 5.12). As determined by the ROC 
curve and optimal cut point analysis for predicting 5% weight loss (described in 
VHFWLRQSDWLHQWVZLWKDWRWDO&$64VFRUHRIZHUHFDWHJRUL]HGDVµDWULVN¶
Those with a MUST score of one, a MST score of more than two or a C-Reactive 
3URWHLQPHDVXUHPHQWRI!PJ/ZHUHDOVRFODVVLILHGDVµDWULVN¶:KHQFRPSDULQJ
the CASQ with the other screening instruments, the highest level of agreement was 
with the MST. The two instruments agreeGLQWKHFODVVLILFDWLRQRIµDWULVN¶LQRI
cases. Overall, the MUST and MST had the highest level of agreement (88%) when 
identifying at risk patients. 
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From cross-tabulation analysis, the percentage agreement between screening instruments, 
ZKHQ LGHQWLI\LQJ SDWLHQWV DV µDW ULVN¶ LV VKRZQ )RU H[DPSOH WKH 0867 DQG &$64 RQO\
agreed in their FODVVLILFDWLRQ RI SDWLHQWV DV µDW ULVN¶ LQ  RI FDVHV )RU WKH UHPDLQLQJ
cases one of the instruments classified patients at risk, the other did not. 
 
5.2.10 Comparison of the CASQ and other screening instruments as predictors of 
10% weight loss  
ROC curve analysis was used to establish how the CASQ performed when 
predicting 10% weight loss compared with the other screening instruments (Table 
5.13). As discussed above, the area under the curve represents the probability that 
for a randomly chosen person who is a case, i.e. has lost 10% of their body weight 
during the study period, for C-Reactive Protein, the MUST and MST instruments, 
the results will be a high score, than for a randomly chosen person who is not a 
case. When measuring C-Reactive Protein, this means that if two people were 
selected at random from our sample, one who had lost more than 10% body weight 
and one who had not, the probability of the one who had lost more than 10% body 
weight having a raised C-Reactive Protein would be 80%. 
 
The optimal cut point can be determined by taking the maximum sum of sensitivity 
and specificity, where the specificity/sensitivity is nearest to one. Table 5.13 shows 
the optimum cut point for the MUST and MST to be greater than or equal to one and 
two respectively. This corresponds with the cut points currently used in clinical 
practice. C-Reactive Protein analysis suggests that the optimum cut point is 
>15mg/L. At this level the sensitivity of the instrument is 83% and the specificity 
81%. In addition, the positive predictive value (PPV), or proportion of patients with a 
high C-Reactive Protein who lost greater than 10% body weight, was 30%. The 
negative predictive value (NPV), or proportion of patients with low C-Reactive 
Protein who did not lose greater than 10% weight loss, was 98%.  
 
For all instruments, the area under the curve was highest when predicting 10% 
weight loss when compared with 5% weight loss (CRP, C statistic = 0.65 95% CI = 
0.52 to 0.77; MST, C statistic = 0.59 95%CI = 0.48 to 0.70; MUST, C statistic = 0.57 
95%CI = 0.46 to 0.68). 
Table 5.12: Proportion of agreement between screening instruments  
 
 CASQ MST MUST CRP 
CASQ  64.1% 55.5% 53.9% 
MST   88.0% 66.6% 
MUST    66.4% 
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ROC curve analysis was performed for the four instruments to determine their ability to 
predict 10% weight loss. For each instrument, the area under the curve (C), with 95% 
confidence intervals and the corresponding P value are shown. Using the optimal cut points 
the sensitivity (Sn), specificity (Sp) and positive (PPV) and negative (NPV) predictive values 
are shown. For C-Reactive Protein, the cut point used in clinical practice is also included.  
 
5.2.11 Exploratory modelling using multiple linear regression analysis 
To build a model of the optimal set of variables that could comprise a screening 
instrument to predict weight change, multiple linear regression analysis was used. 
Two potential models were explored. The first model was fitted using the 
percentage weight change at follow up as the dependent variable, and the twelve 
items from the CASQ, plus the total CASQ score, as predictor variables. As a 
backward variable selection process was used initially, all 13 predictor variables 
were put into the model, at each step, the variable with the highest P value was 
dropped.  Variables were retained where P < 0.10 for log-likelihood ratio tests. The 
resulting model (Table 5.14) consisted of three of the variables; CASQ item 6, 
relating to the amount of snacks eaten, CASQ item 9, concerning sickness and 
nausea and CASQ item 12 regarding level of pain. The predictive equation derived 
from the modelling process is as follows, where the constant regression coefficient 
is -17.68 and the relative predictive power of the model (r2) equals 0.12: 
 
% weight change = -17.68 + (CASQ item 6 score x 1.45) + (CASQ item 9 score x 
1.14) + (CASQ item 12 score x 1.81) 
 
The closer the r2 value is to one, the greater the ability of the model to predict 
percentage weight change. 
 
 
 
5.13: Comparison of the sensitivity and specificity of the CASQ and other screening 
instruments when predicting 10% weight loss  
 
Screening 
instrument 
C 
statistic 
S.E 95% 
Confidence 
Interval 
P 
value 
Cut 
point 
Sn 
(%) 
Sp 
(%) 
PPV 
(%) 
NPV 
(%) 
CRP  0.80 0.08 0.66 to 0.95 <0.01 >10 83.3 70.0 21.7 97.7 
     >15 83.3 80.8 30.0 98.0 
CASQ 0.75 0.05 0.65 to 0.84 <0.01 29 70.6 68.7 20.7 95.3 
MUST 0.67 0.07 0.52 to 0.81 0.02  50.0 83.0 26.5 93.1 
MST 0.63 0.08 0.48 to 0.78 0.08  50.0 76.4 20.5 92.6 
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Table 5.14: Model 1 determined by multiple linear regression analysis using CASQ 
items and total score as predictor variables 
 
Predictor 
variable 
Regression coefficient 
(B) 
S.E. 95% confidence 
intervals 
P value 
CASQ item 12 1.81 0.60 0.63 to 2.99 0.01 
CASQ item 6 1.45 0.59 0.27 to 2.62 0.02 
CASQ item 9 1.14 0.60 -0.04 to 2.33 0.06 
Model 1, derived from multiple linear regression, contains the optimum set of CASQ items 
that could be used to predict weight change. For these three items, the regression coefficient 
(B), along with the standard error (S.E.), 95% confidence interval and corresponding P value 
are shown. 
 
The second model was fitted, again using the percentage weight change at follow 
up as the dependent variable. This time there were 21 predictor variables. These 
included the 12 items of the CASQ, total CASQ score, age, gender, diagnosis, 
treatment intent plus measurements taken at baseline including BMI, MUST, 
percentage weight change and C-Reactive Protein. As with the first model, a 
backward variable selection process was used, fitting all 21 predictor variables into 
the model. Again, at each step, the variable with the highest P value was dropped 
and where P < 0.10 for log-likelihood ratio tests, the variables were retained in the 
final model. The second resulting model (Table 5.15) consisted of five variables; 
CASQ items 4 and 12 relating to enjoyment of food and level of pain, baseline 
measurements of MUST score, BMI and age. The predictive equation derived from 
this modelling process is as follows, where the constant regression coefficient is -
1.73 and the relative predictive power of the model (r2 ) equals 0.26: 
 
% weight change = -1.73 + (CASQ item 4 score x 1.67) + (CASQ item 12 score x 
1.69) - (MUST score x 3.40) ± (BMI baseline x 0.28) ± (Age x 0.09) 
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Model 2, derived from multiple linear regression, contains the optimum set of variables that 
could be used to predict weight change. For these five items, the regression coefficient (B), 
along with the standard error (S.E.), 95% confidence interval and corresponding P value are 
shown. 
 
5.2.11.1 Analysis of predicted values and residuals 
To determine the robustness of the proposed models, the distribution of the 
residuals, i.e. the difference in the observed data and computed data calculated 
from the predictive equation, were explored. Figures 5.9 and 5.10 show that for 
each model, a plot of the residuals against the predicted values produces a random 
featureless scatter. These results suggest that the proposed models are indeed 
linear.  
 
 
Figure 5.9: Model 1: Distribution of residuals. For model 1, the graph shows the 
predicted values plotted against the residual values as computed from the multiple 
linear regression predictive equation.  
 
 
Table 5.15: Model 2 determined by multiple linear regression analysis using 21 
predictor variables 
 
Predictor 
variable 
Regression coefficient 
(B) 
S.E. 95% confidence 
intervals 
P value 
CASQ item 4 1.67 0.49 0.71 to 2.63 <0.01 
CASQ item 12 1.69 0.50 0.71 to 2.67 <0.01 
MUST score -3.40 1.19 -5.75 to 1.04 0.01 
Baseline BMI -0.28 0.12 -0.51 to -0.05 0.02 
Age (years) -0.09 0.05 -0.18 to 0.01 0.06 
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Figure 5.10: Model 2: Distribution of residuals. For model 2, the graph shows the 
predicted values plotted against the residual values as computed from the multiple 
linear regression predictive equation.  
 
&R[¶VUHJUHVVLRQIRUVXUYLYDODQDO\VLV 
To investigate the relationship between the total CASQ score and additional 
PHDVXUHGYDULDEOHVZLWKVXUYLYDODXQLYDULDWH&R[¶V UHJUHVVLRQDQDO\VLVDGMXVWHG
for age, was performed (Table 5.16). As to be expected, those who were receiving 
palliative treatment had a poorer prognosis and were almost four times, and at least 
twice as likely, to die during the 22 month time period (HR = 3.84, 95% CI 2.02 to 
7.28, P <0.001). Participants who had a serum C-Reactive Protein of greater than 
10mg/L had a similar, four-fold greater risk of death compared with those who had a 
low C-Reactive Protein (HR =  3.66, 95% CI 2.16 to 6.18), P <0.001). In addition, 
results suggested that in the groups of subjects with a MUST score of one, or a 
MST score of two or more, the death rate was almost twice of that of those deemed 
DWµQRULVN¶E\WKHVFUHHQLQJLQVWUXPHQWV+5 &,WR3 
and HR = 1.60, 95% CI 1.01 to 2.53, P = 0.04 respectively). Those participants with 
a poorer performance status and those who were not eating well, also had a two- 
fold increased risk of dying. Hazard ratios of less than one, at the 5% significance 
level, were seen when investigating the outcome of total CASQ score and 
percentage weight change at baseline. These results imply that for those 
participants who scored higher on the CASQ, and for those who put on weight 
during the months preceding the study, there was a smaller risk of dying compared 
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with those with low CASQ scores, or those who lost weight. Hazard ratios for all 
other variables, adjusted for age, were not statistically significant at the 5% level. 
 
7DEOH8QLYDULDWH&R[¶VUHJUHVVLRQDQDO\VLVDGMXVWHGIRUDJH 
 
Predictor Variable Hazard 
Ratio 
S.E. 95% confidence 
intervals 
P value 
Treatment intent 3.84 1.25 2.02  to 7.28 <0.01 
C-Reactive Protein 3.66 0.98 2.16 to 6.18 <0.01 
Eating poorly 2.01 0.47 1.28 to 3.17 <0.01 
Total CASQ score 0.92 0.02 0.89 to 0.95 <0.01 
Performance status 1.65 0.30 1.12 to 2.37 0.01 
Baseline % weight change 0.94 0.20 0.91 to 0.98 0.01 
MUST  1.81 0.44 1.12 to 2.92 0.02 
MST 1.60 0.37 1.01 to 2.53 0.04 
Social circumstances 1.37 0.39 0.79 to 2.39 0.27 
BMI at baseline 0.98 0.03 0.93 to 1.04 0.57 
Age 1.00 0.01 0.97 to 1.02 0.79 
Gender 0.96 0.22 0.62 to 1.50 0.87 
Tumour group 1.02 0.24 0.64 to 1.61 0.95 
'HULYHG IURP XQLYDULDWH &R[¶V UHJUHVVLRQ DQDO\VLV WKH KD]DUG UDWLR VWDQGDUG HUURU 6(
95% confidence interval and corresponding P value for each predictor variable are shown. 
 
To determine the model of best fit, multivariate analysis using a backward variable 
selection process was used, putting all predictor variables into the model where 
P<0.1. At each step of the process the variable with the highest P value was 
dropped.  Variables were retained where P <0.05 for log-likelihood ratio tests. The 
resulting model, adjusted for age (Table 5.17), consisted of four variables; C-
Reactive Protein, treatment intent, total CASQ score and percentage weight change 
at baseline. Each, when adjusted for the remaining three predictor variables, plus 
age, was an independent significant prognostic factor of survival. 
 
7DEOH&R[¶VPXOWLYDULDWHUHJUHVVLRQDQDO\VLVIRUVXUYLYDODGMXVWHGIRUDJH 
 
Predictor Variable Hazard 
Ratio 
S.E. 95% confidence 
intervals 
P value 
Treatment intent 4.05 1.64 1.83 to 8.96 <0.01 
C-Reactive Protein 2.69 0.76 1.55 to 4.67 <0.01 
Total CASQ score 0.93 0.02 0.90 to 0.97 <0.01 
Baseline % weight change 0.93 0.03 0.88 to 0.99 0.02 
'HULYHG IURP PXOWLYDULDWH &R[¶V UHJUHVVLRQ DQDO\VLV DGMXVWHG IRU DJH the hazard ratio, 
standard error (S.E.), 95% confidence interval and corresponding P value for the predictor 
variables which comprise the final model are shown. 
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,QYLHZRIWKH LPSDFWRIWUHDWPHQW LQWHQWRQVXUYLYDO WKH&R[¶VUHJUHVVLRQDQDO\VLV
was re-run with two groups. The first analysis was performed with participants 
receiving curative treatment, and the second with participants receiving palliative 
treatment. Table 5.18 shows the univariate analysis, adjusted for age, for those 
receiving curative treatment. The results suggested that participants who were 
eating poorly were five times more likely to die than those whose eating was not 
compromised (HR =  5.20, 95% CI 1.49 to 18.20, P = 0.01). The only other variable 
that resulted in a hazard ratio that was statistically significant was related to the 
social circumstances of participants (HR = 2.30, 95%CI 0.99 to 5.31, P = 0.05). 
However, as the 95% confidence intervals cross zero it may be assumed that, in 
terms of survival, there is no real difference between those who live alone and those 
that do not. Following the multivariate analysis, using the method described above, 
DQG ZKHQ DGMXVWLQJ IRU DJH RQO\ µHDWLQJ SRRUO\¶ UHPDLQHG DQ LQGHSHQGHQW
prognostic factor of survival in the curative treatment group (Table 5.19). 
 
7DEOH  3DUWLFLSDQWV UHFHLYLQJ FXUDWLYH WUHDWPHQW 8QLYDULDWH &R[¶V UHJUHVVLRQ
analysis adjusted for age 
 
Predictor Variable Hazard 
Ratio 
S.E. 95% confidence 
intervals 
P value 
Eating poorly 5.20 3.32 1.49 to 18.20 0.01 
Social circumstances 2.30 0.98 0.99 to 5.31 0.05 
C-Reactive Protein 6.25 6.05 0.94 to 41.60 0.06 
MUST 3.11 1.88 0.95 to 10.20 0.06 
MST 1.44 0.56 0.89 to 2.34 0.14 
Baseline % weight change 0.92 0.05 0.82 to 1.03 0.15 
Baseline BMI 0.92 0.07 0.78 to 1.07 0.27 
Performance status 1.89 1.15 0.57 to 6.22 0.30 
Total CASQ score 0.95 0.05 0.86 to 1.06 0.38 
Gender 0.59 0.40 0.16 to 2.22 0.43 
Tumour group 0.69 0.57 0.13 to 3.48 0.65 
Age 0.99 0.03 0.93 to 1.06 0.88 
For subjects receiving curative treatment (n = 52), XQLYDULDWH&R[¶VUHJUHVVLRQDQDO\VLVZDV
performed. The hazard ratio, standard error (S.E.), 95% confidence interval and 
corresponding P value for each predictor variable are shown. 
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7DEOH3DUWLFLSDQWVUHFHLYLQJFXUDWLYH WUHDWPHQW&R[¶Vmultivariate regression 
analysis for survival adjusted for age 
Predictor Variable Hazard 
Ratio 
S.E. 95% confidence 
intervals 
P value 
Eating poorly 4.93 3.35 1.30 to 18.65 0.02 
'HULYHG IURP PXOWLYDULDWH &R[¶V UHJUHVVLRQ DQDO\VLV DGMXVWHG IRU DJH WKH KD]DUG UDWLR
standard error (S.E.), 95% confidence interval and corresponding P value for the predictor 
variables which comprise the final model are shown. This analysis included participants 
receiving curative treatment (n=52). 
 
The results from the univariate analysis, adjusted for age, for those receiving 
palliative treatment are shown in Table 5.20. For this group of subjects, as with the 
group as a whole, those with an elevated serum concentration of C-Reactive Protein 
(>10mg/L) were more likely to die during the study period when compared with 
those with a normal serum C-Reactive Protein concentration (HR = 2.76, 95% CI = 
1.59 to 4.79, P < 0.001). Furthermore, those with lower total CASQ scores and 
those who had lost weight prior to the study were also at an increased risk of death 
(HR = 0.91, 95%CI 0.88 to 0.95, P < 0.001 and HR = 0.94, 95% CI = 0.90 to 0.99, P 
= 0.02 respectively). For this group, following the multivariate analysis, when  
adjusting for age, total CASQ scores and C-Reactive Protein remained independent 
prognostic factors of survival in the palliative treatment group (Table 5.21). 
 
Table 5.20: 3DUWLFLSDQWV UHFHLYLQJSDOOLDWLYH WUHDWPHQW8QLYDULDWH&R[¶V UHJUHVVLon 
analysis adjusted for age  
 
Predictor Variable Hazard 
Ratio 
S.E. 95% confidence 
intervals 
P value 
C-Reactive Protein 2.76 0.78 1.59 to 4.79 <0.001 
Total CASQ score 0.91 0.02 0.99 to 0.95 <0.001 
Baseline % weight change 0.94 0.02 0.90 to 0.99 0.02 
MUST 1.84 0.51 1.07 to 3.16 0.03 
Performance status 1.44 0.28 0.99 to 2.11 0.06 
Eating poorly 1.56 0.40 0.97 to 2.59 0.07 
MST 1.11 0.09 0.95 to 1.30 0.19 
Baseline BMI 1.02 0.03 0.95 to 1.08 0.63 
Tumour group 0.89 0.22 0.55 to 1.44 0.64 
Age 1.00 0.01 0.97 to 1.02 0.87 
Social circumstances 1.04 0.24 0.66 to 1.62 0.88 
Gender 1.02 0.25 0.64 to 1.64 0.92 
)RU VXEMHFWV UHFHLYLQJ SDOOLDWLYH WUHDWPHQW Q    XQLYDULDWH &R[¶V UHJUHVVLRQ DQDO\VLV
was performed. The hazard ratio, standard error (S.E.), 95% confidence interval and 
corresponding P value for each predictor variable are shown. 
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7DEOH3DUWLFLSDQWVUHFHLYLQJSDOOLDWLYHWUHDWPHQW&R[¶VPXOWLYDULDWHUHJUHVVLRQ
analysis for survival adjusted for age 
 
Predictor Variable Hazard 
Ratio 
S.E. 95% confidence 
intervals 
P value 
Total CASQ score 0.92 0.02 0.88 to 0.95 <0.001 
C-Reactive Protein 2.51 0.72 1.42 to 4.42 0.001 
'HULYHG IURP PXOWLYDULDWH &R[¶V UHJUHVVLRQ DQDO\VLV DGMXVWHG IRU DJH WKH KD]DUG UDWLR
standard error (S.E.), 95% confidence interval and corresponding P value for the predictor 
variables which comprise the final model are shown. This analysis included participants 
receiving palliative treatment (n=133). 
 
5.3 Discussion 
5.3.1 Phase II study design 
The key objectives for Phase II of the study were to: 
1. Obtain an estimate of the reliability of the CASQ. 
2. Determine the predictive validity of the CASQ 
3. Determine the optimal cut points and overall performance of the CASQ at 
predicting clinically significant weight loss over three months.  
4. Propose an optimum screening instrument to predict clinically significant 
weight loss over three months.  
 
As with reliability testing, ascertaining the degree of validity that a new instrument 
has, is essential if it is to be used within a healthcare setting. As there is no single 
test to determine if indeed an instrument is measuring what it is supposed to, an 
overall judgment, taking account of several measures of validity, should be made 
(Streiner and Norman, 2008). In this study, the principal reason for developing a 
new instrument was to be able to predict which people with cancer, who are not 
already malnourished, are going to lose weight in the future. Such a tool would allow 
nutritional treatment to be prioritised and commenced where needed, before the 
downward spiral of malnutrition, and possibly cachexia, begins. For this reason, one 
of the key objectives of Phase II of the study was an estimate of the predictive 
validity of the CASQ, in terms of weight loss over a three month period. As clinically 
significant weight loss is in practice monitored over a three to six month period 
(NICE, 2006), and given the fact that this particular population of patients can have 
a relatively poor prognosis, three months was thought to be an appropriate time 
interval. An important consideration when conducting a predictive validation study, 
is that practice is not changed due to the outcome from administering the new 
instrument. When conducting research within a clinical environment it is often 
difficult to uphold what is normal practice. To standardise this element of the study, 
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all participants were offered a booklet on how to improve their dietary intake, 
irrespective of their response to the questionnaire. Clinic staff were asked to 
continue with their usual practice with regards to the provision of nutritional advice. 
This, in some instances, would have resulted in a referral to a dietitian. Despite 
potentially influencing the weight status of study participants, to withhold this 
nutritional intervention for research purposes would not have been ethical. 
Additionally, the presence of a research dietitian in the out-patient clinics may have 
led to an increased awareness of the nutritional care of patients and influenced 
outcomes. Furthermore, for those who participated, taking part in a research study 
about appetite and symptoms could have influenced their actions during the study 
period. The expected result from these changed actions would have been a 
decrease in weight loss seen over the study period. As data concerning the 
nutritional treatment or dietetic intervention for each participant was not collected, 
the degree to which this may have influenced results cannot be established. 
 
$V WKHUH LV QR H[LVWLQJ µJROG VWDQGDUG¶ WHVW IRU predicting weight loss, it was not 
possible to determine the concurrent validity of the CASQ. As will be discussed 
later, to help determine the validity of the CASQ, in addition to establishing its 
predictive validity, the performance of the CASQ was compared with existing, 
validated, screening instruments. 
 
5.3.1.1 Phase II study population 
Of those potential participants who were initially screened using the MUST, almost 
one in three (30%) had a score of two or more and were identified as being at high 
risk of malnutrition. As these people had already lost a clinically significant amount 
of weight, they were excluded from participating in the study. Using this figure to 
determine the proportion of patients with lung and upper GI cancer who are at high 
risk of malnutrition should be approached with caution as those undergoing the 
screening process were not selected at random or on the basis of, for example, 
being recently diagnosed. Sampling bias may have had an impact on the results. In 
addition, directly comparing these results to studies which have used an alternative 
screening instrument is difficult, DVDVWDQGDUGGHILQLWLRQRIµDWULVNRIPDOQXWULWLRQ¶LV
not available. Moreover, such studies quote the proportion of patients with a single 
diagnosis, or undergoing a specific cancer therapy, who are malnourished (Segura 
et al., 2005; Isenring et al., 2006; Chauhan et al., 2007; Renshaw et al., 2008). In 
this present study the figure was calculated across two tumour groups and in 
patients undergoing both curative and palliative treatment.  
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It is the intention that the CASQ will be used to predict weight loss in people with 
cancer. As such it was important for the study sample to be representative of this 
population (Streiner and Norman, 2008). The study sample was diverse in terms of 
gender and age and reflected the patterns seen within the cancer population as a 
whole. Sixty percent of participants were male. This is no doubt due to the type of 
cancers being investigated. With the exception of pancreatic cancer, lung, 
oesophageal and stomach cancer are more common in men (Office for National 
Statistics, 2009). Participants were, almost exclusively, white and British. This 
broadly reflects the population presenting to cancer services locally and must be 
borne in mind when interpreting findings (East Midlands Public Health Observatory, 
2004). Based on their performance status, most subjects were independent and 
able to carry out all but the most strenuous activities of daily living. It is possible that 
those excluded from participating in the study due to previous weight loss may have 
had a poorer performance status as the two parameters have been shown to be 
strongly associated in previous studies (Dewys et al.,1980; Deans et al., 2009).  
Finally, when considering the reasons why patients (n=16) with a MUST score of 
one or less were excluded from participating, the main reason was that it was 
deemed ethically inappropriate by the researcher. Other exclusion criteria, such as 
ascites or dementia were rare. It should be noted that the validity of the CASQ has 
not been determined in patients with these conditions.  
 
Participants were chosen on the basis of having a diagnosis of lung or upper GI 
cancer and, within the study sample, there was a reasonable split between the two 
groups. It is important to acknowledge that the predictive validity of the CASQ has 
only been established in this set of patients, and not in all cancer diagnoses. To 
extrapolate the results to, for example, people with colorectal or breast cancer 
would not be appropriate (Streiner and Norman, 2008).  
 
The time since diagnosis ranged from less than one month to more than five years. 
What became apparent during the recruitment phase of the study was that although 
the majority of patients were currently having palliative treatment, or receiving neo-
adjuvant or adjuvant chemotherapy, others had received curative treatment and 
ZHUH SRVVLEO\ LQ HIIHFW µGLVHDVH IUHH¶ ,W LV LPSRUWDQW WR FRQVLGHU ZKHWKHU WKHVH
patients should have been excluded from the study. In practice it is extremely 
difficult to determine if someone is indeed free of disease and there is ambiguity at 
the point that the decision is made. It is fair to say that, in terms of disease status, 
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the sample appears to be representative of patients attending a medical oncology 
clinic. 
 
The objective of the study was to determine the ability of the CASQ to predict 
clinically significant weight loss and at the planning stage of the study it was 
considered necessary to have a study population which was relatively stable in 
these terms, and who were not at high risk of malnutrition. The MUST was used to 
classify subjects accordingly. One component of the MUST is a calculation of 
percentage unplanned weight loss over the previous three to six months. This 
parameter can be difficult to ascertain with any degree of accuracy for two reasons. 
The first is WKDW WKHDVVHVVRU LVRIWHQ UHOLDQWRQDSHUVRQ¶V UHFDOORI WKHLUSUHYLRXV
weight, which may or may not be accurate. Secondly, there may be a large 
discrepancy between percentage weight loss calculated at the three and six month 
time intervals. For the purpose of the study, the decision was made to record 
percentage unplanned weight loss over the preceding three months. This may have 
improved recruitment rates but could lead one to question the stability of the sample 
in terms of weight loss. Potentially, some participants may have been excluded from 
the study had weight loss been calculated over six months. If this had happened, 
whether more or less weight loss over the study period would have been seen is 
unknown. Ultimately, the outcome of this should not have affected the predictive 
ability of the CASQ.  
 
5.3.1.2 Baseline nutritional screening 
At baseline, the mean weight and BMI of recruited subjects were 74.4kg and 
26.0kg/m2 respectively. These findings differ from previous studies. In a group of 
151 patients with gastrointestinal or lung cancer, Khalid et al. (2007) found the 
mean weight and BMI to be lower, 69kg and 24.1kg/m2. However, the population 
recruited for the present study excluded those with a BMI of less than 18.5kg/m2, or 
those who had already lost more than 10% of their body weight. For this reason it is 
understandable that the mean weight and BMI were higher in the present study. In 
fact, over half of subjects had a BMI which classified them as being overweight or 
obese (WHO, 1998). Despite this, for one in five, their weight loss over the previous 
three months was between five and ten percent. Although this did not exclude them 
from taking part in the study, as they were not categorised by MUST as being at 
high risk of malnutrition, if over a short time frame the weight loss is of clinical 
significance (NICE, 2006). In practice these findings re-iterate the importance of 
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GHWHUPLQLQJ KRZ PXFK ZHLJKW VRPHRQH KDV ORVW DQG QRW MXGJLQJ D SHUVRQ¶V
nutritional status based solely on their BMI.  
 
The Malnutrition Screening Tool (MST) was validated in people with cancer 
undergoing chemotherapy or radiotherapy (Ferguson et al., 1999; Isenring et al., 
2006). This instrument classifies a person at nutritional risk if they have 
unintentionally lost more than five kilograms, or if they have lost up to five kilograms 
and have a poor appetite. Almost one third of study participants were classified as 
at nutritional risk using the MST. In clinical practice, the outcome of this would have 
been immediate nutritional intervention. This is in contrast to using the MUST where 
all patients who were identified as needing immediate nutritional intervention had 
been excluded from taking part in the study. This may lead us to question the 
guidelines for the use of MUST in this patient population. This issue will be 
discussed further in section 5.3.5. 
 
Systemic inflammation, as determined by serum C-Reactive Protein, is commonly 
recognised as a component of the cachexia syndrome (McMillan, 2009). Previous 
research has established the significance of a raised C-Reactive Protein level 
(>10mg/L) in terms of reduced function, prognosis and quality of life in people with 
cancer (Fearon et al., 2006). Other studies have found a lower level of greater than 
5mg/L as being prognostic of survival (Wang et al., 2009). Thirty-seven percent of 
the participants in the present study had an elevated serum C-Reactive Protein 
concentration, greater than 10mg/L. This is a smaller proportion than documented in 
research by Brown et al. (2006) which suggests that up to 78% of patients with 
advanced lung or upper GI cancer may have elevated levels. Variation from 
previous results may be due to having a truncated sample, where those with noted 
weight loss, and potentially raised C-Reactive Protein, were excluded. In addition, 
although the majority of patients studied here had non-curative disease this does 
not necessarily equate to advanced disease.  
 
In clinical practice, albumin has often been used as a marker of nutritional status. 
However, as it is a negative acute phase protein, serum levels drop during times of 
metabolic stress, infection and inflammation. Also, it is affected by hydration status 
and a long half life makes it inappropriate as an indicator of nutritional status when 
used in isolation (Chojnowska, 1996). Despite these limitations, serum 
concentrations of albumin have been shown by some to be a prognostic indicator in 
terms of quality of life (Vigano et al., 2000). In the present study, one in five 
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participants had a low serum albumin. For the reasons previously discussed, it is 
difficult to draw conclusions from these findings in terms of nutritional status. 
However, it may indicate that approximately 20% of this study sample were clinically 
unstable.  
 
Since this study was planned, and data collection commenced, diagnostic criteria 
for cachexia have been developed (Evans et al., 2008). Applying these criteria to 
the present study sample suggests that 5% of participants had cachexia. 
Interestingly, all those who met the diagnostic criteria had a diagnosis of upper GI 
cancer, and all scored less than 30 (mean = 19) on the CASQ. However, the figure 
of 5% could be misleadingly low. The diagnosis of presence of cachexia in this 
study sample was limited to use of the measured variables, i.e. BMI less than 
20kg/m2 or weight loss of at least 5% in 12 months or less, plus three from a raised 
C-Reactive Protein >5mg/L, albumin less than 3.2g/dL, presence of anorexia or 
fatigue. Data was not collected to enable an assessment of muscle strength, fat free 
mass and haemaglobin concentrations. 
 
To summarise, in a sample of 185 people with lung or upper GI cancer who were 
not at high risk of malnutrition, as categorised by the MUST, the majority were 
overweight or obese. Despite this, a small number met the diagnostic criteria for the 
cachexia syndrome and more had a raised C-Reactive Protein level or low serum 
albumin, all of which carry negative implications in terms of function, quality of life 
and prognosis. When determining the study sample, the initial aim was to test the 
CASQ in a population who were not already malnourished, the reasoning being that 
validated screening instruments, such as the MUST and MST, were already 
available to identify malnourished patients. Although the study sample aim was 
achieved when using the MUST to define malnutrition, it was clear from other 
measured variables, including the MST, that a proportion of the sample may have 
already been malnourished or indeed cachectic. Overall, this evidence suggests 
that the sample in the present study was possibly representative of the cancer 
population as a whole, rather than as intended, only those who were not 
malnourished. This has implications for the translation of findings. In particular, 
when defining the population in which the CASQ has predictive validity. 
 
5.3.2 Cancer Appetite and Symptom Questionnaire responses 
Completion of the CASQ by 181 study participants provided information on the type, 
and severity of symptoms experienced by patients with lung and upper GI cancer. 
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Potential CASQ scores ranged from zero to 48. The mean (SD) score was 30 (7) 
and the range was from five to 45, suggesting that some patients were indeed 
experiencing impairment in terms of appetite and symptoms.  
 
Overall, results showed that there was no statistical difference between the severity 
and the types of symptoms experienced by people with lung and upper GI cancers. 
This is similar to the findings of Khalid et al. (2007) where, aside from appetite loss 
being more prevalent in those with gastrointestinal disease, they also found no 
difference in symptoms across the groups at presentation.  
 
To explore the responses to the questionnaire in more detail, the twelve CASQ 
items can be grouped into three domains; appetite, food intake and symptoms. 
 
5.3.2.1 Appetite 
Appetite can be defined as a desire to eat which is expressed in terms of hunger 
and satiety. Teitelbaum (1964) describes a tri-modal approach to feeding, being 
regulated by the physical pangs of hunger, the pleasure of eating i.e. appetite, and 
the satiety which brings about the end of consumption. To add detail to this 
description, the pleasure of eating can be split into the desire to eat and the 
enjoyment of food. Responses to CASQ items one to four indicated how participants 
perceived these subjective experiences. 
  
Previous research suggests that the prevalence of anorexia, or loss of appetite, in 
patients with lung and upper GI cancer is in the region of 40 to 60% (Khalid et al., 
2007; McKernan et al., 2008; Bovio et al., 2009). However, no study appears to 
distinguish between the different aspects of hunger, appetite and enjoyment of food. 
In addition, comparisons of figures are difficult due to the heterogeneity of the study 
samples.  Within the present study, item three of the CASQ asked participants to 
UHVSRQGWR³%HIRUHHDWLQJ,IHHOKXQJU\«´5HVSRQVHVVXJJested that only around 
one third of participants regularly experienced the physical pangs of hunger around 
eating times. Furthermore, results imply that one in five subjects experienced early 
satiety. Despite this, when asked about their appetite, i.e. their desire to eat, just 
over half judged this as being good or very good and almost three quarters said that 
they enjoyed the food that they ate often or most of the time. These findings suggest 
that within this sample of patients with cancer, there was a marked difference in 
their experiences associated with these different aspects of food intake. 
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Experiencing a poor appetite does not necessarily equate to lack of enjoyment of 
food. These theories will be explored further in Chapter 6. 
 
5.3.2.2 Food intake 
A reduction of food intake in patients with advanced cancer, and specifically cancers 
of the lung and upper GI tract has been reported in the literature (Giacosa et al., 
1996; Khalid et al., 2007; Bovio et al., 2009). Differences in the methodology used 
for collecting dietary intake data can lead to problems with the interpretation of such 
studies. Furthermore, a clear definition of what constitutes a meal or a snack, and 
the subjectivity of the terms, may be reasons why the pattern of dietary intake is 
seldom reported. Hutton et al. (2006) investigated the patterns of dietary intake in 
people with advanced cancer. Analysis from three day diet diaries suggested that 
81% of participants ate breakfast, lunch and evening meal. This finding is in contrast 
with the results of the present study where approximately only two-thirds of 
participants reported eating three meals a day. Hutton et al. (2006) also highlighted 
the importance of snacking to ensure daily energy requirements are met. Indeed, 
within the present study, snacking was a frequent occurrence, with 80% having at 
least one snack a day. A contributing factor to this may be the upper GI diagnoses 
of subjects, which in practice often results in smaller, more frequent eating episodes 
due previous gastrointestinal surgery and the presence of adverse gastrointestinal 
symptoms. 
 
5.3.2.3 Symptoms 
People with cancer often experience numerous symptoms, many of which impact on 
appetite and food intake. Research suggests that symptom burden may change 
dependent on the stage of disease as well as the treatment pathway (Cooley, 2000; 
Teunissen et al., 2007). In addition, within clinical practice, symptoms often go 
unrecognised (Yavuzsen et al., 2009). Although not a comprehensive list of 
symptoms, responses to items seven to 12 of the CASQ suggest that the symptom 
burden in patients with lung and upper GI cancer is high. Previous research appears 
to focus on specific groups of patients with, for example, lung cancer or incidence of 
symptoms at presentation (Khalid et al., 2007; Lovgren et al., 2008; Yavuzsen et al., 
2009). Although the literature supports the findings in the present study, in terms of 
the types of symptoms experienced by participants (Teunissen et al., 2007), when 
looking more closely, the proportion of CASQ respondents with reduced energy 
levels and pain appeared to be lower compared with previous research (Lovgren et 
al., 2008). This could in part be due to the diversity of the sample in terms of stage 
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of diagnosis and treatment plan. In addition, the sample excludes some patients 
deemed at high nutritional risk where symptom burden is likely to be greater. 
 
Other symptoms, such as altered taste, nausea and vomiting, are often more 
commonly associated with anti cancer therapies (Cohen, 2007; Rehwaldt, 2009). 
Despite this Khalid et al. (2007) found that approximately one in five patients who 
were not receiving treatment experienced taste changes and nausea. Moderate to 
severe taste changes and frequent nausea were reported by a third of CASQ 
respondents, highlighting the extent of these problems. 
 
In summary, findings suggest that a high proportion of patients with lung and upper 
GI cancer experienced symptoms which can impact on appetite. As a consequence, 
for a considerable number, their eating pattern did not follow the traditional model of 
three meals a day. Despite this, three quarters of patients regularly enjoyed the food 
that they ate. 
 
5.3.3 Predictive validity of the Cancer Appetite and Symptom Questionnaire 
7KH SUHGLFWLYH YDOLGLW\ RI WKH &$64 ZDV H[DPLQHG XVLQJ 3HDUVRQ¶V FRUUHODWLRQ
coefficient. As can be seen from the scatter plot (Figure 5.5), there was a positive 
correlation between the total CASQ score and percentage weight change. The 
Pearson correlation coefficient (r = 0.32, P< 0.001) and regression coefficient (B = 
0.32 95%CI = 0.17 to 0.47, P <0.001) support this finding. Within the literature there 
is little agreement as to what value of r is acceptable. Ferguson (2009) suggests a 
guideline where r should be a minimum of 0.2 and values of 0.5 and 0.8 represent a 
moderate and strong association respectively. With this in mind, of the 12 individual 
CASQ items, half had statistically significant correlations with percentage weight 
change, where r > 0.2. These items were in relation to appetite, early satiety, 
enjoyment of food, snacks, nausea and pain. However, as with the total CASQ 
score, results suggest only weak associations between these individual items and 
percentage weight change. These findings lead one to question the strength of the 
CASQ as an instrument to predict weight loss in this population. However, as the 
correlation coefficient is only a marker of a linear relationship between two 
variables, the ability to draw firm conclusions from these results is limited. As will be 
discussed in subsequent sections, the association between the total CASQ score, 
and individual items, was explored further with the use of multiple linear regression 
techniques. 
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5.3.4 The Cancer Appetite and Symptom Questionnaire as a screening instrument 
for predicting weight loss 
The ideal screening instrument should be simple, practical and quick to administer. 
An instrument with these properties is likely to have a higher completion and 
compliance rate within clinical practice, something which is vital if the screening 
process is going to have a beneficial impact on patient care. It is hard to dispute the 
fact that the CASQ fulfils these criteria as it is self-administered by the patient and, 
by and large, takes no more than five minutes to complete. The optimum screening 
instrument should also have a high sensitivity, specificity, PPV and NPV. However, 
in practice, a screening instrument with these characteristics is difficult to develop, 
and a trade-off between these properties is often required. As it is important that a 
screening instrument is able to identify those who are at risk, with as few people as 
possible being missed, a high sensitivity is paramount. In addition, an instrument 
with a high NPV will mean that for those with a negative test result, it is unlikely that 
they have been misclassified. The optimum cut point of the CASQ score to predict 
greater than 5% weight loss was 31/32 (C statistic = 0.64; sensitivity 65%, 
specificity 62%, PPV 33%, NPV 86%), and to predict greater than 10% weight loss 
was 29/30 (C statistic = 0.75; sensitivity 71%, specificity 69%, PPV 21%, NPV 
95%). In terms of sensitivity and the NPV, it appears from these results that the 
CASQ is performing at its optimum when predicting greater than 10% weight loss. 
Specificity at both levels was quite low, suggesting that there would be a number of 
people wrongly identified as being at risk. When predicting greater than 10% weight 
loss the PPV was at its lowest, implying that only 21% of patients with positive test 
results, i.e. a low CASQ score, were correctly identified as being at risk. It is 
important to consider that the PPV can be dependent on the prevalence of weight 
loss. A low prevalence could result in a low PPV, despite having an instrument with 
acceptable sensitivity and specificity (Altman and Bland, 1994). Depending on the 
agreed intervention for at risk individuals, both the low specificity and low PPV could 
potentially increase workload and costs, as well as possibly causing unnecessary 
anxiety for the patient. 
 
5.3.5 Comparison of the Cancer Appetite and Symptom Questionnaire with other 
screening instruments and variables 
Correlations suggested that, in addition to total CASQ scores being associated with 
percentage weight change, other measured variables were too. Of the variables 
tested, C-Reactive Protein was found to have the strongest correlation (r = -0.3, P 
<0.001). As serum C-Reactive Protein concentrations increased, so did percentage 
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weight loss. As highlighted earlier, previous research has established the 
significance of a raised C-Reactive Protein level (>10mg/L) in terms of reduced 
function, prognosis and quality of life in people with cancer (Fearon et al., 2006; 
Vigano et al., 2000). Other studies have noted that C-Reactive Protein levels are 
raised in people with lung cancer who have lost greater than 5% weight (Scott et al., 
1996). Results from the present study concur with those of Mahmoud and Rivera 
(2002) who found C-Reactive Protein to be positively correlated with weight loss in 
people with advanced cancer. Certainly, in terms of those patients with lung and 
upper GI cancer, it appears that this association is not confined to those with 
advanced disease.  
 
When compared with the CASQ, MUST and MST, C-Reactive Protein as a 
screening instrument to predict greater than 10% weight loss had the highest 
sensitivity, specificity, PPV and NPV. Interestingly, the specificity and PPV were at 
their optimum when a cut point of 15mg/L was used. This is higher than both the 
upper limit of normality which is used in clinical practice, and the level above which 
previous studies have used when testing its predictive capabilities.  
 
Results suggested that in the studied population, when compared with the MUST 
and MST, the CASQ had a greater sensitivity and NPV when predicting greater than 
10% weight loss. Both the MUST and MST had a sensitivity of only 50%. This 
suggests that both instruments would miss half of all patients who were at risk. 
Although prediction of weight loss was not studied, previous research by Bauer and 
Capra (2003), when investigating the use of MUST as a screening instrument for 
malnutrition, found that it was not sensitive enough to be used within the oncology 
setting. This research was, however, conducted with a relatively small group of in-
SDWLHQWV DQG XVHG VXEMHFWLYH JOREDO DVVHVVPHQW DV WKH µJROG VWDQGDUG¶ $ PRUH
recent comparison of the MUST, MST and the MNA adds further evidence to the 
fact that the MUST may lack the desired sensitivity within the cancer population 
(Roulston and McDermott, 2009), although in this study the MST, along with the 
MNA, was found to be an appropriate alternative. Interestingly in the present study, 
the highest level of agreement, in terms of identifying those people at risk or not at 
risk, was between the MUST and MST. Limitations, in terms of an agreed definition 
of malnutrition need to be considered when interpreting these findings. 
 
To summarise, it appears that, in addition to the CASQ, C-Reactive Protein can be 
used to predict those out-patients with lung and upper GI cancer who are likely to 
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experience greater than 10% weight loss over the proceeding three months. For C-
Reactive Protein, using a cut point of 15mg/L will give the optimum performance. In 
addition, when compared with the MUST and MST, the CASQ was better at 
predicting weight loss in this group of people with cancer. It is however important to 
consider that the low PPV of the CASQ may mean that in its current format, it is 
inappropriate for use within the clinical setting.  
 
5.3.6 Determining the optimum model for predicting weight loss 
As highlighted above, although the CASQ can predict both 5% and 10% weight loss 
over three months, its PPV is unacceptably low. This issue may be able to be 
improved through the refinement of the CASQ, in terms of the number of items 
included, or the inclusion of additional variables which are predictive of weight loss. 
If solely focusing on the CASQ, exploratory multiple linear regression suggests that 
items six (number of snacks), nine (nausea and vomiting) and twelve (pain), 
combined, result in the optimum screening instrument to predict weight loss. 
Interestingly, none of these three items consider any aspect of appetite although it 
can be seen how they all may influence weight change. When considering 
additional variables, analysis suggests that an instrument containing CASQ items 4 
(enjoyment of food) and 12 (pain), along with MUST score, BMI and age are most 
predictive of weight change. These models would need to be tested prospectively to 
determine their use within clinical practice.  
 
5.3.7 Survival analysis 
Although the primary objective of this phase of the study was to determine the 
predictive validity of the CASQ, it was of interest to see if the instrument itself, or 
any of the other measured variables were predictive of survival. Multivariate 
analysis performed on the whole sample,  when adjusted for age, suggested that, in 
addition to whether someone is receiving curative or palliative treatment, a high 
serum C-Reactive Protein level, low CASQ score and high percentage weight loss 
at baseline were all independent predictors of survival. These results concur with 
those of others studying similar patient populations. On multivariate analysis 
McKernan et al. (2008) found tumour stage, treatment intent, appetite loss and C-
Reactive Protein to be predictive of survival in patients with gastro-oesophageal 
cancer. Also, in patients with inoperable NSCLC, C-Reactive Protein, weight loss, 
performance status and fatigue have been shown to be predictors of survival (Scott 
et al., 2002). In the present study, when the analysis was repeated in a split sample, 
WKHYDULDEOHµHDWLQJSRRUO\¶ZDVPRVWSUHGLFWLYHRIVXUYLYDOIRUWKRVHZKRKDGFXUDEOH
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disease. For those with incurable disease, C-Reactive Protein and total CASQ 
scores remained the most predictive variables in terms of survival. For these 
analyses it is important to consider the difference in the sample between the two 
groups. In particular, the number of participants with curative disease that died 
during the study period was low, 11 compared with 72 in the palliative group. This is 
likely to have strongly influenced the results of the regression analysis.  
 
5.4 Conclusion 
In conclusion, the CASQ has been shown to have predictive validity in terms of 
future weight loss in out-patients with lung and upper GI cancer. Total CASQ score 
has also been identified as an independent predictor of survival. As a screening 
instrument, the optimal CASQ score cut point to predict greater than 5% weight loss 
is 31/32, and to predict greater than 10% weight loss is 29/30. However, due to its 
relatively low PPV, routine use of the CASQ within clinical practice must be 
questioned. A revised instrument, such as one incorporating CASQ items four 
(enjoyment of food) and 12 (pain), along with age, BMI and MUST score, needs to 
be tested prospectively. Also to be highlighted is the use of C-Reactive Protein, as 
both a predictor or weight loss, and of survival. Alternatively, testing the instrument 
in a more diverse population, rather than one that excluded those who were 
malnourished as defined by the MUST, may result in improved performance 
statistics. 
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CHAPTER 6: PHASE III: A QUALITATIVE EXPLORATORY STUDY 
 
6.1 Introduction 
Numerous people with cancer experience a reduction in their food intake which 
significantly affects their nutritional status, function and quality of life (Fearon et al., 
2006). In addition, the impact of their weight loss and nutritional problems on their 
family and caregivers should not be forgotten (Hopkinson et al., 2006). Previous 
research focuses on determining the extent of the problem, as well as trying to 
provide solutions such as pharmacological and nutritional management strategies. 
An improved understanding of the experiences and perceptions of people with 
cancer and their carers, in terms of the factors which influence their nutritional 
status, may help improve compliance to treatment as well as enabling the 
development of more patient centred approaches. The key objectives for Phase III 
of the study were to: 
1. Describe the experiences of people with lung or upper gastrointestinal 
cancer, and their carers, regarding the factors influencing weight change. 
2. Explore the causes and influencing factors of weight change in people with 
lung or upper GI cancer.  
3. Propose a conceptual model of influences on weight change in people with 
cancer. 
4. Identify areas for improvement regarding the nutritional management of 
people with cancer. 
 
A qualitative exploratory study conducted following the principles of the Straussian 
approach to grounded theory (Strauss and Corbin, 1994) was used to meet these 
objectives. Theoretical sampling techniques were employed to recruit patients with 
lung or upper GI cancer, who were participating in Phase II of the study, along with 
their partner or carer. Data were collected using semi-structured interviews which 
were transcribed verbatim and subsequently analysed using techniques described 
in the tradition of grounded theory. Summarisation and interpretation of key 
categories led to the emergence of core concepts. From this, a theoretical 
framework relating to the influences on weight change was developed. 
 
6.2 Findings 
This section begins with a description of the participants in the sample used for the 
collection of qualitative data. It goes on to describe the findings from the study. The 
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following section discusses the categories found to influence food intake. These 
were µsymptoms¶, µself-management¶, µattitude to body weight¶, µsocial support¶ and 
µclinical support¶. 
 
The core process that emerged from the analysis of the transcribed data was 
µLQIOXHQFLQJ IRRG LQWDNH¶ The subsequent discussion explains how the interplay 
between the categories and sub-categories helps to explain this core process. The 
chapter ends with the proposal of a conceptual model of the process of the 
influences on weight change in people with cancer. 
 
Direct quotations have been used throughout the discussion to denote the contrary 
and concurring views of the interviewees. To help maintain anonymity, names used 
when highlighting quotes are pseudonyms.  
 
6.2.1 Characteristics of the sample 
Qualitative data collection took place concurrently with the Phase II study during the 
10 months from August 2008 to June 2009. Ten potential interviewees who met the 
criteria were approached and nine agreed to take part. Listed alphabetically, Table 
6.1 describes the characteristics of these patient participants.  Initially, sampling 
was purposeful with Alison and Christine being the first two participants to be 
interviewed. They were selected based on their diagnosis, social circumstances and 
weight loss. Following this the intention was to sample patients theoretically. 
However, not all participants had a spouse or carer available at the time of 
interview. In addition, the time constraints imposed by the completion of the Phase II 
study meant that a more diverse study sample, in terms of diagnosis, treatment 
intent and inclusion of a carer was not achieved. In total five males and four females 
were interviewed, four of whom were receiving curative, and five palliative, 
treatment. The sample was diverse in terms of age (range 45 to 77 years) and time 
since diagnosis (range 3 to 12 months).  All but one of the patient interviewees were 
married, and in each of these cases they were asked if their spouse would like to be 
involved. Three of the wives of male patients took part in the interviews. Of note is 
that at the time of interview all but one of the interviewees had a BMI within the 
healthy parameters (range, 20.8 to 26.3 kg/m2). 
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Table 6.1: Characteristics of Phase III patient interviewees 
 
Name Interview 
with 
partner 
Age Marital 
status 
Diagnosis 
 
Months 
since 
diagnosis 
Treatment 
intent 
1st CASQ 
score 
2nd CASQ 
score 
BMI at 
interview 
(kg/m2) 
Study 
weight 
change 
(%) 
Alison No 45 Widow Oesophagus 3 Curative 25 26 20.9 -9 
 
Bill No 64 Married Stomach 4 Curative 32 25 24.5 -11 
 
Christine No 59 Married Pancreas 8 Curative 21 25 22.3 -7 
 
David Yes 63 Married Lung 9 Palliative 28 28 23.6 -16 
 
Doreen No 77 Married Lung 11 Palliative 38 23 23.5 -2 
 
Ian Yes 59 Married Lung 7 Palliative 33 29 23.2 -9 
 
Len No 70 Married Bile duct 5 Curative 35 24 26.3 0 
 
Paul Yes 71 Married Oesophagus 11 Palliative 28 23 23.2 -11 
 
Peggy No 67 Married Lung 12 Palliative 35 21 20.8 0 
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6.2.2 Symptoms 
A significant category identified during the axial coding of the transcripts was 
µV\PSWRPV¶ 7KH LPSDFW RI V\PSWRP GLVWUHVV LQ SHRSOH ZLWK FDQFHU LV ZHOO
documented in the literature (Bovio et al., 2009; Cooley, 2000; Grosvenor et al., 
1989). This is a notion supported by the findings of the present study where all 
participants talked about symptoms which affected their wellbeing and nutritional 
intake. Weight loss and a reduced appetite were the most common. However, it was 
the other symptoms which often contributed to their existence. Table 6.2 shows the 
19 symptoms that were expressed by the participants. This category was sub-
divided into weight loss, gastrointestinal symptoms, pain, fatigue and psychological 
symptoms. 
 
Table 6.2: Symptoms experienced by Phase III patients 
 
Symptom Participant 
1. Weight loss Alison, Bill, Christine, David, Doreen, 
Ian, Len, Paul, Peggy 
2. Reduced appetite Alison, Bill, Christine, David, Doreen, 
Ian, Len, Paul, Peggy 
3. Vomiting Alison, Bill, David, Doreen, Ian, Len 
4. Pain Alison, Bill, David, Ian, Len, Paul 
5. Nausea Alison, Bill, Christine, David, Doreen, 
Peggy 
6. Taste changes Alison, Bill, Christine, David, Paul 
7. Reduced energy levels Alison, Christine, Ian, Paul 
8. Anxiety Alison, Christine, Peggy 
9. Early satiety Bill, Christine, Len 
10. Weakness Bill, David, Ian 
11. Tiredness Alison, Christine, Ian 
12. Aversion to smells Alison, Bill 
13. Indigestion Alison, Paul 
14. Constipation Bill, Paul 
15. Diarrhoea Christine, Len 
16. Sore mouth / throat Bill, Ian 
17. Bloated Bill 
18. Hiccups Paul 
19. Feeling cold Ian 
 
6.2.2.1 Weight loss 
All participants made reference to changes in their body weight. Over the course of 
their treatment some had lost only one or two pounds and, at the time of interview, 
appeared more concerned about being overweight. For others, the decrease in their 
weight was an obvious worry for both themselves and their family: 
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I was worried about, and the weight was just dropping off.......I thought, I 
NQRZ,¶YHDOZD\VZDQWHGWREHWKLQEXW,¶PJRLQJWREHOLNHDEHDQSROHDWWKLV
rate. (Alison, oesophageal cancer) 
 
%HFDXVH,FRXOGVHHKLPORVLQJWKHZHLJKWWKHQDQG\RXNQRZKHFRXOGQ¶W
HDW KH FRXOGQ¶W VZDOORZ FRXOGQ¶W VLS ZDWHU DQG , VD\V ,V WKHUH DQ\WKLQJ
else you can give KLP",DQ¶VZLIHOXQJFDQFHU 
 
Previous research shows that weight loss can occur at any stage of the cancer 
journey (Deans et al., 2007, Tonouchi et al., 2008, Bruce and Hodson, 2004, 
Andreyev et al., 1998) and analysis of these interviews confirmed this. Several of 
the participants talked about losing weight prior to the diagnosis of cancer being 
made. For two of them it was one of the symptoms that highlighted that there was a 
problem. For others, the side effects of treatment; surgery, chemotherapy or 
radiotherapy, resulted in weight being lost. The analysis of the data from this study 
suggests that there was individuality to the experience. For example, despite 
chemotherapy being predominantly associated with adverse symptoms and weight 
loss, two of the participants put weight on during this period: 
 
I then had three courses of chemotherapy, which honestly... I went through 
WKDW DEVROXWHO\ EULOOLDQWO\  <RX NQRZ \RX FRXOGQ¶W \RX FRXOGQ¶W IDXOW
anything..... And I actually put on weight, over chemotherapy. (Ian, lung 
cancer) 
 
Most of the participants clearly linked weight loss to the fact that they were not 
eating the same as previously. In addition, other factors, for example, the ageing 
process and pre-existing medical conditions, such as diabetes, were also 
implicated. Overall, the main reasons given for losing weight were associated with 
the symptoms that patients were experiencing.  
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6.2.2.2 Gastrointestinal symptoms 
6.2.2.2.1 Reduced appetite 
Participants experienced an array of gastrointestinal symptoms. The most 
commonly reported, which was experienced by all of the patients who were 
interviewed, was a reduced appetite.  As previously discussed in this thesis, along 
with the physiological sensations of hunger and satiety, appetite is one stage in the 
process of feeding (Teitelbaum, 1964). The subjective phenomenon of appetite, 
described as the pleasure of eating, encompasses both the desire to eat and the 
enjoyment of food.  In this study tKH WHUP µDSSHWLWH¶ ZDV IUHTXHQWO\ XVHG E\
participants and was often put into context by making a comparison to what they 
judged as normal: 
 
Just this pattern: very good appetite, comparatively speaking all the way 
through to the chemotherapy and then bad appetite after the chemotherapy 
getting progressively worse. Stopped the chemotherapy good appetite 
again. (David, lung cancer) 
 
Just over half of those interviewed also directly referred to hunger. One in particular 
demonstrated the physiological aspect of this sensation: 
 
>7XPP\ UXPEOHV@  $K  'LG \RX KHDU WKDW" 7KDW¶V KXQJU\ WKDW¶V ZKDW ,¶P
doing a lot, it lets me know. (Len, bile duct cancer) 
 
For others, reference was made to feeling, or not feeling, hungry. Two of the 
SDUWLFLSDQWVWDONHGDERXWµEHLQJUHDG\IRULW¶: 
 
$QG,ZDVQ¶WUHDG\IRUP\OXQFK,GLG,GLGKDYHDVDQGZLFKRUVRPHWKLQJ
EXW,ZDVQ¶WDVHDJHUIRULW. (Doreen, lung cancer) 
 
A desire for food, in those words, was only mentioned by one of the patients: 
 
I used to enjoy eating chocolate before having the stent, no, and I KDYHQ¶W
UHDOO\ JRW D GHVLUH GRQ¶W KDYH DQ\ GHVLUH WR HDW D ORW RI FKRFRODWH DW DOO. 
(Paul, oesophageal cancer) 
 
Along the same vein, several participants made reference to what can be construed 
as a desire to eat, such as ³not feeling like eating´, or there being ³nothing that they 
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fancied´. Additionally, the enjoyment of food was something that was talked about 
by most.  ,QWRGD\¶VVRFLHW\ZKHUHIRRGLVDYDLODEOH LQDEXQGDQFHHQMR\PHQW LVD
key factor when it comes to eating (Clarke, 1998). ,Q3DXO¶VFDVH, the seriousness of 
lack of enjoyment of food was evident: 
 
$QG WKH IDFW WKDW \RX NQRZ \RX¶UH QRW JRLQJ WR SDUWLFXODrly enjoy it, and 
\RX¶UHQRWVLWWLQJGRZQWRLI,FDQXVHWKHH[SUHVVLRQOLYLQJWRHDW\RXNQRZ
,¶PHDWLQJMXVWWROLYH. (Paul, oesophageal cancer) 
 
Finally, all three of the participants who had had surgery to remove part, or all, of 
their stomach complained of early satiety: 
 
%HFDXVHP\DSSHWLWH LVVWLOODVPXFKDVLW¶VHYHUEHHQBut I just get fuller 
quicker. 2EYLRXVO\ , KDYHQ¶W JRW WKH VWRPDFK WKDW , KDG. (Len, bile duct 
cancer) 
 
Further exploration of the phenomenon of appetite in the data suggested that 
merely asking someone what their appetite is like will result in a purely subjective, 
good, bad or non-existent, response. Furthermore, the sensations of hunger, desire 
to eat, enjoyment of food and satiety may well be mutually exclusive. As such, the 
focus of any assessment of appetite should include all of these four aspects of the 
feeding process. Aside from appetite, the taste and smell of food were highlighted 
as areas of concern for patients.  
 
6.2.2.2.2 Taste and smell 
Palatability, or the taste and smell of food, also play an important role in the eating 
process (Yeomans, 1998). However, the dimensions of palatability in people with 
cancer are generally less well researched (Bernhardsen et al., 2009). Four of the 
patients who were interviewed in this study spoke about disturbances in their taste 
which influenced their food intake. All related these changes to times when they 
were having chemotherapy. Taste changes were described in a variety of ways. 
Some said that food tasted horrid and others spoke about a lack of taste. A 
preference for sweet foods was expressed by some. Another participant said foods 
had a metallic taste:  
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$QG LW¶V YHU\ , NQRZ LQ P\ KHDUW , RXJKW WR EH KDYLQJ VRPHWKLQJ EXW
EHFDXVHZH¶YHJRW this lack of taste, and what you have got sometimes, like 
a metallick\WDVWHEXW,MXVWGRQ¶WZDQWWRHDW. (Christine, pancreatic cancer) 
 
In addition, the off-putting smell of food, specifically meat, was mentioned by two of 
the participants who were receiving chemotherapy: 
 
6RPHWLPHVWKHVPHOORIIRRG,PHDQIRRG¶VQHYHUERWKHUHGPHWKHVPHOO
RILWHYHQZKHQ,¶YHEHHQSUHJQDQW7KDW¶VQHYHUERWKHUHGPHEXWWKLVWLPH
it was like, one night I decided I¶G GRP\VSDJKHWWLERORJQDLVHDQG,¶GVWDUWHG
it and I went to them, I said Helen,FDQ¶WGRLWWKHVPHOO,KDGWRJRXSVWDLUV
out the way, the smell, because certain, meat, probably, you know,  was 
MXVW«$OLVRQRHVRSKDJHDOFDQFHU 
 
:HOO , GRQ¶W NQRZ UHDOO\ LW WKH VPHOO SDUWLFXODUO\ PHDW SXWs you off. (Bill, 
stomach cancer)  
 
Other studies concur with the findings here that patients having chemotherapy may 
experience altered taste and smell, with these often undisclosed symptoms 
impacting on both their physical and psychological well being (Bernhardson et al, 
2008). Overall, research in this area is limited. An improved understanding of the 
experience and impact of these symptoms could help with the provision of support 
and self-management. 
 
6.2.2.2.3 Nausea and vomiting 
All participants talked about nausea, and/or vomiting. Those with oesophageal 
cancer also mentioned the discomfort caused by indigestion and hiccups. The 
analysis suggests that these were symptoms, particularly nausea and vomiting, that 
had a great impact on nutritional intake and overall well being: 
 
6KH¶G >*3@ VWDUWHG PH RII RQ VRPH OLNH JDVWUR- anti-sickness tablets but 
WKH\ZHUHQ¶WZRUNLQJZKDWHYHU , WRRNGLGQ¶WZRUN $QGRIFRXUVHDV WLPH
went on, I was just being more and more sick, and it got that, sometimes I 
FRXOGQ¶t keep water down and the weight was just literally, was just dropping 
off. (Alison, oesophageal cancer) 
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Although chemotherapy was given by several of the participants as the reason why 
they were suffering with these symptoms, other causes included the tumour, µpain 
relief medication¶, nutritional supplements and over-eating. Most talked about being 
given µanti-sickness medication¶, and for some this was clearly seen as a panacea: 
 
But I was feeling sick now and again, and I dLGQ¶WIHHOOLNHVRPXFKWRHDW,
did eat, but nothing, not, not as much as I normally did.  Especially 
EUHDNIDVW  ,¶G SHUKDSV KDYH P\ EUHDNIDVW SRUULGJH DQG MXVW D FRXSOH RI
spoonfuls and I felt sick.  But it was usually middle of the nights I felt sick.  
But these tablets they gave me were marvellous.  It stopped it straight away. 
(Doreen, lung cancer) 
 
For others, despite changes in the type of medication, these symptoms persisted: 
 
, IHOW QDXVHRXV WRGD\ GRQ¶W NQRZ ZK\....TKH\¶YH KDG WR DOWHU P\ VLFNness 
WDEOHWVWKUHHWLPHVQRZEHFDXVHWKH\ZHUHQ¶WKDYLQJDny effect.  But, we get 
through [laughs]. (Christine, pancreatic cancer) 
 
One of the patients thought that being sick was an inevitable part of the treatment 
and this lack of information had prevented her from seeking help: 
 
......and the family said I think you should phone the hospital. NR,WKLQNLW¶V
SDUWRI LW LI\RX\RXNQRZDQG\RX¶YHJRW WKHFKHPR LW¶VDOO WKLVDWWDFNLQJ
your body.  And, like I say, I just persevered with it, and when I went back, 
and he says, well, really you should have contacted us. (Alison oesophageal 
cancer) 
 
Others, despite medication routinely being prescribed, did not comply with the anti-
emetic treatment. Peggy recounts an observation that she made in the 
chemotherapy clinic:  
 
«\RX¶YHJRWWRDSSURDFKLWZLWKWKHULJKW,PHDQ,GLGVHHDODG\RQFHZKHQ
,ZHQWWKDWKDGMXVWKDGDGULSDQGVKHZDVLQWKHZDLWLQJURRPDQGVKH¶V
tearing open the tablets, because she said, Oh, well, I better take one just in 
case I feel sick, and I thought, you know, just wait and see if you, because 
WKHVLFNQHVVSDUWRILWDQG,¶YHJRWWKUHHNLGVWRPHZDVOLNHWKHSUHJQDQF\
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sickness, the early morning sickness, that was all, just slightly nauseous.  
Which I still get in the mornings. (Peggy, lung cancer) 
 
Despite ZDQWLQJWR³do as she was told´, Peggy later went on to talk more about why 
she was reluctant to take the tablets: 
 
The, the slight sickness, I never took any of the big boxes of sickness 
tablets.  The only ones I WRRNDQG,GLGQ¶WWDNHDOORIWKRVH......I just took two 
DGD\RUHYHQRQHDGD\DQG\RXNQRZEHFDXVH,WKRXJKWZHOO,¶GEHWWHU
GRDV,¶PWROGWRGR>ODXJKV@$QGWKHQ,QRWLFHGWKH\¶YHJRWVRPHVWHURLGV
LQVR,ZDVQ¶WWRRNHHQRQWKDW. (Peggy, lung cancer) 
 
This suggests that compliance with prescribed anti-emetic treatment is variable, a 
finding that is supported within the literature (Jakobsen and Herrstedt, 2009; 
Osterberg and Blaschke, 2005). Non-compliance with medication is a phenomenon 
which has been studied for many years and has implications economically and in 
terms of health of the individual (Osterberg and Blaschke, 2005). In this case, poor 
compliance may have been due to the severity of the symptoms experienced, but 
could also be due to the underlying attitudes and beliefs of the individual. In 
particular, it appeared that Peggy took a stoical approach to her healthcare and was 
possibly reassured by the fact that she did not need as much help as other people. 
Alison believed it was just part of the process and had to be endured. Other people 
are reluctant to take any medication, sometimes due to the concern over possible 
side effects (WHO, 2003). As healthcare professionals, assessing the potential 
concerns of patients which may contribute to the issue of non-compliance could 
help address this issue. The belief by some patients, that certain symptoms are an 
inevitable part of the disease or treatment, may be harder to dispel. 
 
6.2.2.2.4 Change in bowel habits 
Change in bowel habits, either constipation or diarrhoea, was identified as a 
concern for several of the participants. Constipation was described as a significant 
problem by Bill: 
 
The biggest thing was my bowels, that was, you know, that was terrible, I 
mean, it was like, fourteen days with not going at all. Oh, it was terrible.  You 
NQRZ-XVW\RXNQRZ\RXMXVWDQGWKHQ,FDPHKRPHDQGWKHILUVW«VL[
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days at home. Well, you felt bloated all the while and horrible. (Bill, stomach 
cancer) 
 
Patients who had had surgery to resect part of their pancreas referred to issues with 
diarrhoea. Both had been prescribed Creon to help with malabsorption problems. 
For one of them this had resolved the symptoms: 
 
I had to go back and see the surgeon like, three month after the operation, 
for a check-up and one of his assistants, the young doctor there, he asked 
PHZKDWWKHSUREOHPZDVDQG,VDLG:HOO,ZDVQ¶WSXWWLQJZHLJKWRQDQG,
ZDVJRLQJWRWKHORR$QGKHVXVVHGRXWWKDWWKDW¶VZKDWLWZDVDQGWKDW¶V 
ZKDW , QHHGHG WKHVH &UHRQ WDEOHWV  6R ,¶P WDNLQJ WKHP DQG ,¶P DOO ULJKW
HYHU\WKLQJ¶VDOOULJKW. (Len, bile duct cancer) 
 
For the other, the symptoms were ongoing and the psychosocial consequences 
were becoming unmanageable:  
 
Yeah, well, this is it and LW¶V DFWXDOO\ JRW DQG , VDLG WKLV WKH RWKHU GD\ LWV
DFWXDOO\JRWWRWKHSRLQWZKHUH,GRQ¶WUHDOO\ZDQWWRJRRXW$QGWKDW\RXJHW
into a vicious circle then.  I mean, I went to Lincoln, could be last week, I 
think with Trevor, and I got in to Lincoln, and I just went into panic mode 
EHFDXVH,WKRXJKW,GRQ¶WNQRZZKHUHWKHORRLVDQGLW¶VVWXSLG,GRQ¶WNQRZ
ZKHUHWKHORRVDUH$QGWKHQLWFDXVHGDUHDFWLRQ>ODXJKV@$QG,VDLG,¶YH
JRWWRJRKRPH,¶YHJRWWRJRKRPH$QG,WKRXJKW,VDLGZHwere actually 
RQWKHSRLQWRIFRPLQJKRPH,VDLG1R,¶PJRLQJWRVWLFNWKLVRXW%XWLW¶VLW
MXVWFDXVHVPHVWUHVVWRJRRXW,GRQ¶WOLNHLW. (Christine, pancreatic cancer) 
 
In this case, the patient was convinced that the diarrhoea was an inevitable 
symptom of the chemotherapy which increased her increased anxiety about going 
out and enjoying normal activities.  
  
6.2.2.3 Pain 
Several of the participants talked about experiencing pain. From the analysis it 
seemed that the causes of pain were variable. One participant talked about a pre-
existing condition that caused him back pain. The presence of the tumour, or the 
treatment given for it, caused physical pain for others. Radiotherapy had mDGH,DQ¶V
throat so sore that he was unable to swallow, clearly influencing his food and fluid 
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intake. He openly expressed the degree of discomfort that he had experienced: 
 
,¶YHKDGSDLQLQP\OLIHEHIRUH<RXNQRZEHFDXVHZHKDGDGLVHDVHFDOOHG
ulcerated colitis.  I had that for twelve years until I had all my bowels 
UHPRYHG6R,¶YHKDGSDLQ%XWWKHSDLQZKHQ\RXFDQ¶WHYHQVZDOORZ\RXU
RZQVDOLYD\RXFDQ¶WGULQNDQd I was having to take this medicine to kill the 
pain and kill the burning, long enough just to take a drink....... When you got 
pain like that, the only, the pain I could put it down to, the type of pain, is if 
\RX¶YHHYHUVHHQWKH$OLHQWKHILOP"«,WFRmes out your chest«LWVWDUWHGRII
just there like that and then all of a sudden it was across all your chest and 
you just felt as though your chest was just going to explode. (Ian, lung 
cancer) 
 
Another participant, Paul (oesophageal cancer), despite having been on strong 
analgesics, appeared to play down his symptoms and needed to be prompted by his 
wife to discuss them:  
 
3DXO¶VZLIHYou did have your pain though, Paul. 
 
Paul: I have this pain from having the stent fLWWHG« 
 
3DXO¶VZLIHYou had a pain that went into his left hand side of his chest.  
 
Paul: «D FHUWDLQ DPRXQW RI GLVFRPIRUW VRPH GLVFRPIRUW DQ\ZD\«EXW LW
seems to have settled down a bit.  I mean, I was having doses of morphine 
for a little while, as well as Paracetamols.  
 
This may be linked to the reluctance of patients to disclose the extent of symptom 
burden, an issue highlighted by other authors (Von Roenn et al., 1993) and one 
which makes the management more challenging. 
 
6.2.2.4 Fatigue 
Fatigue is an ongoing issue for many people who have cancer, with some studies 
reporting up to 60% of patients being affected (Stone et al., 2000). Fatigue 
encompasses several aspects related to quality of life, and as such has physical, 
cognitive and affective features (Servaes et al., 2002). In this study the participants 
described physical fatigue as feeling tired, having a lack of energy or feeling weak. 
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The youngest patient to be interviewed discussed her lack of energy the most: 
 
I mean, that was, it was horrendous, in fact, one morning, I remember 
IHHOLQJWKDW,GLGQ¶WHYHQKDYHWKHHQHUJ\WRJHWXSDQG,WKRXJKW,MXst want 
to curl up and die. ,KDYHQRW ,FDQ¶WSXWP\FKLOGUHQWKURXJKDOO WKLVDQG,
MXVW,GLGQ¶WHYHQKDYHWKHHQHUJ\WRJHWRXWRIEHG$OLVRQRHVRSKDJHDO
cancer). 
 
Analysis of the interviews suggests that the impact of fatigue was significant, from 
denying participants the opportunity to continue enjoyed pastimes such as golf, to 
causing additional physical problems. One person talked about an accident that had 
occurred as a result of feeling fatigued: 
 
I mean, I walked all round Clumber Park.  I suppose we must have walked 
about four miles.  But, when I was going back, I actually said, I suddenly felt 
DVWKRXJK,¶GKLWDEULFNZDOODQG,MXVWIHOWYHU\WLUHGDQGXQIRUWXQDWHO\,IHOO
$QG,¶YHVSUDLQHGmy ankle badly. But I think that was to do with tiredness, 
,¶GKLW WKLVZDOODQG , MXVW , VXSSRVH ,ZDVQ¶WSLFNLQJP\ IHHWXSDQG , IHOO
And spread-eagled in the mud.  [laughs]  And I find that even now I get to 
WKH SRLQW VRPHWLPHV , WKLQN ,¶P KXQJU\ WKDW ,¶P QRW , GRQ¶W UHDOO\ ZDQW
DQ\WKLQJEXW ,NQRZ LWDOO ,¶PGRLQJ LVGRLQJDYLFLRXVFLUFOHEHFDXVH , IHHO
tired.  All I want to do is just go to bed. My duvet days, as I call them.  
>ODXJKWHU@  %XW , WKLQN D ORW RI WKDW LV EHFDXVH RI ZKDW ,¶P QRW HDting. 
(Christine, pancreatic cancer)   
 
In several of the cases, wanting to go to, or stay in bed was the expressed 
treatment of choice. There was also an association made between a lack of energy 
and a reduced intake of food.  One of the male participants describes a similar 
experience and belief including feeling unusually cold and spending more time 
sleeping to overcome symptoms: 
 
I used to come in [from work], you know, did about six hours at work and 
came back home or four hours at work and come back home.  I used to get 
into bed, I used to more or less go straight to bed, because I was cold.  
%HFDXVH,ZDVQ¶WWDNLQJDQ\IRRGLQWREXUQWRJLYHPHDQ\HQHUJ\,¶GJHW
LQWR EHG  ,¶G JHW QLFH DQG ZDUP WKHQ WKH QH[W PLQXWH LW¶G EH IRXU KRXUV
ODWHU$QG,FRXOGQ¶WUHPHPEHUGURSSLQJRIIWRVOHHS. (Ian, lung cancer) 
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Conversely, two of the other male participants felt that the weakness that they were 
experiencing was due to a lack of activity and mobility. One of them, a farmer, felt 
that getting back to his normal routine was going to help get his strength back: 
 
Yeah, getting back on to my legs has been the biggest problem.  You know, 
I have to be careful I dLGQ¶WIDOORYHU I mean, being in all the time, you know, 
LW¶V«WKDW¶V EHHQ WKH WURXEOH JHWWLQJ VRPH DLU LQWR \RXU OXQJV  <RX NQRZ
1RZZLWKZRUNLQJDJDLQOLNH,¶PRXWDJDLQOLNH\RXNQRZ,¶PJHWWLQJEHWWHU
you know. (Bill, stomach cancer) 
 
The physical dimensions of fatigue were clearly expressed by the study sample. For 
most, the resulting effect was a reduction in activity. Winningham and colleagues 
(1994 cited by Armes et al., 2004) propose a model of fatigue in which a decrease 
in physical activity is an important determinant when considering the impact of 
symptoms on the development of fatigue. It is likely that the subsequent effect 
would be a decrease in functional status.  
 
In the present study, only one participant mentioned a lack of motivation, and this 
was in relation to carrying out routine tasks such as cooking. Cognitive aspects, 
such as loss of concentration or attention were not included in the discussion. That 
is not to say that these aspects of fatigue were not significant, just that they were 
not raised in relation to the nutritional issues discussed. 
 
6.2.2.5 Psychological symptoms 
In addition to the physical symptoms experienced by people with cancer, 
psychological and emotional symptoms are often present (Butt et al., 2008). In 
particular, symptoms of anxiety are common and have been shown to have a 
negative impact on quality of life (Stark et al., 2002; Brown et al., 2009). Generally, 
such symptoms may be less well expressed and, if unaddressed, may impact on the 
emotional well being of the patient and their carer (Kennifer et al., 2008). In this 
study, in relation to nutritional factors, there was a gender difference in the reporting 
of psychological symptoms, with the men being less likely to disclose these feelings. 
Several of the female participants did express feelings of anxiety, worry and stress. 
For one, the anxiety was caused by not being able to eat and losing weight:  
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..... it was only through me being so, like I say, lethargic, I was worried, 
EHFDXVH,NQHZ,ZDVQ¶WJHWWLQJWKHQXWULHQWV ,ZDVQ¶WJHWWLQJDQ\WKLQJLQWR
my body..... I was worried about, and the weight was just dropping 
off...(Alison, oesophageal cancer) 
 
For others it was the other way round with the anxiety being perceived as the root of 
the reduced appetite and intake: 
 
7KHDSSHWLWHKDGJRQHDVZHOO,WZDV,MXVWGLGQ¶WZDQW,MXVWGLGQ¶WZDQWWR
HDW2ULI,JHWVRPHWKLQJLQIURQWRIPHDQG,WKLQN2K,FRXOGQ¶WHDWWKLVRU
I might eat half of it and the rest of it go in the bin.  But I think, some of that 
was due to anxiety......One of the biggest losses [in weight] was over that 
period when they told me that the cancer had returned.  Now whether that 
ZDVDQ[LHW\ WKDW¶VZKHQ,VWDUWHGWRKDYHWKLVELJGURSDQGVLQFHWKHQ LW¶V
been dropping. (Christine, pancreatic cancer) 
 
The perpetual nature of anxiety causing weight loss, and weight loss causing 
anxiety was pointed out by another participant: 
 
$QG LW¶VVRUWRID OLWWOHELWRIDYLFLRXVFLUFOHEXWVD\,ZHLJKHGP\VHOIDnd 
WKHQ ,¶G ORVW D SRXQG RU D SRXQG DQG D KDOI , PHDQ , GLG DOWKRXJK P\
VFDOHVDUHQ¶WDFFXUDWHDV ,VDLGDSRXQGDQGDKDOI WZRSRXQG WKHQ\RX
VWDUWWRSDQLFRU\RXVWDUWWRZRUU\DQGWKHQEHFDXVH\RX¶UHZRUU\LQJ\RX
GRQ¶WIHHOKXQJU\. (Peggy, lung cancer) 
 
In addition to expressing feelings of anxiety, emotional upset, and the impact on her 
husband, was also talked about by one of the women: 
 
I mean, I find the emotional side of it terrible some days.  And, for no 
DSSDUHQWUHDVRQWKHUHGRHVQ¶W seem to be any reason, I just get very, very 
XSVHW 6R LW¶VDOOSDU IRU WKHFRXUVHLW¶VSDUWRI WKH WUHDWPHQW\RXNQRZ
DQG,DFFHSWWKDWEXWVRPHGD\VLW¶VTXLWHGLIILFXOWWRDQGRIFRXUVHLWGRHVQ¶W
help then, because then, my husband gets upset LW¶V D YLFLRXV FLUFOH EXW
[laughs]. (Christine, pancreatic cancer) 
 
Although not directly linked to the discussion of nutrition, the spouses that were 
interviewed also talked about the worry or upset that they felt at times: 
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....and then, the following mRUQLQJ ,DQ VD\V WR PH , FDQ¶W ILJKW WKLV QR
ORQJHUDQG,WKLQNWKDWZDVRXUORZHVWZHUHQ¶WLW"«WKLQNZHERWKJRWXSVHW
then. ,DQ¶s wife, lung cancer)  
 
In one case, the extent of the impact on the family caregiver had led to emotional 
support being sought: 
 
,W¶VYHU\KDUGWRFRPHWRWHUPVZLWK:HOOZKHQZHGLGFRPHWRWHUPVZLWKLW
in the fact that we were putting all our expectations on having the operation 
LQ 0DUFK DQG WKHQ ZKHQ WKDW GRRU ZDV VODPPHG , WKLQN WKDW¶V ZKHQ ZH
really sort of felt, well, what else is there?  I must admit I was traumatised for 
quite a while, and the GP was very good to me and so was the Macmillan 
nurse.  And I go now to a support group. (PDXO¶VZLIHRHVRSKDJHDOFDQFHU 
 
Finally, other emotions expressed by participants included shock, fear and 
frustration. At the time of diagnosis, three of the patients talked about feeling 
shocked. Len also disclosed that he felt scared. Reasons given for feeling frustrated 
varied. Alison was frustrated because, despite feeling hungry, the nausea and 
vomiting was preventing her from being able to eat. For Bill it was not being able to 
get out on his farm: 
 
[I am feeling] probably a bit niggling, FDQ¶WJHWRXWWKHKRXVHDOOWKHWLPH\RX
NQRZ  6HH WKLQJV \RX ZDQW WR GR DQG FDQ¶W<HDK 7KDW¶V WKH ELJJHVW
WURXEOH<RXZDQWWRGRVRPHWKLQJWKDW\RXFDQ¶WGR>ODXJKV@ (Bill, stomach 
cancer) 
 
In summary, findings from this study sample confirm the high number of physical 
and psychological symptoms that are experienced by people with cancer, 
supporting what has previously been reported in the literature (Cleeland et al., 2000; 
Teunissen et al., 2007). The analysis of this study data highlights how these 
symptoms can impact on appetite, food intake and weight status. In addition, there 
is the acknowledgement of a vicious cycle of symptoms where one may perpetuate 
the next, as in the case of anxiety and anorexia. Although there are clusters of 
symptoms which are common to a specific cancer or treatment, there is certainly 
uniqueness to the experiences of an individual. Furthermore, some people view 
certain symptoms as an inevitable part of having cancer and are therefore less likely 
to seek advice from a healthcare professional. Others may play down the extent or 
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their ailments or may have pre-existing conditions which impact on their symptom 
burden.  
 
To minimise the negative impact of physical and psychological symptoms on food 
intake and overall quality of life in people with cancer, it is the responsibility of the 
healthcare professional to ensure that a comprehensive assessment of all 
symptoms is conducted as part of routine clinical care. Considering the number of 
screening and assessment tools that are available, it is unlikely that there will be 
universal agreement on the detail of the assessment process. It is important to 
remember, as demonstrated in this study, that there is great individuality to the 
symptom experience. 
 
6.2.3 Self-management 
Another category that emerged from the analysis of the interview transcripts was the 
self-management strategies used by participants to maintain or improve their 
weight. A framework for self-management theory has developed over several 
decades and is grounded in the assumption that individuals self-care to maintain 
health and wellbeing (Orem, 2001). Discussion and study of this theory has 
increased over recent years, with self-management being used in the clinical setting 
to help improve the treatment of chronic conditions such as cancer (Larson et al., 
1999), obesity (Butryn et al., 2007) and asthma (Myers, 2002). In the U.K., self-
management features highly within the NHS Plan in helping to promote a patient-
centred health care service (Department of Health, 2004; Department of Health, 
2005). In this study, two sub-categories were identified relating to self-management. 
The first was self-monitoring using weight or other observations. The second was 
the changes that were made to dietary habits, by individuals and by their carers, in 
order to help manage their condition. 
 
6.2.3.1 Self-monitoring  
Within the literature, the term self-management has become interchangeable with 
self-care, self-action and self-monitoring. Within this context, it should be 
emphasised that self-monitoring is indeed one aspect of the self-management 
framework (Wilde and Garvin, 2007). Strategies for self-monitoring include 
observation, measurement and recording of certain parameters, such as weight, 
along with a personal awareness of changes in symptoms, activities of daily living 
and cognition (Wilde and Garvin, 2007). 
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Self-monitoring of weight was something that all participants in this study did. 
However, this was not always done using weight as the measured parameter. 
Change in the fit or size of their clothing was one of the first markers of weight loss 
for some people. Observation of the shape or size of their body was another. Within 
the study sample two of the participants weighed themselves daily: 
 
:HOO QR , MXPS RII DQG RQ HYHU\ GD\ >ODXJKV@  , GRQ¶W DFWXDOO\ ZULWH LW
GRZQ«3HJJ\/XQJFDQFHU 
 
Others talked about weekly or less frequent measurements. Of the three who did 
not check their weight at home, two had previously never done so, and Alison 
(oesophageal cancer) had deliberately decided not to have scales in the house due 
to having a teenage daughter. Although there was sometimes an absence of the 
use of weighing scales, it was clear that other self-monitoring techniques, such as 
observation of appearance or fit of clothing, were being used: 
 
:DVSUREDEO\VL]H IRXUWHHQ\HDKSUREDEO\ IRXUWHHQ ,¶GJRQHdown a little 
bit over Christmas, so I probably a size fourteen then.......I notice like my 
FORWKHVZHUHJHWWLQJWRRELJDQGWKHQDOORIDVXGGHQ ,¶GVD\ LWZDVTXLWH
IURP-DQXDU\WRVD\SUREDEO\WKHPLGEHJLQQLQJRI0DUFKLWZDVQ¶WWRREDG
a weight loss but then after that, it was quite rapid.  It seemed to sort of, I 
really dropped down like another dress, size eight, size ten. (Alison, 
oesophageal cancer) 
 
For men, rather than relating this to the size of their clothing, the observations were 
made in terms of the use of belts or braces: 
 
But, look at the belt now.... those two are the ones I normally use [pointing to 
the buckle holes in his belt]. When you all of a sudden, you have to start and 
PDNHH[WUDKROHVWKHUHDQGWKHUH«(Ian, lung cancer) 
 
Some of the participants also made reference to how they had noticed changes in 
the appearance of parts of their body: 
 
<HDK,PHDQ,¶PVXUSULVHGDFWXDOO\,FDQMXVWJHWP\KDQGURXQGP\ZULVW
LWDQGWKDW¶VVRPHWKLQJ,KDYHQ¶WEHHQDEOHWRGRVLQFH,ZDs about twenty 
eight  [laughs]. (David, lung cancer) 
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DQG,NQHZZLWK OLNHP\IDFHEHFDXVH,¶YHJRWTXLWHDURXQGHGIDFHDQG
my face was just like quite sunken as well.....But I know when my face goes 
GUDZQWKDW,¶YHQRWEHHQHDWLQJEHFDXVHLWMXVWWends to go from there, you 
know. (Alison, oesophageal cancer) 
 
Both of the participants who weighed themselves daily alluded to the fact that 
constant self-weighing may be having a negative impact: 
 
As far as my weight is concerned, it was at ten [stone] two [pounds] in 
November.  Every time I had chemotherapy, I seemed to put three or four 
pounds on, went straight up three or four pounds straightaway, but some of 
it tailed off, but I managed to push my weight up, on our scales anyway, to 
about ten ten, weLJKHG LQ WKH PRUQLQJ  ZH¶YH PRQLWRUHG DOPRVW WRR
FORVHO\GRQ¶WZH"(Paul, oesophageal cancer) 
 
A number of different reasons were given by participants as to why self-weighing 
took place. For some of them it was habit and had started prior to their diagnosis of 
cancer: 
 
:HOO ZH XVHG WR ZHLJK UHJXODU DQ\ZD\  0\ ZLIH VWDUWHG WKDW RII  6KH¶V
always trying to keep her weight down. (Len, bile duct cancer) 
 
Others began following the commencement of treatment and kept a written record 
of their progress: 
 
I usually stick to once a week rather than popping on the scales every day, I 
PHDQ , GLGQ¶W XVHG WR WKDW ZDV SDUW RI WKH SUREOHPEXW , KDYH NHSW D
record, actually, over, ever since I came back, soon as we came home from 
hospital, just to see, out oI LQWHUHVW UHDOO\ KRZ LW¶V GRLQJ. (Christine, 
pancreatic cancer) 
 
Analysis suggested that where weight loss was not perceived as an issue, self-
monitoring was conducted to help prevent weight gain: 
 
:HOOLW¶VOHYHOOHGRIIURXQGQLQHVWRQHEHFDXVH,WKLQk, I did put some on at 
&KULVWPDVDQG,DLQ¶WJRWWKDWRII>ODXJKV@EXW,DOZD\VZHLJKHGPHZLWK
my clothes off.  Now, they weigh, at the hospital, they weigh me with 
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HYHU\WKLQJ RQ OLNH  6R WKDW SXWV D IHZ SRXQG RQ GRQ¶W LW? (Doreen, lung 
cancer) 
 
Wilde and Garvin (2007) conclude that the aim of self-monitoring is to create an 
awareness and understanding that will facilitate a change in action, or guide clinical 
intervention from a healthcare provider. Certainly, a change in behaviour, as a 
consequence of the self-monitoring process, was discussed by one participant: 
 
But, yes, I do monitor it.  But, when I have lost, say, a pound, again, I think, 
ZHOOLI\RXHDWLWZLOOKHOS«(Peggy, lung cancer) 
 
Also, following the observation of weight loss, Alison sought advice from a 
healthcare professional: 
 
,ZDVZRUULHGEHFDXVH,NQHZ,ZDVQ¶WJHWWLQJWKHQXWULHQWV,ZDVQ¶WJHWWLQJ
anything into my boG\$QGWKDWZDVZKHQ,VDLGFDQ¶W\RX,VDZDQXUVH
...... I actually mentioned that, because I was worried about, and the weight 
was just dropping off (Alison, oesophageal cancer) 
 
Not all participants were involved to the same degree in self-monitoring of weight 
status. ,QWKLVVDPSOHJHQGHUGLIIHUHQFHVZHUHDSSDUHQWWKURXJKRXWWKHSDUWLFLSDQW¶V
discussion of self-monitoring of weight. All but one of the women interviewed 
weighed themselves at home. 7KH RQH ZKR GLGQ¶W EHOLHYHG WKDW KDYLQJ ZHLJKLQJ
scales in the house was a threat to her young daughter. Furthermore, it appeared 
that the men that self-monitored their weight were encouraged to do so by their 
spouse:  
 
I weigh myself daily.  And I have to report [laughter]. (Paul, oesophageal 
cancer) 
 
Within the literature there is a dearth of information regarding the use of self-
monitoring in nutrition support for undernutrition and cachexia. No reference was 
located that refers to the recommended techniques or frequency of self-weighing in 
a nutritionally compromised cancer population. Despite the lack of guidance, some 
individuals take it upon themselves to engage in this activity. Anecdotally, dietitians 
in the U.K. recommend self-monitoring of weight, where deemed appropriate, 
usually on a weekly basis. However, there is ongoing debate as to the aptness of 
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this, particularly with patients receiving palliative treatment. Studies exploring the 
use of self-monitoring in obesity management have highlighted the possible 
negative psychological implications, in terms of altered mood and self esteem, of 
regular self-weighing (Ogden, 1996). Certainly within this study, it appeared that 
those who weighed themselves daily had an almost obsessive attitude to any small 
changes in their weight status. Within the cancer population, particularly when the 
concern is around deterioration in nutritional status, research is needed to identify 
the potential advantages and disadvantages of this aspect of self-care. Further 
exploration of the concept will provide valuable knowledge which will enable the 
healthcare team to educate patients as to the most appropriate techniques. 
 
6.2.3.2 Change in dietary habits 
In this study it was clear that several of the individuals had adapted their dietary 
habits in an attempt to alleviate symptoms or to improve their weight status. These 
findings concur with those of Hopkinson (2007) who describes a theory of self-
management related to changes in eating habits made by people with advanced 
cancer. In this study most individuals changed from what they perceived as a 
healthy diet to one that included unhealthy foods.  One of the participants here 
expressed this with a note of satisfaction: 
 
,¶P HDWLQJ ,¶P HDWLQJ QRZ PRUH IDWWHQLQJ WKLQJV WKDQ ,¶YH EHHQ GRLQJ
previously.  Because all RI D VXGGHQ ,¶YH JRW OLFHQVH WR HDW WKRVH WKLQJV
becaXVH ,¶PQRWSXWWLQJ ZHLJKW RQ But now, I tend to be a bit relaxed 
about it and have some biscuits or a cake, because, the satisfaction of 
NQRZLQJ,¶PQRWJRLQJ,¶PQRWSXWWLQJZHLJKWRQ. (Len, bile duct cancer) 
 
For others, having to miss out fruit and vegetables and choose unhealthy foods in 
order to deal with unpleasant symptoms resulted in feelings of concern: 
 
6R,ZDVOLWHUDOO\OLYLQJRQµ6KRUWLH¶V¶ELVFXLWVDWWKHWLPH>ODXJKWHU@1RWYHry 
JRRGIRUWKHEXWWKDW¶VDOO,FRXOGPDQDJHWRNHHSGRZQZDVDSODLQELVFXLW
with lots of sugar on, to try and keep the energy level,PHDQ,¶YHDOZD\V
ORYHGIUXLWDQGYHJHWDEOHVEXW,IRXQG,FRXOGQ¶WHDWDORWRIIUHVKIUXLW,ZDV
trying to eDWOLNH,PHDQLW¶GWDNHPHDERXWDQKRXUWRHDWDEDQDQD. (Alison, 
oesophageal cancer) 
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The importance of continuing to include healthy foods in the diet was also 
expressed by those caring for individuals: 
 
....but he has to have some [vegetables].   %HFDXVH LW¶V LPSRUWDQW IRU KLV
nourishment.  So I try and put a bit on for him and he can get just a little bit 
GRZQLW¶VEHWWHUWKDQQRQHLVQ¶WLW? 3DXO¶s wife, oesophageal cancer)  
 
Similar observations, ZKHUH DQ LQGLYLGXDO¶V EHOLHIV DERXW WKH W\SHV RI IRRGV WKDW
should be eaten could not be achieved, have been made by other researchers 
(Hopkinson, 2007). Negative feelings, such as guilt and anxiety, associated with 
these changes in eating behaviour may be detrimental to both the patient and their 
carer resulting in conflict within the relationship. Furthermore, as the focus is on 
prioritising low energy density, high fibre foods, weight status may be adversely 
affected. 
 
Aside from changing the composition of the diet, other self-management strategies, 
such as changing the meal pattern or texture of the food, were used to influence 
dietary intake. These activities were often initiated, and talked about, by the female 
spouses: 
 
, WKLQN LW¶VJRLQJWRFRPH though, to having smaller meals, more frequently.  
5DWKHU WKDQKDYLQJDSDWWHUQRI EUHDNIDVW OXQFKDQGGLQQHU KH¶VJRLQJ WR
KDYH WR KDYH VRPHWKLQJ SHUKDSV PRUH VXEVWDQWLDO DW HOHYHQ R¶FORFN
VRPHWKLQJ PRUH VXEVWDQWLDO DW IRXU R¶FORFN. 3DXO¶V ZLIH RHVophageal 
cancer) 
 
Finally, although not a change in dietary habits per se, one of the participants also 
disclosed how, following the observation of the action of a friend, she changed the 
way she managed her medication: 
 
Well, I was taking it, all I was told was to take one before I had a meal, or 
with a meal.  So I was actually taking it with my meal.  I have a friend, 
DFWXDOO\ZKR¶VKDGWKHVDPHRSHUDWLRQVKH¶VDOVRRQ&UHRQDQG,NQRZVKH
always takes hers sort of part way through her meal, so I thougKW2K,¶OOGR
this. (Christine, pancreatic cancer) 
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In summary, the findings of this study suggest that individuals with cancer, and their 
family care givers, employ personally devised self-management strategies in an 
attempt to improve their nutritional intake and status. $Q LQGLYLGXDO¶V XQGHUO\LQJ
knowledge and beliefs about diet and healthy eating may play an important role in 
their decisions regarding the self-management of nutritional issues. Furthermore, 
previous research suggests that variables such as demographics may also impact 
on the ability of an individual to self-manage their condition (Dodd and Dibble, 
1993).  Whilst some individuals make these changes willingly, for others, decisions 
to move away from what is perceived as a healthy diet may be shrouded in anxiety. 
Factors influencing self-management strategies used by people with cancer to 
address nutritional problems need to be explored further. In practice healthcare 
professionals should be aware that patients may be employing these techniques 
and should include a discussion of, and support, their use. 
 
6.2.4 Attitude to body weight 
Attitude to body weight was another category identified during the axial coding of 
the transcripts. Body image per se is an area which is often researched within the 
cancer population with previous research regularly focusing on the negative 
psychological impact of weight loss and its meaning (Poole & Froggatt, 2002).  In 
the present study, attitudes to body weight were mixed, with an apparent gender 
difference. Generally, participants talked about their body weight, often relating it 
EDFN WR WKHLU µQRUPDO¶RUSUH-illness status. For women, despite having lost weight 
due to illness or treatment, being thin was still seen as desirable. Weight 
maintenance was their aim, gaining weight was not. Following their diagnosis of 
cancer, all of the women that were interviewed appeared to have an optimistic 
attitude towards weight loss: 
 
,ZHQWWRWKLVSDUWLFXODUGLQQHU,SXWWKHRXWILWRQWKDW,KDGQ¶WZRUQIRUDIHZ
months and I suddenly thought, Oh, oh, that fits a bit better.  You know, 
because I knew in my heart that I should be doing something about it, 
because it just, it had gradually crept on over the last couple of years...... 
%XWVRDV,VDLGLW¶VPRUHRIWKHIDFWRIORVLQJWKHZHLJKWUHDOO\QRZ,PHDQ
,GRQ¶W,GRQ¶WZDQWWRSXWRQZKDW,KDGRQEXW,DOVRZDQWWR,¶GOLke to see 
it levelling out a little bit, you know. (Christine, pancreatic cancer) 
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LWZDVJUHDW WR WHOO \RX WKH WUXWK LWZDVJUHDW DOO WKH , FDQ¶W DGPLW DQ\
RWKHU WKH ZHLJKW ORVV ZDV MXVW RK ,¶G ORYH WR VWD\ OLNH WKDW.. (Alison, 
oesophageal cancer) 
 
Although Peggy commented that she wished that she had this figure when she was 
twenty five, she clearly associated weight loss with negative consequences. This 
observation has been commented on by other researchers (Hopkinson, 2006): 
 
.....well, whHWKHULWPHDQVLW¶VWKHEHJLQQLQJRIWKHHQGRQFH\RXVWDUWORVLQJ
DQDZIXOORWRIZHLJKW,GRQ¶WNQRZ. (Peggy, lung cancer) 
 
The attitude of trying to maintain what they classed as a desirable weight was 
echoed by two of the male interviewees. However, they only talked about how they 
had struggled to maintain their weight prior to being diagnosed with cancer: 
 
The year before, yeah.  And, and, I was very pleased, eleven [stone] four 
[pounds], I could still get into all my, you know, things were good, it was 
good.  But of course, when we were on [the cruise], I come back and I was a 
bit more and a bit more and sort of getting up to eleven [stone] ten [pounds] 
and all, and eleven [stone] twelve [pounds] DQG WKDW¶V ZKDW , ZDV  , ZDV
struggling to keep under, I was working and doing whatever singing and 
doing whatever I could to keep my weight down.  But actually, I was about 
eleven ten or eleven twelve. (Len, bile duct cancer) 
 
Once diagnosed with cancer, the male interviewees who had lost weight tended to 
focus their discussion on trying to put weight back on and were generally hopeful 
that this would happen: 
 
$V ,VD\P\ZHLJKW¶V gradually come back up.  It dropped after the 
first session I went down to ten four, so I managed to get a couple of 
pounds on in the first three weeks.  On, in the first week, sorry.  
7KDW¶VWKHILUVWZHHNRILWDQGWKHQDJDLQLW¶VWHQIRXU$QGWHQILYH
so I just, gradually, just gradually coming up in the first few sessions 
of chemo (Paul, oesophageal cancer) 
 
Throughout these discussions only one talked about the importance of weight gain 
in terms of getting his strength back: 
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,¶PKRSLQJWRSXWLWEDFNRQDJDLQPLQG\RX,¶YHORVWLWRQP\OHJV
WKDW¶VZKHUH,¶YHORVWLW,QP\OHJVDQGDUPV«DLQ¶WORVWDQ\IDWLW¶V
MXVWPXVFOH,¶YHORVW. (Bill, stomach cancer) 
 
These findings suggest that attitude to body weight is one factor which may 
contribute to an LQGLYLGXDO¶V RYHUDOO SHUFHSWLRQ RI ERG\ LPDJH. This in turn may 
impact on their desire to eat, and food intake. It may be postulated that, previous to 
their diagnosis of cancer, the women, and some of the men, had issues around 
body image, or more specifically, body size. As previous research suggests, in any 
population this is not unusual, with women being more likely to be dissatisfied with 
their body image than men (Algars et al, 2009).  
 
Finally, although exploration of body image per se was not a key objective of this 
study, other dimensions of this construct were highlighted by some of the 
participants. Peggy had worked in the theatre for many years. She talked in detail 
about changes in her physical appearance: 
 
Well, I keep thinking my face looks very haggard..... my teeth are completely 
VRUWRIGHVWUR\HGDQGWKDWWKHFKHPRGRHVDIIHFWWKHPDELWWRRGRHVQ¶WLW"
$QG , WKLQN EHFDXVH ,¶YH JRW QR WHHWK WKH\¶UH VR , ORRN LQ WKH PLUURU
sometimes, I think, God, you know, I look really gaXQW%XW,KDYHQ¶WORVWDQ\
ZHLJKWVR , WKLQNDJDLQ LW¶VDOO LQ WKHPLQG ,GRQ¶W WKLQNP\KDLUZHOO ,
FDQ¶W UHDOO\ WHOOQRZEHFDXVH LW LVVRRYHUJURZQ ,GRQ¶W WKLQN LW¶VHYHUTXLWH
got back.  It breaks off very, very easily. (Peggy, lung cancer) 
 
Whereas Bill, who lived and worked on a farm, associated changes with a loss of 
function: 
 
,¶YH ORVW LW RQ P\ OHJV WKDW¶V ZKHUH ,¶YH ORVW LW  ,Q P\ OHJV DQG DUPV
:HDNHU \HDK \HDKDV , VD\ ,¶YH QRW EHHQ XVLQJ WKHP WKDW¶V KDOI LW
all...6RUWRIVLWWLQJURXQGIRUDPRQWKDLQ¶WPH. (Bill, stomach cancer) 
 
The analysis suggests that gender differences may be significant when considering 
attitudes to body weight and image, a hypothesis from body image theory which is 
supported by the literature (Algars et al. 2009). It is likely that these variations may 
stem from aspects of evolutionary theory where female attractiveness and male 
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strength were valuable reproductive attributes. Today, it is probable that images 
presented in the media reinforce these primitive traits, relating to the perception of 
body image in both men and women (Groesz et al, 2002; Hargreaves and 
Tiggemann, 2009). As established by Price (1992), it is important to consider that 
individuals with cancer may have pre-existing issues around body image. Long 
standing attitudes to body weight may impact on their perception of risk, related to 
weight change. What is seen by a healthcare professional as being a significant 
decrease in weight may be viewed by the individual as a positive part of the cancer 
experience. In these situations, dietary counselling with an aim to increasing weight 
needs to be handled sensitively, with open discussion as to the potential benefits of 
weight maintenance or gain. What must be considered, when working with people 
with cancer, is that their values and previous social construct are liable to play a role 
in their feeling of self-worth and attitude to body image. 
 
6.2.5 Social support 
Social support was another category that was identified during the analysis process. 
In relation to nutritional intake, most study participants talked about friends or family 
who provided support regarding food and nutrition. More specifically, one area 
which emerged through the analysis of the data was the provision of meals by 
family members. Some of the male and female patients discussed how they 
prepared the households meals. For others it was their spouses who usually took on 
this task. The wife of one of the male patients expressed some of the challenges 
around taking on this responsibility: 
 
$QGLW¶VDVKDPHEHFDXVH,WU\WRJLYHKLPORWVRIYDULHW\PRUHWKLQJVWKDW,
know that that he could, or he should obviously be able to eat, buWWKHUH¶VQR
SDWWHUQ6RPHWLPHVKH¶OOHDWKLVILVKOHPRQVROHHDVLO\RWKHUWLPHVKHILQGV
GLIILFXOW\ ZLWK LW  6R WKHUH LVQ¶W DFWXDOO\ D VHW PHDO WKDW \RX VD\ ZHOO KH¶V
definitely going to be able to eat this, it varies from day to day.  Sometimes 
you¶UH DEOH WR KDYH D ELW RI EHHI DUHQ¶W \RX" 2U FKLFNHQ  %XW WKHUH¶V QR
JXDUDQWHHLQWKHWLPHWKDW,FRRNIRUKLPWKDWKH¶VJRLQJWRDFWXDOO\EHDEOHWR
HDW WKDW $QG WKDW¶V GLVDSSRLQWLQJ YHU\ GLVDSSRLQWLQJ IRU KLP  %XW DOVR
very demoralising for me.  I have spent a lot of time trying to cook something 
\RX WKLQN ZHOO WKDW¶OO EH DOO ULJKW DQG WKDW¶V JRW JRRG QRXULVKPHQW DQG LW
VKRXOG EH IDLUO\ HDV\ WR HDW EXW LW GRHVQ¶W WXUQ RXW WKDW ZD\  3DXO¶V ZLIH
oesophageal cancer) 
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Previous work suggests that the gender of the patient, and their family caregiver, 
may influence the level of satisfaction when it comes to providing support around 
the preparation of meals (Locher et al., 2009). In this study, as only female spouses 
were interviewed, confirmation of this theory is not possible. However, there were 
similarities in the findings in relation to the frustration felt by one of the female 
caregivers DW KHU KXVEDQG¶V LQDELOLW\ WR HDW KHU PHDOV ,QGHHG Whe findings of this 
study suggest that family care giving is not without its problems. Concern at the 
GHWHULRUDWLRQRIKHUKXVEDQG¶VFRQGLWLRQZKHQVKHZDVVXSSRVHGWREHORRNLQJDIWHU
him, was expressed by another of the female caregivers: 
 
And also, and then, you know, how difficult it is for the carer to try all sorts of 
GLIIHUHQWWKLQJVWRWU\DQGHQFRXUDJH«HQFRXUDJHWKHPWRHDW$QGDWZKDW
SRLQWGR\RXVD\&RPHRQOHW¶VFKLYY\\RXDQGOHW¶VJHW\RXJRLQJEHFDXVH
\RX¶UH MXVW JRLQJGRZQKLOO UDSLGO\ DQG \RXGRQ¶WZDQW WKDW WRKDSSHQ LQD
sense, on \RXUZDWFK>ODXJKV@$VLWZHUH$QG\RX¶UHQRW,¶PQRWQXUVH-
WUDLQHG , XVHG WR EH DQ RFFXSDWLRQDO WKHUDSLVW VR \RX NQRZ WKHUH¶V WKDW
JRLQJRQLQWKHEDFNRIP\PLQGNQRZLQJWKDW\RXNQRZ,¶YHJRWWRNHHSKLV
mood up and also his strength, and this is just not going to help. 'DYLG¶V
wife) 
 
One of the male participants used humour when referring to a situation where his 
wife had been disappointed by his inability to eat her cooking: 
 
1RZP\ZLIHIXQQ\ZKDWKDSSHQHGP\ZLIHVDLG\RXGRQ¶WZDQWWRHat that 
ZKHQ,JHW\RXKRPH\RXGRQ¶WKDYHWRHDWWKDWKRUULEOHKRVSLWDOIRRG$QG
ZKHQ,FDPHKRPH,ZHQWRIIP\IRRG$QGVKHFRXOGQ¶WEHOLHYHLWEHFDXVH
VKH¶G VHHQ PH HDW KRZ ,¶G HDWHQ LQ KRVSLWDO  $QG WKHQ ZKHQ , FDPH
KRPHDQG,ZDVQ¶WHDWLQJ KHUFRRNLQJZHOO,ZDVQ¶WYHU\SRSXODU>ODXJKWHU@. 
(Len, bile duct cancer) 
 
Another of the participants was a widow and lived with her teenage daughter. In this 
situation, where there was the absence of a spouse, there were indications that 
other female family members were involved in aspects of care giving around eating 
and meal times: 
 
I know people are trying to helSDQGOLNHP\PXPVD\V,¶OOGR\RXVRPHOLYHU
DQG\RXNQRZOLNH,VD\,FDQRQO\PDQDJHDOLWWOHELWEXW,¶OOWU\DQ\WKLQJLI,
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WKLQN LW¶V JRLQJ WR HVSHFLDOO\ LI LW¶V WR JHW PH VRPH HQHUJ\$QG P\
daughter was doing the smoothies as well, like, with strawberries and 
banana and I found I could drink them so I knew I was getting my fruit down 
me and I enjoyed them and she was putting like ice in it and everything, they 
were lovely. (Alison, oesophageal cancer) 
 
The analysis suggests that family members also unwittingly provide support. An 
example of this was discussed by one of the women: 
 
Last night I had quite a good meal.  My son and his partner came over and I 
DWHZKDW,ZRXOGFDOODQRUPDOPHDOODVWQLJKW\RXNQRZEXWWRGD\¶VQRWVR
good toGD\,FDQ¶WDFWXDOO\««WKLQN2K,FRXOGVLWGRZQDQG,FRXOGUHDOO\
enjoy that meal.  I mean, I ate my meal last night and I did eat it all and I 
VXSSRVH EHFDXVH ZH KDG FRPSDQ\ DV ZHOO LW PDNHV D GLIIHUHQFH \RX¶UH
QRW«EXW LW¶V EHFDXVH , VXSSRVHZHKad company last night, it takes your 
mind off it a little bit....Yeah, you were talking, I was eating, which was, which 
is logical, I suppose [laughs]. (Christine, pancreatic cancer) 
 
Some of the other participants also talked about going out to eat at restaurants: 
 
<RX NQRZ ,¶YH EHHQ RXW ZLWK WKH FKLOGUHQ IRU D FRXSOH RI PHDOV ZKLFK ,
FRXOGQ¶WMXVWEHIRUH,VWDUWHGWKHFKHPR,PHDQWKHODVWWLPHZDVWKHHQGRI
May, my eldest son was home from the marines and he took me and my 
daughter to the pictures and we wenWLQ1DQGR¶VILUVWDQG,VD\VRK,¶OOMXVW
KDYHWKUHHFKLFNHQZLQJVDQG,¶GPDQDJHRQHDQG,KDGWRUXQWRWKHWRLOHW
DQGDOOQLJKW,ZDVQ¶WYHU\ZHOO$QGTim VDLG,¶PJRLQJWRWDNH\RXKRPH, I 
went, no, LW¶VQRWGHIHDWLQJPHOLNHWKLV«EXt about three or four weeks ago, 
ZHZHQWLQ1DQGR¶VDQG,KDGWKHWKUHHFKLFNHQZLQJVDQG,PDQDJHGQHDUO\
three of them. (Alison, oesophageal cancer)  
 
<RX NQRZ ZH¶YH EHHQ RXW UHFHQWO\ DQG TXLWH RIWHQ ,¶OO KDYH SkWp RU
something, just to, a starter, just, just for my meal rather than the main 
course, things like that. (Paul, oesophageal cancer) 
 
Despite having to adapt eating behaviour, continuation of this social activity appears 
to be important. 
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In addition to talking about support provided by family members, participants also 
received advice from friends and family. For some, the advice was difficult to follow: 
 
0\PRWKHULQODZ¶VWULHGWRJHWPH to eat CoUULJDQPRVVEHFDXVHVKH¶V,ULVK
>ODXJKWHU@$QG,ZHQWQRZD\,WKLQNLW¶VOLNHDVHDZHed that they boil up 
DQGZKHQLW¶VGRQH LWEHFRPHVZKLWHDQGLW ORRNVOLNHZKLWHSRUULGJHDQGLW
sets like a jelly.  [laughter]  I says to her, I will not eat that.......But no, people 
have tried to say Oh, eat this, like friends, eat this, eat that, but LW¶VQRWLI\RX
GRQ¶WIDQF\LWDVZHOO\RX¶YHJRW,WKLQNVRPHWLPHV\RXGRKDYHWRIDQF\LW. 
(Alison, oesophageal cancer) 
 
For others the advice helped: 
 
I got introduced to them [Fortisip] D IULHQG RI PLQH¶V RWKHU KDOI KDV JRW
pancreat- anyway, got it somewhere like that and he felt sick the whole time 
DQGFRXOGQ¶WHDW6RKHJRWSXWRQWKRVHDQGhis wife called in to see me at 
the shop one day and she said, oh, -DFN¶VJRWWKHVH\RXNQRZLI\RXGRQ¶W
LI\RXFDQ¶W\RXNQRZ\RXfeel a bit nauseous, she said, he lives on them.  
So anyway, I had one and I thought, wHOO ,GRQ¶WGULQNPLONEHFDXVH,PH
DQG PLON GRQ¶W UHDOO\ JR WRJHWKHU EXW , KDG WKH EDQDQD RQH DQG , UHDOO\
enjoyed it.  And, anyway, so I, you know, have those. (Peggy, lung cancer) 
 
In summary, the findings from this study suggest that the family members are 
involved in the day to day provision of nutritional care of patients. Negative aspects 
of the role of family caregivers were not expressed by the patients, although the 
analysis suggests that some of the female caregivers, at times, found providing this 
support a challenge. In addition to providing practical support, patients receive 
advice around what to eat from family and friends, advice that they may choose to 
try to follow, or not. Observation at the time of interview suggests that without such 
support and encouragement, some patients¶ nutritional intake would deteriorate 
further. That said, the burden on the carer must not be forgotten. Contrary to the 
findings of other studies, here none of the patients expressed negativity at the 
support that had been offered around eating and drinking (Hopkinson and Corner, 
2006). Eating is often seen as a social event, and for some, this is lost when 
appetite and food intake deteriorate (Hopkinson and Corner, 2006). Despite 
experiencing adverse symptoms around eating, going out to restaurants was still an 
important activity in patients¶ lives. As theorised by others, this activity may be linked 
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to wanting to maintain some sort of normality and the associated belief that this is a 
sign to themselves or others that they are fighting the cancer (Shragge et al., 2007). 
On a practical level, the unwitting support offered by family and friends, which 
engage the patient in eating as a social activity, may be a valuable strategy in the 
improvement of food intake. 
 
6.2.6 Clinical support 
Clinical support was the final category identified through the analysis of the data. All 
of the people interviewed in this study sample, since being diagnosed with cancer, 
had regular reviews with a healthcare team. The professionals that were talked 
DERXWE\WKHSDUWLFLSDQWVLQFOXGHGRQFRORJLVWV*3¶VQXUVHVDQGGLHWLWLDQVDuring 
the axial coding, two sub-categories linked to clinical support emerged from the 
data; monitoring and nutritional advice. 
 
6.2.6.1 Monitoring by the clinical team 
Guidelines within the U.K. recommend that all patients are weighed on admission to 
hospital, at their first attendance at an out-patient clinic or when there is any cause 
for concern (NICE, 2006). Therefore, it is not surprising that most of the patients 
interviewed made reference to having their weight monitored by a healthcare 
professional at some point in time. Monitoring of weight occurred in the in-patient 
and out-patient setting, although the frequency of this cannot be established.  For 
some patients, being weighed was an indication that body weight was something 
that needed to be checked: 
 
WelO,¶YHQHYHUWRRNDQ\QRWLFHXQWLOWKH\VWDUWHGZHLJKLQJPHDWWKHFKHPR
clinics, like. (Bill, stomach cancer) 
 
For others, it gave reassurance that their weight was not a concern at that point in 
time, but potentially caused anxiety by the suggestion that weight loss was 
inevitable:  
 
And when I went in to have my operation, she said, a week you know, they 
ZHLJK \RX DQG HYHU\WKLQJ VKH VDLG 2K \RX¶UH ULJKW RQ \RX¶UH ZLWKLQ WKH
SDUDPHWHUVDQGVKHVD\V\RX¶YHJRWDQLFHZHLJKWWRJRLQWRLWEHFDXVHshe 
says you are going to lose some weight, but she says I think I was just on 
WKHWRSOLQHRI«(Christine, pancreatic cancer) 
 143 
 
 
Regrettably, even when decreasing, regular monitoring of weight did not always 
equate to acknowledgement of a problem or to the provision of nutritional advice: 
 
Nobody had seen me, I mean, they was weighing me but nobody had 
actually [seen me], it was only through me being so, like I say, lethargic. 
(Alison, oesophageal cancer) 
 
This is a finding supported by other researchers who found that in the out-patient 
setting, referral into dietetic services was inadequate (Baldwin et al., 2006). 
 
Undoubtedly, regular monitoring of body weight by healthcare professionals does 
have advantages in terms of helping to identify, and monitor, those patients who are 
in need of nutritional support and intervention (NICE, 2006). It may also be a 
reassurance to the patient and their carers that their weight loss is being monitored. 
Additionally, where a change is detected, self-management strategies may be 
implemented to address these issues. However, as was seen in this study, despite 
a significant decrease in weight being identified by the healthcare professional, 
further action is not always taken. It is essential, not only for patient satisfaction, but 
also for improving outcomes, that there are protocols and services in place which 
lead to the provision of individualised nutritional assessment, counselling and 
intervention in these cases.  
 
Although not highlighted as a major concern by this group of patients, consideration 
must also be given to the potential distress caused by the activity of weighing 
(Hopkinson, 2007). For some individuals, their family and carers, weight loss is seen 
as a sign of disease progression, with constant monitoring leading to increased 
anxiety (Poole and Froggatt, 2002; Reid et al., 2009). Particularly for those with 
advanced disease, discussion as to the benefits of regular monitoring of weight 
should take place.  
 
6.2.6.2 Nutritional advice from the clinical team 
Several of the participants talked about receiving nutritional advice from nurses, 
doctors, dietitians or nutritionists. Specifically, since being diagnosed with cancer, 
three of the patients interviewed had received advice from a dietitian. Whilst in 
hospital, Paul had seen a dietitian following the insertion of his stent. He appeared 
happy with the timing of the referral and the information that he had received. He 
had also been told by his G.P. that a referral could be made to a dietitian should he 
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so wish. Despite this, he was still losing weight and the nutritional supplements that 
he had been prescribed by his G.P. were probably lower in energy density than 
those that would have been prescribed by a dietitian:  
 
I chatted to the G.P. this afternoon, went to get some, another prescription 
for the Ensure drink.  And, he were just talking to me generally how I was 
and saying well, if I want to chat more with the dietiWLDQKH¶OODUUDQJH LW IRU
me. The thing at the moment if I can keep on eating solids then I prefer to. 
(Paul, oesophageal cancer) 
 
One interpretation of his final comment may be that he believed that if he saw a 
dietitian she would advise him against eating solid food, possibly resulting in a 
reluctance to access this service. 
 
As discussed above, despite losing weight, Alison had to ask the oncologist if she 
could speak to someone regarding her diet. Following this she saw a dietitian on a 
couple of occasions where ways of increasing the energy density of her diet, as well 
as modifying the texture, were discussed. She was also prescribed nutritional 
supplements. Although Alison appeared pleased with the advice she had received, 
she was unable to comply with some aspects. In particular, the advice to puree her 
food was not followed: 
 
I used to do it for the babies when I, you know, do the food, it was all fresh 
food and everything and I used to purée it all down and taste the thing, mm, 
\RXNQRZWKDW¶V,WKLQNLW¶V,GRQ¶WNQRZZKHWKHULW¶VWKHWKRXJKW,¶YHZRUNHG
ZLWKLWDQGWKHQWKHWKRXJKWRI,¶YHJRWWRHDWWKDWDQG,¶PWKLQNLQJZHOOLW¶V
only like, yRXNQRZ LW¶VDOO WKH IRRGV WRJHWKHU EXW , WULHG LW D FRXSOHDQG ,
FRXOGQ¶WHDW LW $QG, WKRXJKWP\SRRUEDELHV  >ODXJKWHU@...... I think it was 
the thought and then with the taste of it, I think, all the tastes together, you 
know, like if you, I tried to do the broccoli and a bit of potato and I did liver, 
0XPKDGGRQHPHOLNHOLYHUDQGDJDLQWRWU\DQGJHWWKDWDQGVKH¶GGRQe 
liver in gravy and I thought oK,¶OOSXUpHLW XSRKRKQR, MXVWFDQ¶W <et I 
could eat it just as it was. (Alison, oesophageal cancer) 
 
Intake of texture modified diets in patients with dysphagia, due to the appearance, 
taste and texture, is traditionally poor (Wright et al$OLVRQ¶VH[SHULHQFHDQG
3DXO¶VUHOXFWDQFHWRPRYHDZD\IURPVROLGIRRGVVXJJHVWVWKDWWhis is also the case 
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in people with cancer. The psychological aspect of likening the texture to the food 
that you eat as a dependent baby may be of issue.  
 
Compliance with prescribed nutritional supplements, in terms of type and quantity, 
was also a problem for some of the participants. Ian had been provided with a bag 
of supplements by the radiotherapy department but was disappointed that there had 
been nobody available to talk to at that point about his diet. He finally saw a dietitian 
when his swallowing had deteriorated to the point that he was unable to swallow his 
own saliva and compliance with the advice was impossible: 
 
Fortisips and Fortijuce.  I tried to take them.  I managed to get them down 
about two or three times but every one of them made me sick. (Ian, lung 
cancer) 
 
Like Ian, Christine had been prescribed nutritional supplements without the 
assessment and support of a dietitian. She described being given µDEDJIURPWKH
KRVSLWDO¶ and the difficulty she had taking them. Despite having ORVW µWKUHH VWRQH¶, 
Christine was still waiting to see a dietitian: 
 
When I came to clinic, they [oncologist] DFWXDOO\VDLGZHOO\RX¶UHVWLOOORVLQJ
ZHLJKW %XW ,KDG ,KDGQ¶W lost as much as obviously I have now but, she, 
she said, well, try the Fortisips and they gave me some in a bag from the 
hospital....... I try and have, as I said, one or other, I mean, I think they 
mentioned to me the other day they thought I ought to be having three a day.  
$QG WKHUH¶V MXVW , GRQ¶W WKLQN WKHUH¶V DQ\ ZD\ , FRXld cope with three, 
because she said, ZHOO WKDW¶OO JLYH \RX QLQH DERXW QLQH KXQGUHG FDORULHV
$QG,FDQPDQDJHRQHDGD\RYHUDVSUHDGRXWEXW,FDQ¶W,GRQ¶WWKLQN,
could cope with three. (Christine, pancreatic cancer) 
 
Assessment, individualised treatment and monitoring by a dietitian have been 
shown to minimise inappropriate prescribing practices, and have financial benefits 
(Skinner and Smith, 2008). Regardless of this, the analysis from the present study 
suggests that there is inappropriate use of nutritional supplements in clinical 
practice and, despite having seen a dietitian, none of the three participants were 
receiving ongoing monitoring or follow-up. 
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In addition to receiving nutritional advice from a dietitian, some of the participants 
described the advice that they had got from other members of the healthcare team. 
Following surgery, one of the men that was interviewed remembered being given a 
leaflet and had been told tR HDW µlittle and often¶. The advice given by another 
healthcare professional to another of the patients was less reliable: 
 
I put myself onto pineapple because they said about the time when I went to 
RQFRORJ\ WKDW¶V ZKHQ WKH PDQDJHU VDLG SLQHDSSOH ZLOO KHOS \RX ZLWK \RXU
appetite, pineapples, and I went and got [laughter] loads of pineapple so I 
was trying to eat that ..... (Alison, oesophageal cancer) 
 
Finally, in addition to a lack of dietary advice, one participant talked in detail about 
the problems that she had experienced related to one of her prescriptions, and the 
mixed messages that she had received from the two teams involved in her care: 
 
%XW RI FRXUVH ,¶P WDNLQJ WKH &UHRQ EHFDXVH WKH\¶Ye removed part of the 
pancreas, and unfortunately, they never gave me the leaflet, I had been 
WDNLQJ LW ILYH PRQWKV DQG WKH\ GLGQ¶W JLYH PH WKH OHDIOHW WR WHOO PH KRZ ,
should be takiQJLW$QGWKHRWKHUWKLQJWKDW¶VKDSSHQHGLVLQWKLVODVWZHHN
LVWKH\¶YHDFWXDOO\WDNHQPHRIIDQRWKHUPHGLFDWLRQWKDWWKHKRVpital where I 
had my surgery VDLG,¶YHJRWWRWDNHIRUOLIHZKLFKLV,WKLQNLV/DQ]RSUazole.  
Because the Oncologist tells PHWKDWWKH\¶YHWKHWZRGRQ¶WPL[6RZKDW
WKH\¶YH GRQH WKH\¶YH DFWXDOO\ RQ 7XHVGD\ WKH\¶YH WROG PH QRW WR WDNH LW
DQ\PRUH %XW ,¶P LQDELWRIDFOHIWVWLFN LQDFWXDO IDFWEHFDXVH WKHQXUVH
from the first hospital tells me I ought to be taking it. (Christine, pancreatic 
cancer)  
 
In summary, analysis of the data suggests that the experiences, in terms of the 
nutritional monitoring and advice that the participants of this study received, were 
variable. Prescribed nutritional supplements had been given out without a detailed 
assessment, resulting in non-compliance and waste. In addition, for those who did 
see a dietitian, there were issues around the timing of nutritional advice. Despite 
these factors, unlike the findings from other studies (Hopkinson and Corner, 2006), 
patients were generally pleased with the advice that they had received. However, 
compliance with dietary treatment was not always achieved. Due to the absence of 
ongoing support and monitoring from the dietetic service, non-compliance, or further 
nutritional problems, failed to be recognised. In order to improve the nutritional 
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treatment and advice given to patients, changes in the provision of services needs 
to occur. Routine screening for nutritional deficiencies must be implemented to 
ensure that all patients who are at risk of malnutrition are identified in a timely 
manner (NICE, 2006). In addition, services need to be in place to allow for the 
individualised nutritional assessment, treatment and ongoing monitoring, by a 
GLHWLWLDQ  )LQDOO\ WR LPSURYH WKH SDWLHQW¶V H[SHULHQFH FRQVLVWHQW DQG UHOLDEOH
treatment advice is essential. 
 
6.2.7 Understanding the influences on food intake 
As a result of the analysis of the transcribed data, the core process that emerged 
was µinfluences on food intake¶. The categories and sub-categories previously 
discussed in this chapter connect and interrelate. This allows an explanation of what 
influences the food intake in people with cancer to be made. Analysis of the 
relationships between the categories led to the conclusion that the influences on 
food intake were a fluid process. They could change from one time point to the next 
depending on, for example, the treatment being received or the physical and 
psychological state and circumstances of the individual. Although there was a clear 
individuality to the lived experience, it was evident that these experiences came 
from a shared reality. The following discussion summarises this core process. 
 
The final analysis showed that weight loss could occur at any stage of the cancer 
trajectory. For some patients, a significant amount of weight was lost prior to being 
diagnosed with the disease and was one of the first signs that there was a problem. 
Having surgery was another time when weight loss was likely to occur. The increase 
in symptom burden surrounding chemotherapy or radiotherapy also led to some 
patients losing weight, although this was not a universal experience.  
 
Monitoring of weight was something that happened during hospital visits, seemingly 
on a regular basis for those receiving chemotherapy treatments. However, the 
nutritional treatment of patients who had lost weight was managed, at best, in an ad 
hoc, untimely manner with few patients being referred to dietetic services, and none 
receiving the necessary ongoing support and monitoring. Dietary advice and 
nutritional supplements were prescribed by several members of the healthcare 
team. Patient compliance was variable, with the palatability of sip feeds as well as 
the inability to take a pureed diet being commented on as barriers. 
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In addition to having their weight measured at the hospital, self-monitoring of weight 
status was common. Males and females were involved in this act although it 
appeared that for the men this was something that was encouraged by their 
spouses. In addition, the frequency of self-weighing varied. It was evident that, for 
some, becoming obsessed by their weight was a concern. It was less clear whether 
it helped or hindered motivation to eat and ultimately maintenance of weight status, 
and this needs to be explored further. 
 
Gender difference was also apparent when considering attitude to body weight. 
Although the women acknowledged that they did not want to lose any more weight, 
they appeared pleased to have lost weight as a consequence of their illness. On the 
other hand, the men felt confident that they would be able to put back on what they 
had lost and were more likely to link the weight loss to a decrease in their function 
and strength.  
 
Food intake was clearly influenced by the presence of adverse symptoms. At some 
stage of the disease process and its treatment patients experienced a reduction in 
appetite. More specifically, their desire to eat and enjoyment of food was affected. In 
addition, the physiological pangs of hunger were reduced and, for those who had 
had gastrointestinal surgery to remove part of their stomach, there was an increase 
in early satiety. Nausea and vomiting were other commonly experienced symptoms 
which greatly impacted on food intake. Either occurred at any time point and was 
not solely associated with chemotherapy. This is contrary to the experiences of 
changes in taste and aversion to smells which were specifically linked to times of 
chemotherapy treatment. Along with other commonly reported complaints such as 
bowel problems, pain and fatigue, the impact of symptoms on both the patient and 
their carers lives was significant, affecting them both psychologically and socially. 
Symptoms such as anorexia, nausea and vomiting undoubtedly affected the 
experience of going out to eat. However, it was clear that this was still an important 
part of life and despite having to make adjustments to their food choices, something 
that patients persevered with.  
 
Men and women mostly appeared happy to discuss their experiences of physical 
symptoms although some of the men seemed more reluctant to talk about the bowel 
problems that they had been having or the extent of their pain, particularly when in 
front of their spouses. In addition, the psychological and emotional distress 
experienced as a consequence of the disease was only addressed by the female 
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patients and female carers, suggesting a gender difference in the reporting of this 
issue. 
 
In addition to receiving advice from healthcare professionals, patients certainly 
attempted to self-manage their symptoms and condition. In terms of manipulating 
food intake to overcome issues of weight loss, nausea or vomiting, this included 
making changes to the types of food eaten as well as the portion sizes and texture. 
However, these changes were often misinformed as the emphasis appeared to be 
on HDWLQJ D µKHDOWK\¶ GLHW, high in fruit and vegetables and low in fat and sugar, 
principles which, for someone at nutritional risk, are inappropriate. A sense of guilt 
surrounded the inability of the patient to follow healthy eating guidelines, this was 
alongside frustration from caregivers who felt that it was important to aid their 
recovery.  
 
Family and friends evidently offered their advice and support to help encourage food 
intake. The conscious offers of help may or may not have been able to be 
implemented by the patient. It is likely that the unconscious efforts, such as sitting 
down to a meal with the patient thus distracting them from the eating process, or 
encouraging them to partake in social activities, may have helped the most. Finally, 
for those caring for someone with cancer, the challenges that arose, including those 
associated with food intake and nutritional status should not be underestimated.  
 
6.2.8 A conceptual model of the process of influences on weight change in people 
with cancer 
A conceptual model of influences on weight change in people with cancer is 
proposed to help illustrate the relationships between the categories (Figure 6.1). 
The model was developed from the five categories that were identified in the data, 
QDPHO\ µV\PSWRPV¶ µVHOI-PDQDJHPHQW¶ µDWWLWXGH WR ZHLJKW¶ µVRFLDO VXSSRUW¶ DQG
µFOLQLFDO VXSSRUW¶ ,Q DGGLWLRQ WR WKH UHODWLRQVKLSV EHWZHHQ WKHVH FDWHJRULHV WKH
model presents the theory that food intake, and hence weight, is influenced by many 
things. Overall, these factors which may act to motivate, or de-motivate the eating 
process resulting in an increase or decrease in food intake, are specific to the 
individual and in a state of constant flux. What follows is a discussion of the 
relationships between the elements within the model, as well as explanation as to 
how the qualitative data supports this framework. 
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Figure 6.1: Conceptual model of the process of influences on weight change in 
people with cancer. Solid line, relationships noted in the data; dotted line, existing 
hypotheses. 
 
 
The disease itself will be one of the factors which determines what treatment will be 
given to the patient. Both the cancer and its multimodal therapies can result in 
numerous adverse symptoms. In addition, many people with cancer will also have 
pre-existing co-morbidities which may be contributing to the symptom burden.  The 
aim of any treatment will be to cure or palliate the cancer, and along with this will 
hopefully come a reduction in symptoms. The findings of the present study showed 
that many of the participants experienced an array of physical and psychological 
symptoms caused by a combination of the tumour and its treatment. Furthermore, 
for one patient, the significance of ongoing pain from an old injury was evident in the 
data. It was clear that at different times of the disease and treatment trajectory, the 
severity and consequences of such symptoms varied, and for some, following 
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treatment, there was a definite improvement in symptom burden. For others the 
opposite was true, with chemotherapy, radiotherapy and surgery being implicated 
as causal factors. 
 
As found in the study data, and the existing literature, many patients with cancer 
experience a reduction in appetite (Teunissen et al. 2007). For some this may be a 
symptom in isolation, but for others the decrease in appetite is as a consequence of 
other symptoms such as nausea, vomiting or anxiety. Yet another group of patients 
may continue to have a good appetite, despite experiencing such problems. This 
phenomenon was explained by some of the participants in the study whose food 
intake had been decreased as a consequence of early satiety and vomiting but who 
continued to express feelings of hunger and desire to eat. 
 
 
Whatever the cause of the symptoms, it is likely that there will be an impact on the 
nutritional intake of the person. In turn, even small adjustments to food intake may 
positively or negatively impact on the burden of symptoms such as nausea or 
vomiting. If ongoing, the conscious or subconscious adjustments to food intake will 
result in a change in weight in either direction, ultimately impacting on function and 
quality of life. Findings from this study, and others, demonstrate how malnutrition 
and weight loss can impair quality of life in people with cancer, varying from an 
inability to pursue favourite pastimes, to a loss of independence (Nourissat et al., 
2008). Impairment in nutritional status and quality of life may then directly impact on 
the level of symptom burden. This was seen in the present study where weight loss 
and reduced functional capacity probably resulted in increased symptoms of anxiety 
and fatigue.  
 
Self-management strategies employed by individuals may directly improve food 
intake. For example, in the present study, participants changed their eating pattern 
or attempted to include more energy dense foods. Indirectly, self-management 
WHFKQLTXHV PD\ DOVR OHVVHQ WKH V\PSWRP EXUGHQ $Q LQGLYLGXDO¶V DWWLWXGH LV DOVR
likely to influence nutritional intake in either direction. Indeed, findings from the 
present study represent how attitude to weight and body image can impact on a 
SHUVRQ¶VIRRGLQWDNH7KHGDWDDOVRVXSSRUWVWKHWKHRU\WKDWVHOI-management and 
attitude were inter-related concepts. The findings suggest that the approach taken 
to self-PDQDJHPHQWZDVDIIHFWHGE\WKHLQGLYLGXDO¶VDWWLWXGHVDQGEHOLHIV WKLVZDV
particularly seen by those taking a stoical approach to managing their condition. 
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In this context, social support relates to the support that an individual receives from 
family or friends. This may be in terms of the practical assistance offered such as 
preparation of meals, encouragement, or the giving of knowledge with the intention 
of enabling more appropriate food choices. This support, depending on the level 
and reliability, could result in either an increase or a decrease in food intake. It was 
evident from the current study that for some, without the assistance of their 
spouses, food intake would have deteriorated further. For those offering support it is 
OLNHO\ WKDWREVHUYDWLRQDQGDZDUHQHVVRI WKH LQGLYLGXDOV¶FKDQJLQJIRRG LQWDNHDQG
weight informed their help and advice. 
 
Clinical support can also directly or indirectly influence nutritional intake. Here 
clinical support refers to the support and advice that are provided from a member of 
the healthcare team regarding the nutritional management of the patient. 
Quantitative research tentatively shows that this type of support, such as the 
provision of dietary information or the prescription of nutritional supplements, can 
increase nutritional intake (Stratton et al, 2003; Baldwin and Weekes, 2008). This 
was also suggested by the findings of the present study where participants reported 
an improved intake following advice. In addition, providing advice and treatment for 
adverse symptoms may also lead to an improvement in appetite and ability to eat.  
 
In summary, when nutritional intake is negatively affected, the results can be 
catastrophic. This may present as weight loss and malnutrition and is followed by a 
reduction in function and ability to conduct the normal activities of daily living. In 
addition, the psychosocial implications need to be considered. The discussed 
conceptual model aims to demonstrate the perpetuating and complex nature of the 
influences on weight in patients with cancer. A greater understanding of the factors 
which influence nutritional status may help in the provision of support.
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CHAPTER 7: FINAL DISCUSSION AND CONCLUSIONS 
 
7.1 Introduction 
The methodological approach and results of the individual three phases of the study 
have been discussed in the preceding sections of this thesis. The purpose of this 
final chapter is to assimilate and summarise the overall key findings. In addition, 
limitations to the project will be discussed and what has been learnt regarding the 
research process will be highlighted. The chapter will conclude with a discussion of 
the implications for clinical practice and areas where further research is warranted.  
 
7.2 Study rationale 
Malnutrition is common in patients with cancer, particularly of the lung and upper 
gastrointestinal tract (Chauhan et al., 2007; Bozzetti, 2008; Halliday et al., 2009). In 
addition, the number of people who have the cachexia syndrome is likely to be 
significant (Laviano et al., 2005; Fox et al., 2009). Those who experience such 
symptoms are in a state of negative energy and protein balance caused by a 
combination of reduced nutritional intake and abnormal metabolism. The resulting 
effect is weight loss, muscle wasting, fatigue and psychological disturbances all of 
which may increase morbidity, impair quality of life and reduce survival (DeWys et 
al., 1980; Capuano et al., 2008; Nourissat et al., 2008; Swinton et al., 2008). 
Currently, there are no satisfactory treatments for cachexia. However, an increased 
knowledge of the underlying pathophysiology is allowing new therapies to emerge. It 
is probable that improved patient outcomes are more likely if these treatments are 
offered alongside conventional nutritional support and before significant weight loss 
has occurred. A better understanding of the complex processes that have an effect 
on weight change in people with cancer, along with a simple means of identifying 
patients at greatest risk of future weight loss would help to target such an approach. 
Existing screening instruments can help to identify those who are already 
malnourished (Bauer et al., 2002; Stratton et al., 2004; Isenring et al., 2006). 
However, within the literature, no tool when tested with people who have cancer 
appears to be predictive of weight loss.   
 
This study used a mixed method exploratory approach to develop a deeper 
understanding of the complex factors that have an effect on, and can predict, weight 
change in people with cancer. Phases I and II were conducted sequentially and 
used quantitative methodology to test the reliability and validity of the CASQ. Phase 
III, an exploratory qualitative study following the principles of grounded theory, was 
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conducted concurrently alongside phase two. The key objectives which were 
achieved were to: 
1.  Obtain an estimate of the reliability of the CASQ. 
2. Determine the predictive validity of the CASQ 
3. Determine the optimal cut points and overall performance of the CASQ at 
predicting clinically significant weight loss over three months.  
4. Propose an optimum screening instrument to predict clinically significant 
weight loss over three months.  
5. Describe the experiences of people with lung or upper gastrointestinal 
cancer, and their carers, regarding the factors influencing weight change 
6. Explore the causes and influencing factors of weight change in people with 
lung or upper GI cancer.  
7. Propose a conceptual model of influences on weight change in people with 
cancer. 
8. Identify areas for improvement regarding the nutritional management of 
people with cancer. 
 
7.3 Summary of findings 
The aim of the following section is to integrate the findings from all three phases of 
the study and to discuss and summarise the key points. Noteworthy is that the 
objective of the qualitative phase was to understand the range of views held by the 
participants regarding their dietary intake and weight. It is therefore not appropriate 
to make claims about the distribution of those views across a population. This 
means that the findings are not generalisable in the quantitative sense. However, 
findings from the qualitative data analysis clearly indicate the experiences and 
challenges of the participants, and their carers, in terms of managing their weight 
status, thus adding to our understanding of this phenomenon. 
 
7.3.1 The experiences of people with lung or upper gastrointestinal cancer, and their 
carers, regarding the factors influencing weight 
 
7.3.1.1 A vulnerable population 
An improved understanding of the experiences of people with lung and upper GI 
cancer, and their carers, regarding the factors influencing weight change came from 
the findings of the Phase II and Phase III studies. The results indicated that this 
population was extremely vulnerable in terms of risk from nutritional related 
concerns and malnutrition. Although limited by the lack of a consensus definition of 
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malnutrition, this is a finding that is undisputed by previous research (Laviano et al., 
2005; Bozzetti et al., 2009). In the present study, despite recruiting people not 
deemed at high risk of malnutrition as defined by the MUST, at recruitment, almost 
50% of the Phase II sample was identified as at risk by the validated MST. In 
DGGLWLRQ GXULQJ WKH VWXG\¶V three month follow-up period, 55% of participants lost 
weight. The low total CASQ scores obtained from a number of the patients (total 
&$64VFRUHQ  IXUWKHUVXSSRUWV WKHFRQFOXVLRQ WKDW WKRVHSDWLHQWVZLWK
lung or upper GI cancer experience multiple appetite and symptom related 
problems, a finding that is supported by the existing literature (Teunissen et al., 
2009). It is also noteworthy that the Phase II study data suggest that, in terms of 
symptoms experienced, there were no significant differences between the 
responses of those patients who had lung cancer compared with those who had 
upper GI, a finding that concurs with the findings of others (Khalid et al., 2007).  
 
The impact of the symptom burden was also explicit throughout the Phase III study 
data. In particular, our comprehension of this phenomenon has been enhanced by 
being able to appreciate the individual complexities of the lived experience as well 
as the self-management strategies employed by patients trying to deal with their 
situation and disease. The findings from the present study regarding symptom 
burden and self-management techniques concur with those found by other 
researchers (Hopkinson, 2006; Hopkinson, 2007). For example, previous work has 
proposed a theory of self-management of changing eating habits in people with 
advanced cancer (Hopkinson, 2007). As concluded from the present study, it is 
likely that the promotion of self-management techniques by healthcare staff may 
help patients to facilitate self-action, and ultimately gain an improved sense of well 
being. 
 
7.3.1.2 Malnutrition, an unrecognised problem 
The lack of awareness of malnutrition and its consequences have been realised for 
decades. Florence Nightingale wrote about such concerns in the 19th Century: 
µ(YHU\FDUHIXOREVHUYHURI WKHVLFNZLOODJUHH LQWKLV WKDWWKRXVDQGVRISDWLHQWVDUH
annually starved in the midst of plenty, from want of attention to the ways which 
DORQHPDNHLWSRVVLEOHIRUWKHPWRWDNHIRRG««KDYHDUXOHRIWKRXJKWDERXW\RXU
patient's diet; consider, remember how much he has had, and how much he ought 
to have to-GD\¶1LJKWLQJDOH 1860). In truth her observations could well have been 
written in the present day. It was evident from the analysis of the qualitative data in 
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the present study that, despite the identification and risk of malnutrition being raised 
as important issue in several national and international policy guidelines (NICE, 
2006, ESPEN, 2006, BDA, 2009), patients¶ nutritional needs were still going 
unaddressed in clinical practice. Despite losing weight, several of the participants 
interviewed had not received advice to help address their nutritional concerns. 
These are findings that are supported by larger quantitative research studies (Kelly 
et al., 2000; Baldwin et al., 2006). A recent document published by The British 
Dietetic Association highlights the key role of the dietitian in ensuring that 
malnutrition is both recognised and treated (BDA, 2009). However, as discussed in 
the document, addressing the issues of malnutrition within the hospital and 
community settings needs a coordinated multidisciplinary approach. Findings from 
the present study suggest that there may be some way to go before this important 
area of healthcare is effectively managed. 
 
7.3.2 Development and validation of the Cancer Appetite and Symptom 
Questionnaire 
Research suggests that in the cancer population the majority of patients, particularly 
those with gastrointestinal disease, experience symptoms which impact on their 
ability to eat and ultimately their weight and nutritional status (Laviano et al., 2005). 
Hence, in this group of patients where the prevalence of malnutrition is so high, the 
need for nutritional screening in clinical practice should be questioned (Elia, 2005). 
It is important to consider that in addition to identifying patients who are 
malnourished, other reasons for implementing a screening instrument may include 
raising awareness of the issue and prioritisation of workload. Within this field, 
recently published research continues to focus on the validity testing of existing 
malnutrition screening instruments within specific cancer populations (Gioulbasanis 
et al., 2008; Roulston and McDermott, 2008; Stoyanoff et al., 2009). To date there 
remains no conclusion as to which is the most appropriate instrument to screen for 
malnutrition in the clinical setting. It is likely that an instrument with predictive 
capabilities would aid intervention in a more timely manner. Although other 
researchers have investigated how weight loss per se may be able to predict 
morbidity and mortality (Temel, 2004; Fearon et al., 2006), little has been published 
postulating what variables, if any, are able to predict those who will lose weight. A 
recent small study (n=58) in a group of patients who had cancer aimed to identify 
what factors were able to predict involuntary weight loss. However, due to the study 
being published only in abstract form it is not possible to determine the actual 
methodology used, or the detail of what combination of variables were found to 
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predict weight loss (Blum et al. 2009). Within the literature, no screening instrument 
could be located which is able to predict patients with cancer who are at risk of 
future weight loss, making the current study investigating the predictive validity of 
the CASQ, unique.  
Earlier research, using content validity testing with an expert panel, led to the 
development of the 12-item CASQ from the previously validated Council on Nutrition 
Appetite Questionnaire (CNAQ). When tested for reliability with the Phase I study 
participants, the internal consistency and test-retest reliability was acceptable. To 
determine the predictive validity of the instrument, field testing within the Phase II 
study population suggested that the optimum cut point of the CASQ score to predict 
greater than 5% weight loss was 31/32 and to predict greater than 10% weight loss 
was 29/30. Noteworthy is the similarity of the cut points for predicting these two 
different degrees of outcome. The CASQ was performing at its optimum when 
predicting greater than 10% weight loss. Here the sensitivity of the instrument was 
71%, specificity 69%, positive predictive value (PPV) 21% and negative predictive 
value (NPV) 95%. In combination, the findings from Phases I and II of the present 
study suggest that the CASQ is reliable and can predict weight loss over three 
months. However, the low specificity and low PPV imply that some patients would 
be incorrectly classified as being at risk, potentially increasing workload and costs, 
as well as impacting on anxiety levels of the patient and their carers. In addition, 
compared with the validity testing of other malnutrition screening instruments, the 
performance of the CASQ was found to be sub-optimal (Isenring et al., 2006; 
Stoyanoff et al., 2009). Overall, the study results imply that in its current form the 
12-item CASQ is not appropriate for use within clinical practice.  
Finally, it is also important to consider if it is actually possible to predict weight loss 
in this cancer population. It is feasible that there are unknown underlying processes 
which resulted in the CASQ lacking predictive validity.   
 
7.3.3 Development of an optimum screening instrument to predict clinically 
significant weight loss 
Existing nutritional screening instruments vary in their content. Generally they 
include anthropometric measurements such as BMI and percentage weight change, 
as well as aspects of disease status and its impact on nutritional intake or 
requirements (Stratton et al., 2004; Kyle et al., 2006). Some also take into account 
symptom burden such as appetite loss and mood (Vellas et al., 1999; Isenring et al., 
2006). In patients who have cancer, the metabolic consequences of the cachexia 
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syndrome are also important factors to consider when determining nutritional risk. 
To date there is no screening instrument which also incorporates this element of the 
condition.  
 
In Phase II of the present study, exploratory multiple linear regression techniques 
were used to determine the model which contains the optimum set of variables 
which could be used to predict clinically significant weight loss over a three month 
period. Results suggested that when adjusted for age, CASQ items 4 (enjoyment of 
food) and 12 (pain), along with MUST score and BMI were most predictive of weight 
change. Interestingly, this model did not include the inflammatory marker C-
Reactive Protein which had the strongest correlation with percentage weight change 
of all the variables tested during the Phase II study. In addition, C-Reactive Protein, 
when compared with the ability of the CASQ, MUST and MST to predict weight 
change, was shown to have the highest sensitivity, specificity, NPV and PPV. 
Furthermore, as supported by previous research, C-Reactive Protein was also 
found to be an independent predictor of survival (Scott et al., 2002; McKernan et al., 
2008). With the recent proposed definition and diagnostic criteria for the cachexia 
syndrome (Evans et al. 2008), it seems reasonable to suggest that C-Reactive 
Protein is an important variable to measure when considering the nutritional risk of 
this group of patients. When compared with the measurement of other markers of 
the cachexia syndrome, such as TNF-Į ,/-1 or IL-6, as a routine and established 
test, the UHODWLYH HDVH RI GHWHUPLQLQJ D SDWLHQW¶V VHUXP &-Reactive Protein 
concentration in clinical practice should also be considered. 
 
7.3.4 A conceptual model of influences on weight change in people with cancer 
The findings from the Phase III qualitative study led to a conceptual model of the 
processes of the influences on weight change in people with cancer being 
developed. In addition, Phase II study data has provided further insight into the 
appetite, symptoms and food intake of this cancer population. From the study data 
there is also evidence in support of nutritional status being compromised by weight 
loss in those who experience an increased symptom burden.  
 
What the initial model does not include is the relationship between the cachexia 
syndrome and change in weight. From the findings of the present study, and 
understanding of the literature, a revised model (Figure 7.1) demonstrates the 
proposed interplay between cachexia and the influences on weight change in 
people with cancer. People with cancer who develop the cachexia syndrome exhibit 
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a number of symptoms such as fatigue and a reduced appetite which can impact on 
food intake and hence nutritional status (Inui, 2002). Evidence also exists to support 
the theory that weight status impacts on treatment outcomes (Andreyev et al. 1998). 
Furthermore, the metabolic effects of the condition, for example the increase in 
energy requirements, are likely to have a direct influence on weight resulting in a 
reduction of lean body mass and adipose tissue (Fouladiun et al., 2005). This, along 
with the direct effects of the condition, can impair function and quality of life. The 
extent to which pre-cachexia directly impacts on symptoms and weight change is 
not yet understood. 
 
Analysis of the data supports the theory that clinical support should be implemented 
DW HYHU\ VWHS RI WKH SDWLHQW¶V MRXUQH\ DQG VKRXOG HQFRPSDVV DOO HOHPHQWV RI WKH
proposed model. This includes addressing the underlying disease and its treatment, 
the cachexia syndrome and any pre-existing conditions which may be impacting on 
symptom burden. Nutritional management strategies should be initiated and should 
provide ongoing support and advice regarding maximisation of nutritional intake. 
Clinical support should also address issues of self-management and acknowledge 
the underlying attitudes and beliefs of patients, in addition to aiding and supporting 
the social support provided by family and caregivers. 
 
Finally, as previously discussed, if the treatment of malnutrition and cachexia is to 
be successful, interventions must be initiated in a timely manner. The ideal 
opportunity for this would be in the pre-cachectic stage and/or when the symptoms 
which impact on food intake are minimal. Current screening instruments, such as 
the MUST and MST, identify those who are at risk much further down the process, 
i.e. once food intake has already been impaired. Novel screening initiatives should 
target the early stages of the disease trajectory.  
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Figure 7.1: Final conceptual model of the process of influences on weight change in 
people with cancer. Solid line, relationships noted in the Phase III data; dotted line, 
existing hypotheses.  
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7.4 Limitations of the study 
 
7.4.1 Phases I and II study sample 
As experienced during the current study, the development and validation of any 
screening instrument is a complex process. Importantly, an instrument only has 
proven reliability or validity in the population in which it has been tested. In terms of 
the present study, this means that the reliability of the CASQ has only been 
ascertained in people with breast, prostate and colorectal cancer who are having 
UDGLRWKHUDS\,QDGGLWLRQWKHLQVWUXPHQW¶VSUHGLFWLYHYDOLGLW\KDVEHHQGHWHrmined in 
a different population, i.e. out-patients with lung or upper GI cancer. Furthermore, in 
the Phase II study population, although there was diversity in terms of age and time 
since diagnosis, all but one of the participants were white and British. Finally, the 
initial intention was to determine the predictive validity of the CASQ in a population 
that was not at high risk of malnutrition. However, the evidence suggests that this 
was not achieved, as a high proportion of the participants was classed as 
malnourished by the MST. Rather than being a limitation, this can be viewed as a 
strength, as the predictive validity of the CASQ has been determined in a more 
diverse sample in terms of risk of malnutrition. However, despite the inclusion of 
some patients who were at risk of malnutrition, the performance status of 
participants and the range of CASQ scores obtained, specifically the limited number 
of people with very low scores, suggested that the study sample was truncated. All 
of these factors limit the inferences which can be made about reliability and validity 
of the CASQ.  
7.4.2 Phase II follow-up duration 
In the Phase II study, the ability of the CASQ to predict weight loss was determined 
over a three month follow-up period. This duration was chosen due to the overall 
poor prognosis of this group of patients, particularly those with lung and pancreatic 
disease. Consideration must be given to whether the results could have been 
affected by the length of follow-up. One possibility is that the CASQ has better 
predictive capabilities over a longer time period. The need to question the follow-up 
duration is supported by the fact that the follow-up period used when testing the 
predictive validity of the original eight item CNAQ was six months (Wilson et al., 
2005). In this study, the sensitivity and specificity of the CNAQ were greater than 
that of the CASQ. 
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7.4.3 Phase II sample size 
Secondary analysis of the Phase II study data used multiple regression to explore 
which items of the CASQ, and what other factors, were predictive of weight loss. 
Although this analysis was only speculative in nature, when interpreting the results 
consideration must be given to the sample size, more specifically the low number of 
events, i.e. patients who lost weight, per variable. Less than five events per variable, 
as was present in this study analysis, could potentially have lead to bias of the 
regression coefficients and hence bias in the conclusion of the optimum model to 
predict weight loss (Peduzzi et al., 1996). It could also be possible that the relatively 
low number of patients who lost greater than 5% (n=38) and 10% (n=18) body 
weight during the study period impacted on the ROC curve analysis, and may have 
been a contributing factor which resulted in the similar CASQ score cut points for 
the two different outcomes. 
 
7.4.4 Phase III study 
When the Phase III study was designed the intention was to explore the predictors 
of weight loss in patients with lung and upper GI cancer.  Instead, the categories 
which emerged from the transcript data were focussed around what influenced 
weight change. This led to some of the findings from the data being similar to the 
work of Hopkinson et al. (2006 and 2007). There were however a number of 
differences which demonstrate the originality of the current study. For example, the 
samples studied by Hopkinson et al. included only those patients with advanced 
disease and their carers. Furthermore, the findings of the current study were 
explored in the context of improving the nutritional care of patients. In contrast, the 
focus of the work of Hopkinson et al. (2006) was helping patients and their families 
to live with weight loss.  
 
The methods used for sampling Phase III recruits and analysing the data may have 
led to limitations in the study findings. Although the intention was to use theoretical 
sampling, due to practical and time constraints, overall the final sample was one of 
convenience. It did not, for example, include any male spouses or carers. Neither 
were there any patients with upper GI cancer who were receiving palliative 
treatment. In addition, following the final interview, although it was felt at the time 
that no new categories were emerging from the data, a deeper analysis of the data 
was only conducted later. Therefore, whether true saturation of the data was 
actually achieved is questionable. Both of these limitations may have resulted in 
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categories relating to weight change in people with cancer not being discovered and 
hence, the conceptual model being incomplete. 
 
Finally, one of the strengths of qualitative research is that the data generated can be 
used to develop theory. On reflection, the qualitative part of this study could have 
been conducted first and the findings used to inform the development of the CASQ. 
It is possible that this may have influenced the themes of the items included in the 
CASQ and may have resulted in an instrument with a more comprehensive 
coverage of symptoms. Although the instrument was designed with the intention of it 
being used as a screening tool to predict weight loss within clinical practice, 
increasing awareness of overall symptom burden is likely to be beneficial.  
 
7.4.5 Researcher reflexivity 
Although not a limitation, it is important to reflect on how researcher reflexivity may 
have contributed to the study findings. Willig (2001) describes two types of 
reflexivity; personal reflexivity and epistemological reflexivity. Personal reflexivity is 
the consideration of how the researchers¶ own beliefs, opinions and experiences 
may have influenced the construction of meaning from the study findings. In the 
present study the researcher was a dietitian with over ten years¶ experience of 
working within an oncology and palliative care clinical setting. It is important to 
realise that it is not feasible for the researcher not to bring preconceived beliefs or 
opinions to this study, particularly regarding what may influence food intake in 
people with cancer. In addition, there was an existing understanding of the research 
evidence base surrounding the phenomenon and process of nutritional intake which 
were explored in this study. Having an awareness of reflexivity certainly helped to 
prevent existing opinions influencing the construction of meaning and theory from 
this data. Furthermore, as a novice researcher, undertaking this work has 
strengthened the understanding of the qualitative research process, in particular, 
during the analysis stage, the importance of categories emerging from the data 
rather than from predetermined beliefs.  
 
One aspect of epistemological reflexivity is how the research study design may 
influence the construction of meaning (Willig, 2001). A point to consider is that the 
findings from the present study may have been limited by the format of the semi-
structured interview questions.  For example, the aim was to use open, non-leading 
questions. However, one of the questions asked if the patient had experienced 
symptoms and another if they received any advice regarding their eating and 
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drinking. Inclusion of these questions meant that it was unlikely that symptoms and 
aspects of support were not going to be present in the data, and hence the model of 
influences on food intake. A final point to consider is the meaning of what was said 
by those who were interviewed. From the perspective of the researcher there is the 
belief that what the interviewees said was their verbal expression of the mental 
processes surrounding the experiences that they had. It is also important to 
consider how the presence of the researcher, a dietitian, may have influenced what 
the participants disclosed, for example, when discussing issues of healthy eating. 
 
7.5 Comments on the research process 
In addition to the implications for clinical practice, it is important to acknowledge 
what has been learnt regarding the research process. The challenges of recruiting 
patients, particularly those receiving palliative care, into research studies have been 
previously reported in the literature (Ewing et al., 22¶0DUDet al., 2009). Indeed, 
recruitment to the present study was found to be challenging. Despite there being 
no intervention and the participant research burden being comparatively low for this 
study, some of those approached felt unable to participate. Reasons given for 
UHIXVDOZHUHUHODWHGWR µKDYLQJWRRPXFKWRFRSHZLWK¶RUEHLQJXQDEOHWRUHDGWKH
participant information sheet due to not having spectacles with them. Others who 
had received curative treatment felt that it was inappropriate to be given an 
LQIRUPDWLRQVKHHWZLWKD WLWOHRI µSUHGLFWLQJZHLJKW ORVV LQFDQFHU¶ ,W LV LPSRUWDQW WR
consider that patients diagnosed with cancer are likely to receive a plethora of 
information, particularly around the time of diagnosis. Some may be unable to deal 
with the additional burden of participating in a research study. In addition, a 
proportion of the U.K. population has low literacy levels (National Literacy Trust, 
2009) and for some people, the request to read several pages of study information 
may be daunting. Several potential participants commented on the length of the 
information sheet for what they deemed to be a study that involved filling in a 
questionnaire. In particular, WKHVHFWLRQHQWLWOHGµ:KDWLIVRPHWKLQJJRHVZURQJ¶OHG
them to think that they had missed something that they would need to do. Issues 
such as these need to be addressed sensitively by the researcher, ensuring that 
patients feel informed, but not pressurised to participate. Further consideration to 
the format of participant information sheets and the wording may also be beneficial.  
 
Recruitment of participants to this study was extremely time consuming and took 
longer than predicted. The most effective way was for the researcher to attend the 
out-patient clinics. This is a method that has been found to be successful by others 
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2¶0DUDet al., 2009). Simply screening notes and visiting the clinic to see ad-hoc 
patients resulted in potential participants being missed as inevitably clinics did not 
run to time. In addition, relying on busy clinic staff to be involved in the recruitment 
process proved to be ineffective. As a dietitian working in a clinical research setting 
it is favourable to work alongside an established multi-professional research team. 
This not only provides a source of knowledge and experience but also enables the 
challenges of research to be conducted in a supportive environment. Finally, to 
ensure recruitment of a diverse sample, in addition to assisting recruitment rates, a 
multi-centred collaboration may prove to be beneficial. 
 
7.6 Implications for practice and future research 
The dietetic profession is a practice-based discipline and, as in all areas of 
healthcare, a sound research evidence base is paramount to ensure the health and 
wellbeing of service users as well as maintaining the credibility of the profession. 
The evidence base is derived from research which is used as a tool to both develop 
and test theories. In the present study, Phases I and II involved the testing of the 
K\SRWKHVLV WKDW µD VLPSOe and practical screening instrument, with demonstrated 
reliability and validity, can predict clinically significant weight loss in people with lung 
RUXSSHU*,FDQFHU¶5HVXOWVIURPWKHWZRVWXGLHVDOORZXVWRDFFHSWWKLVK\SRWKHVLV
However, for the reasons previously discussed, implementation of the CASQ into 
the clinical setting is not appropriate. For this reason, no implications in terms of 
changing clinical practice have evolved from the testing of this hypothesis. 
Nonetheless, as will be discussed in the following section, from the three phases of 
the study, new substantive theories have emerged related to the further 
development of a screening instrument to predict weight loss, evaluation of 
symptoms and the influences on weight change in people with cancer. Conducting 
further research will enable these theories to be tested, following which they may 
become generalisable. In particular, the model developed from the Phase III study 
provides insight into the processes involved regarding nutritional concerns of the 
individual and the way that they self-manage their condition. For dietitians or any 
healthcare professionals, this improved understanding may enable a more holistic 
approach when assessing, treating and monitoring the care provided to service 
users. 
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7.6.1 Predicting weight loss screening instrument 
Further research is required to develop a screening instrument which is able to 
predict clinically significant weight loss in the cancer population. Following multiple 
linear regression techniques with the Phase II study data, two models were 
proposed. The first included CASQ items six (snacks), nine (nausea) and 12 (pain). 
If the purpose of the intended instrument is solely to predict weight loss then further 
testing of this model may be warranted. However, completion of a tool with these 
particular items would give little evaluation of symptoms. In addition, it is interesting 
that this model does not directly include any item relating to appetite. The second 
proposed model included CASQ items four (enjoyment of food) and 12 (pain), 
MUST score, BMI and age. A model such as this could have a dual purpose of 
screening for malnutrition and predicting weight loss (Appendix 30). For example, 
HVWDEOLVKLQJ WKH SDWLHQW¶V 0867 VFRUH ZKLFK LQFOXGHV FDOFXODWLon of BMI, would 
identify those patients who were at risk from malnutrition. This data, along with age 
and responses to CASQ items four and 12 could then be used to determine their 
risk of future weight loss. It is possible that the themes of these two items have the 
greatest influence on food intake and hence weight status. As seen in the Phase III 
study data, enjoyment of food emerged as an important aspect in the feeding 
process. Pain was also identified from the qualitative data as influencing food intake 
as well as overall sense of wellbeing. The prospective validity testing of a model 
such as this would need to be conducted with a diverse sample of patients with 
cancer. Furthermore, research would need to focus on the scoring of the item 
responses and, as discussed below, the nutritional intervention point following 
MUST screening.  
 
Overall, the results from the Phase II study also suggested that a third option of 
testing C-Reactive Protein as a predictor of weight loss is warranted.  In clinical 
practice the usual reference range for serum C-Reactive Protein concentration is 0 
to 10mg/L. Findings from this study suggested that serum concentrations of 
>15mg/L may be predictive of weight loss. Further prospective testing with a larger 
sample size of patients with cancer would need to be conducted to establish the 
optimum cut-point for C-Reactive Protein. In clinical practice C-Reactive Protein is 
not always routinely analysed, therefore there would be practical and financial 
issues of implementing this aspect of screening. As our understanding of the 
cachexia syndrome improves, and with a worldwide consensus definition hopefully 
imminent, research should also focus on the screening of patients with the 
syndrome or, ideally, those in a pre-cachectic state. It is probable that C-Reactive 
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Protein would be included in such a tool. A validated instrument will enable 
therapies to be commenced as early as possible in the disease trajectory with the 
hope of stabilising, if not improving, function and quality of life. 
 
7.6.2 Screening for malnutrition 
The British Dietetic Association and the National Institute for Health and Clinical 
Excellence both support the use of the MUST in clinical practice (NICE, 2006; BDA, 
2009). However, a critical review of the literature showed that the usefulness of the 
MUST in identifying those at risk of malnutrition remains uncertain in patients with 
cancer. Findings from this Phase II study following multiple linear regression 
techniques suggest that, when adjusted for all other variables, a MUST score of one 
remained an independent predictor of weight loss. This implies that in groups of out-
patients with lung or upper GI cancer, being identified at moderate risk from 
malnutrition may warrant nutritional intervention. Further testing of the MUST 
WKURXJKRXWWKHFDQFHUSRSXODWLRQXVLQJDFXWRIIRIDVDQLQWHUYHQWLRQSRLQW LV
now needed. Dietetic services that are struggling to cope with the current workload 
demands will find an increase in referral rates from those being identified by the 
MUST as being at moderate, as opposed to high risk, a challenge. That said, 
consideration needs to be given to the advantages of providing dietary intervention 
at an earlier stage in the disease trajectory.  
 
7.6.3 Evaluation of symptoms 
The importance of identifying symptoms which influence food intake was evident 
from Phase III of the study. In addition to being able to predict weight loss, the 
CASQ could also be used within clinical practice to evaluate patients¶ symptoms. 
This may be as part of the initial assessment process, or following implementation 
of treatment. From the integration of the findings from Phase III of the present study 
with the existing CASQ, a 16-item tool for the evaluation of appetite and symptoms 
for use in people with cancer, has been proposed (Appendix 31). Phase III study 
findings suggested that items one (appetite), two (satiety), three (hunger) and four 
(enjoyment of food) provided important information on the four elements of the 
feeding process, i.e. the physiological sensations of hunger, the desire to eat, 
enjoyment of eating, and feelings of satiety. It was therefore considered important to 
include these items in the proposed evaluation tool. However, from the qualitative 
data, the subjectivity of appetite was emphasised, with patients comparing their 
current state to what they deemed normal.  In an attempt to improve the clarity and 
meaning of item one (appetite), it has been proposed that it be reworded to include 
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WKH ZRUGV µGHVLUH WR HDW¶  ,QGLUHFWO\, CASQ items five (number of meals) and six 
(number of snacks) may provide information on appetite. However, during Phase II 
of the study, patients were often unsure of what defined a meal and a snack 
suggesting that the wording was ambiguous. In addition, if the tool is to evaluate 
appetite and symptoms, it is questionable whether items five and six relating to the 
number of meals and snacks eaten are necessary. On this basis, these two items 
have not been included in the proposed evaluation tool. The six remaining items of 
the CASQ relating to nausea and vomiting, taste, mood, energy levels and pain 
were all symptoms experienced by the Phase III study sample, signifying that they 
were indeed relevant and should be included in the proposed tool. However, as 
respondents during Phase II of the study were unsure of the difference between the 
two items relating to taste only CASQ item eight (taste changes) has been included. 
Furthermore, guided by the qualitative data analysis, in its current form the range of 
symptoms covered by the CASQ is not exhaustive. It has therefore been proposed 
that new items are included on the subject of weight loss, indigestion, sore 
mouth/throat, vomiting, constipation, diarrhoea and anxiety. Finally, a question has 
been added to capture any additional symptoms that patients may be experiencing. 
The proposed tool would need to be tested prospectively within the cancer 
population before being implemented into clinical practice. 
 
7.6.4 Self-monitoring of weight 
Findings from the Phase III study suggest that self-monitoring of weight is 
something that patients with cancer routinely do. This technique has been used to 
assist weight loss in the obese but is not something that has previously been 
reported in the literature to promote stabilisation or weight gain in the cancer 
population. Further research to investigate the optimum frequency of self-monitoring 
of weight in people with cancer may be able to positively influence motivation to eat 
or compliance with dietary treatment, and hence weight status.  
 
7.6.5 Influence of body image on compliance to dietetic treatment 
Another area for further research is in relation to the influence of perceived body 
image on compliance to treatment. Findings from the qualitative data, which are 
previously unreported in the literature, suggest that some people initially may be 
pleased with losing weight as this leads to an improved body image. As a dietitian 
providing nutritional support to patients with cancer, acknowledgement of this as a 
potential barrier to compliance is important. Further research in this area may help 
to establish whether this phenomenon is established throughout the cancer 
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population, if age or gender influence perceptions and what the best management 
strategies may be.  
 
7KHµKHDOWK\HDWLQJ¶FRQIOLFW 
,Q DQ HUD ZKHUH WKH PHVVDJHV RI KHDOWK\ HDWLQJ DQG µILYH D GD\¶ DUH ZHOO-heard 
mantras, findings from the qualitative data suggest that adherence to these 
guidelines remains important for patients with cancer, their family and carers. Being 
unable to eat healthy foods such as fruit and vegetables was an obvious concern for 
patients and their carers. Further exploration and understanding of these beliefs 
may help improve the type and quality of the dietary advice which is offered with a 
view to assisting patient compliance. 
 
7.7 Final conclusion 
In conclusion, the findings from this study have provided a deeper understanding of 
the complex factors that have an effect on, and can predict, weight change in 
people with cancer. The results from the psychometric testing of the Cancer 
Appetite and Symptom Questionnaire imSO\ WKDW WKHK\SRWKHVLV WKDW µDVLPSOHDQG
practical screening instrument, with demonstrated reliability and validity, can predict 
FOLQLFDOO\ VLJQLILFDQW ZHLJKW ORVV LQ SHRSOH ZLWK OXQJ RU XSSHU *, FDQFHU¶ FDQ EH
accepted. However, further developmental work and testing needs to be conducted 
before it is appropriate for use in clinical practice. From this study arises an increase 
in awareness of the individual and complex social processes which surround the 
issues of food intake and weight management in people with cancer. This 
knowledge can inform dietitians and healthcare professionals, influence their 
nutritional management strategies, with the hope of providing more holistic care and 
an enhanced experience for service users. 
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Council on Nutrition Appetite Questionnaire (CNAQ) 
 
Name:_________________________________Sex (circle): Male Female 
Age:________________Weight:____________Height:_______________ 
Date:_____________________ 
 
Administration Instructions: Ask the subject to complete the questionnaire 
by circling the correct answers and then tally the results based upon the 
following numerical scale: a = 1, b = 2, c = 3, d = 4, e = 5. The sum of the 
scores for the individual itemVFRQVWLWXWHV WKH&1$4VFRUH&1$4VFRUH
28 indicates significant risk of at least 5% weight loss within six months. 
 
1. My appetite is 
a) Very poor 
b) poor 
c) average 
d) good 
e) very good 
 
2. When I eat 
a) I feel full after eating only a few mouthfuls 
b) I feel full after eating about a third of a meal 
c) I feel full after eating over half a meal 
d) I hardly ever feel full 
 
3. I feel hungry 
a) rarely  
b) occasionally 
c) some of the time 
d) most of the time  
e) all of the time 
 
4. Food tastes 
a) very bad 
b) bad 
c) average 
d) good 
e) very good 
 
5. Compared to when I was younger food tastes 
a) much worse 
b) worse 
c) just as good 
d) better 
e) much better 
 
 
 
 
 
Appendix 1: Council on Nutrition Appetite Questionnaire (CNAQ) 
209 
 
 
6. Normally I eat 
a) less than one meal a day 
b) one meal a day 
c) two meals a day 
d) three meals a day 
e)  more than three meals a day 
 
 
7. I feel sick or nauseated when I eat 
a) most times 
b) often 
c) sometimes 
d) rarely 
e) never 
 
8. Most of the time my mood is 
a) very sad 
b) sad 
c) neither sad nor happy 
d) happy 
e) very happy 
_____________________________________________________________ 
 
Appendix 2: Simplified Nutritional Appetite Questionnaire (SNAQ) 
 
210 
 
Simplified Nutritional Appetite Questionnaire (SNAQ) 
 
Name:_________________________________Sex (circle): Male Female 
Age:________________Weight:____________Height:_______________ 
Date:_____________________ 
 
Administration Instructions: Ask the subject to complete the questionnaire 
by circling the correct answers and then tally the results based upon the 
following numerical scale: a = 1, b = 2, c = 3, d = 4, e = 5. The sum of the 
scores for the individual items constitutes the SNAQ score. S1$4VFRUH14 
indicates significant risk of at least 5% weight loss within six months. 
 
1. My appetite is 
f) Very poor 
g) poor 
h) average 
i) good 
j) very good 
 
2. When I eat 
a) I feel full after eating only a few mouthfuls 
b) I feel full after eating about a third of a meal 
c) I feel full after eating over half a meal 
d) I hardly ever feel full 
 
3. Food tastes 
f) very bad 
g) bad 
h) average 
i) good 
j) very good 
 
4. Normally I eat 
e) less than one meal a day 
f) one meal a day 
g) two meals a day 
h) three meals a day 
e)  more than three meals a day 
 
 
_____________________________________________________________ 
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Cancer Appetite and Symptom Questionnaire 
 
Please tick the box that most closely reflects your experiences with appetite 
and symptoms at the present time. 
 
0\DSSHWLWHLV« 
 very poor 
 poor 
 average 
 good 
 very good 
 
:KHQ,HDW,IHHOIXOO« 
 without having eaten anything 
 after eating only a few mouthfuls  
 after eating about a third of a 
meal 
 after eating over half a meal 
 after eating a full meal  
%HIRUHHDWLQJ,IHHOKXQJU\« 
       rarely  
 occasionally 
 some of the time 
 most of the time 
 all of the time 
 
,HQMR\WKHIRRG,GRHDW« 
 most times 
 often 
 sometimes 
 rarely 
 never 
$WSUHVHQW,HDW« 
 
 less than one meal a day 
 one meal a day 
 two meals a day 
 three meals a day 
 more than three meals a day 
 
6. At present I eat (in addition to or 
LQVWHDGRIPHDOV« 
 no snacks 
 one snack a day 
 two snacks a day 
 three snacks a day 
 four or more snacks a day 
 
7. Compared to before I was ill, 
IRRGWDVWHV« 
      much worse 
 worse 
 just as good 
 better 
 much better 
 
$WSUHVHQW,KDYH« 
 
 no changes in taste  
 mild taste changes 
 moderate taste changes 
 severe taste changes 
 no taste at all 
 
9. I feel sick or nauseated before 
,HDWRUZKHQ,HDW« 
 most times 
 often 
 sometimes 
 rarely 
 never 
0RVWRIWKHWLPHP\PRRGLV« 
 
 very sad 
 sad 
 neither sad nor happy 
 happy 
 very happy 
11. Most of the time my energy   
OHYHOLV« 
 very high 
 high  
 moderate 
 low  
 very low 
0RVWRIWKHWLPHP\SDLQLV« 
 
 very mild or no pain  
 mild 
 moderate 
 severe  
 very severe  
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EORTC QLQ-C30 (version 3) 
We are interested in some things about you and your health. Please answer all of the 
questions yourself by circling the number that best applies to you. There are no "right" or 
"wrong" answers. The information that you provide will remain strictly confidential. 
Please fill in your initials:  
Your birth date (Day, Month, Year):  
Today's date (Day, Month, Year):  
______________________________________________________________________
_____ 
 
Not at      A  Quite   
Very 
  All  Little  a Bit 
 Much 
1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase?      1     2      3      
4 
2. Do you have any trouble taking a long walk?       1      2      3     
4 
3. Do you have any trouble taking a short walk outside 
of the house?           1            2           3           
4 
4. Do you need to stay in bed or a chair during the day?      1            2           3           
4 
5. Do you need help with eating, dressing, washing 
yourself or using the toilet?         1            2           3           
4 
 
During the past week:      Not at      A       Quite    
Very 
  All      Little     a Bit    
Much 
6. Were you limited in doing either your work or other 
daily activities?          1            2           3          4 
7. Were you limited in pursuing your hobbies or other 
leisure time activities?          1            2           3          4 
8. Were you short of breath?         1            2           3          4 
9. Have you had pain?          1            2           3          4 
10. Did you need to rest?         1            2           3          4 
11. Have you had trouble sleeping?        1            2      3     4 
12. Have you felt weak?         1      2           3          4 
13. Have you lacked appetite?         1            2           3          4 
14. Have you felt nauseated?         1            2           3          4 
15. Have you vomited?          1            2           3          4 
 
 
During the past week:      Not at      A         Quite   
Very 
                All     Little      a Bit    
Much 
16. Have you been constipated?         1           2            3          4 
17. Have you had diarrhea?         1           2            3          4 
18. Were you tired?         1           2            3          4 
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19. Did pain interfere with your daily activities?       1           2            3          4 
20. Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television?      1           2            3          4 
21. Did you feel tense?          1           2            3          4 
22. Did you worry?          1           2            3          4 
23. Did you feel irritable?          1           2            3          4 
24. Did you feel depressed?         1           2            3          4 
25. Have you had difficulty remembering things?      1           2            3          4 
26. Has your physical condition or medical treatment 
interfered with your family life?        1           2            3          4 
27. Has your physical condition or medical treatment 
interfered with your social activities?        1           2            3          4 
28. Has your physical condition or medical treatment 
caused you financial difficulties?        1           2            3          4 
 
For the following questions please circle the number between 1 and 
7 that best applies to you 
 
29. How would you rate your overall health during the past week? 
       1       2       3       4        5       6       7 
Very poor    Excellent 
 
30. How would you rate your overall quality of life during the past week? 
      1        2       3       4        5       6       7 
Very poor         Excellent 
 
© Copyright 1995 EORTC Study Group on Quality of Life. All rights reserved. Version 3.0 
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Subjective global assessment (SGA) 
(Select appropriate category with a checkmark, or enter numerical 
value ZKHUHLQGLFDWHGE\³´ 
 
 
 
A. History 
1. Weight change 
Overall loss in past 6 months: amount = # ___________ kg; % loss = # __________ 
Change in past 2 weeks:  ___________________ increase, 
___________________ no change, 
___________________ decrease. 
   
2. Dietary intake change (relative to normal) 
___________No change, 
___________Change ________________duration = # ____________________ weeks 
________________type: __________ suboptimal liquid diet,  _________ full liquid diet 
  __________ hypocaloric liquids,       _________ starvation. 
 
 
3. Gastrointestinal symptoms (that persisted for >2 weeks) 
________none, ________nausea, ________vomiting, _________diarrhoea, ______anorexia. 
 
 
4. Functional capacity 
___________ No dysfunction (e.g., full capacity), 
___________ Dysfunction _________________ duration = #   _______________weeks. 
                            ______________ type:               ________working suboptimally, 
    ________ambulatory, 
          ________bedridden. 
 
5. Disease and its relation to nutritional requirements 
Primary diagnosis (specify) _________________________________________________ 
Metabolic demand (stress) : ____________  no stress,______________low stress, 
                    ____________moderate stress, ____________high stress. 
_____________________________________________________________________________________________________________ 
 
 
B. Physical (for each trait specify: 0 = normal, 1+ = mild, 2+ = moderate, 3+ = severe). 
# __________________________________loss of subcutaneous fat (triceps, chest) 
# __________________________________muscle wasting (quadriceps, deltoids) 
# __________________________________ankle edema 
# __________________________________sacral edema 
# __________________________________ascites 
 
 
 
C. SGA rating (select one) 
________________________ A = Well nourished 
________________________ B = Moderately (or suspected of being) malnourished 
________________________ C = Severely malnourished 
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Malnutrition Screening Tool (MST) 
 
Question       Score 
Have you lost weight without trying?    
No         0  
Unsure       2 
Yes        See below 
 
If yes, how much weight (kg) have you lost? 
1-5        1 
6-10        2 
11-15        3 
>15        4 
Unsure        2 
 
Have you been eating poorly because of a  
decreased appetite? 
No        0 
Yes        1 
 
Total score =  
_______________________________________________ 
Score of two or more = patient at risk of malnutrition 
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Mini Nutritional Assessment 
                                             MNA
®
 
 
Complete the screen by filling in the boxes with the appropriate numbers. Total the numbers for the final screening 
score. 
 
 
Last name:        First name:  
 
Sex:    Age:   Weight, kg:   Height, cm:  Date:  
 
Screening  
 
A Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing or  
swallowing difficulties?  
0 = severe decrease in food intake  
1 = moderate decrease in food intake  
2 = no decrease in food intake  
 
B Weight loss during the last 3 months  
0 = weight loss greater than 3 kg (6.6 lbs)  
1 = does not know  
2 = weight loss between 1 and 3 kg (2.2 and 6.6 lbs)  
3 = no weight loss  
 
C Mobility  
0 = bed or chair bound  
1 = able to get out of bed / chair but does not go out  
2 = goes out  
 
D Has suffered psychological stress or acute disease in the past 3 months?  
0 = yes 2 = no  
 
E Neuropsychological problems  
0 = severe dementia or depression  
1 = mild dementia  
2 = no psychological problems  
 
F1 Body Mass Index (BMI) (weight in kg) / (height in m2)  
0 = BMI less than 19  
1 = BMI 19 to less than 21  
2 = BMI 21 to less than 23  
3 = BMI 23 or greater  
 
IF BMI IS NOT AVAILABLE, REPLACE QUESTION F1 WITH QUESTION F2. 
DO NOT ANSWER QUESTION F2 IF QUESTION F1 IS ALREADY COMPLETED. 
 
 
F2 Calf circumference (CC) in cm  
0 = CC less than 31  
3 = CC 31 or greater  
 
 
Screening score  
(max. 14 points)  
 
12-14 points:  Normal nutritional status  
8-11 points:  At risk of malnutrition  
0-7 points:  Malnourished 
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Glasgow Prognostic Score (GPS) 
 
C-Reactive Protein >10mg/L score = 1 
C-Reactive Protein <10mg/L score = 0 
 
Albumin <35g/L score = 1 
Albumin >35g/L score = 0 
 
Total score =  
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The Prognostic Inflammatory Nutritional Index (PINI) 
 
PINI = [alpha 1-acid glycoprotein (AAG) x C-reactive protein (CRP)] divided by 
[albumin x prealbumin])  
 
The prognostic value of the score is as follows: >30 = life risk, 21-30 = high risk, 11-
20 = medium risk, 1-10 = low risk and <1 = minimal risk; normal, healthy individual 
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FAACT (Version 4) 
Below is a list of statements that other people with your illness have said are important. By 
circling one (1) number per line, please indicated how true each statement has been for you 
during the past 7 days. 
______________________________________________________________________ 
 
PHYSICAL WELL-BEING    Not A little Some- Quite Very 
       at all    bit what  a bit much 
 
GP1 I have a lack of energy......................................   0    1   2    3    4 
GP2 I have nausea.....................................................   0    1   2    3    4 
GP3  Because of my physical condition, I have trouble 
 meeting the needs of my family........................   0    1   2     3    4 
GP4 I have pain.........................................................   0    1   2    3    4 
GP5 I feel bothered by side effects of treatment.......   0     1   2    3    4 
GP6 I feel ill..............................................................   0    1   2    3    4 
GP7 I am forced to spend time in bed.......................   0    1   2    3    4 
 
 SOCIAL/FAMILY WELL-BEING   Not A little Some- Quite Very 
       at all    bit what  a bit much 
GS1 I feel close to my friends....................................   0    1   2    3    4 
GS2 I get emotional support from my family............   0    1   2    3    4 
GS3  I get support from my friends............................   0    1   2     3    4 
GS4 My family has accepted my illness....................   0    1   2    3    4 
GS5 I am satisfied with family communication about 
my illness..........................................................   0     1   2    3    4 
GS6 I feel close to my partner (or the person who is  
my main support)...............................................   0    1   2    3    4 
 
Q1 Regardless of your current level of sexual activity, 
 please answer the following question. If you prefer 
 QRWWRDQVZHULWSOHDVHFKHFNWKLVER[ rDQGJRWR  
 the next section. 
 
GS7  I am happy with my sex life.............................   0    1   2     3    4 
 
 
 
 
EMOTIONAL WELL-BEING     Not A little Some- Quite Very 
       at all    bit what  a bit much 
 
GE1 I feel sad............................................................   0    1   2    3    4 
GE2 I am satisfied with how I am coping with my  
illness................................................................   0    1   2    3    4 
GE3  I am losing hope with the fight against my  
illness .................................................................    0    1   2     3    4 
GE4 I feel nervous.....................................................     0    1   2    3    4 
GE5 I worry about dying...........................................   0     1   2    3    4 
GE6 I worry that my condition will get worse...........   0    1   2    3    4 
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FUNCTIONAL WELL-BEING    Not A little Some- Quite Very 
       at all    bit what  a bit much 
 
GF1 I am unable to work (include work at home)......   0    1   2    3    4 
GF2 My work (include work at home) is fulfilling.....   0    1   2    3    4 
GF3  I am able to enjoy life.........................................    0    1   2     3    4 
GF4 I have accepted my illness.................................     0    1   2    3    4 
GF5 I am sleeping well..............................................   0     1   2    3    4 
GF6 I am enjoying the things I usually do for fun......   0    1   2    3    4 
GF7 I am content with the quality of my life right now 0    1   2    3    4 
 
 
 
 
 
 
 
ADDITIONAL CONCERNS    Not A little Some- Quite Very 
       at all    bit what  a bit much 
 
C6 I have a good appetite........................................   0    1   2    3    4 
ACT1 The amount I eat is sufficient to meet my needs.   0    1   2    3    4 
ACT 2 I am worried about my weight............................    0    1   2     3    4 
ACT 3 Most food tastes unpleasant to me.....................     0    1   2    3    4 
ACT 4 I am concerned about how thin I look................   0     1   2    3    4 
ACT 6 My interest in food drops as soon as I start to eat   0    1   2    3    4 
ACT7  ,KDYHGLIILFXOW\HDWLQJULFKRUµKHDY\¶IRRGV    1   2    3    4 
ACT9 My family and friends are pressuring me to eat...   0    1   2    3    4 
O2 I have been vomiting............................................   0    1   2    3    4 
ACT10 When I eat, I seem to get full quickly..................   0    1   2    3    4 
ACT11 I have pain in my stomach area............................   0    1   2    3    4 
ACT13 My general health is improving...........................   0    1   2    3    4 
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Predicting weight loss in people with cancer: Development of a 
screening tool  (Phase I) 
Patient Information Sheet 
Please read this information carefully and feel free to ask any questions or to request 
further information. 
 
Investigators: Vanessa Siddall (Research Dietitian) 
       Dr. Andrew Wilcock (Reader/Consultant in Palliative Medicine) 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please read the following information carefully and discuss it with others if 
you wish.  Ask us if there is anything that is not clear or if you would like more 
information.  You should take time, at least 24 hours, to decide whether or not you 
wish to take part.  Thank you for reading this. 
 
What is the purpose of the study? 
Many people with cancer will experience a reduced appetite and weight loss. This is 
associated with symptoms of muscle weakness, fatigue and altered mood, which 
can interfere with activities of daily living. These symptoms can be difficult to treat 
but we know that providing advice about food and diet to people as early as 
possible can help.   
This study will look at the development of a questionnaire which can be used to 
identify those people who are most at risk of losing weight.  
 
Why have I been invited to participate? 
You have been chosen because you are attending a radiotherapy department for 
treatment for cancer. 
 
Do I have to take part? 
You are under no obligation at all to take part in this study. It is up to you to decide 
whether or not you take part. If you do decide to take part you will be given this 
information sheet to keep and will be asked to sign a consent form, which you will 
be given a copy of. If you decide to take part, you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw at any time, or a decision 
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not to take part, will not affect the standard of care you receive either at home or in 
hospital. 
 
What will happen to me if I take part? 
The study involves completing a short questionnaire about appetite and symptoms. 
Completing the questionnaire should take about 5 minutes. You need to fill in the 
questionnaire on two separate occasions one week apart. This can be done during 
your visits to the radiotherapy department. No additional visits to the hospital will be 
necessary.  
 
What are the side effects of taking part? 
There are no side effects from taking part. 
 
What are the possible disadvantages and risks of taking part? 
We do not believe that there are any disadvantages of taking part other than 
providing approximately10 minutes of your time. 
 
What are the possible benefits of taking part? 
There are no direct benefits to you by taking part in this study but by taking part you 
are helping to develop our knowledge of the best ways of improving services given to 
people with cancer. 
 
What if something goes wrong? 
If taking part in this research harms you, there are no special compensation 
DUUDQJHPHQWV ,I \RX DUH KDUPHG GXH WR VRPHRQH¶V QHJOLJHQFH \RX PD\ KDYH
grounds for legal action but as in other cases in civil law you would need to employ 
a lawyer and pay for their services in the usual way. Regardless of this, if you wish 
to complain about any aspect of the way you have been approached or treated 
during the course of this study, you may wish to cRQWDFWWKH7UXVW¶V3DWLHQW$GYLFH
and Liaison Service (PALS), Hospital Headquarters, Nottingham City Hospital, 
FREEPOST MID21426, Nottingham, NG5 1BR. Tel: 0800 0521195. 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the study will be kept strictly 
confidential. With your consent, we would inform your GP of your participation. 
The information that you provide will be entered onto a database controlled by the 
research team.  The data will be entered onto the database in an anonymised form 
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(e.g. you will be identified by a number not by your name).  Access to the database 
containing the data is restricted to authorised personnel and is password protected. 
 
What will happen to the results of the research study? 
This study is being undertaken as part of a PhD educational qualification and the 
study results will be used to write a report as part of this qualification. Results from 
the study will be published in medical journals and presented at national and 
international research meetings.  You will not be referred to by name or be identified 
in any presentation or report of the study results. If you withdraw your consent to 
participate in the study, no new data will be collected or processed.  However, you 
may be asked to agree to some of the data already collected about you being used. 
During this study, you have the right to access the data relating to your taking part in 
the study, and, in the event of any inaccuracies about you being recorded in the 
study data, you have the right to request that such data be corrected. Please talk to 
the research team about this. 
  
Who is organising and funding the research? 
The study is co-ordinated by Ms.Vanessa Siddall and Dr Wilcock at the University of 
Nottingham. It is funded by The National Cancer Research Institute. 
All research in the NHS is looked at by an independent group of people called a 
Research Ethics Committee, to protect your safety, rights, welfare and dignity. This 
study has been reviewed and given a favourable opinion by the Derbyshire 
Research Ethics Committee. 
 
Contact for further information 
Please keep this sheet to think about the study and to discuss with your family or 
friends. We will happily see you and your relatives or friends together to answer any 
questions about the study. 
Whilst on the study, if you (or your own family doctor) have any additional questions, 
please contact one of the research team on 0115 962 7619.    
Ms. Vanessa Siddall          - Research Dietitian 
Dr Andrew Wilcock    - Reader/Consultant  
Sr Cathann Manderson  - Research Sister  
Dr Dough Hooper   - Research Specialist Registrar 
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Study Number: 07/H0401/92 
Patient study identification number: 
 
 
 
Consent Form 
 
Title of Project:   Predicting weight loss in people with cancer: Development of a 
  screening tool. (Phase I) 
 
Investigators: Dr Andrew Wilcock (Reader/Consultant in Palliative Medicine and 
Oncology) 
    Ms Vanessa Siddall (Research Dietitian) 
   
         
        The patient should complete the whole of this sheet himself/herself. 
 
 
Please initial box 
 
1. I confirm that I have read and understood the patient information sheet version 1.2 
dated July 2007 for the above study and have had the opportunity to ask questions.              
 
2. I understand that my participation is voluntary and that I am free to withdraw at any  
 time, without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible  
individuals or the research team where it is relevant to my taking part in this research.  
I give permission for these individuals to have access to my records. 
 
4. I agree to my G.P being informed about my participation in the study. 
 
5. I agree to take part in the above study. 
 
 
  
 
______________________ ________________ ____________________ 
Name of patient Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(If different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher Date Signature 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes. 
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Eastern Cooperative Oncology Group (ECOG) 
Performance status 
 
 
Grade  Scale 
 
0            Fully active, able to carry out all predisease activity without restriction. 
 
1 Restricted in physically strenuous activity, but not ambulatory and able 
to carry out work of a light or sedentary nature eg. light housework, 
office work. 
 
2 Ambulatory and capable of all self-care, but unable to carry out work 
activities. Up and about more than 50% of waking hours. 
 
3 Capable of only limited self-care, confined to bed or chair for more than 50% 
of waking hours. 
 
4 Completely disabled. Cannot carry out any self-care. Totally confined to bed 
or chair. 
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 Dear 
 
In 2006 the National Institute for Health and Clinical Excellence (NICE),  
an organisation responsible for providing national guidance on the  
prevention and treatment of health problems, made a recommendation 
 that all hospital outpatients should be screened to identify those at risk  
of malnutrition and weight loss. 
 
Here at Nottingham University Hospitals NHS Trust we would like to put  
into practice the screening process in our outpatient clinics. The screening 
 process involves having your height and weight measured by a member  
of staff and telling us if for any reason you have not been able to eat or drink 
 for the last 5 days. If you do not wish to be included in the screening process 
 please let a member of the clinic staff know. 
 
As well as putting into practice the screening process our hospital research 
 team is looking for people to take part in a study who have not lost a large 
 amount of weight over the past three to six months.  
 
If you are eligible and interested in taking part a member of our research 
 team will speak to you at your clinic visit to discuss the study. 
 
Yours faithfully, 
 
 
 
 
 
 
           Consultant Physician 
Appendix 19: Phase II/III participant information sheet 
 
231 
 
 
 
 
Predicting weight loss in people with cancer: 
Development of a screening tool 
 
Patient Information Sheet 
 
Please read this information carefully and feel free to ask any questions or to request further 
information. 
 
Investigators: Vanessa Siddall(Research Dietitian) 
    Dr Andrew Wilcock (Reader/Consultant in Palliative    
    Medicine) 
   
You are being invited to take part in a research study. Before you decide whether to 
take part it is important for you to understand why the research is being done and 
what it will involve.  Please read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would 
like more information.  You should take time reading this and deciding whether or 
not you would wish to take part. If you do not feel able to make a decision today but 
over the next 2 to 3 days decide that you would like to take part in the study please 
contact a member of the research team on the telephone number below so that it 
can be arranged. Thank you for reading this. 
 
What is the purpose of the study? 
Many people with cancer will experience a reduced appetite and weight loss. This is 
associated with symptoms of muscle weakness, tiredness and altered mood, which 
can interfere with activities of daily living. These symptoms can be difficult to treat 
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but we know that providing advice about food and diet to people as early as possible 
can help.   
This study will look at how certain measurements and a questionnaire can be used 
to identify those people who are most at risk of losing weight.  It will also ask people 
with cancer and their partners or carers about their experience of losing weight and 
any information that they have received about food and diet. From this we may be 
able to decide on the best way to help people with cancer maintain their weight. 
 
Why have I been invited to participate? 
You have been chosen because of your diagnosis of cancer and your weight has not 
changed by a significant amount.  
 
Do I have to take part? 
You are under no obligation at all to take part in this study. It is up to you to decide 
whether or not you take part. If you do decide to take part you will be given this 
information sheet to keep and will be asked to sign a consent form, which you will be 
given a copy of. If you decide to take part, you are still free to withdraw at any time 
and without giving a reason. A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you receive either at home or in 
hospital. 
 
What will happen to me if I take part? 
The study involves completing a short questionnaire about appetite and symptoms. 
Completing the questionnaire should take about 5 minutes.  We would also like you 
to have a blood sample taken (2 teaspoons of blood). If you have already had a 
blood test today, with your permission, we will use this sample. Alternatively, if you 
feel able, we can arrange for a blood sample to be taken from you at the clinic visit 
today. 
A member of the research team will write down information about your diagnosis, 
treatment, weight and any previous weight loss and activity level. 
In three months time you will need to be weighed again.  If you are due to come to 
the clinic in three months time a member of the research team or clinic staff will 
record your weight there. If you do not have an out patient appointment in three 
months time a member of the research team can visit you at home. Alternatively you 
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can choose to attend and be weighed at Hayward House at Nottingham City 
Hospital which ever is most convenient for you.  
At the end of the study we will interview up to 20 of the people that have lost weight 
over the three month period.  You may be invited to be interviewed and if you have a 
partner or carer they will also be asked if they want to take part. It will involve 
answering questions and talking to a researcher about your appetite, weight and any 
advice and support that you have received about food and diet.  You will be given 
the option to be interviewed at home or at the hospital. The interview should not last 
longer than one hour. To help us analyse the results the session will be tape 
recorded.  
In the event of an additional hospital visit being required for either parts of the study, 
reasonable travel expenses will be reimbursed. 
If you would like to take part in the first part of the study but do not wish to be 
interviewed please tell us. 
 
What are the side effects of taking part? 
There are no side effects from taking part. For some people talking about their 
diagnosis and treatment may raise some emotional issues. 
 
What are the possible disadvantages and risks of taking part? 
We do not believe that there are any disadvantages of taking part other than 
providing approximately 10 to 20 minutes of your time today and approximately 10 
minutes in three months time.  
If you are interviewed this would take up to an hour of your time.  
 
What are the possible benefits of taking part? 
There are no direct benefits to you by taking part in this study but by taking part you 
are helping us to develop our knowledge of the best ways of improving services given 
to people with cancer. 
 
 
What if something goes wrong? 
If taking part in this research harms you, there are no special compensation arrangements. 
,I\RXDUHKDUPHGGXHWRVRPHRQH¶VQHJOLJHQFH\RXPD\KDYHJURXQGVIRUOHJDODFWLRQbut 
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as in other cases in civil law you would need to employ a lawyer and pay for their services in 
the usual way. Regardless of this, if you wish to complain about any aspect of the way you 
have been approached or treated during the course of this study, you may wish to contact 
WKH7UXVW¶V3DWLHQW$GYLFHDQG/LDLVRQ6HUYLFH3$/6+RVSLWDO+HDGTXDUWHUV1RWWLQJKDP
City Hospital, FREEPOST MID21426, Nottingham, NG5 1BR. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the study will be kept strictly 
confidential. With your consent, we would inform your GP of your participation. 
The information that you provide will be entered onto a database controlled by the 
research team.  The data will be entered onto the database in an anonymised form 
(e.g. you will be identified by a number not by your name).  Access to the database 
containing the data is restricted to authorised personnel and is password protected. 
 
What will happen to the results of the research study? 
This study is being undertaken as part of a PhD educational qualification and the 
study results will be used to write a report as part of this qualification. 
 
Results from the study will be published in medical journals and presented at 
national and international research meetings.  You will not be referred to by name or 
be identified in any presentation or report of the study results. If you withdraw your 
consent to participate in the study, no new data will be collected or processed.  
However, you may be asked to agree to some of the data already collected about 
you being used. 
 
During this study, you have the right to access the data relating to your taking part in 
the study, and, in the event of any inaccuracies about you being recorded in the 
study data, you have the right to request that such data be corrected. Please talk to 
the research team about this. 
  
Who is organising and funding the research? 
The study is co-ordinated by Vanessa Siddall and Dr Wilcock at the University of 
Nottingham. It is funded by The National Cancer Research Institute. 
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All research in the NHS is looked at by an independent group of people called a Research 
Ethics Committee, to protect your safety, rights, welfare and dignity. This study has been 
reviewed and given a favourable opinion by the Derbyshire Research Ethics Committee. 
 
Contact for further information 
Please keep this sheet to think about the study and to discuss with your family or 
friends. We will happily see you and your relatives or friends together to answer any 
questions about the study.  
Whilst on the study, if you have any additional questions, please contact one of the 
research team on 0115 962 7619. 
    
Vanessa Siddall          - Research Dietitian 
Dr Andrew Wilcock    - Reader/Consultant  
Sr Cathann Manderson  - Research Sister  
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Study Number: 07/H0401/92 
Consent Form 
 
Title of Project:  Predicting weight loss in people with cancer: Development of a 
screening tool. 
 
 Investigators: Dr Andrew Wilcock (Reader/Consultant in Palliative Medicine and 
Oncology) 
and Ms Vanessa Siddall (Research Dietitian) 
   
      
The patient should complete the whole of this sheet 
himself/herself. 
Please initial each box. 
 
1. I confirm that I have read and understood the patient information sheet version 1.3 
dated February 2008 for the above study and have had the opportunity to ask questions.              
 
2. I understand that my participation is voluntary and that I am free to withdraw at any  
 time, without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible  
individuals or the research team where it is relevant to my taking part in this research.  
I give permission for these individuals to have access to my records. 
 
4. I agree to my G.P being informed about my participation in the study. 
 
5. I agree to take part in the above study, including if required being interviewed.   
    OR 
 I agree to take part in the first part of the study but do not wish to be interviewed. 
 
 
          ______________________ ________________ ____________________ 
          Name of patient    Date Signature 
 
 
         _______________________ ________________ ____________________ 
       Name of Person taking consent    Date Signature 
        (If different from researcher) 
 
 
        _________________________ ________________ ____________________ 
         Researcher    Date Signature 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes.
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Predicting Weight Loss Study 
Screening for Malnutrition using the Malnutrition Universal Screening Tool (MUST) 
 
 
 
 
Date:            /         /    
 
 
 
Height:               metres 
 
Weight:  kilograms  Body mass Index (BMI):                        kg/m2 
        
 
Total MUST score  = 
______________________________________________________________________ 
 
Interpretation of MUST score 
0 1 2 or more 
Low Risk Medium Risk High Risk 
Routine Clinical Care Observe Treat* 
 
Repeat screening 
Hospital ± weekly 
Care Homes ± monthly 
Community ± annually for special 
groups e.g >75 years 
 
Document dietary intake for three 
days if in-patient of care in care 
home 
 
If improved or adequate intake ± 
little clinical concern; if no 
improvement ± clinical concern 
follow local policy 
 
Repeat screening. Hospital ± 
weekly. Care home ± at least 
monthly. Community ± at least 
every 2-3 months 
 
 
 
Refer to dietitian, Nutritional 
Support Team or implement local 
policy 
 
Improve and increase overall 
nutritional intake - All patients 
have been given a dietary 
LQIRUPDWLRQERRNOHWµ*HWWLQJDORW
out of a OLWWOH¶ 
 
Monitor and review care plan 
Hospital ± weekly 
Care Home ± monthly 
Community ± monthly 
 
*Unless detrimental or no benefit is 
expected from nutritional support 
 
 
 
1.Body Mass Index 
BMI MUST score  
> 20 (>30 obese) 0  
18.5 ± 20 1  
<18.5 2  
2.Unplanned weight loss in past 3-6 months 
% Weight Loss MUST score  
<5 0  
5-10 1  
>10 2  
3. Acute disease effect score MUST score  
If patient is acutely ill and there has been or is likely to be no nutritional intake for> 5 days 2  
Affix patient sticker 
All risk categories: 
Treat underlying condition and provide help and advice on food 
choices, eating and drinking when necessary. 
 
Record malnutrition risk category 
 Obesity: Record presence of obesity. For 
those with underlying conditions, these are 
generally controlled before the treatment of 
obesity 
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GETTING A LITTLE FROM A LOT  
  
 
Introduction 
  
There may be times when you do not feel like  
eating very much. It is important that you eat to  
provide your body with enough energy, protein,  
vitamins and minerals. This will help with your  
recovery, maintain your weight and regain your strength. 
  
If you are eating less, it is important to eat as  
nourishing a diet as possible. 
  
This booklet will give you ideas for food and drinks to have when 
your appetite is small and suggests ways to increase the amount 
of nourishment in your meals. 
 
 
General Hints 
  
 Eat small, frequent meals every 2-3 hours. This is often easier 
 than 3 main meals and can be just as nourishing. 
  
 Drink nourishing fluids, e.g. milky drinks and fruit juice, instead  
 of tea, coffee and water. 
  
 Eat when you fancy and eat any time you are hungry. 
  
 Try to avoid cooking smells if these are putting you off eating. 
  
 Avoid drinking a lot of liquid with your meals as it may fill you up 
and put you off your food. 
  
 Do not rush meals and eat slowly if you need to. 
  
 0DNHWKHPRVWRIµJRRGGD\V¶DQGSUHSDUHIRRGVZKLFKFDQEH 
XVHGZKHQ\RXGRQ¶WIHHOOLNHFRRNLQJ 
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Try to include the following:- 
  
 Use at least one pint of milk every day. Full cream milk is much 
higher in energy and protein than skimmed or semi-skimmed. 
  
 You can enrich milk by adding 3 - 4  tablespoons of dried milk 
power into a jug of milk and stir it in well. This can be used in  
place of ordinary milk throughout the day. 
  
  
  
  
  
  
 Dairy foods can also be good sources of protein and energy, so  
try to include two servings a day. This includes thick and creamy 
yogurts or fromage frais, 50g hard  cheese or soft cheese spread, 
1 bowl of milk pudding or 2 - 3 scoops of ice cream. 
  
  
  Aim to have 2 servings every day of meat, fish, chicken, eggs, 
beans or baked beans, nuts or peanut butter as these provide  
protein. 
  
  
  
  
  
 Try to drink  nourishing fluids between meals. Add hot milk to  
malted drinks like Horlicks or Ovaltine, Cocoa or drinking  
chocolate, instant or packet soup, yeast or beef extract. 
  
  
  
  
  
  
 
Add cold milk to blackcurrant juice, milk shake flavourings 
(powder or syrup), yogurt, or mashed banana or ice cream. You 
can use a blender to make milk shakes or try bottles or cartons of 
ready made milk shake 
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Ways to enrich your food 
  
To make the most of your food, you should make sure that it 
contains lots of energy. The following foods can be useful. 
  
 Butter and margarine. Use these generously on toast, add to  
vegetables and potatoes. 
  
 Sugar, glucose syrup, treacle and honey can be added to foods  
to give extra energy and add sweetness but remember that they 
 are not suitable if you have diabetes. 
  
 Add salad cream, mayonnaise or dips to salads or sandwiches  
or try with breadsticks,  crisps or raw vegetables as a  
snack. 
  
Milk 
  
 Use full cream or enriched milk to make up packet soups,  
condensed soup or soup in a cup. 
  
 Use milk instead of water to make up jelly and instant desserts.  
You could also use evaporated or condensed milk. 
  
 
Cream 
  
 Add a swirl to stewed, tinned or fresh fruit or to any kind of  
pudding. 
  
 Can be added into soups to give extra nourishment. 
  
 Add into sauces, breakfast cereals or hot drinks. 
  
Cheese 
   
 Grate cheese and add to baked beans, eggs, soups, sauces,  
fish, macaroni cheese and vegetables. 
  
 Add to jacket potatoes and mix into mashed potatoes. 
  
 Try hard or soft cheese with crackers as a snack. 
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 Full fat cream cheese can be spread on bagels, scones, cake 
 e.g. fruit, carrot or in sandwiches, bread, toast or as a dip. 
  
Eggs 
  
 Cook any way you wish for an alternative to meat or fish. 
  Add cheese to egg dishes for extra nourishment. 
  
 Egg custard can be made with enriched milk or bought, and 
 makes a good pudding or snack. 
  
Meat or Fish 
  
 If meat is too tough, try a slow cooking method e.g. casseroling 
 or use mince meat. 
  
 Try ready minced turkey, pork or lamb for a change from beef, or  
use corned beef in cooking.  
  
 Try flaking fish with parsley, cream or cheese sauce, made with  
enriched milk. 
  
 Fried fish is very high in energy, if you can tolerate it. 
  
 Tinned meat and fish can be more convenient and easier to  
prepare. 
  
Soups 
  
 Try adding minced or liquidised  meat to meat soup. 
  
 Add cheese, cream or enriched milk to creamy soups. 
  
Yogurt and Fromage Frais 
  
 A good source of protein. Choose thick and creamy, greek style  
or whole milk varieties for more energy. 
  
 Can be used to make drinks and milkshakes. 
  
Breakfast Cereals 
  
 Make a good snack at any time of the day. 
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 Mix with full cream, enriched, condensed or evaporated milk or  
warm milk for a softer texture. 
  
 Make porridge with enriched milk or add cream. 
  
 Sweeten breakfast cereals and porridge with sugar, glucose,  
honey, syrup, jam (if you are not diabetic). 
  
Nourishing Meal Ideas 
  
 Chilled or frozen meals can be used if they are more convenient  
and easier for you to prepare e.g. shepherds pie, lasagne, fish  
pie. You could also use boil in the bag fish with a creamy sauce. 
  
 Jacket potatoes with lots of butter and a filling of baked beans,  
cheese (cream or grated), fish or chicken with mayonnaise,  
coleslaw. 
  
 Omelettes or scrambled eggs with added ham and/or cheese. 
  
 Mince or stew with meat or chicken and plenty of gravy or sauce,  
served with potatoes boiled or mashed with butter, milk and/or  
cheese. 
  
 Tinned beans, spaghetti or ravioli on bread or toast with butter  
and cheese topping. 
  
 Soups with added minced meat, fish, cream or cheese. 
  
 Macaroni or cauliflower cheese. 
  
 Tinned or smoked fish with bread or toast and butter. 
 
  
 Corned beef hash.  
  
 Sandwiches or toasties filled with cold meat, tinned fish, hard or  
cream cheese, egg and mayonnaise, peanut butter. Add  salad 
cream and mayonnaise.  
 
 Oven ready fish or fish fingers with chips. 
  
 Sausages, bacon, egg with tomato or baked beans and bread  
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or toast with lots of butter. Try these as a meal or at breakfast if 
 you can manage it. 
  
 Meat or pork pies, sausage rolls, scotch eggs with bread and  
butter. 
Puddings and Snacks  
 If you cannot face a full meal, puddings and snacks can be eaten 
instead and can be just as nourishing. Try eating them between  
meals if you cannot manage them at meal times. It can be useful 
to keep tins or packets in stock to eat whenever you feel you can  
manage. 
  
 
Puddings 
  
 Tinned rice or milky puddings. 
  
 Tinned sponge puddings. 
  
 Packets of blancmange, instant whip, custard or jelly, made up  
with enriched milk or cream. 
  
 Trifle, cheesecake, mousse, egg custard, crème caramel can  
often be bought in individual portions and kept chilled in the  
refrigerator. 
  
 Tinned fresh or stewed fruit, with custard or cream. 
  
 Gateau, fruit, sponge or chocolate cake or cake slices eaten with  
topping of custard or cream. 
 
 Fruit crumble or fruit pie with cream or custard. 
  
 Yogurt, particularly thick and creamy, whole  milk or greek style 
or fromage frais can be eaten on their own or as a topping with 
many of the above puddings. 
  
 Add ice cream to any of the above puddings, or eat on its own. 
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Snacks 
  
 Crackers, bread, bread rolls or toast with hard or soft cheese,  
pate or peanut butter. 
  
 Toasted muffins, crumpets, pikelets, pancakes or teacakes with 
 butter and sweet toppings. 
  
 Nuts make a good, protein snack if you can manage them. 
 Cakes, biscuits, chocolate, crisps, pastries and pies can all  
provide extra energy.  
 Food Supplements 
  
 A range of nourishing, enriched drinks are available in a variety 
of sweet and savoury flavours.  They should ideally be taken  
between meals and should not be used in place of meals.  
Examples include Complan,  Buildup, Vita Food and Nourishment. 
  
 Dietary supplements are also available on prescription and are  
sometimes recommended for certain patients.   
Examples include Fortisip, Fortijuice, Enlive,Ensure, ProvideExtra, 
Calogen, Calshake, Maxi Jul and Polycal. 
  
The way these are taken can vary and they are designed to suit 
different needs.  Your doctor or dietitian will have discussed 
whether or not you need these supplements and if so, which type 
to choose and how often you should take them. 
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Here is an example menu to show how you could try to 
increase your intake:- 
  
Breakfast:  
Toast with extra butter/margarine²jam/honey/marmalade/lemon curd. 
Cereal with full fat milk, extra sugar/honey. 
Porridge made with enriched milk with honey/sugar. 
Coffee/tea with enriched milk, sugar/honey. 
Poached or scrambled eggs on toast. 
  
Mid Morning: 
Biscuits/crackers/nuts. 
Milky drink made with enriched milk. 
  
Lunch: 
Meat/fish/eggs with gravy/sauce made with enriched milk/cheese added. 
Mashed potatoes with extra butter/margarine/enriched 
Milk added.  Vegetables with butter/margarine added. 
  
Mid Afternoon: 
Milky drink made with enriched milk. 
Sponge pudding/cake/tinned fruit with cream/condensed milk/ice cream. 
Egg custard/rice pudding/thick & creamy yoghurt. 
  
Evening Meal: 
Soup with cream/meat/pulses added. 
Toast with lots of butter/baked beans & cheese/ or jacket  
potato/cream cheese. 
  
Bed Time: 
Milky drink with crumpets/toast/scones & butter. 
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            Please ask for: Research Team                  City Hospital Campus 
 
 
 
Hayward House Specialist Palliative Care Cancer Unit  
Hucknall Road  
Nottingham 
NG5 1PB 
Direct Dial: 0115 9627619 
Tel: 0115 969 1169 ext 46842 
Fax: 0115 9627619 
 
 
 
 
Title of Project:  Predicting weight loss in people with cancer: 
Development 
of a screening tool 
 
 Investigators: Ms Vanessa Siddall (Research Dietitian) 
   Dr Andrew Wilcock (Reader/Consultant 
in Palliative Medicine and Oncology) 
      
    
Re:  
 
 
 
 
Dear Dr  
 
I am writing to inform you that your patient has agreed to participate in a study 
currently being carried out at Hayward House, Nottingham City Hospital. The aim of 
the study is to develop a screening tool that will identify people with cancer who 
are at greatest risk of future weight loss. I have enclosed a copy of the patient 
information sheet for you to read. 
 
If you have any questions about the study please feel free to contact me on the 
number above.  
 
 
Yours sincerely, 
 
 
 
Ms Vanessa Siddall 
Research Dietitian 
 
 
 
 
 
 
Enc: Patient information shee
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Predicting weight loss in people with cancer: 
Development of a screening tool 
 
Volunteer Information Sheet 
Please read this information carefully and feel free to ask any questions or to request further information. 
 
Investigators: Vanessa Siddall (Research Dietitian) 
    Dr Andrew Wilcock (Reader/Consultant in Palliative 
     Medicine) 
  
You are being invited to take part in a research study. Before you decide whether to take part 
it is important for you to understand why the research is being done and what it will involve.  
Please read the following information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear or if you would like more information. You should take time, 
at least 24 hours, to decide whether or not you wish to take part.  Thank you for reading this. 
 
What is the purpose of the study? 
You have been invited to participate in this study as a partner or carer of someone who has 
cancer.  
Many people with cancer will experience a reduced appetite and weight loss. This is 
associated with symptoms of muscle weakness, tiredness and altered mood, which can 
interfere with activities of daily living. These symptoms can be difficult to treat but we know 
that providing advice about food and diet to people as early as possible can help.   
This study will ask people with cancer and their partners or carers about their experience of 
losing weight and any information that they have received about food and diet. From this we 
may be able to decide on the best way to help people with cancer maintain their weight. 
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Do I have to take part? 
You are under no obligation at all to take part in this study. It is up to you to decide whether or 
not you take part. If you do decide to take part you will be given this information sheet to keep 
and will be asked to sign a consent form, which you will be given a copy of. If you decide to 
take part, you are still free to withdraw at any time and without giving a reason.  
 
What will happen to me if I take part? 
Along with your partner or the person that you care for, the study will involve answering 
questions and talking to a researcher about their appetite, weight and any advice and support 
that you have received regarding food and diet.  You will be given the option to be interviewed 
at home or at the hospital. The interview should not last longer than one hour. To help us 
analyse the results the session will be tape recorded.  
In the event of an additional hospital visit being required reasonable travel expenses will be 
reimbursed. 
 
What are the side effects of taking part? 
There are no side effects from taking part. For some people talking about a diagnosis of 
cancer and its treatment may raise emotional issues. 
 
What are the possible disadvantages and risks of taking part? 
We do not believe that there are any disadvantages of taking part other than providing 
approximately one hour of your time. 
 
What are the possible benefits of taking part? 
There are no direct benefits to you by taking part in this study but by taking part you are 
helping us to develop our knowledge of the best ways of improving services given to people with 
cancer. 
What if something goes wrong? 
If taking part in this research harms you, there are no special compensation arrangements. If you are 
KDUPHGGXHWRVRPHRQH¶VQHJOLJHQFH\RXPD\KDYH grounds for legal action but as in other cases in 
civil law you would need to employ a lawyer and pay for their services in the usual way. Regardless of 
this, if you wish to complain about any aspect of the way you have been approached or treated during 
tKH FRXUVH RI WKLV VWXG\ \RX PD\ ZLVK WR FRQWDFW WKH 7UXVW¶V 3DWLHQW $GYLFH DQG /LDLVRQ 6HUYLFH
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(PALS), Hospital Headquarters, Nottingham City Hospital, FREEPOST MID21426, Nottingham, NG5 
1BR. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the study will be kept strictly confidential.  
The information that you provide will be entered onto a database controlled by the research 
team.  The data will be entered onto the database in an anonymised form (e.g. you will be 
identified by a number not by your name).  Access to the database containing the data is 
restricted to authorised personnel and is password protected. 
 
What will happen to the results of the research study? 
This study is being undertaken as part of a PhD educational qualification and the study results 
will be used to write a report as part of this qualification. 
 
Results from the study will be published in medical journals and presented at national and 
international research meetings.  You will not be referred to by name or be identified in any 
presentation or report of the study results 
During this study, you have the right to access the data relating to your taking part in the 
study, and, in the event of any inaccuracies about you being recorded in the study data, you 
have the right to request that such data be corrected. Please talk to the research team about 
this. 
Who is organising and funding the research? 
The study is co-ordinated by Vanessa Siddall and Dr Wilcock at the University of Nottingham. 
It is funded by The National Cancer Research Institute. 
All research in the NHS is looked at by an independent group of people called a Research 
Ethics Committee, to protect your safety, rights, welfare and dignity. This study has been 
reviewed and given a favourable opinion by the Derbyshire Research Ethics Committee. 
 
Contact for further information 
Please keep this sheet to think about the study and to discuss with your family or friends. We 
will happily see you and your relatives or friends together to answer any questions about the 
study.  
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Whilst on the study, if you have any additional questions, please contact one of the research 
team on 0115 962 7619. 
    
Vanessa Siddall          - Research Dietitian 
Dr Andrew Wilcock    - Reader/Consultant  
Sr Cathann Manderson  - Research Sister  
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         Study Number: 07/H0401/92 
 
Consent Form 
 
Title of Project:  Predicting weight loss in people with cancer: Development of a 
screening tool. 
 
 Investigators: Dr Andrew Wilcock (Reader/Consultant in Palliative Medicine and Oncology) 
and Ms Vanessa Siddall (Research Dietitian) 
   
         
The volunteer should complete the whole of this sheet 
himself/herself. 
 
 
Please initial each box. 
 
1. I confirm that I have read and understood the volunteer information sheet version 1.1 
dated February 2008 for the above study and have had the opportunity to ask questions.              
 
2. I understand that my participation is voluntary and that I am free to withdraw at any  
 time, without giving any reason, without my legal rights being affected. 
 
 
3. I agree to take part in the above study. 
 
 
 
 
 
         ______________________ ________________ ____________________ 
         Name of volunteer Date Signature 
 
 
         ______________________ ________________ ____________________ 
      Name of Person taking consent Date Signature 
       (If different from researcher) 
 
 
       ________________________ ________________ ____________________ 
         Researcher Date Signature 
 
 
 
         1 for volunteer; 1 for researcher. 
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Predicting Weight Loss in People with Cancer 
 
Interview Schedule 
 
Introduction 
Explanation about proceedings 
Consent 
 
General discussion about treatment received since diagnosis 
General discussion about weight history starting just before diagnosis. 
 
1. Have you noticed any changes in your weight recently? 
a. What was the first thing that you noticed? 
b. Are there any other things that you have noticed? 
 
 
2. Have you experienced any symptoms that you associate with losing weight such as: poor 
appetite, taste changes, feeling full quickly, sickness, bowel problems, pain, low mood, 
reduced energy levels. 
 
 
3. What has your eating pattern been like over the last few weeks? 
24 hour recall 
 
4. Have you received any advice about what to eat and drink either over the last few weeks or 
since diagnosis? 
a. What was the advice? 
b. Did you find the advice easy to follow? 
i. If not why not? 
c. When were you given the advice? 
d. Who gave the advice? 
 
 
5. Is there anything that you think would have been helpful to you? 
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  Study Protocol 
Predicting weight loss in people with cancer:  
Development of a screening tool. 
 
Background Information 
Cachexia is a complex multifactoral syndrome the main characteristics of which are malnutrition and 
weight loss, anorexia and systemic inflammation. Research suggests that cachexia is the cause of at 
least 20% of deaths in people with cancer.1 In addition, the prevalence of malnutrition, weight loss and 
anorexia in this group is up to 85% dependent on the site and stage of the disease. 2 3 Those who lose 
weight are affected both physically and psychologically, experiencing poorer quality of life, treatment 
outcomes and increased adverse symptoms.4-7 
If treatment for cachexia and malnutrition is to be successful early detection and intervention is essential. 
8  Despite the significance of nutrition in improving outcomes and maintaining the quality of life in people 
with cancer, this is an area in which there is little research and evidence on which to base practice. 
Resources available to offer nutritional support to those in need are also extremely limited.  
Many nutrition related screening tools have been developed but few have been validated specifically 
with people who have cancer and none appear to cover the range of factors associated with cancer-
related cachexia anorexia syndrome.  
This study aims to assess the performance, individually and in combination of the following measures: 
(i) the Appetite and Symptom Questionnaire (ASQ); 
(ii) the Malnutrition Universal Screening Tool (MUST); 
(iii) C-Reactive Protein (CRP) level; 
in predicting percentage weight loss over three months. Taken together these three measures 
encompass all elements of cancer-related anorexia cachexia: appetite and symptoms affecting food 
intake (ASQ); weight loss and malnutrition (MUST) and systemic inflammation (CRP).  
By identifying the best combination of these measures (and the exploration of the performance of shorter 
versions of [i] and [ii]) it is anticipated that a validated simple and practical screening tool will be 
developed to identify patients who are at risk of future weight loss. This will allow nutritional treatment to 
be prioritised and commenced where needed before the downward spiral of cachexia and malnutrition 
begins. 
 
Measures 
 
The 12 item Appetite and Symptom Questionnaire (ASQ)  
The Council on Nutrition Appetite Questionnaire (CNAQ) is an established screening tool used to assess 
appetite. It is an eight-item tool, relating to appetite and symptoms, developed and validated within the 
general population in the U.S.A..9 In 2005/2006 initial content validity testing and modification of the 
CNAQ for people with cancer was performed in Nottingham (Porock, Wilcock and Siddall in preparation). 
Using responses from service users, caregivers and health care professionals, the CNAQ has now been 
modified to a 12 item Appetite and Symptom Questionnaire (ASQ) which focuses on the issues specific 
to people with cancer and receiving cancer treatment as well as the principal symptoms affecting 
appetite. It is the items included in the ASQ that we will be testing and using to develop the screening 
tool. 
 
The three step Malnutrition Universal Screening Tool (MUST)  
NICE guidelines(2006) recommend that all patients should be screened for malnutrition using a 
validated tool such as the MUST.10 The MUST, can identify those patients who have already lost a 
significant amount of weight but is not designed to predict future weight loss meaning nutritional 
treatment may be offered too late and therefore be less effective. Furthermore, previous research 
highlights that the MUST may not be specific enough to be used in the cancer population.11 
 
 
 
C-Reactive Protein (CRP)  
C-Reactive Protein (CRP) is a biochemical marker of systemic inflammation. It is an acute phase plasma 
protein which, during periods of systemic inflammation, as seen in the cachexia syndrome, levels 
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EHFRPHUDLVHG(OHYDWHGSODVPDFRQFHQWUDWLRQVRI&53PJ/KDYHEHHQDVVRFLDWHGZLWKDGYHUVH
function and prognosis in patients with cancer.12 13 
 
Overall aim of the study 
To identify people with cancer who are at greatest risk of future weight loss by the development of a 
simple and practical screening tool. 
 
Expected outcomes 
1. An estimate of the reliability of the Appetite and Symptom Questionnaire (phase I). 
2. A screening tool based on the ability of the optimal combination of items from the three measures 
(ASQ, MUST, CRP) to predict clinically significant weight loss over three months (phase II). 
3. Estimates of the sensitivity and specificity at various cut-points of the developed screening tool in 
predicting clinically significant weight loss (> 10% weight loss or between 5% and 10% weight loss with a 
BMI <20kgm2) over three months (phase II). 
4.Exploration of the experiences of people with lung or gastrointestinal cancer and their carers regarding 
the initial signs of weight loss (phase III). 
 
Methodology 
 
There will be three phases to the study: 
 
Phase I - Reliability study 
A short-term longitudinal study, with two test-points one week apart will be used to meet expected 
outcome 1. 
 
Phase II ± Development of the screening tool  
A longitudinal observational study with two test-points, three months apart will be used to meet 
outcomes 2 and 3. 
 
Phase III - Cross examination of the screening tool 
A qualitative exploratory study involving face to face semi-structured interviews. 
 
Phase I 
 
Patient inclusion criteria 
(i)Adults, over 18 years of age, with a confirmed diagnosis of cancer, receiving radiotherapy. 
 
Patient exclusion criteria 
(i) Receiving radiotherapy to the head, neck or upper gastrointestinal tract area. 
(ii) Any condition impairing their ability to swallow. 
(ii) Unable to provide written informed consent and therefore complete the questionnaire due to cognitive 
impairment.  
 
Patient recruitment and consent  
Patients with a diagnosis of cancer (n=35) who are receiving curative radiotherapy at Nottingham City 
Hospital will be recruited to complete the ASQ on two occasions, one week apart. To test reliability of a 
nutrition screening tool subjects should have a stable weight and appetite and have minimal external 
factors which are likely to influence these points. The group of patients detailed above have been 
chosen as they: 
 have a diagnosis of cancer as do the participants in Phase II of the study, 
 
 are likely to be clinically stable over the duration of one week, i.e. not at high risk of disease or 
treatment related appetite and weight loss, 
 are easy to access as they attend daily for treatment. 
We expect to be able to recruit 35 patients within a 4 week period. Written consent will be obtained by a 
member of the research team at least 24 hours after the participant has been given a written information 
sheet about the study. 
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Details of power calculations and sample size 
Advice has been taken from the Trent Research and Development Support Unit and by Dr Tony Arthur 
an expert in epidemiology and statistics at the School of Nursing, University of Nottingham. 
A sample size of 35 at two time points will allow us to detect a correlation coefficient of 0.7 with 95% 
confidence intervals that exclude a lower limit of 0.5.14  
This is at an appropriate level to determine the reliability of the ASQ. 
 
Primary outcome measure  
Response to the Appetite and Symptom Questionnaire  
 
 
Phase II 
 
Patient inclusion criteria 
(i) Adults, over 18 years of age, with a confirmed diagnosis of primary lung or gastrointestinal cancer. 
 
Patient exclusion criteria 
 (i) Lost > 10% of their pre-illness stable body weight; 
(ii) Lost between 5 and 10% of their pre-illness stable body weight with a BMI < 20kg/m2; 
(iii) BMI < 18.5 kg/m2 
Those patients meeting exclusion criteria (i) ± (iii) have already lost a clinically significant weight amount 
of weight. As we intend to develop a screening tool that will predict weight loss this group should not be 
included. 2 10 
(iv) Receiving enteral tube feeding or parenteral nutrition. 
(v) Unable to provide written informed consent and therefore complete the questionnaire due to cognitive 
impairment. 
(vi) Not able to be weighed. 
 
Patient recruitment and consent  
Potential participants (n=185 approx) will be those attending outpatients at Nottingham University 
Hospitals Trust with a diagnosis of lung or gastrointestinal cancer.  
We expect to be able to recruit patients at an average rate of 15 per month from the respiratory and 
gastrointestinal oncology clinics at the hospital. These clinics have been chosen as patients with these 
cancers have a high incidence of nutritional deficiencies.2  
Patients attending the clinic will be given in the clinic waiting area a letter from the Clinician informing 
them that they will be screened for risk of malnutrition using the Malnutrition Universal Screening Tool 
(MUST). The letter will also tell them that if their weight is stable they will be approached by a member of 
the research team to see if they are willing to participate in the study.  
The Malnutrition Universal Screening Tool (MUST) score will be calculated and recorded by a by a 
member of the research team. This will involve patients having their weight and height measured and 
body mass index and unplanned percentage weight loss over the previous 3 to 6 months calculated. 
They will also be asked if due to acute illness they have had or are likely to have no nutritional intake for 
GD\V 
Weight and height measurements will be screened by member of research team to identify those 
patients who meet the study criteria.  
Patients will be offered a written advice leaflet about ways to improve their nutritional intake. Those 
patients identified as being at risk of malnutrition from the MUST will be identified as being at risk to the 
Clinician in clinic by a letter in the notes. 
Those patients who are not identified by MUST as being at risk of malnutrition, and who meet the 
inclusion criteria for the study will be given a patient information sheet by a member of the research 
team.  
As long a time period that is practical within the clinic setting will be given between the patient receiving 
the information sheet, being approached by a member of the research team and being asked to consent. 
Reasoning for not giving the potential participants longer to consider taking part is that obtaining data in 
a timely manner is essential when investigating the prediction of weight loss over a three month period.  
Those patients identified at clinic as eligible to participate would be required to come back to the hospital 
within 2 to 3 days to be consented, complete the ASQ and have an additional blood test. This would 
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potentially increase levels of inconvenience and stress for the patient and be costly in terms of time and 
money. 
Subjects will be recruited to the study over a 15 month period. Participation in the study will last for 3 
months. After three months participants will have their weight measured and percentage weight loss will 
again be calculated. To minimise attrition, those subjects not able to attend clinic for three month follow 
up will be given the option to attend Hayward House at Nottingham City Hospital or to be visited at their 
home.  
Allowing for around a 15% attrition rate we aim to end up with 160 participants. 
Details of power calculations and sample size 
To avoid over-fitting when building the model to develop the screening tool we will need data from a 
minimum of 10 participants for each item (covariate). Our target sample of 160 will allow us to include up 
to 16 of the items measured. 15,16  
 
Primary outcome measure 
 weight loss 
At baseline participants will be weighed using calibrated scales and have their height measured by a 
member of the research team. They will be asked about unplanned weight loss over the previous 3 to 6 
months. From this information body mass index and percentage weight loss will be calculated. 
If the subject meets the inclusion criteria and consent is obtained this information will be used and they 
will then be asked to complete the additional outcome measures. They will be weighed at 3 months and 
percentage weight loss calculated over the 3 month period. 
 
Other outcome measures 
 
1. Malnutrition Universal Screening Tool Score 
The initial screening of patients will involve all those attending clinic to have the Malnutrition Universal 
Screening Tool (MUST) score calculated. For those patients eligible to participate  in the study the 
MUST score will be included as one of the outcome measures. 
 
2. Response to the Appetite and Symptom Questionnaire  
Patients will be asked to self-complete the 12 item Appetite and Symptom Questionnaire at base line. 
 
 
3. Blood sampling 
At baseline participants will have a venous blood sample taken to establish the level of C-Reactive 
Protein. Analysis will be carried out by the pathology department at Nottingham City Hospital Campus, 
Nottingham University Hospitals NHS Trust. 
 
4. Clinical Condition 
Diagnosis and stage of disease, treatment and performance status will be recorded at base line.  
 
Phase III 
 
Patient Inclusion criteria 
(i) Participants of phase II 
(ii) Weight loss over the three month study period. 
 
Patient Exclusion criteria 
(i) Unable to understand spoken English language. 
(ii) Unable to provide written informed consent. 
 
Volunteer Inclusion Criteria 
(i) Partner or carer of a patient participant within phase II of the study. 
 
Volunteer Exclusion Criteria 
(i) Unable to understand spoken English language. 
(ii) Unable to provide written informed consent. 
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Recruitment, sampling and consent 
Potential participants will be those patients attending the out patient clinics at Nottingham City Hospital 
recruited into phase II of the study as described above.  
At recruitment participants will be asked to indicate on the consent form if they agree to be interviewed if 
required. 
Theoretical sampling will be adopted to ensure an appropriate selection of cases. Following the three 
month study period potential participants will be contacted by telephone and invited to be interviewed. 
Where a partner or main carer is identified by the patient they too will be asked if they are interested in 
participating. On agreement, a volunteer information sheet will be posted out to them and consent will be 
taken prior to the interview taking place. It is envisaged that including the partner or carer will add to the 
depth of information, particularly regarding indicators of weight loss, appetite and food preparation. The 
sample will also include single male and female patients.  
Participants will be asked to attend Oncology Out-patients or Hayward House Palliative Care Unit at 
Nottingham City Hospital at a time convenient to themselves. They will also be given the option to be 
visited at home. As the study is exploratory it is anticipated that no more than 20 subjects will participate. 
 
Data collection 
The interviews will all follow the same semi-structured format and will be conducted in a private room 
with a member of the palliative care research team. Participants will be asked to recall their experiences 
or observations of losing weight, particularly regarding the signs and symptoms that contributed to the 
weight loss. Information about the amount, type and source of any dietary advice that they have 
received will be also be gathered as will their experiences of any influences on ability to comply. Patient 
participants will also be asked to complete the ASQ at this visit. 
The interview will be digitally recorded and then transcribed by a member of the research team. 
Participants will be assigned a false name when the interview is transcribed, and the recording will be 
destroyed when no longer needed for study purposes. 
 
Data Analysis 
 
Following data cleaning procedures all data will be analysed using SPSS version 14.5 and Stata version 
9. In order to increase the credibility and validity of the study, there will be triangulation of the results 
from all three phases. 
 
Phase I 
For test-retest reliability we will use the intraclass correlation coefficient to estimate the variation 
between participants in terms of ASQ scores as a proportion of WKHWRWDOYDULDWLRQ&URQEDFK¶VDOSKDZLOO
also be applied to test the internal consistency of the ASQ.  
  
Phase II 
To build the model that will determine the optimal set of variables that will comprise the screening tool, 
multiple linear regression analysis will be used. Variables will be retained where p = <0.05 for log-
likelihood ratio tests. To address the potential problem of collinearity a correlation matrix will be used 
which will alert us to pairs of individual items that are highly correlated.  A forward variable selection 
process will be used to identify the best models. This will allow greater control over the model building 
process and further identify any problems of collinearity.17 
To check the robustness of the model to deviations from the model's assumptions, bootstrap resampling 
will be used. The optimal cut off will be determined from the ROC curve analysis which will determine the 
sensitivity and specificity for each cut point. Positive and negative predictive values will be estimated at 
each cut-off.18 
 
Phase III 
Data organization and retrieval will be managed using the qualitative software package NVivo. Thematic 
DQDO\VLVZLOOEHSHUIRUPHGRQWKHGDWDWRKLJKOLJKWVLPLODULWLHVRUGLIIHUHQFHVEHWZHHQHDFKSDUWLFLSDQW¶V
experience with regards to a particular topic. Themes will be compared within and across all transcripts 
noting similarities and differences until saturation is reached. Summarisation and interpretation of the 
thematic analysis will permit theory development. 
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Dissemination  
Results will be reported in peer reviewed journals such as Oncology and European Journal of Clinical 
Nutrition. In addition to this they will be presented at both national and international level. 
At the end of the study a lay summary will be available for participants upon request  
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Screening for malnutrition in cancer 
 
Height:               metres 
 
Weight:  kilograms  Body mass Index (BMI):                        kg/m2 
        
 
 
 
Total MUST score:  =  
 
 
 
0 
 
 
 
 
 
1 
 
 
 
 
 
2 or more 
Low Risk Risk High Risk 
Monitor Treat Treat 
 
Predicting weight loss in cancer 
 
 
To be completed by the patient: 
 
1. My age is« 
 younger than 40 
 40 to 50 
 50 to 60 
 60 to 70 
 older than 70 
 
3,HQMR\WKHIRRG,GRHDW« 
 never 
 rarely 
 sometimes 
 often 
 most times 
 
To be completed by healthcare staff: 
 
BMI is.... 
 < 18.5 
 18.5 - 20 
 20 - 25 
 25 - 30 
 > 30 
 
 
 
20RVWRIWKHWLPHP\SDLQLV« 
 very severe 
 severe 
 moderate 
 mild 
 very mild or no pain 
 
 
 
 
 
 
 
 
 
 
MUST score is........ 
 6 
 4 or 5 
 2 or 3 
 1 
 0 
1.Body Mass Index 
BMI MUST score   
> 20 (>30 obese) 0  
18.5 ± 20 1  
<18.5 2  
2.Unplanned weight loss in past 3-6 months 
% Weight Loss MUST score  
<5 0  
5-10 1  
>10 2  
3. Acute disease effect score MUST score  
If patient is acutely ill and there has been or is likely to be no nutritional intake for> 5 days 2  
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Evaluation of Appetite and Symptoms 
 
Please tick the box that most closely reflects your experiences with appetite and symptoms at the 
present time.  
 
0\DSSHWLWHGHVLUHWRHDWLV« 
      very poor 
 poor 
 average 
 good 
 very good 
 
:KHQ,HDW,IHHOIXOO« 
 without having eaten anything 
 after eating only a few mouthfuls  
 after eating about a third of a meal 
 after eating over half a meal 
 after eating a full meal  
 
%HIRUHHDWLQJ,IHHOKXQJU\« 
 rarely  
 occasionally 
 some of the time 
 most of the time 
 all of the time 
 
,HQMR\WKHIRRG,GRHDW« 
 never 
 rarely 
 sometimes 
 often 
 most times 
 
  
5. Over the last 6 months my weight has 
    decreased by approximately.......  
 more than 2 stone (13kg) 
 1 stone to 2 stone (6kg to 13kg) 
 ½ stone to 1 stone (3kg to 6kg) 
 less than ½ stone (3kg) 
 not at all 
 
,KDYHLQGLJHVWLRQ«..... 
 never 
 less than once a month 
 2 to 3 times a month 
 more than once a week 
 all the time 
,KDYHDVRUHPRXWKRUWKURDW« 
 all the time 
 more than once a week 
 2 to 3 times a month 
 less than once a month 
 never 
$WSUHVHQW,KDYH« 
 no taste at all  
 severe taste changes 
 moderate taste changes 
 mild taste changes 
 no changes in taste 
 
9. I feel sick or nauseated before I eat or when I 
HDW« 
 most times 
 often 
 sometimes 
 rarely 
 never 
 
10. I vomit...... 
 every day 
 more than once a week 
 2 to 3 times a month 
 less than once a month 
       never 
11. ,IHHOFRQVWLSDWHG« 
 all the time 
 every week 
 2 to 3 times a month 
 less than once a month 
 never 
 
 
 
12. I have diarrhoea....   
 every day 
 more than once a week 
 2 to 3 times a month 
 less than once a month 
 never 
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0RVWRIWKHWLPHP\HQHUJ\OHYHOLV« 
 very low 
 low 
 moderate 
 high 
 very high 
 
0RVWRIWKHWLPHP\PRRGLV« 
       very sad 
 mostly sad 
 neither sad nor happy 
 mostly happy 
 very happy 
 
 
 
0RVWRIWKHWLPHP\SDLQLV« 
 very severe 
 severe 
 moderate 
 mild 
 very mild or no pain 
 
,IHHODQ[LRXV« 
       all of the time 
 most of the time 
 some of the time 
 occasionally 
 never  
 
 
 
Other symptoms that I experience are:  
 
_________________________________________________________________________________________
_________________________________________________________________________________________
______________________________________________________________________________________ 
 
 
 
